HOME@>@‹³ŽºÐ‰î@>@Œ¤‹†‹ÆÑ(˜_•¶¥Šw‰ï”­•\)@>@‘“àŠw‰ï

‹³ŽºÐ‰î

‹³ŽºÐ‰î

Œ¤‹†‹ÆÑ(˜_•¶¥Šw‰ï”­•\)

‘“àŠw‰ï

2018”N 2017”N 2016”N
2015”N 2014”N 2013”N
2012”N 2011”N 2010”N
2009”N 2008”N 2007”N
2006”N 2005”N  

2018”N
    ‘æ82‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi3ŒŽ23“ú`25“úA2018”NA‘åãŽsj

    ƒRound Table Discussion„

  1. Shimokawa H. How to Perform Clinical Trials/Studies Successfully: Report from Tohoku University
  2. ƒSymposium„

  3. Sakata Y, Nochioka K, Abe R, Oikawa T, Kasahara S, Sato M, Aoyanagi H, Miura M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Evidence for Sex Differences in Japanese Patients with Chronic Heart Failure -A Report from the CHART-2 Study-
  4. Konno R, Tatebe S, Sugimura K, Satoh K, Aoki T, Yamamoto S, Sato H, Kozu K, Shimokawa H. Immunosuppressive Therapy Ameliorates Severe Pulmonary Hypertension and Refractory Vasospastic Angina in a Patient with Eosinophilic Granulomatosis with Polyangiitis
  5. ƒControversy„

  6. Sakata Y, Nochioka K, Miyata S, Shimokawa H. Transition of Left Ventricular Ejection Fraction in Heart Failure: Is HFmrEF Closer to HFpEF than to HFrEF?
  7. ƒSpecial Session„

  8. Takahashi J, Hao K, Satoh K, Shimokawa H. Temporal Trends in Prevalence and Outcomes of Geriatric Patients with Acute Myocardial Infarction Complicated with Heart Failure -Lessons from Miyagi AMI Registry Study-
  9. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  10. Ohyama K, Matsumoto Y, Takanami K, Ota H, Nishimiya K, Sugisawa J, Tsuchiya S, Amamizu H, Uzuka H, Suda A, Shindo T, Kikuchi Y, Hao K, Tsuburaya R, Takahashi J, Miyata S, Sakata Y, Takase K, Shimokawa H. Evidence for Enhanced Inflammation of Coronary Adventitia and Perivascular Adipose Tissue in Patients with Vasospastic Angina -A Multi-modality Imaging Study-iÅ—DGÜŽóÜj
  11. ƒPlenary Sessions„

  12. Uzuka H, Matsumoto Y, Nishimiya K, Ohyama K, Amamizu H, Morosawa S, Hirano M, Shindo T, Kikuchi Y, Hao K, Shiroto T, Takahashi J, Shimokawa H. Renal Denervation Suppresses Coronary Hyperconstricting Responses after Drug-Eluting Stent Implantation in Pigs in Vivo through the Kidney-Brain-Heart Axis
  13. Sugisawa J, Matsumoto Y, Suda A, Tsuchiya S, Ohyama K, Shindo T, Ikeda S, Hao K, Kikuchi Y, Takahashi J, Ota H, Shimokawa H. Impaired Vasodilator Capacity of Coronary Microvessels in Patients with Vasospatic Angina -Adenosine-Stress Myocardial CT Perfusion Imaging Study-
  14. ƒTopic„

  15. Tatebe S. Diastolic Dysfunction in Adults with Congenital Heart Disease
  16. ƒLate Breaking Cohort Studies 2 (HF)„

  17. Nochioka K, Sakata Y, Shiroto T, Oikawa T, Abe R, Kasahara S, Sato M, Aoyanagi H, Takahashi J, Miyata S, Shimokawa H. Prognostic Impact of Impaired Glucose Tolerance in Relation with Microalbuminuria in Patients with Chronic Heart Failure: The SUPPORT Trial Subanalysis
  18. ƒOral Presentations (English)„

  19. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Miyata S, Arai H, Furukawa K, Fukumoto Y, Taki Y, Shimokawa H. Brain White Matter Abnormalities Associated with Memory Impairment in Patients with Chronic Heart Failure
  20. Amamizu H, Matsumoto Y, Morosawa S, Ohyama K, Uzuka H, Hirano M, Sugisawa J, Tsuchiya S, Sato K, Suda A, Shindo T, Ikeda S, Nishimiya K, Kikuchi Y, Hao K, Shiroto T, Takahashi J, Shimokawa H. Important Roles of Cardiac Lymphatic Duct System in the Regulation of Coronary Vasomotion in Pigs in Vivo
  21. Sunamura S, Satoh K, Kurosawa R, Ohtsuki T, Kikuchi N, Md Elias Al-Mamun, Shimizu T, Ikeda S, Suzuki K, Satoh T, Omura J, Nogi M, Mohammad Abdul Hai Siddique, Miyata S, Miura M, Shimokawa H. Rho-kinase and Cyclophilin A as Novel Therapeutic Targets for Cardiac Dysfunction and Post-Capillary Pulmonary Hypertension
  22. Nogi M, Satoh K, Sunamura S, Kikuchi N, Sato T, Kurosawa R, Omura J, Md Elias Al-Mamun, Mohammad Abdul Hai Siddique, Kudo S, Akiyama M, Kawamoto S, Saiki Y, Shimokawa H. SmgGDS Prevents Thoracic Aortic Aneurysm Formation and Rupture by Phenotypic Preservation of Aortic Smooth Muscle Cells
  23. Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Matsumoto Y, Sakata Y, Shimokawa H. Sex Differences in Coronary Microvascular Dysfunction in Patients with Vasospastic Angina
  24. Hao K, Takahashi J, Miyata S, Sato K, Shindo T, Ikeda S, Kikuchi Y, Shiroto T, Matsumoto Y, Sakata Y, Shimokawa H. Sex Differences in Clinical Characteristics and Outcome of Patients with Acute Myocardial Infarction with Non-Obstructive Coronary Artery(MINOCA)
  25. Aoki T, Sugimura K, Tatebe S, Yamamoto S, Shimizu T, Yaoita N, Sato H, Kouzu K, Konno R, Terui Y, Nochioka K, Satoh K, Shimokawa H. Normalization of Hemodynamic Responses to Exercise as a Final Goal of Balloon Pulmonary Angioplasty in Patients with CTEPH
  26. Kikuchi Y, Takahashi J, Sato K, Sugisawa J, Tsuchiya S, Suda A, Shindo T, Ikeda S, Hao K, Shiroto T, Matsumoto Y Sakata Y, Shimokawa H. Beneficial Effects of Fasudil, a Selective Rho-kinase Inhibitor, for the Treatment and Prevention of PCI-related Myocardial Ischemia
  27. Kikuchi N, Satoh K, Kurosawa R, Yaoita N, Md. Elias Al-Mamun, Mohammad Abdul Hai Siddique, Omura J, Sato T, Nogi M, Sunamura S, Miyata S, Shimokawa H. Selenoprotein P Promotes Vascular Smooth Muscle Cell Proliferation and Pulmonary Hypertension -A Possible Novel Therapeutic Target-
  28. Kozu K, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Shimizu T, Nochioka K, Sato H, Konno R, Satoh K, Miyata S, Shimokawa H. Sex Differences in Hemodynamic Responses and Long-term Survival to Optimal Medical Therapy in Patients with Pulmonary Arterial Hypertension
  29. Mohammad Abdul Hai Siddique, Satoh K, Kurosawa R, Md. Elias Al-Mamun, Kikuchi N, Omura J, Satoh T, Nogi M, Sunamura S, Shimokawa H. Identification of Emetine as a Novel Therapeutic Agent for Pulmonary Hypertension in Rats -High-throughput Screening of 5,562 Compounds-
  30. Sato K, Hao K, Takahashi J, Cui Y, Shindo T, Ikeda S, Kikuchi Y, Matsumoto Y, Shiroto T, Sakata Y, Shimokawa H. Temporal Trends in the Treatment and Outcomes of Heart Failure in Super-Old Patients with Acute Myocardial Infarction
  31. Otsuki T, Satoh K, Shimizu T, Ikeda S, Yaoita N, Sato T, Omura J, Kikuchi N, Kurosawa R, Sunamura S, Nogi M, Sugimura K, Aoki T, Tatebe S, Nochioka K, Yamamoto S, Takahashi J, Miyata S, Shimokawa H. Important Prognostic Impacts of Serum Levels of Adipsin in Patients with Coronary Artery Disease
  32. ƒOral Presentations (Japanese)„

  33. Terui Y, Sugimura K, Ota H, Sato H, Nochioka K, Tatebe S, Aoki T, Yamamoto S, Kozu K, Konno R, Takase K, Shimokawa H. Usefulness of Cardiac MRI in the Management of Cancer Patients Treated with Anthracyclines -Progress in Cardio-oncology-
  34. Kasahara S, Sataka Y, Nochioka K, Abe R, Oikawa T, Sato M, Aoyanagi H, Miura M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Development of a Conversion Formula between B-type Natriuretic Peptide and N-terminal Pro BNP Levels
  35. Aoyanagi H, Sakata Y, Nochioka K, Shiroto T, Oikawa T, Abe R, Kasahara S, Sato M, Takahashi J, Miyata S, Shimokawa H. Impact of Transition of Left Ventricular Ejection Fraction in Patients at Risk for Heart Failure: Report from the CHART-2 Study
  36. ƒFeatured Research Session„

  37. Kurosawa R, Satoh K, Kikuchi N, Omura J, Sato T, Nogi M, Sunamura S, Al-Mamun Md. Elias, Mohammad Abdul Hai Siddique, Shimokawa H. Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension -High-throughput Screening of 5,562 Compounds-
  38. ƒPoster Sessions (English)„

  39. Miki K, Nakano M, Hasebe Y, Kimura Y, Chiba T, Fukasawa K, Morosawa S, Shimokawa H. Prevalence and Risk Factors of Silent Cerebral Infarction in Patients with Atrial Fibrillation
  40. Morosawa S, Yamamoto H, Hirano M, Uzuka H, Ohyama K, Hasebe Y, Nakano M, Fukuda K, Takayama K, Shimokawa H. Validation of a New Shock Wave Catheter Ablation System for Ventricular Tachyarrhythmias in Pigs in Vivo
  41. Yamamoto S, Suzuki H, Sugimura K, Tatebe S, Aoki T, Sato H, Kozu K, Konno R, Ota H, Takanami K, Takase K, Nochioka K, Shimokawa H. Assessment of Cardiac Autonomic Nerve Functions by 123I-Meta-Iodobenzylguanidine Imaging in Patients with Anderson-Fabry Disease
  42. Chiba T, Nakano M, Hasebe Y, Kimura Y Fukasawa K, Miki K, Morosawa S, Fukuda K, Shimokawa H. Prognostic Significance of Left Ventricular Ejection Fraction Relevant to Myocardial Damage in Patients with Cardiac Sarcoidosis
  43. Shindo T, Ito K, Eguchi K, Kurosawa R, Kagaya Y, Monma Y, Ichijo S, Shiroto T, Kanai H, Shimokawa H. Low-intensity Pulsed Ultrasound Ameliorates Left Ventricular Dysfunction in ApoE-deficient Mice with Acute Myocardial Infarction in Vivo
  44. ƒPoster Sessions (Japanese)„

  45. Tatebe S, Sugimura K, Saito M, Sakata Y, Satoh K, Aoki T, Yamamoto S, Shimizu T, Sato H, Otsuki T, Kozu K, Konno R, Terui Y, Kawano K, Kimura M, Adachi O, Saiki Y, Shimokawa H. Clinical Profiles of Pregnant Women with Heart Disease
  46. Abe R, Sakata Y, Nochioka K, Oikawa T, Kasahara S, Sato M, Aoyanagi H, Miura M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Sex Differences in Health Consciousness and Prognosis of Patients with Chronic Heart Failure -A Report from the CHART-2 Study-
  47. Fukasawa K, Fukuda K, Nakano M, Hasebe Y, Kimura Y, Chiba T, Miki K, Shimokawa H. Impact of Sinus Rhythm Maintenance on Exercise Tolerance after Catheter Ablation in Patients with Non-Paroxysmal Atrial Fibrillation
  48. Eguchi K, Shindo T, Ito K, Kurosawa R, Kagaya Y, Monma Y, Ichijo S, Miyata S, Taki H, Kanai H, Shimokawa H. Crucial Role of Endothelial Nitric Oxide Synthase in the Therapeutic Effects of Low-intensity Pulsed Ultrasound for Dementia in Mice
  49. Tsuchiya S, Matsumoto Y, Sugisawa J, Kikuchi Y, Takahashi J, Kawamoto S, Kumagai K, Saiki Y, Shimokawa H. Evidence for Improved Cognitive Functions after TAVI in Elderly Patients with Severe Aortic Stenosis -Involvement of the Heart-Brain Interaction-
  50. Konno R, Tatebe S, Sugimura K, Satoh K, Aoki T, Yamamoto S, Shimizu T, Sato H, Kozu K, Terui Y, Adachi O, Kimura M, Saiki Y, Shimokawa H. Hepatitis C Virus Positivity Adversely Impacts Cardiac Functions and Long-term Prognosis in Patients with Adult Congenital Heart Disease
  51. Sato M, Sakata Y, Oikawa T, Abe R, Kasahara S, Aoyanagi H, Miura M, Nochioka K, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics and Prognostic Factors in Elderly Patients with Chronic Heart Failure -A Report from the CHART-2 Study-
  52. Oikawa T, Sakata Y, Nochioka K, Miura M, Abe R, Kasahara S, Sato M, Aoyanagi H, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Prognostic Impact of Triglycerides Levels in the Secondary Prevention of Patients with Myocardial Infarction -A Report from the CHART-2 Study-
  53. ‘æ47‰ñ“ú–{S–¬ŠÇì“®•¨Ž¿Šw‰ïi2018”N2ŒŽ9“ú`10“úA’·èŽsj

    ƒƒCƒuƒjƒ“ƒOƒZƒ~ƒi[„

  54. ‰ºìG–¾FŽ‰Ž¿ˆÙíÇf—ÂÌÅV‚Ì’mŒ©
  55. ƒYIAƒZƒbƒVƒ‡ƒ“„

  56. »‘ºTˆê˜YA²“¡Œö—YA•àV —ºA‘å’Î’mLA‹e’n‡—TAMd Elias AL-MamunA´… ‹œA’r“c®•½A—é–ØN‘¾A²“¡‘åŽ÷A‘呺~ˆêA–ì–Ø³“¹AMohammad Abdul Hai SiddiqueA‹{“c •qA‰ºìG–¾F¶S•s‘S‚É”º‚¤”x‚ŒŒˆ³Ç”­Ç‚É‚¨‚¯‚éROCK1‚ÆROCK2‚Ì–ðŠ„•ª’S‚̉ð–¾iÅ—DGÜŽóÜj
  57. “c’†C•½A”’ŒË ’A_ŒË–ΗYAꎓ¡‘åŽ÷AˆÉ“¡H‘ãAˆä‹‚—z—SAŠ’JãÄŽqA²“¡¹—¢A‰ºìG–¾F”xzŠÂ‚¨‚æ‚Ñ”x‚ŒŒˆ³Ç‚É‚¨‚¯‚é“à”çˆË‘¶«‰ß•ª‹É”½‰ž‚Ìd—v«|’áŽ_‘f—U”­«”x‚ŒŒˆ³Ç‚ð’†S‚Æ‚µ‚½ŒŸ“¢|iÅ—DGÜŽóÜj
  58. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j”­•\„

  59. “V…G˜aA¼–{‘׎¡A”‘ò ‘EA‘åŽR@”nA‰F’Ë—T‹IA•½–쓹ŠîA™àV A“y‰® ‘A²“¡ŒöˆêA{“c •jAi“¡’q•FA’r“c®•½A¼‹{Œ’‰îA‹e’n —ƒA‰H”ö´‹MA”’ŒË ’A‚‹´ A‰ºìG–¾FŠ¥“®–¬‰ßŽûk”½‰ž‚É‚¨‚¯‚éS‘ŸƒŠƒ“ƒpŠÇ‚Ìd—v«|ƒuƒ^“®•¨ƒ‚ƒfƒ‹‚ð—p‚¢‚½ŒŸ“¢|
  60. –ì–Ø³“¹A²“¡Œö—YAH“¡ rA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A»‘ºTˆê˜YA•àV —ºA‘å’Î’mLA‰ºìG–¾F‘å“®–¬•½ŠŠ‹Ø×–E‚ÌŒ`Ž¿•ÛŽ‚ð‹@˜‚Æ‚µ‚½‹¹•”‘å“®–¬áŽ‚ÌŒ`¬‚Æ”j—ô‚ɑ΂·‚éSmgGDS ‚Ì—\–h“IŠÖ—^
  61. “›ˆä³lAŠì–¼”üAâ—œ‚Ü‚äŽqA¼èr”ŽA’‡@ª~ŽqA²“¡Œö—YA‰ºìG–¾AVèÍFÉŽ_‰–^ˆŸÉŽ_‰–‚Ì•s‘«‚Í‘ãŽÓÇŒóŒQAŒŒŠÇ•s‘SAS‘Ÿ“Ë‘RŽ€‚ðŽä‹N‚·‚é
  62. “›ˆä³lA¶‰z‹M–¾AéŒË‹MŽuAâ—œ‚Ü‚äŽqA¬“cŒjŽmA‰¤ ŽîÇA–L•½—R”üŽqA˜aò OlAŽR“c‘s—ºA‰ºìG–¾A–öŒ´‰„ÍA–˜a”ŽAŒ} аF’áŽ_‘f«”x‚ŒŒˆ³‚É‚¨‚¯‚霑NO ‡¬y‘fŒn‚̕یì“I–ðŠ„
  63. “›ˆä³lA‹v•Û“c—zHA–ìŒûŽ•FAâ—œ‚Ü‚äŽqA¼èr”ŽA’‡@ª~ŽqA‰ºìG–¾A{‰ÁŒ´ˆê”ŽAŠ_‰Ô ŠwF”][ǂɂ¨‚¯‚éNO ‡¬y‘f‚Ì—LŠQ‚Èì—pF«·‚¨‚æ‚уeƒXƒgƒXƒeƒƒ“‚ÌŠÖ—^
  64. ‘æ11‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2018”N1ŒŽ20“ú`21“úA•Ÿ‰ªŽsj

    ƒ‹¤ÃƒVƒ“ƒ|ƒWƒEƒ€„

  65. ‚‹´ F“Œ“ú–{‘åkЂªzŠÂŠí޾г‚É‹y‚Ú‚µ‚½‰e‹¿‚Æ«·
  66. â“c‘וFF–«S•s‘Sf—Âɂ¨‚¯‚é«·F CHART-2Œ¤‹†‚©‚ç‚Ì’mŒ©
  67. ƒ—DG‰‰‘èŒó•âŒû‰‰„

  68. ‹yì‘ì–çAâ“c‘וFAŒã‰ªL‘¾˜YAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YA²“¡‰ë”VA–ö ”£A”’ŒË ’A‹{“c •qA‰ºìG–¾FSŒŒŠÇ޾ггŽÒ‚É‚¨‚¯‚邪‚ñŽ€–S‹K’èˆöŽq‚Æ«·i—DGÜŽóÜj
  69. ŽO–ØŒi‘¾A’†–ì ½A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò ‘EA‰ºìG–¾F”ñ•Ù–ŒÇ«S–[ד®Š³ŽÒ‚É‚¨‚¯‚閳njó«”][ǂ̫·‚ÌŒŸ“¢
  70. ç—t‹M•FA’†–ì ½A’·’J•”—Y”òA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘¾A”‘ò ‘EA‰ºìG–¾FS‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒXгŽÒ‚É‚¨‚¯‚éS‘ŸÄ“¯Šú—Ö@‚Ì—LŒø«‚ÉŠÖ‚·‚é«·
  71. ²“¡ŒöˆêA‚‹´ A‰H”ö´‹MAi“¡’q•FA’r“c®•½A‹e’n —ƒA¼–{‘׎¡A‹{“c •qAâ“c‘וFA‰ºìG–¾F‚—î‹}«S‹Ø[ÇŠ³ŽÒ‚É‚¨‚¯‚éƒvƒ‰ƒCƒ}ƒŠ[Š¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—ÃŒø‰Ê‚Ì«·‚ÉŠÖ‚·‚錟“¢
  72. ®–ì —ºAŒš•”r‰îAâ“c‘וFA™‘ºGˆê˜YA²“¡Œö—YA”’ŒË ’AˆÀ’B —A–Ø‘º³lA—§–ì Ž A’†“‡O“¹A¬ŽRk‘¾˜YAâV–؉ÀŽA‰ºìG–¾F¬læ“V«S޾ггŽÒ‚É‚¨‚¯‚é”x‚ŒŒˆ³Ç‚Ì«·
  73. –ö ”£Aâ“c‘וFAŒã‰ªL‘¾˜YA”’ŒË ’A‹yì‘ì–çAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YA‚‹´ A‹{“c •qA‰ºìG–¾FS•s‘S”­Ç‚ƒŠƒXƒNгŽÒ‚É‚¨‚¯‚é¶Žº‹ìo—¦‚ÌŒoŽž“I•ω»‚Ì«·
  74. ƒƒ|ƒXƒ^[”­•\„

  75. ‰H”ö´‹MA‚‹´ A²“¡ŒöˆêAi“¡’q•FA’r“c®•½A‹e’n —ƒA¼–{‘׎¡A‹{“c •qAâ“c‘וFA‰ºìG–¾F”ñ•ÂÇ«Š¥“®–¬‚𔺂¤S‹Ø[ÇiMINOCAjгŽÒ‚Ì—Õ°‘œ|‹{錧AMI“o˜^Œ¤‹†|
  76. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YAŒã‰ªL‘¾˜YA”’ŒË ’A‚‹´ A‹{“c •qA‰ºìG–¾F‚—îS•s‘SгŽÒ‚Ì—Õ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚É‚¨‚¯‚é«·|CHART-2Œ¤‹†‚©‚ç‚Ì•ñ|
  77. Š}Œ´M‘¾˜YAâ“c‘וFAŒã‰ªL‘¾˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA”’ŒË ’A‚‹´ A‹{“c •qA‰ºìG–¾FBNP‚ÆNT-proBNP‚Ì‘ŠŠÖ‚É‚¨‚¯‚é«·
  78. Œš•”r‰îA™‘ºGˆê˜YA²“¡Œö—YA–ؗ³’jAŽR–{¹DA´… ‹œAÖ“¡¹—˜Aì–쌤ŒåAˆÀ’B —A‰ºìG–¾FzŠÂŠíƒRƒ“ƒTƒ‹ƒe[ƒVƒ‡ƒ“‚ªs‚í‚ꂽ”DPÇ—á‚ÌŒŸ“¢

Œ¤‹†‹ÆÑˆê——‚Ö@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2017”N
‘æ2‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï“Œ–kŽx•”’n•û‰ïi2017”N12ŒŽ3“úAå‘äŽsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€„

  1. ¼–{‘׎¡A’|“à‰ëŽjA“y‰® ‘A‹e’r —ƒAì–{r•ãAŒF’J‹Iˆê˜YA‰H”ö´‹MAi“¡’q•FA’r“c®•½A‚‹´ A㌎³”ŽAâV–؉ÀŽA‰ºìG–¾FTAVIp‘O‚Æ–«Šú‚Ì‚—îŽÒƒtƒŒƒCƒ‹•]‰¿FTAVIŒã‚¹‚ñ–ς̗\‘ª‚Æ•af˜AŒg‚Ìd—v«
  2. ƒˆê”ʉ‰‘èiŒûqj„

  3. ²“¡ŒöˆêA‰H”ö´‹MA™àV A“y‰® ‘Ai“¡’q•FA’r“c®•½A‹e’n —ƒA¼–{‘׎¡A‚‹´ A‰ºìG–¾F‰^“®•‰‰×—U”­«Š¥¹k‹·Sǂ̂P—á
  4. HŒŽŽO“ÞA™‘ºGˆê˜YA–ؗ³’jA™àV AŠ`‰Ô—²ºA‰ºìG–¾A㌎³”ŽFCTEPH‚ÆPAH‚̊ӕʂɂ¨‚¯‚éŒÄ‹CƒKƒX•ªÍ‚Ì—L—p«
  5. ™àV A–ؗ³’jAHŒŽŽO“ÞA®–ì —ºA_’ÃŽ–çA²“¡ —yAŽR–{¹DAŒš•”r‰îA™‘ºGˆê˜YA‰ºìG–¾F–«ŒŒð•ÂÇ”x‚ˆ³Ç‚É‚¨‚¯‚é‰^“®‘Ï—e”\‚Ɖ^“®ŽžŒŒs“®‘Ô‚ÌŒŸ“¢
  6. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA²“¡ —yA_’ÃŽ–çA®–ì —ºAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾F‰^“®•‰‰×‰ESƒJƒe[ƒ‹‚ɑ΂·‚錌s‘ԕω» \ƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚ÌŒø‰Ê”»’è‚ւ̉ž—p
  7. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  8. –x —ÇŽqA‰H”ö´‹MA’·’J•”—Y”òA–ؗ³’jA™‘ºGˆê˜YAŠìƒAƒ†ƒ~A–¾’¿çŒbA—é–ØŽõŽ÷AHŒŽŽO“ÞAŠ`‰Ô—²ºA‰ºìG–¾FS•s‘SгŽÒ‚Ì“úí¶Šˆ‚É‚¨‚¯‚é–â‘è“_‚‚¢‚Ă̌Ÿ“¢
  9. ‘æ165‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2017”N12ŒŽ2“úAå‘äŽsj

    ƒYIAÇ—á”­•\•”–å„

  10. “y‰® ‘A¼–{‘׎¡A‹e’n —ƒA™àV Ai“¡’q•FA’r“c®•½A‰H”ö´‹MA‚‹´ Aì–{r•ãAŒF’J‹Iˆê˜YAâV–؉ÀŽA–x“à‹v“¿A‰ºìG–¾FTAVI ‚É‚æ‚èvWF ‚•ªŽq—Ê‘½—ʑ̌‡‘¹‚̉ü‘P‚Æ–Ñ׌ŒŠÇŠg’£Ç‚ÌÁ‘Þ‚ð”F‚ß‚½Heyde ÇŒóŒQ‚̈ê—ái—DGÜŽóÜj
  11. ƒYIAŒ¤‹†”­•\•”–å„

  12. ç—t‹M•FA’†–ì ½A’·’J•”—Y”òA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘¾A”‘ò ‘EA•Ÿ“c_“ñA‰ºìG–¾FS‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒXгŽÒ‚ÌS‹ØáŠQ‚ÉŠÖ˜A‚µ‚½¶ŽºŽûk”\‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿i—DGÜŽóÜj
  13. ƒˆê”ʉ‰‘è„

  14. ƈä—m•ãA™‘ºGˆê˜YA²“¡ —yAŒã‰ªL‘¾˜YAŒš•”r‰îA–ؗ³’jAŽR–{¹DA_’ÃŽ–çA®–ì —ºA‘å“c‰pŠöA‚£ Œ\A‰ºìG–¾Fanthracycline ŒnRŠà܂ɂæ‚éS“Å«‚Ì‘gDŠw“I•]‰¿‚É‚¨‚¯‚éS‘ŸMRI ‚Ì—L—p«
  15. ²“¡ —yA™‘ºGˆê˜YAŒš•”r‰îA–ؗ³’jAŽR–{¹DA´… ‹œA_’ÃŽ–çA®–ì —ºAƈä—m•ãA²“¡Œö—YA‰ºìG–¾F––½Œ^”x“®–¬‹·ó‚̈ê—á
  16. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA´… ‹œA²“¡ —yA_’ÃŽ–çA®–ì —ºAƈä—m•ãAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾Fƒoƒ‹[ƒ“”x“®–¬Œ`¬pŒã‚̉^“®•‰‰×‰ESƒJƒe[ƒeƒ‹ŒŸ¸
  17. Œš•”r‰îA™‘ºGˆê˜YA–ؗ³’jAŽR–{¹DA´… ‹œA²“¡ —yA‘å’Î’mLA_’ÃŽ–çA®–ì —ºAƈä—m•ãA²“¡Œö—YA‰ª“cŽ“TAˆÀ’B —AHê”ü‹IA‰ºìG–¾F¶‘Ì”xˆÚA‚ðŽ{s‚µ‚½¬Ž™Šú”­Ç‚Ì”x“®–¬«”x‚ŒŒˆ³Ç‚Ì‚P—á
  18. Š}Œ´M‘¾˜YAâ“c‘וFAŒã‰ªL‘¾˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA–ö ”£A”’ŒË ’A‚‹´ A‹{“c •qA‰ºìG–¾FHFpEF гŽÒ‚É‚¨‚¯‚éŠÈ•Ö‚È—\Œã—\‘ªƒŠƒXƒNƒXƒRƒA|CHART-2 Œ¤‹†‚©‚ç‚Ì•ñ|
  19. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YA–ö ”£AŽO‰Y³’¨AŒã‰ªL‘¾˜YA”’ŒË ’A‚‹´ A‹{“c •qA‰ºìG–¾F‚—îŽÒS•s‘S‚Ì—Õ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚¨‚æ‚Ñ«·‚ɂ‚¢‚Ă̌Ÿ“¢|CHART-2Œ¤‹†‚©‚ç‚Ì•ñ|
  20. ²“¡ŒöˆêA‰H”ö´‹MA™àV A“y‰® ‘Ai“¡’q•FA’r“c®•½A‹e’n —ƒA¼–{‘׎¡A‚‹´ A‰ºìG–¾F‰^“®•‰‰×—U”­«Š¥¹k«‹·Sǂ̂P—á
  21. i“¡’q•FA‚‹´ A¼–{‘׎¡A”’ŒË ’A‹e’n —ƒA‰H”ö´‹MA’r“c®•½A{“c •jA™àV A“y‰® ‘AŠ’JãÄŽqA²“¡ŒöˆêAƈä—m•ãA–ö ”£A‰ºìG–¾F˜J쎞Œ“ˆÀÃŽž‹¹’ɂ𔺂¤S‹Ø‰Ë‹´‚ð‡•¹‚µ‚½Š¥¹k«‹·Sǂ̈ê—á
  22. –ö ”£Aâ“c‘וFAŒã‰ªL‘¾˜YA”’ŒË ’A‹yì‘ì–çAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YA²“¡‰ë”VA‚‹´ A‹{“c •qA‰ºìG–¾FS•s‘SƒXƒe[ƒW‚ªS–[ד®‚Æ—\Œã‚Ƃ̊֌W‚É‹y‚Ú‚·‰e‹¿‚Æ«·FCHART-2 Œ¤‹†‚©‚ç‚Ì’mŒ©
  23. ’·’J•”—Y”òAŽO–ØŒi‘¾A”‘ò ‘EA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA’†–ì ½A‰ºìG–¾FS–[ד®‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½‰i‹vŒ^‰º‘åÖ¬ƒtƒBƒ‹ƒ^[—¯’uŒã‚̈ê—á
  24. ’†–ì ½A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘¾A”‘ò ‘EA‰ºìG–¾FV‹K3D ƒ}ƒbƒsƒ“ƒOƒVƒXƒeƒ€Rhythmia ‚É‚æ‚Á‚ÄŒŸo‚³‚ꂽ”÷¬“dˆÊ‚Ö‚ÌŽ¡—ª‘tŒ÷‚µ‚½’ÊíŒ^S–[‘e“®Ç—á
  25. –Ø‘º‹`—²A’†–ì ½A’·’J•”—Y”òAç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘¾AŒš•”r‰îA‰ºìG–¾Fƒtƒ@ƒ[Žl’¥ÇªŽ¡pŒã‚ÌATP Š´Žó«S–[•p”‚ɑ΂µAƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ðŽ{s‚µ‚½ˆê—á
  26. ŽO–ØŒi‘¾A’†–ì ½A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò ‘EA‰ºìG–¾Fƒpƒbƒ`ƒeƒXƒgŒ‹‰Ê‚ÉŠî‚«AƒSƒAƒeƒbƒNƒX‚ðŽg—p‚¹‚¸‚ÉICD Ažp‚ðŽ{s‚µ‚½‹à‘®ƒAƒŒƒ‹ƒM[‚Ì‚P—á
  27. âV“¡Œ³ˆêA–ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA´… ‹œA²“¡ —yA_’ÃŽ–çA®–ì —ºAƈä—m•ãAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾F”][Ç‚ð”­Ç‚µt-PA ‚ÆŒŒð‰ñŽû—Ö@‚É‚æ‚èŒãˆâǂȂ­‰ü‘P‚µ‚½DCM ‚̈êÇ—á
  28. ™àV A‹e’n —ƒA“y‰® ‘A²“¡ŒöˆêAƈä—m•ãA–ö ”£Ai“¡’q•FA’r“c®•½A‰H”ö´‹MA”’ŒË ’A¼–{‘׎¡A‚‹´ Aâ“c‘וFA‰Í’à ‘Aì–{r•ãAâV–؉ÀŽA‰ºìG–¾F‹}«S•s‘S”­Ç‚ðŒ_‹@‚É”­Œ©‚³‚ꂽ‹‘å¶Žº“àŒŒð‚Ì‚P—á
  29. ŽR–{¹DA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îA²“¡ —yA_’ÃŽ–çA®–ì —ºA‰ºìG–¾F‘å“®–¬Šî•”’uŠ·Œã‚Ì”DPoŽY‚Ì‚P—á
  30. ‘æ58‰ñ“ú–{–¬ŠÇŠw‰ïŠwpW‰ïi2017”N10ŒŽ19“ú`21“úA–¼ŒÃ‰®Žsj

    ƒJCAA‘Il”­•\„

  31. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡@—yA_’ÃŽ–çA®–ì@—ºAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚̕“I•]‰¿\’·Šú—\Œã‚Ƈ•¹ÇiÅ—DGÜŽóÜj
  32. ƒƒ|ƒXƒ^[”­•\„

  33. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡@—yA_’ÃŽ–çA®–ì@—ºAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾Fƒoƒ‹[ƒ“”x“®–¬Œ`¬pŒã‚Ì–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚¨‚¯‚é‰^“®•‰‰×‰ESƒJƒe[ƒeƒ‹
  34. ‘æ21‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2017”N10ŒŽ12“ú`14“úAH“cj

    ƒYIA R¸u‰‰ —Õ°„

  35. ²“¡ŒöˆêA‚‹´@A›Á@Œ³‹gA‰H”ö´‹MA‹{“c@•qAâ“c‘וFA‰ºìG–¾F‚—î‹}«S‹Ø[ÇŠ³ŽÒ‚É‚¨‚¯‚é—ˆ‰@ŽžS•s‘S‡•¹‚Ì•p“x‚Æ—\Œã‚ÌŒoŽž“I•ω»‚ÉŠÖ‚·‚錟“¢|‹{éAMI“o˜^Œ¤‹†|i—DGÜŽóÜj
  36. ‰H”ö´‹MA‚‹´@Aâ“c‘וFA‹{“c@•qA”’ŒË@’AŒã‰ªL‘¾˜YA‰ºìG–¾FS•s‘SгŽÒ‚É‚¨‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚ÌŽc‘¶‹·ó‚ª—\Œã‚É—^‚¦‚é‰e‹¿‚Æ¶Žº‹ìo—¦‚Ƃ̊֘A
  37. ƒYIA R¸u‰‰ Šî‘b„

  38. »‘ºTˆê˜YA²“¡Œö—YA´…@‹œA—é–ØN‘¾A’r“c®•½A‘呺~ˆêA‹e’n‡—TA•àV@—ºA–ì–Ø³“¹A‰ºìG–¾Fƒ}ƒEƒX‚̈³•‰‰×S•s‘Sƒ‚ƒfƒ‹‚É‚¨‚¯‚éROCK1‚ÆROCK2‚Ì–ðŠ„‚Ìˆá‚¢
  39. ƒˆê”ÊŒû‰‰„

  40. ™‘ºGˆê˜YAŽR–{¹DA–ؗ³’jAŒš•”r‰îA–î”ö”ÂM—TA²“¡@—yA_’ÃŽ–çA®–ì—ºA²“¡Œö—YA‰ºìG–¾FƒAƒ“ƒ_[ƒ\ƒ“Eƒtƒ@ƒuƒŠ[•a‚Ìf’f‚É‚¨‚¯‚錌Ÿ÷’†ƒOƒƒ{ƒgƒŠƒAƒIƒVƒ‹ƒXƒtƒBƒ“ƒSƒVƒ“‘ª’è‚Ì—L—p«
  41. ’†–ì@½A’·’J•”—Y”òA–Ø‘º‹`—²A[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘¾A”‘ò@‘EA‰ºìG–¾FƒGƒ“ƒpƒOƒŠƒtƒƒWƒ““Š—^‚ªS•s‘S‰ü‘P‚É‘tŒ÷‚µ‚½“œ”A•a‡•¹‹•ŒŒ«S‹ØÇ‚̈ê—á
  42. ®–ì@—ºAŒš•”r‰îA™‘ºGˆê˜YA²“¡Œö—YA–ؗ³’jAŽR–{¹DAˆÀ’B@—A–Ø‘º³lAâV–؉ÀŽF¬læ“V«S޾ггŽÒ‚É‚¨‚¯‚éHCV—z«‚ÌS‹@”\‚â—\Œã‚É—^‚¦‚é‰e‹¿
  43. Œã‰ªL‘¾˜YAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YA²“¡‰ë”VA”’ŒË@’A‚‹´A‹{“c@•qA‰ºìG–¾FŒoŒûƒuƒhƒE“œ•‰‰×ŽŽŒ±‚Æ”÷—ʃAƒ‹ƒuƒ~ƒ“”A‚É‚æ‚é–«S•s‘SгŽÒ‚ÌƒŠƒXƒN•]‰¿|SUPPORTŽŽŒ±ƒTƒu‰ðÍ|
  44. ’ÒŒOØŽqAâ“c‘וFAŒã‰ªL‘¾˜YAŽO‰Y³’¨Aˆ¢•”—Ú—žA‹yì‘ì–çA”’ŒË@’A‚‹´@A‹{“c@•qA‰ºìG–¾F¶Žº‹ìo—¦‚ª’†’ö“x‚ɕۂ½‚ꂽS•s‘S‚Ì—Õ°“I“Á’¥FCHART-2Œ¤‹†‚©‚ç‚Ì’mŒ©
  45. Š}Œ´M‘¾˜YAâ“c‘וFAŒã‰ªL‘¾˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA”’ŒË@’A‚‹´A‹{“c@•qA‰ºìG–¾F¶Žº‹ìo—¦‚̕ۂ½‚ꂽ–«S•s‘SгŽÒ‚É‚¨‚¯‚éŠÈ•Ö‚È—\Œã—\‘ªƒŠƒXƒNƒXƒRƒA |CHART-2Œ¤‹†‚©‚ç‚Ì•ñ|
  46. ’|“à‰ëŽjA¼–{‘׎¡Aì–{r•ãA“y‰®@‘A‚‹´@A‹{“c@•qA㌎³”ŽArˆäŒ[sAâV–؉ÀŽA‰ºìG–¾FTAVIp‘O‚Æ–«Šú‚É‚¨‚¯‚é‚—îŽÒƒtƒŒƒCƒ‹•]‰¿FTAVIpŒã‚¹‚ñ–ς̗\‘ª‚ƃtƒŒƒCƒ‹ƒKƒCƒh•af˜AŒg‚Ìd—v«
  47. ‘å’Î’mLA²“¡Œö—YA–î”ö”ÂM—TA‘呺~ˆêA‹e’n‡—TA•àV@—ºA»‘ºTˆê˜YA–ì–Ø³“¹A‹{“c@•qA‰ºìG–¾FƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éS•s‘SгŽÒ‚Ì’·Šú—\Œã—\‘ª
  48. ‹yì‘ì–çAâ“c‘וFAŒã‰ªL‘¾˜YAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YA²“¡‰ë”VA”’ŒË@’A‚‹´A‹{“c@•qA‰ºìG–¾FS•s‘SгŽÒ‚É‚¨‚¯‚邪‚ñŽ€–SƒŠƒXƒN‚Ì‘‰Á |CHART-2Œ¤‹†‚©‚ç‚Ì•ñ|
  49. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  50. Œš•”r‰îA™‘ºGˆê˜YA–ؗ³’jAŽR–{¹DAâV“¡¹—˜Aì–쌤ŒåA–Ø‘º³lAˆÀ’B@—A²“¡Œö—YA‰ºìG–¾FS޾㇕¹”DP‚ÌŒŸ“¢ |“Œ–k‘åŠw•a‰@‚ÌŒoŒ±|
  51. ƒƒ|ƒXƒ^[„

  52. ˆ¢•”—Ú—žAâ“c‘וFAŒã‰ªL‘¾˜YA‹yì‘ì–çAŠ}Œ´M‘¾˜YA²“¡‰ë”VAŽO‰Y³’¨A”’ŒË’A‹{“c@•qA‰ºìG–¾F–«S•s‘SгŽÒ‚ÌŒ’NŠÇ—ˆÓޝ‚Æ—\Œã‚É‚¨‚¯‚é«·‚ÉŠÖ‚·‚錤‹† |CHART-2Œ¤‹†‚©‚ç‚Ì•ñ|
  53. ²“¡@—yA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA´…@‹œA²“¡Œö—YA•ŸŒ´‹KŽqA‘å“c‰pŠöA‰ºìG–¾FS‘ŸMRI‚ªf’f‚É—L—p‚¾‚Á‚½SƒAƒ~ƒƒCƒh[ƒVƒX‚̈ê—á
  54. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YAŒã‰ªL‘¾˜YA”’ŒË@’A‚‹´A‹{“c@•qA‰ºìG–¾F‚—î–«S•s‘SгŽÒ‚Ì—\Œã‚¨‚æ‚Ñ—\Œã‹K’èˆöŽq‚ɂ‚¢‚Ä|CHART-2Œ¤‹†‚©‚ç‚Ì•ñ|
  55. Š}Œ´M‘¾˜YAâ“c‘וFAŒã‰ªL‘¾˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA”’ŒË@’A‚‹´A‹{“c@•qA‰ºìG–¾FHFpEFABorderline HFpEFAHFrEF‚É‚¨‚¯‚éBNP‚Ì—\Œã—\‘ª”\‚Ì”äŠr|CHART-2Œ¤‹†‚©‚ç‚Ì•ñ|
  56. –Ø‘º‹`—²A•Ÿ“c_“ñA’†–ì@½A’·’J•”—Y”òA[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘¾A‡‰®‰ë•FA‰ºìG–¾FŠ´õƒŠ[ƒh”²‹Ž‚É‚æ‚èS•s‘S‚©‚ç‚̉ü‘P‚ª‰Â”\‚ƂȂÁ‚½•s®–¬Œ´«‰EŽºS‹ØÇ‚̈ê—á
  57. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  58. ‰ºì@G–¾FR‹ÃŒÅ—Ö@‚É‚¨‚¯‚éÅV‚Ì’mŒ©
  59. ™‘º@Gˆê˜YFfabry•a ‘Šúf’f‚Ì‚½‚ß‚ÌŽŽ‚Ý
  60. ‘æ212‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi9ŒŽ9“úA2017”NA·‰ªŽsj
  61. ²“¡ŒöˆêA‰H”ö´‹MA™àV@A“y‰®@‘Ai“¡’q•FA’r“c®•½A‹e’n@—ƒA¼–{‘׎¡A‚‹´@A‰ºìG–¾F‰^“®•‰‰×‚Æ–òÜ•‰‰×‚Ì—¼ŽÒ‚ª—z«‚ðŽ¦‚µ‚½Š¥¹k«‹·SÇ‚Ì1—á.
  62. •y‰iŒc‘¾A²“¡@ê¡A™‘ºGˆê˜YAŒš•”r‰îA–ؗ³’jAŽR–{¹DA´…@‹œA_’ÃŽ–çA®–ì@—ºA‰ºìG–¾F––½Œ^”x“®–¬‹·ó‚Ì1—á.
  63. ‘æ23‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi7ŒŽ15“ú`16“úA2017”NAŠò•ŒŽsj
  64. ˆ¢•”—Ú—žAâ“c‘וFAŽO‰Y³’¨A¬–죄¶A’ÒŒOØŽqA‹yì‘ì–çAŠ}Œ´M‘¾˜YA²“¡‰ë”VA–ö@”£AŒã‰ªL‘¾˜YA”’ŒË@’A‚‹´@A‹{“c@•qA‰ºìG–¾F“ú–{‚Ì–«S•s‘SгŽÒ‚É‚¨‚¯‚é‰^“®Kе‚Æ—\Œã‚ÉŠÖ‚·‚錤‹† -CHART-2Œ¤‹†‚©‚ç‚Ì•ñ-
  65. ‘æ70‰ñ“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïŠwpW‰ïi2017”N6ŒŽ28“ú`29“úA‚‚­‚ÎŽsj

    ƒŒû‰‰”­•\„

  66. ‹e’n‡—TA²“¡Œö—YAMd. Elias-Al-Mamun, Mohammad Abdul Hai Siddique, ‘呺~ˆêA²“¡‘åŽ÷A–ì–Ø³“¹A»‘ºTˆê˜YA‹{“c@•qA‰ºìG–¾FV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“P‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\D
  67. ‘æ164‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2017”N6ŒŽ10“úA·‰ªŽsj

    ƒYIAÇ—á”­•\•”–å„i*—DGÜŽóÜj

  68. *™àVA‰H”ö´‹MA“y‰®‘Ai“¡’q•FA‹e’n—ƒA¼–{‘׎¡A‚‹´A™‘ºGˆê˜YAâ“c‘וFA‰ºìG–¾FŠ¥¹k«‹·SÇ‚ð‡•¹‚µ‚»‚̉Á—Âɂæ‚è‰^“®‘Ï—e”\‚ª’˜–¾‚ɉü‘P‚µ‚½”ì‘åŒ^S‹ØÇ‚Ì1—á
  69. ƒYIAŒ¤‹†”­•\•”–å„i*Å—DGÜŽóÜj

  70. *_’ÃŽ–çA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡—yA®–ì—ºA@Œã‰ªL‘¾˜YA²“¡Œö—YA‹{“c•qA‰ºìG–¾F”x“®–¬«”x‚ŒŒˆ³Ç‚Ì’·Šú—\Œã‚ɑ΂·‚é‰ES‹@”\‚Æ«·‚ÌŠÖ˜A
  71. ƒˆê”ʉ‰‘è„

  72. ’†–ì½A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘¾A”‘ò‘EA‰ºìG–¾FpŒãˆê‰ß«–[ŽºƒuƒƒbƒN‚ð’æ‚µ‚½’†Šu•›“`“±˜H‚ð—L‚·‚éWPWÇŒóŒQ‚̈ê—á
  73. ’·’J•”—Y”òAŽO–ØŒi‘¾A–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA’†–ì½A‰ºìG–¾F‘m–X•Ù—Ö3 Žž•ûŒü‚ÉS–[Å‘Šú‹»•±•”ˆÊ‚ð”F‚ß‚½fast/slow Œ^AVNRT ‚̈ê—á
  74. ’†–ì½A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘¾A”‘ò‘EA‰ºìG–¾FReverse common AFL ‚É—ÞŽ—‚µ‚½propagation ‚ð’æ‚µ‚½LLRA‹NŒ¹AT ‚̈ê—á
  75. ŽR–{¹DA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îA²“¡—yA_’ÃŽ–çA®–ì—ºAŒã‰ªL‘¾˜YA@²“¡Œö—YA‰ºìG–¾F“¯ˆê‰ÆŒn“àFabry •aгŽÒ‚É‚¨‚¯‚é—Õ°‘œ
  76. ²“¡—yA™‘ºGˆê˜YAŒš•”r‰îA–ؗ³’jAŽR–{¹DA–î”ö”ÂM—TA_’ÃŽ–çA®–ì—ºA@²“¡Œö—YA•ŸŒ´‹KŽqA‰ºì@G–¾FSƒAƒ~ƒƒCƒh[ƒVƒX‚ÌŠÓ•Ê‚ÉS‘ŸMRI T1 ƒ}ƒbƒsƒ“ƒO‚ª—L—p‚Å‚ ‚Á‚½‘½”­«œ‘Žî‚̈ê—á
  77. “y‰®‘A¼–{‘׎¡A‹e’n—ƒA™àVA‰H”ö´‹MA‚‹´Aì–{r•ãAŒF’J‹Iˆê˜YAâV–؉ÀŽA‰ºìG–¾FValsalva “´Œa‚©‚猟“¢‚µ‚½ŒoƒJƒe[ƒeƒ‹“I‘å“®–¬•Ù’uŠ·piTAVIj device ‚Ì‘I‘ð@- “–‰@‚É‚¨‚¯‚éŒoŒ±-
  78. ™àVA¼–{‘׎¡A“y‰®‘A{“c•jAi“¡’q•FA‰H”ö´‹MA‹e’n—ƒA‚‹´Aâ“c‘וFA‰ºìG–¾F‰^“®—U”­«Š¥¹k‚É”º‚¤–³ÇŒó«S‹Ø‹•ŒŒ‚Ì1 —á
  79. ‹e’n—ƒA“y‰®‘A™àVA{“c•jAi“¡’q•FA‰H”ö´‹MA”’ŒË’A¼–{‘׎¡A‚‹´A‰ºìG–¾FŠ¥¹k•”ˆÊ‚̊펿“I‹·ó‚Ìis‚ðOFDI ‚ÅŠÏŽ@‚Å‚«‚½1 —á
  80. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡—yA_’ÃŽ–çA®–ì—ºAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚Ì’·Šú—\Œã
  81. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡—yA_’ÃŽ–çA®–ì—ºAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾FƒgƒŒƒvƒƒXƒeƒBƒjƒ‹‚ð”牺“Š—^‚Å“±“ü‚µ‚½”x“®–¬«”x‚ŒŒˆ³Ç‚Ì5 Ç—á
  82. ®–ì—ºAŒš•”r‰îA™‘ºGˆê˜YA–ؗ³’jAŽR–{¹DA–î”ö”ÂM—TA²“¡Œö—YAˆÀ’B—A¬ŽRk‘¾˜YAâV–؉ÀŽA‰ºìG–¾FBridge to candidacy ‚Æ‚µ‚đ̊OŽ®VAD ‚Æ”xŒŒŠÇŠg’£–ò—Ö@‚ðs‚Á‚½C³‘匌ŠÇ“]ˆÊÇ‚Ì1 —á
  83. HŽR³”NA‰Í’ÑA‹g‰ªˆê˜NAˆÀ’B—AŒF’J‹Iˆê˜YA‚‹´A™‘ºGˆê˜YA–ؗ³’jAì–{r•ãA‰ºìG–¾AâV–؉ÀŽF“–‰@‚É‚¨‚¯‚éAž‚ÝŒ^¶S•â•lHS‘Ÿ50 —á‚̬Ñ
  84. ˆ¢•”—Ú—žAâ“c‘וFA‹{“c•qAŽO‰Y³’¨AŠ}Œ´M‘¾˜YA‹yì‘ì–çA²“¡‰ë”VA–ö”£AŒã‰ªL‘¾˜YA”’ŒË’A‚‹´A‰ºìG–¾F–«S•s‘SгŽÒ‚É‚¨‚¯‚錒NŠÇ—ˆÓޝ‚Æ«·‚ÉŠÖ‚·‚錤‹†-CHART-2 Œ¤‹†‚©‚ç‚Ì•ñ-
  85. ²“¡‰ë”VAâ“c‘וFA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YA–ö”£AŒã‰ªL‘¾˜YA”’ŒË’A‚‹´A‹{“c•qA‰ºìG–¾F‚—îŽÒS•s‘S‚Ì—Õ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚ɂ‚¢‚Ă̌Ÿ“¢-CHART-2 Œ¤‹†‚©‚ç‚Ì•ñ-
  86. Š}Œ´M‘¾˜YAâ“c‘וFAŒã‰ªL‘¾˜YAˆ¢•”—Ú—žA‹yì‘ì–çA²“¡‰ë”VA–ö”£A”’ŒË’A‚‹´A‹{“c•qA‰ºìG–¾FHFpEFAHFmrEFAHFrEF ‚É‚¨‚¯‚éBNP ‚Ì—\Œã—\‘ª”\-CHART-2 Œ¤‹†‚©‚ç‚Ì•ñ-
  87. ‘æ2‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïi2017”N6ŒŽ2`3“úAŽD–yŽsj

    ƒ”ªŠªÜŽóÜu‰‰„

  88. ²“¡Œö—YF’vŽ€«Ž¾Š³”x‚ŒŒˆ³Ç‚Ì‘S‚­V‚µ‚¢•aˆö’`”’‚É’…–Ú‚µ‚½Ž¡—ÖòŠJ”­
  89. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  90. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA»‘ºTˆê˜YA–ì–Ø³“¹AMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA‰ºìG–¾F“œ”A•aŽ¡—Öòƒƒgƒzƒ‹ƒ~ƒ“‚É‚æ‚é”x‚ŒŒˆ³ÇŽ¡—Â̊ù‘¶–òÄŠJ”­
  91. ™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA_’ÃŽ–çA²“¡@—yA®–ì@—ºA²“¡Œö—YA‰ºìG–¾FCTEPH ‚É‚¨‚¯‚é“à•žŽ¡—Ã
  92. ™‘ºGˆê˜YAŒš•”r‰îA–ؗ³’jAŽR–{¹DA–î”ö”ÂM—TA_’ÃŽ–çAé“c—SŽqAΈä’q“¿A‰ºìG–¾FäPŒ´•aŠÖ˜A”x‚ŒŒˆ³Ç‚É‚¨‚¯‚é”xŒŒŠÇŠg’£–òŽg—p‚ÌŽÀÛ
  93. Œš•”r‰îAâ“c‘וFA™‘ºGˆê˜YA®–ì@—ºAˆÀ’B@—A–Ø‘º³lA—§–ì@Ž A’†“‡O“¹A¬ŽRk‘¾˜YAâV–؉ÀŽA‰ºìG–¾F¬læ“V«S޾ггŽÒ‚Ì”x‚ŒŒˆ³Ç ] ‘½Ž{Ý“o˜^Œ¤‹†‚©‚ç]
  94. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA»‘ºTˆê˜YA–ì–Ø³“¹AMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA‰ºìG–¾FŒŒ´’†ƒTƒCƒgƒJƒCƒ“‚É‚æ‚錌ŠÇ“à”çAMPK —}§‚Æ”x‚ŒŒˆ³‘£i‹@\
  95. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“„

  96. Œš•”r‰îA™‘ºGˆê˜YA_’ÃŽ–çA–ؗ³’jA‰ºìG–¾F”x‚ŒŒˆ³ÇгŽÒ‚ÉŠÖ‚·‚é‘OŒü‚«‘å‹K–ÍŽÀ‘Ô’²¸
  97. ƒ‰ï’·“Á•ÊŠé‰æ„

  98. Satoh K, Shimokawa H. Identification of Novel Therapeutic Targets for Pulmonary Arterial Hypertension.
  99. ƒYIA ƒZƒbƒVƒ‡ƒ“iŠî‘bE—DG‰‰‘èj„

  100. ²“¡‘åŽ÷A²“¡Œö—YA–î”ö”ÂM—TAAl-Mamun Md EliasASiddique Mohammad Abdul HaiA‹e’n‡—TA‘呺~ˆêA•àV@—ºA‹{“c@•qA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚¨‚¯‚éV‹K•aˆö’`”’TAFI ‚Ì‹@”\‰ðÍiYIA—DGÜŽóÜj
  101. •àV@—ºA²“¡Œö—YA‹e’n‡—TA‘呺~ˆêA²“¡‘åŽ÷AAbdul Hai Siddique MohammadAElias Al-Mamun Md.A»‘ºTˆê˜YA–ì–Ø³“¹A‰ºìG–¾F–ò•¨ƒXƒNƒŠ[ƒjƒ“ƒO‚É‚æ‚éV‹K”x‚ŒŒˆ³Ž¡—ÖòCelastamycin‚Ì”­Œ©iYIA—DGÜŽóÜj
  102. ‹e’n‡—TA²“¡Œö—YA•àV@—ºAElias-Al-Mamun Md.AAbdul Hai Siddique MohammadA‘呺~ˆêA²“¡‘åŽ÷A–ì–Ø³“¹A‹{“c@•qA‰ºìG–¾FV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“P ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\iYIAÅ—DGÜŽóÜj
  103. ƒˆê”ʉ‰‘è„

  104. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA»‘ºTˆê˜YA–ì–Ø³“¹AMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA‰ºìG–¾F”x“®–¬«”x‚ŒŒˆ³Ç‚É‚¨‚¯‚éV‹K•aˆö’`”’ADAMTS8 ‚Ì‹@”\‰ðÍ
  105. Mohammad Abdul Hai SiddiqueA²“¡Œö—YA•àV@—ºAMd. Elias Al-MamunA‹e’n‡—TA‘呺~ˆêA²“¡‘åŽ÷A–ì–Ø³“¹A»‘ºTˆê˜YA‘å’Î’mLA‰ºìG–¾FDiscovery of Emetine as a Novel Therapeutic Agent for PAH
  106. –î”ö”ÂM—TA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA²“¡Œö—YA‰ºìG–¾F’SŠàгŽÒ‚É‚¨‚¯‚é”xÇðǂ̋ÌÅü—nŒn‚Ì“Á’¥
  107. Md. Elias Al-MamunA²“¡Œö—YA²“¡‘åŽ÷A–î”ö”ÂM—TAMohammad Abdul Hai SiddiqueA‹e’n‡—TA‘呺~ˆêA•àV@—ºA»‘ºTˆê˜YA–ì–Ø³“¹A‰ºìG–¾FRivaroxaban prevents the development of CTEPH in mice
  108. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡@—yA_’ÃŽ–çA®–ì@—ºAŒã‰ªL‘¾˜NA²“¡Œö—YA‰ºìG–¾Fƒoƒ‹[ƒ“”x“®–¬Œ`¬pŒã‚ÌCTEPH ‚É‚¨‚¯‚é‰^“®•‰‰×‰ESƒJƒe[ƒeƒ‹
  109. Œš•”r‰îA™‘ºGˆê˜YA–ؗ³’jAŽR–{¹DA–î”ö”ÂM—TA²“¡@—yA_’ÃŽ–çA®–ì@—ºA²“¡Œö—YA‰ºìG–¾FInoperable CTEPH ‚ɑ΂·‚é BPA Ž¡—Â̒·Šú—\Œã
  110. Œš•”r‰îA™‘ºGˆê˜YA–ؗ³’jAŽR–{¹DA–î”ö”ÂM—TA®–ì@—ºA²“¡Œö—YAˆÀ’B@—A¬ŽRk‘¾˜YAâV–؉ÀŽA‰ºìG–¾F‘ÌŠOŽ®VAD ‚Æ”xŒŒŠÇŠg’£–ò—Ö@‚ðs‚Á‚½C³‘匌ŠÇ“]ˆÊÇ‚Ì1 —á
  111. ®–ì@—ºAŒš•”r‰îA™‘ºGˆê˜YA–ؗ³’jAŽR–{¹DA–î”ö”ÂM—TA²“¡@—yA_’ÃŽ–çA”’ˆä„ŽuA²“¡Œö—YA‰ºìG–¾F“«Š¥¹k«‹·Sǂƒ˜–¾‚È”x‚ŒŒˆ³‚ð‡•¹‚µ‚½EGPA ‚Ì1 —á
  112. …àVˆ»”TA”~“à‚Ђ낦A¯Žq@Œ\A‚–ì^ˆËŽqA–¾’¿çŒbA–ؗ³’jAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA™‘ºGˆê˜YA‰ºìG–¾FƒgƒŒƒvƒƒXƒ`ƒjƒ‹Ž‘±”牺“Š—^гŽÒ‚Ìáu’ɂɑ΂·‚éŠÅŒìƒPƒA
  113. –î”ö”ÂM—TA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚錌ŠÇŠg’£–ò’†Ž~‚̉e‹¿
  114. HŒŽŽO“ÞA™‘ºGˆê˜YA–ؗ³’jAŠ`‰Ô—²ºA㌎³”ŽA‰ºìG–¾FCTEPH ‚ÆPAH ‚̊ӕʂɂ¨‚¯‚éŒÄ‹CƒKƒX•ªÍ‚Ì—L—p«
  115. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡@—yA_’ÃŽ–çA®–ì@—ºA²“¡Œö—YA‰ºìG–¾FƒgƒŒƒvƒƒXƒeƒBƒjƒ‹‚ð”牺“Š—^‚Å“±“ü‚µ‚½5 Ç—á
  116. ²“¡@—yA™‘ºGˆê˜YAŒš•”r‰îA–ؗ³’jAŽR–{¹DA–î”ö”ÂM—TA_’ÃŽ–çA®–ì@—ºA²“¡Œö—YA‘å“c‰pŠöA‰ºìG–¾F‰EŽºŒ`‘ԕω»‚ð’·ŠúŠÏŽ@‚Å‚«‚½“Á”­«”x“®–¬«”x‚ŒŒˆ³Ç‚Ì2 Ç—á
  117. _’ÃŽ–çA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡@—yAŒã‰ªL‘¾˜NA²“¡Œö—YA‹{“c@•qA‰ºìG–¾F”x“®–¬«”x‚ŒŒˆ³Ç‚Ì’·Šú—\Œã‚ɑ΂·‚é‰ES‹@”\‚Æ«·‚ÌŠÖ˜A
  118. ‘æ17‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2017”N5ŒŽ19“ú`20“úA“¿“‡Žsj
  119. ˆä‹‚—z—SAŠ’JãÄŽqAˆÉ“¡H‘ãA“c’†C•½AÖ“¡‘åŽ÷A_ŒË–ΗYA”’ŒË@’A‰ºìG–¾FŠ¥zŠÂ‚ÌPí«ˆÛŽ‚É‚¨‚¯‚éPKG1a‚ÌŽ_‰»“IŠˆ«‰»‚̈Ӌ`‚ÌŒŸ“¢D
  120. “›ˆä³lAâ—œ‚Ü‚äŽqA•½—Ç—YŽiA“à“c‘¾˜YA¼èr”ŽA–ìŒûŽ•FA’‡@ª~ŽqA‰ºìG–¾F2/3t“ENO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚̓ˑRŽ€‚É‚¨‚¯‚é«·D
  121. “›ˆä³lA‹v•Û“c—zHA–ìŒûŽ•FAâ—œ‚Ü‚äŽqA¼èr”ŽA’‡@ª~ŽqA‰ºìG–¾A{‰ÁŒ´ˆê”ŽAŠ_‰Ô@ŠwF”][ǂɂ¨‚¯‚éNO‡¬y‘f‚Ì—LŠQ‚Èì—pF«·‚¨‚æ‚уeƒXƒgƒXƒeƒƒ“‚ÌŠÖ—^D
  122. ‘æ3‰ñ“ú–{S‹ØÇŒ¤‹†‰ïi2017”N4ŒŽ22“úAŠò•ŒŽsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€FS‹ØÇ‚̉摜f’f‚ƃoƒCƒIƒ}[ƒJ[„

  123. ™‘ºGˆê˜YAŽR–{¹DAŒš•”r‰îA–ؗ³’jA–î”ö”ÂM—TA_’ÃŽ–çA²“¡—yA®–ì—ºA‰ºìG–¾FS‹ØÇ‚̉摜f’f‚ƃoƒCƒIƒ}[ƒJ[SFabry•a‚É‚¨‚¯‚鑊úf’f‚Ì‚½‚߂̉摜f’f‚ƃoƒCƒIƒ}[ƒJ[.
  124. ƒƒ|ƒXƒ^[”­•\„

  125. Œã‰ªL‘¾˜YAâ“c‘וFA‹ž—ºˆêA”’ŒË’A’ÒŒOØŽqA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YA²“¡‰ë”VA‚‹´A‹{“c•qA‰ºìG–¾F‰ä‚ª‘‚É‚¨‚¯‚éŠg’£Œ^S‹ØÇ‚Ì—\Œã‚̉ü‘PFCHART-1/2Œ¤‹†‚æ‚è.
  126. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡—yA_’ÃŽ–çA®–ì—ºAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾Aꎓ¡—ÁŽqA‹g’·P–¾A–î賉pFƒgƒ‰ƒ“ƒXƒTƒCƒŒƒ`ƒ“Œ^ƒAƒ~ƒƒCƒh[ƒVƒX‚Ì2—á.
  127. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡—yA_’ÃŽ–çA®–ì—ºA‰ºìG–¾AHŽR³”NAì–{r•ãAâV–؉ÀŽFŒ€ÇŒ^S‹Ø‰Š‚ð‡•¹‚µ‚½–òÜ«‰ß•qÇÇŒóŒQ‚Ì1—á.
  128. ‘æ81‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi3ŒŽ17“ú`19“úA2017”NA‹à‘òŽsj

    ƒPlenary Session„

  129. (PL03-3:Late Complications after Repair in Adult Congenital Heart Disease)Tatebe S, Sugimura K, Aoki T, Yamamoto S, Yaoita N, Kouzu K, Sato H, Satoh K, Shimokawa H. Clinical Importance of Pulmonary Hypertension in Adults with Congenital Heart Disease after Cardiac Surgery.
  130. (PL08-5:“ú–{”­‚̃rƒbƒOƒf[ƒ^‚ð—p‚¢‚½—Õ°Œ¤‹†)Shiroto T, Sakata Y, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Nochioka K, Takahashi J, Miyata S, Shimokawa H. How can We Utilize Clinical Big Data in an Observational Study? \Lessons from the CHART-2 Study\
  131. ƒSymposium„

  132. (SY01-1:’´‚—ŽÐ‰ï‚É‚¨‚¯‚éS•s‘S‚ÌŠÇ—EŽ¡—Ã)Takahashi J, Cui Y, Hao K, Ito K, Shimokawa H. Temporal Trends in the Prevalence and Outcomes of Heart Failure in Geriatric Patients with Acute Myocardial Infarction.
  133. (SY02-1:Vascular Biology as Interactive Science of Cardiovascular Disease)Satoh K, Sunamura S, Nogi M, Kurosawa R, Kudo S, Omura J, Kikuchi N, Sato T, Otsuki T, Suzuki K, Miura M, Aoki T, Tatebe S, Sugimura K, Sakata Y, Shimokawa H. Novel Therapeutic Targets for Cardiovascular Diseases \Rho-kinase, Cyclophilin A and Its Receptor, Basigin\
  134. (SY10-3:Molecular Basis of Cardiovascular Dysfunction in Metabolic Diseases) Godo S, Enkhjargal B, Noda K, Saito H, Shimokawa H. Importance of Endothelial Dysfunction in the Pathogenesis of Cardiovascular Insufficiency in Metabolic Disorders.
  135. (SY12-3: Understanding the Mechanism of Pulmonary Hypertension)Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Sunamura S, Nogi M, Otsuki T, Tatebe S, Aoki T, Sugimura K, Shimokawa H. Thrombin-Activatable Fibrinolysis Inhibitor Plays a Crucial Role in The Development of Chronic Throm-boembolic Pulmonary Hypertension\A Possible Novel Therapeutic Target\
  136. (SY19-2: S‘ŸˆÚA¬ÑŒüã‚Ì‚½‚߂̎æ‚è‘g‚Ý)Aoki T, Sugimura K,Tatebe S, Yamamoto S, Yaoita N, Sato H, Kozu K, Satoh K, Akiyama M, Kawamoto S, Saiki Y, Shimokawa H. Pulmonary Hypertension in Potential Heart Transplant Recipients with Implantable Ventricular Assist Device.
  137. ƒSpecial Session„

  138. (SS12-5:‘å‹K–ÍЊQ‚ÆzŠÂŠí•aFŽñ“s’¼‰ºŒ^\“ìŠCƒgƒ‰ƒt‚Ö‚Ì”õ‚¦)Takahashi J, Shimokawa H. Impact of the Great East Japan Earthquake Disaster on Cardiovascular Diseases.
  139. ƒLate Breaking Cohort Studies„

  140. (LBCS1-2:Heart Failure: Multi-organ Interaction and Treatment)Tatebe S, Sakata Y, Sugimura K, Satoh K, Shiroto T, Konno R, Adachi O, Kimura M, Tateno S, Nakajima H, Oyama K, Saiki Y, Shimokawa H. Clinical Characteristics of Adult Congenital Heart Disease in a Prospective Multicenter Cohort Study \An Initial Report from the CHART-2 Study\
  141. (LBCS2-1:Bio- and Genetic Markers for Cardiovascular Events)Odaka Y, Takahashi J, Tsuburaya R, Nishimiya K, Hao K, Matsumoto Y, Ito K, Sakata Y, Miyata S, Manita D, Hirowatari Y, Shimokawa H. Plasma Levels of Serotonin as a Novel Biomarker for Co-presence of Coronary Microvascular Dysfunction in Patient with Vasospastic Angina.
  142. (LBCS4-1:Environmental Factors of Atrial Fibrillation and Treatment)Sakata Y, Yamauchi T, Nochioka K, Shiroto T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Takahashi J, Miyata S, Ninomiya T, Shimokawa H. Establishment of Predictive Models of New-onset Atrial Fibrillation Based on Clinical Background: Insights from the CHART-2 and the Hisayama Studies.
  143. (LBCS6-6:Advanced Vascular Interventions: Techniques and Outcomes)Aoki T, Sugimura K, Tatebe S, Yamamoto S, Yaoita N, Kozu K, Sato H, Konno R, Nochioka K, Satoh K, Shimokawa H. Long-term Beneficial Effects of Balloon Pulmonary Angioplasty on Hemodynamics and Prognosis in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.
  144. ƒLate Breaking Cohort Studies-poster„

  145. (LBCSP2-2:Systemic Thrombosis and Treatment)Shiroto T, Sakata Y, Nochioka K, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Takahashi J, Miyata S, Shimokawa H. Temporal Trend in Antithrombotic Therapies in Patients with Cardiovascular Diseases \Report from the CHART-2 Study\
  146. (LBCSP1-3:Risk Factor Analysis for Cardiovascular Events)Kozu K, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Sato H, Nochioka K, Satoh K, Miyata S, Shimokawa H. Long-term Prognosis of Patients with Pulmonary Hypertension for All Subtypes \A Single Center Experience\
  147. ƒJapan Heart Foundation Satoh Memorial Award Lecture„

  148. Satoh K. Development of Novel Therapies for Cardiovascular Diseases by Clinical Application of Basic Research.
  149. ƒCirculation Journal Award Session„

  150. (Clinical Investigation:Second Place)Suzuki H. Hippocampal Blood Flow Abnormality Associated with Depressive Symptoms and Cognitive Impairment in Patients with Chronic Heart Failure.
  151. ƒYoung Investigator's Award Finalists Lectures (Basic Research)„

  152. Kikuchi N, Satoh K, Omura J, Satoh T, Kurosawa R, Nogi M, Sunamura S, Otsuki T, Numano K, Yaoita N, Yamamoto S, Tatebe S, Aoki T, Sugimura K, Shimokawa H. Selenoprotein P Promotes Pulmonary Arterial Smooth Muscle Cell Proliferation and Pulmonary Arterial Hypertension. iÅ—DGÜŽóÜj
  153. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  154. Odaka Y, Takahashi J, Suda A, Komatsu M, Kikuchi Y, Hao K, Matsumoto Y, Sakata Y, Miyata S, Shimokawa H. Plasma Concentration of Serotonin is a Novel Biomarker for Coronary Microvascular Dysfunction in Patients with Suspected Angina and Unobstructive Coronary Arteries.
  155. ƒYoung Investigatorfs Award for International Students Finalists Lectures„

  156. Mohammad Abdul Hai Siddique, Satoh K, Kurosawa R, Md. Elias-Al Mamun, Kikuchi N, Omura J, Sato T, Nogi M, Sunamura S, Shimokawa H. Identification of Emetine as a Novel Therapeutic Agent for Pulmonary Hypertension in Rats\Highthroughput Screening of 5,562 Compounds\
  157. ƒLuncheon Seminar„

  158. (LS67-2:zŠÂŠí“à‰Èˆã‚Ì“úíf—ÂÉö‚Þˆâ“`«Ž¾Š³)Sugimura K.ƒtƒ@ƒuƒŠ[•a‚É‚¨‚¯‚鑊úf’fE‘ŠúŽ¡—ÂÌd—v«`“–‰@@zŠÂŠí“à‰È‚É‚¨‚¯‚éf’fEŽ¡—Â̎æ‚è‘g‚Ý.
  159. ƒOral Presentation (English)„

  160. (OE-063:Fontan/ACHD)Kimura Y, Fukuda K, Nakano M, Hasebe Y, Chiba T, Miki K, Tatebe S, Kimura M, Adachi O, Saiki Y, Shimokawa H. Clinical Impact of Atrioventricular Conduction Disturbance on Lethal Ventricular Arrhythmias in Patients with Total Correction of Tetralogy of Fallot.
  161. (OE-079:Angina Pectoris (Clinical) 1)Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Komatsu M, Odaka Y, Matsumoto Y, Sakata Y, Shimokawa H. Rho-kinase Inhibition with Intracoronary Fasudil Restores Coronary Microvascular Dysfunction in Patients with Vasospastic Angina.
  162. (OE-141:Heart Failure (Laboratory/Biomarkers)1)Otsuki T, Satoh K, Omura J, Kikuchi N, Sato T, Kurosawa R, Sunamura S, Nogi M, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Miyata S, Shimokawa H. Plasma Levels of Cyclophilin A are Associated with Increased Mortality in Patients with Heart Failure.
  163. (OE-205:Heart Failure (Basic))Sunamura S, Satoh K, Suzuki K, Kudo S, Ikeda S, Omura J, Kikuchi N, Sato T, Kurosawa R, Nogi M, Numano K, Shimizu T, Shimokawa H. Crucial Role of ROCK1 to Maintain Cardiac Contractile Function in Response to Chronic Pressure-Overload in Mice.
  164. (OE-248:Heart Failure (Laboratory/Biomarkers) 2)Nochioka K, Sakata Y, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Miura M, Shirato T, Miyata S, Takahashi J, Shimokawa H. Incidence and Determinant Factors of Hospitalization for Worsening Heart Failure in Patients Treated with Diuretics in the CHART-2 Study.
  165. (OE-259:Pulmonary Circulation)Omura J, Satoh K, Kikuchi N, Satoh T, Kurosawa R, Nogi M, Sunamura S, Ohtsuki T, Kozu K, Suzuki K, Yaoita N, Aoki T, Tatebe S, Sugimura K, Shimokawa H. A Disintegrin and Metalloproteinase with Throm- bospondin Motifs 8 (ADAMTS8) Promotes Hypoxia-induced Pulmonary Hypertension in Mice.
  166. (OE-330:Arrhythmia, Others (Clinical/Diagnosis/Treatment)1)Nakano M, Fukuda K, Hasebe Y, Hirano M, Kimura Y, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Feasibility of Subcutaneous Implantable Cardioverter Defibrillator on the Detection Mechanisms.
  167. (OE-295:Vascular Biology)Nogi M, Satoh K, Kudo S, Omura J, Kikuchi N, Sato T, Sunamura S, Kurosawa R, Otsuki T, Suzuki K, Shimokawa H. Protective Roles of Small GTP-binding Protein GDP Dissociation Stimulator (SmgGDS) against Angiotensin II-induced Thoracic Aortic Dissection and Rupture in Mice.
  168. (OE-366:ACS/AMI (Basic))Shindo T, Ito K, Ogata T, Hatanaka K, Kurosawa R, Eguchi K, Kagaya Y, Monma Y, Shiroto T, Miyata S, Taki H, Kanai H, Shimokawa H. Molecular Mechanisms for Low-intensity Pulsed Ultrasound-induced Angiogenesis: Contribution of Mechano-transduction.
  169. ƒOral Presentation (Japanese) „

  170. (OJ-014:Heart Failure (Laboratory/Biomarkers))Kasahara S, Sakata Y, Nochioka K,Tsuji K, Onose T, Abe R, Oikawa T, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Prognostic Risk Stratification with B-type Natriuretic Peptide for HFpEF, Borderline HFpEF and HFrEF Patients \A Report from the CHART-2 Study\
  171. (OJ-053:Cardiomyopathy/Hypertrophy (Clinical))Yamamoto S, Sugimura K, Suzuki H, Tatebe S, Aoki T, Yaoita N, Sato H, Kozu K, Ota H, Takanami K, Takase K, Satoh K, Shimokawa H. Novel Diagnostic Strategy for Cardiac Involvement in Patients with Anderson-Fabry Disease.
  172. (OJ-079:Heart Failure (Pharmacology))Oikawa T, Sakata Y, Nochioka K, Tsuji K, Onose T, Abe R, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Intensity of Statin Therapy and Prognosis in Patients with Ischemic Heart Failure\A Report from the CHART-2 Study\
  173. (OJ-091:Angina Pectoris (Clinical))Odaka Y, Takahashi J, Hao K, Kikuchi Y, Suda A, Komatsu M, Matsumoto Y, Ito K, Miyata S, Sakata Y, Shimokawa H. Sustained Myocardial Ischemia in Patients with Microvascular Angina Even after Nitrate Administration.
  174. ƒFeatured Research Session„

  175. (FRS-099:Coronary Imaging)Ohyama K, Matsumoto Y, Amamizu H, Uzuka H, Nishimiya K, Morosawa S, Hirano M, Watabe H, Funaki Y, Takahashi J, Ito K, Shimokawa H. Inflammatory Changes of Perivascular Adipose Tissue in the Pathogenesis of DES-induced Hyperconstricting Responses in Pigs \Usefulness of 18F-FDG PET Imaging\
  176. (FRS-106:Pulmonary Circulation)Kurosawa R, Satoh K, Kikuchi N, Omura J, Sato T, Nogi M, Sunamura S, Suzuki K, Hai Siddique Mohammad Abdul, Shimokawa H. Celastramycin Inhibits Pulmonary Arterial Smooth Muscle Cell Proliferation and Ameliorates Hypoxia-induced Pulmonary Hypertension.

    ƒExcellent Case Presentation by Young Careers in English„

  177. (ECP2-1)Sugisawa J, Matsumoto Y, Tsuchiya S, Suda A, Shindo T, Kikuchi Y, Hao K, Takahashi J, Shimokawa H. Silent Myocardial Ischemia Associated with Exercise-Induced Coronary Artery Spasm.
  178. ƒPoster Session (English)„

  179. (PE-264:Heart Failure (Non-pharmacology) 1)Hao K, Takahashi J, Sakata Y, Miyata S, Shiroto T, Nochioka K, Yamauchi T, Tsuji K, Onose T, Oikawa T, Abe R, Sato M, Kasahara S, Shimokawa H. Prognostic Impact of Residual Coronary Artery Stenosis in Patients with Ischemic Heart Failure after Percutaneous Coronary Intervention.
  180. (PE-395:Arrhythmia, Others (Basic))Hirano M, Yamamoto H, Hasebe Y, Fukuda K, Morosawa S, Amamizu H, Oyama K, Uzuka H, Takayama K, Shimokawa H. Development of a Novel Shock Wave Catheter Ablation System\A Validation Study in Pigs in Vivo\
  181. (PE-442:Heart Failure (Basic) 2)Ogata T, Ito K, Shindo T, Hatanaka K, Kurosawa R, Eguchi K, Kagaya Y, Monma Y, Shimokawa H. Low-intensity Pulsed Ultrasound Enhances Angiogenesis and Ameliorates Contractile Cardiac Func-tion of Pressure-Overloaded Hearts in Mice.
  182. (PE-458:Heart Failure (Laboratory/Biomarkers) 2)Sato M, Sakata Y, Nochioka K, Sato K, Onose T, Tsuji K, Oikawa T, Abe R, Kasahara S, Yamauchi T, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics and Prognostic Factors of Elderly Patients with Heart Failure: A Report from the CHART-2 Study.
  183. (PE-685:Coronary Circulation/Chronic Coronary Disease (Basic/Clinical) 2)Uzuka H, Matsumoto Y, Nishimiya K, Ohyama K, Amamizu H, Morosawa S, Hirano M, Shindo T, Kikuchi Y, Hao K, Shiroto T, Ito K, Takahashi J, Fukuda K, Funaki Y, Shimokawa H. Catheter-based Renal Denervation Suppresses Coronary Hyperconstricting Responses after Drug-Eluting Stent Implantation in Pigs in Vivo \Evidence for the Kidney-Brain-Heart Axis\
  184. (PE-393:Arrhythmia, Others (Basic))Morosawa S, Yamamoto H, Hirano M, Uzuka H, Oyama K, Hasebe Y, Nakano M, Fukuda K, Shimokawa H. Impact of a New Shock Wave Catheter Ablation System on the Depth of Myocardial Lesions in Pigs in Vivo.
  185. (PE-786:Pulmonary Circulation 2)Aoki T, Sugimura K, Tatebe S, Yamamoto S, Yaoita N, Sato H, Kouzu K, Nochioka K, Satoh K, Shimokawa H. Effectiveness and Safety of Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.
  186. ƒPoster Session (Japanese)„

  187. (PJ-219:Heart Failure, Atrial Fibrillation, and Obesity)Abe R, Sakata Y, Nochioka K, Onose T, Tsuji K, Oikawa T, Kasahara S, Sato M, Miura M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Association between Health Consciousness and Mortality in Patients with Heart Failure \A Report from the CHART-2 Study\
  188. (PJ-278:Heart Failure (Non-pharmacology))Tsuji K, Sakata Y, Nochioka K, Miura M, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics of Heart Failure Patients with Mid-range Ejection Fraction \A Report from the CHART-2 Study\
  189. (PJ-284:Pulmonary Circulation)Sato H, Ota H, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Kozu K, Satoh K, Shimokawa H. Balloon Pulmonary Angioplasty Improves Biventricular Functions in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension.
  190. (PJ-285:Pulmonary Circulation)Tanaka S, Sato S, Kajitani S, Ikumi Y, Ito A, Saito H, Godo S, Shiroto T, Shimokawa H. Roles of Endothelium-Dependent Hyperpolarization in Pulmonary Microcirculation in Mice \Implications for Pulmonary Hypertension\
  191. (PJ-242: Ventricular Arrhythmia (Clinical/Diagnosis/Treatment)2)Hasebe Y, Fukuda K, Nakano M, Hirano M, Kimura Y, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Impact of Enlarged Left Ventricular Dimension on Ventricular Fibrillation Event in Patients with Ischemic Cardiomyopathy and Implantable Cardioverter Defibrillator.
  192. (PJ-290:ACS/AMI (Clinical/Treatment) 1)Cui Y, Hao K, Takahashi J, Miyata S, Shindo T, Kikuchi Y, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Temporal Trends in Emergency Care and Outcomes of Geriatric Patients with Acute Myocardial Infarction in Japan.
  193. (PJ-311:Gender Differences)Onose T, Sakata Y, Nochioka K, Tsuji K, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Miyata S, Takahashi J, Shimokawa H. Sex Differences in Post-traumatic Stress Disorder in Cardiovascular Patients after the Great East Japan Earthquake \The CHART-2 Study\
  194. (PJ-346:Arrhythmia, Others (Clinical/Diagnosis/Treatment)3)Miki K, Fukuda K, Nakano M, Hasebe Y, Hirano M, Kimura Y, Chiba T, Fukasawa K, Morosawa S, Shimokawa H. Impact of Types of Atrial Fibrillation on Characteristics of Silent Brain Infarcts in Patients with Non-valvular Atrial Fibrillation.
  195. (PJ-673:Cardiac Arrest/Resuscitation)Komatsu M, Takahashi J, Hao K, Kikuchi Y, Odaka Y, Suda A, Matsumoto Y, Sakata Y, Miyata S, Shimokawa H. Long-term Prognosis of Out-of-hospital Cardiac Arrest Survivors with Vasospastic Angina \An Update\
  196. (CP-236:ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Eg‘ÌŠˆ“®6)Takeuchi M, Matsumoto Y, Kawamoto S, Takahashi J, Aoki T, Sugimura K, Miyata S, Kozuki M, Arai H, Saiki Y, Shimokawa H. ŒoƒJƒe[ƒeƒ‹‘å“®–¬•Ù—¯’up‚ɑ΂·‚éŒp‘±“I‚ȃtƒŒƒCƒ‹ƒKƒCƒh‚ÌƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÍApŒã‰ñ•œƒŒƒxƒ‹‚ð—\‘ª‚µAÝ‘îŠú‚ÌQOL ‚ƃtƒŒƒCƒ‹‚ð‰ü‘P‚·‚é.
  197. ‘æ46‰ñ“ú–{S–¬ŠÇì“®•¨Ž¿Šw‰ïi2ŒŽ10“ú`11“úA2017”NA“ß”eŽsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€FS–¬ŠÇì“®•¨Ž¿‚Ì‹´“n‚µŒ¤‹†„

  198. ²“¡Œö—YA‰ºìG–¾F”x‚ŒŒˆ³Ç‚ÌV‹K•aˆö’`”’‚É’…–Ú‚µ‚½‘Šúf’f–@‚ÆV‹KŽ¡—ÖòŠJ”­‚̉”\«
  199. ƒYIAƒZƒbƒVƒ‡ƒ“„

  200. •àV —ºFV‹K”x‚ŒŒˆ³ÇŽ¡—ÖòƒZƒ‰ƒXƒgƒ‰ƒ}ƒCƒVƒ“‚Ì”­Œ©
  201. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  202. –ì–Ø³“¹A²“¡Œö—YAH“¡ rA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A»‘º Tˆê˜YA•àV —ºA‘å’Î’mLAÀ–ì˜a•FA—é–ØN‘¾A‰ºìG–¾FƒAƒ“ƒWƒIƒeƒ“ƒVƒ“2ŽhŒƒ‚ł̃}ƒEƒX‚Ì‹¹•”‘å“®–¬‰ð—£‚¨‚æ‚Ñ‹¹•”‘å“®–¬áŽƒ‚ƒfƒ‹‚É‚¨‚¯‚éSmall GTP-binding Protein GDP Dissociation Stimulator‚̕یì“I‚È–ðŠ„
  203. »‘º Tˆê˜YA²“¡Œö—YA—é–ØN‘¾AH“¡ rA‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A•àV —ºA–ì–Ø³“¹A‘å’Î’mLAÀ–ì˜a•FA‰ºìG–¾Fƒ}ƒEƒX‚̈³•‰‰×S•s‘Sƒ‚ƒfƒ‹‚É‚¨‚¯‚éROCK1‚É‚æ‚éS‹@”\ˆÛŽ‹@\
  204. ²“¡‘åŽ÷A²“¡Œö—YA–î”ö” M—TA‹e’n‡—TA‘呺~ˆêA•àV —ºAMd. Elias Al-MamunAMohammad Abdul Hai SiddiqueA™‘º Gˆê˜YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚¨‚¯‚éV‹K•aˆö’`”’TAFI‚Ì‹@”\‰ðÍ
  205. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV —ºAÀ–ì˜a•FA_’ÃŽ–çA–ؗ³’jAŒš•”r‰îA™‘º Gˆê˜YA‰ºìG–¾FADAMTS8‚Í”x‚ŒŒˆ³‚É‚¨‚¯‚é”xŒŒŠÇƒŠƒ‚ƒfƒŠƒ“ƒO‚ƉES•s‘S‚𑈫‚³‚¹‚é
  206. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  207. ‰ºì G–¾FŽ‰Ž¿ˆÙíÇŽ¡—ÂÌŋ߂Ìi•à
  208. ‘æ10‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2017”N1ŒŽ28`29“úA–¼ŒÃ‰®j

    ƒÅ—DG‰‰‘èÜ„

  209. {“c@•jA‚‹´@A‰H”ö´‹MAi“¡’q•FA¬¼^‹±A¬‘é—I“ñA¼–{‘׎¡Aâ“c‘וFA‰ºìG–¾FŠ¥¹k«‹·SÇŠ³ŽÒ‚É‚¨‚¯‚銥”÷¬ŒŒŠÇ‹@”\ˆÙí‚Ì«·‚ɂ‚¢‚Ă̌Ÿ“¢.
  210. ƒ—DG‰‰‘èŒó•â„

  211. ‹yì‘ì–çAâ“c‘וFAŒã‰ªL‘¾˜YA¬–죄¶A’Ò@ŒOØŽqAŠ}Œ´M‘¾˜YA²“¡‰ë”VA”’ŒË@’A‹{“c@•qA‰ºìG–¾FS‹Ø[ÇŠ³ŽÒ‚Ì—\Œã‚ɑ΂·‚éƒXƒ^ƒ`ƒ“Ž¡—Ẩe‹¿‚Ì’j—·.
  212. Š}Œ´M‘¾˜YAâ“c‘וFAŒã‰ªL‘¾˜YA¬–죄¶Aˆ¢•”—Ú—žA‹yì‘ì–çA”’ŒË@’A‹{“c@•qA‰ºìG–¾F¶Žº‹ìo—¦‚ª–«S•s‘SгŽÒ‚ÌBNP’l‚Æ—\Œã‚Æ‚Ì‘ŠŠÖ‚É‹y‚Ú‚·‰e‹¿‚Æ«·FCHART-2Œ¤‹†‚©‚ç‚Ì•ñ.
  213. _’ÃŽ–çA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA²“¡@ê¡AŒã‰ªL‘¾˜YA²“¡Œö—YA‹{“c@•qF’PˆêŽ{݂ɂ¨‚¯‚é”x‚ŒŒˆ³Ç‘S—Õ°•ª—Þ‚Ì’·Šú—\Œã‚ÌŒŸ“¢.
  214. ƒƒVƒ“ƒ|ƒWƒEƒ€FzŠÂŠí޾г‚É‚¨‚¯‚é«·‚Æ‚»‚̑Ήž„

  215. ‚‹´@A‰ºìG–¾FŠ¥zŠÂ‹@”\ˆÙí‚É‚¨‚¯‚é«·.
  216. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  217. ’Ò@ŒOØŽqAâ“c‘וFAŒã‰ªL‘¾˜YAŽO‰Y³’¨A¬–죄¶A‹yì‘ì–çAŠ}Œ´M‘¾˜YA”’ŒË@’A‹{“c@•qA‰ºìG–¾F–«S•s‘SгŽÒ‚Ì¶Žº‹ìo—¦‚ÌŒoŽž•ω»‚Æ«·@\CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  218. ›Á@Œ³‹gA‰H”ö´‹MA‚‹´@A‹{“c@•qAi“¡’q•FA‹e’n@—ƒA¼–{‘׎¡Aâ“c‘וFA‰ºìG–¾F‚—îS‹Ø[ÇŠ³ŽÒ‚ÌŠ³ŽÒ”wŒi‚Ɖ@“àŽ€–S—¦‚É‚¨‚¯‚é«·‚ɂ‚¢‚Ă̌Ÿ“¢.
  219. ŽO–ØŒi‘¾A•Ÿ“c_“ñA’†–ì@½A’·’J•”—Y”òA•½–쓹ŠîA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò@‘EA‰ºìG–¾FS–[ד®Š³ŽÒ‚Ì•aŠú‚É‚æ‚é¶SލŒŒ—¬‘¬“x’ቺ—\‘ªˆöŽq‚Ì«·‚ÉŠÖ‚·‚錟“¢.

Œ¤‹†‹ÆÑˆê——‚Ö@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2016”N(*µ‘Òu‰‰j
‘æ1‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ï“Œ–kŽx•”’n•û‰ïi2016”N12ŒŽ4“úAå‘äj

    ƒˆê”ʉ‰‘èiŒûqj„

  1. ˆÉ“¡CA‰ºìG–¾A㌎³”ŽFS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚̈ãŽt‘²‘OE‘²Œã‹³ˆç‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²¸Œ‹‰Ê
  2. ƒˆê”ʉ‰‘èiŒûqj„

  3. [àV‹±”V˜NA•Ÿ“c_“ñA’†–ì½A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FAŽO–ØŒi‘¾A‰ºìG–¾FS–[ד®‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‰^“®‘Ï—e”\‚É—^‚¦‚é—L—p«‚ɂ‚¢‚Ä
  4. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  5. ™àVAŠ`‰Ô—²ºA{“c•jAi“¡’q•FA‰H”ö´‹MA‹e’n—ƒA¼–{‘׎¡A‚‹´Aâ“c‘וFA‰ºìG–¾F•ÂÇ«“®–¬d‰»Ç‚ɑ΂·‚é‰^“®—Ö@ŒãA•às‹——£‚̉„’·‚É‚æ‚è‹·S’É‚ªŒ°Ý‰»‚µAŒŒsÄŒš‚ðŽ{s‚µ‚½‚P—á
  6. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  7. HŒŽŽO“ÞA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA’|“à‰ëŽjAŠ`‰Ô—²ºA‰ºìG–¾A㌎³”ŽF”x“®–¬‹·ó‚É‚æ‚é”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒJƒe[ƒeƒ‹Ž¡—ÂƕÀs‚µAˆÀ‘S‚ɉ^“®—Ö@‚ðŽ{s‚µ‚½1—á
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  9. ’|“à‰ëŽjA¼–{‘׎¡A‰ºìG–¾FzŠÂŠíf—Âɂ¨‚¢‚ătƒŒƒCƒ‹‚ð‚ǂ̂悤‚ÉŽ•ž‚·‚é‚©|S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ì–ðŠ„|
‘æ163‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2016”N12ŒŽ3“úAå‘äj

    ƒYIAÇ—á”­•\•”–å„i*Å—DGÜŽóÜj

  1. *®–ì—ºAŒš•”r‰îA™‘ºGˆê˜YA–ؗ³’jAŽR–{¹DA–î”ö”ÂM—TA²“¡—yA_’ÃŽ–çA‰H”ö´‹MA‚‹´A’†–ì½A•Ÿ“c_“ñA‰ºìG–¾A”’ˆä„ŽuAΈä’q“¿A™‰Y‹v•qA’†“ˆ@‘s‘¾FSŽº×“®‚Å”­Ç‚µŠ¥¹k«‹·SǂƔx‚ŒŒˆ³Ç‚ð‡•¹‚µ‚½DŽ_‹…«‘½”­ŒŒŠÇ‰Š«“÷‰èŽîÇiEGPAj‚Ì‚P—á
  2. ƒYIAŒ¤‹†”­•\•”–å„i*Å—DGÜŽóÜj

  3. *’ÒŒOØŽqAâ“c‘וFAŒã‰ªL‘¾˜YAŽO‰Y³’¨A¬–죄¶Aˆ¢•”—Ú—žA‹yì‘ì–çAŠ}Œ´M‘¾˜YA²“¡‰ë”VA”’ŒË’A‚‹´A‹{“c•qA‰ºì@G–¾F–«S•s‘SгŽÒ‚É‚¨‚¢‚Ä¶Žº‹ìo—¦‚̕ω»‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿ |CHART-2 Œ¤‹†‚©‚ç‚Ì•ñ|
  4. ƒˆê”ʉ‰‘è„

  5. ²“¡ŒöˆêA˜Q‘ŬlA™]³A‘ëˆä’¨A‹ž—ºˆêA‰Á“¡“ÖA‰ºìG–¾FÁ‰»ŠÇoŒŒŠ³ŽÒ‚ªŽó‚¯‚Ä‚¢‚½RŒŒð—Ö@‚Æ‚»‚Ì——R
  6. ²“¡—yA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA_’ÃŽ–çA®–ì—ºA²“¡Œö—YA‰ºìG–¾F‘å“®–¬•Ù“ñë•Ù‚É‚æ‚é‘å“®–¬•ٕ½•s‘SÇ‚Æ¶Žºãk–§‰»áŠQ‚ª‡•¹‚µ‚½ˆê—á
  7. ‚–Ø—S‰îAH“¡rA”·Œ’ˆê˜YA£ì«lA‘ŠàVŒ’‘¾˜YAŽR–{‹`lA™³•¶A‰ºìG–¾FdǑ哮–¬•Ù‹·óǂɑ΂·‚é‹Ù‹}ƒoƒ‹[ƒ“Šg’£p‚Ì—Õ°¬Ñ
  8. “y‰®‘A¼–{‘׎¡A‚‹´A™‘ºGˆê˜YA‹e’n—ƒA‰H”ö´‹MAi“¡’q•FA{“c•jA™àVA‰ºìG–¾AŒF’J‹Iˆê˜YAì–{r•ãAâV–؉ÀŽF’áS‹@”\‚𔺂Á‚½dǑ哮–¬•Ù‹·óÇ‚ÉlHS”xƒTƒ|[ƒg‰º‚Å TAVI ‚ðŽ{s‚µ‚½ 2 —á
  9. _’ÃŽ–çA–ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡—yAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾F—¯’u‚©‚ç 1 ”N‚ðŒo‚Ä IVC filter ‚ð”²‹Ž‚µ‚½ 1 —á
  10. ”·Œ’ˆê˜YA£ì«lAH“¡rA‚–Ø—S‰îA‘ŠàVŒ’‘¾˜YAŽR–{‹`lA™³•¶A‰ºìG–¾F”DP 37 T‚Å‚­‚à–Œ‰ºoŒŒ‚ð”­Ç‚µAS•s‘S‚ð‡•¹AS‹@”\’ቺ‚ª‘J‰„‚µ‚½ 1 —á
  11. {“c•jA‚‹´A‰H”ö´‹MA‹e’n—ƒAi“¡’q•FA™àVA¼–{‘׎¡AˆÉ“¡Œ’‘¾A‰ºìG–¾FŠ¥¹k‚É‚æ‚é”ñ•ÂÇ«Š¥“®–¬S‹Ø[Ç (MINOCA) ‚ª‹^‚í‚ꂽˆê—á
  12. ™àVA‰H”ö´‹MA{“c•jA›ÁŒ³‹gAi“¡’q•FA‹e’n—ƒA¼–{‘׎¡A‚‹´AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºì@G–¾F¶‰ñùŽ}‘¤Ž}‚ðÓ”C•a•ςƂ·‚é‹}«S‹Ø[ǂɓû“ª‹Ø’f—ô‚ð‡•¹‚µ‚½‚P—á
  13. Š’JãÄŽqA‹e’n—ƒA“y‰®‘A™àVA{“c•jA›ÁŒ³‹gAi“¡’q•FA‰H”ö´‹MA¼–{‘׎¡A‚‹´AˆÉ“¡Œ’‘¾A‰ºìG–¾Fbó‘B‹@”\˜´iŽž‚ÉŠ¥¹k‚É‚æ‚éSŽº×“®‚ð”­Ç‚µ‚½ˆê—á
  14. ç—t‹M•FA•Ÿ“c_“ñA’†–ì½A’·’J•”—Y”òA•½–쓹ŠîA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘¾A”‘ò‘EA‰ºìG–¾FƒfƒoƒCƒXŠ´õ‚𗈂µƒŒ[ƒU[ƒŠ[ƒh”²‹Ž‚¨‚æ‚є牺Až‚ÝŒ^œ×“®ŠíAž‚Ýp‚ðŽ{s‚µ‚½“Á”­«SŽº×“®Ç—á
  15. ’†–ì½A•Ÿ“c_“ñA’·’J•”—Y”òA•½–쓹ŠîA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘¾A”‘ò‘EA‰ºìG–¾F‰EŽº“û“ª‹Ø‹NŒ¹SŽº•p”‚ɑ΂·‚éƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚½•s®–¬Œ´«‰EŽºS‹ØÇÇ—á
  16. £ì«lAH“¡rA”·Œ’ˆê˜YA‚–Ø—S‰îA‘ŠàVŒ’‘¾˜YAŽR–{‹`lA™³•¶A‰ºìG–¾FSŒ¹«Çð‚ð 2 “x‹N‚±‚µ‚½S–[ד®‚̈ê—á
  17. ŽO–ØŒi‘¾A•Ÿ“c_“ñA’†–ì½A’·’J•”—Y”òA•½–쓹ŠîA–Ø‘º‹`—²Aç—t‹M•FA[àV‹±”V˜NA”‘ò‘EA‰ºìG–¾F‘Oޏ_‚ÌŒ´ˆö‚Æ‚µ‚ÄSŽº•p”‚ÆS–[•p”‚ÌŠÓ•Ê‚ªd—v‚Å‚ ‚Á‚½ƒtƒ@ƒ[Žl’¥ÇpŒã‚Ì‚P—á
  18. [àV‹±”V˜NA•Ÿ“c_“ñA’†–ì½A’·’J•”—Y”òA–Ø‘º‹`—²Aç—t‹M•FAŽO–ØŒi‘¾A‰ºìG–¾F”­ì«S–[ד®Š³ŽÒ‚̉^“®‘Ï—p”\‚ƃJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“‚É‚æ‚é“´’²—¥ˆÛŽ‚ÌŠÖ˜A
  19. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡—yA_’ÃŽ–çAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾AHŽR³”NAì–{r•ãAâV–؉ÀŽFA‚¦ž‚ÝŒ^•â•lHS‘Ÿ‘•’…гŽÒ‚É‚¨‚¯‚é”x‚ŒŒˆ³Ç‚ÉŠÖ‚·‚錟“¢
  20. ”—“c‚Ý‚­A–ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA_’ÃŽ–çA²“¡—yAŒã‰ªL‘¾˜YA²“¡Œö—YA‰ºìG–¾FÄ”­«Š´õ«S“à–Œ‰Š‚̈ê—á
  21. H“¡rAŽR–{‹`lA£ì«lA”·Œ’ˆê˜YA‚–Ø—S‰îA‘ŠàVŒ’‘¾˜YA™³•¶A‰ºìG–¾ FSFA ‚ÌŒŒð«•Âǂɂ¨‚¯‚錌ð—n‰ð—Ö@‚𕹗p‚µ‚½ 2-step EVT –@‚ÌŒŸ“¢
  22. H“¡rAŽR–{‹`lA£ì«lA”·Œ’ˆê˜YA‚–Ø—S‰îA‘ŠàVŒ’‘¾˜YA™³•¶A‰ºìG–¾FOPTIMO Sheathless ƒJƒe[ƒeƒ‹‚Ì•¹—p‚É‚Ä SFA ‚̃Xƒeƒ“ƒg“àŒŒð«•Âǂ̊®‘SŒŒsÄŒš‚ɬŒ÷‚µ‚½ˆê—á
  23. ²“¡‰ë”VAâ“c‘וFAŒã‰ªL‘¾˜YA²“¡Œª“ñ˜YA¬–죄¶A’ÒŒOØŽqA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YAŽR“à‹BA”’ŒË’A‚‹´A‰ºìG–¾A‹{“c•qF‚—îŽÒS•s‘S‚Ì—Õ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq‚ɂ‚¢‚Ă̌Ÿ“¢ |CHART-2 Œ¤‹†‚©‚ç‚Ì•ñ|
  24. _’ÃŽ–çA–ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡—yA²“¡Œö—YA‰ºìG–¾Fƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚ðˆÀ‘S‚ÉŽ{s‚Å‚«‚½ƒnƒCƒŠƒXƒN’†•Œ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̈ê—á
  25. ˆ¢•”—Ú—žAâ“c‘וFAŽO‰Y³’¨A¬–죄¶A’ÒŒOØŽqAŠ}Œ´M‘¾˜YA‹yì‘ì–çA²“¡‰ë”VAŒã‰ªL‘¾˜YA”’ŒË’A‚‹´A‰ºìG–¾A‹{“c•qF“ú–{‚Ì–«S•s‘SгŽÒ‚É‚¨‚¯‚錒NˆÓޝ‚ÆS•s‘S“ü‰@‚ÉŠÖ‚·‚錤‹† |CHART-2 Œ¤‹†‚©‚ç‚Ì•ñ|
  26. ¬–죄¶Aâ“c‘וFAŒã‰ªL‘¾˜YA”’ŒË’A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}Œ´M‘¾˜YA²“¡‰ë”VA‚‹´A‰ºìG–¾A‹{“c•qFS•s‘SгŽÒ‚É‚¨‚¯‚铌“ú–{‘åkÐŒã‚ÌS“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ì—\Œã‚ւ̉e‹¿ |CHART-2Œ¤‹†‚æ‚è|
  27. Œã‰ªL‘¾˜YAâ“c‘וFA¬–죄¶A’ÒŒOØŽqA‹yì‘ì–çAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YA²“¡‰ë”VA”’ŒË’A‚‹´A‰ºìG–¾A‹{“c•qF–«S•s‘S‚ÌS•s‘S“ü‰@D”­ŽžŠúEŠëŒ¯ˆöŽqFCHART-2 Œ¤‹†
‘æ13‰ñ“ú–{zŠÂŠíŠÅŒìŠw‰ïŠwpW‰ïi2016”N10ŒŽ22“úAå‘äj

    ƒ“Á•Êu‰‰„

  1. *‰ºìG–¾FzŠÂŠíŠÅŒì‚É‚¨‚¯‚éƒn[ƒgƒ`[ƒ€‚Ìd—v«
‘æ57‰ñ “ú–{–¬ŠÇŠw‰ï‘‰ïi2016”N10ŒŽ13`15“úA“Þ—Çj

    ƒˆê”ʉ‰‘è@Œûq„

  1. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽO‰Y³’¨AŽR–{¹DA–î”ö”ÂM—TA²“¡—yA_’ÃŽ–çA²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éBPA‚̇•¹Ç‚Æ—\Œã‚ÌŒŸ“¢
  2. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[„

  3. _’ÃŽ–çA–ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽO‰Y³’¨AŽR–{¹DA–î”ö”ÂM—TA—é–ØG–¾A²“¡—yA‰ºìG–¾Fƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚ªˆÀ‘S‚ÉŽ{s‚Å‚«‚½ƒnƒCƒŠƒXƒN’†•Œ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̈ê—á
‘æ20‰ñ“ú–{S•s‘SŠw‰ïi2016”N10ŒŽ7`9“úAŽD–yj

    ƒ“Á•ÊŠé‰æ2 “Á”­«S‹ØÇ’²¸Œ¤‹†”ÇEŠg’£‘Š”ì‘åŒ^S‹ØÇ“o˜^ŠÏŽ@Œ¤‹†”LJ“¯¬‰Ê•ñ `S‹ØÇŒ¤‹†‚ÌÅ‘Oü`i“Á”­«S‹ØÇ’²¸Œ¤‹†”Ç / Šg’£‘Š”ì‘åŒ^S‹ØÇ“o˜^ŠÏŽ@Œ¤‹†”Ç / ‘æ20‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïj„

  1. ‰ºìG–¾FTrends in Clinical Characteristics, Treatments and Prognosis in Patients with Dilated Cardiomyopathy in Japan -Epidemiologic Insights from the CHART Studies-
  2. ƒYIA R¸u‰‰ —Õ°2„

  3. ’ÒŒOØŽqAâ“c‘וFAŽO‰Y³’¨A‹{“c•qAŒã‰ªL‘¾˜YAŽR“à‹BA¬–죄A”’ŒË’A‚‹´A‰ºìG–¾F¶Žº‹ìo—¦‚ª•Û‚½‚ꂽS•s‘SгŽÒ‚Ì—Õ°Šw“I“Á’¥‚ɂ‚¢‚Ä@-CHART-2Œ¤‹†‚©‚ç‚Ì’mŒ©-
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€4 ‹•ŒŒ«S•s‘S‚ÌŽ¡—Ãí—ª„

  5. ‰H”ö´‹MA‚‹´A‹{“c•qAâ“c‘וFA‰ºìG–¾F‹•ŒŒ«S•s‘SгŽÒ‚É‚¨‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚ÌŽc‘¶‹·ó‚ª—\Œã‚É—^‚¦‚é‰e‹¿
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€6 •â•lHS‘Ÿ‚Ì–â‘è“_‚ðl‚¦‚é„

  7. –ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡Œö—YAHŽR³”NAì–{r•ãA֖؉ÀŽA‰ºìG–¾FSŽº•╃fƒoƒCƒXŽg—pгŽÒ‚É‚¨‚¯‚é”x‚ŒŒˆ³Ç‚ÌŒŸ“¢
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€14 S•s‘S‚̃oƒCƒIƒ}[ƒJ[„

  9. ²“¡Œö—YA—é–ØN‘¾A‘å’Î’mLA»‘ºTˆê˜YAH“¡rA’r“c®•½A´…‹œA‰ºìG–¾FS•s‘S‚ÌV‚µ‚¢ƒoƒCƒIƒ}[ƒJ[: Cyclophilin A‚ÆBasigin -Šî‘bŒ¤‹†‚Ì—Õ°‰ž—p-
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€16 S–[ד®‡•¹S•s‘SгŽÒ‚Ì–â‘è“_‚ÆŽ¡—Ãí—ª„

  11. ŽR“à‹BAâ“c‘וFA¬–죄¶A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}Œ´M‘¾˜YA²“¡‰ë”VA‹{“c•qA‰ºìG–¾F–«S•s‘S‚É‚¨‚¯‚éS–[ד®”­ÇŒã‚ÌŒo‰ßŽžŠÔ‚Æ—\Œã‚ւ̉e‹¿‚Ƃ̊֘A‚ÌŒŸ“¢FCHART-2Œ¤‹†‚©‚ç‚Ì’mŒ©
  12. ƒƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€5 “ú–{E‰¢BE•Ä‘S•s‘SŠw‰ï@‡“¯ƒVƒ“ƒ|ƒWƒEƒ€„

  13. â“c‘וFA‰ºìG–¾FHeart Failure Pandemic : Lessons from Japan's Experience
  14. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“3 V‚½‚ÈS•s‘SŽ¡—ÊJ”­Œ¤‹†iŠî‘bA—Õ°A‰uŠwŒ¤‹†‚Ì—§ê‚©‚çj„

  15. â“c‘וFA‰ºìG–¾FV‚½‚ÈS•s‘SŽ¡—ÊJ”­Œ¤‹†:‰uŠwŒ¤‹†‚Ì—§ê‚©‚ç -‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^Œ¤‹†‚©‚ç‚Ì’mŒ©-
  16. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[13 ƒtƒ@ƒuƒŠ[•af—Â̎ÀÛ`‚»‚ÌŽæ‚è‘g‚݂ɂ‚¢‚Ä`„

  17. ™‘ºGˆê˜YFƒtƒ@ƒuƒŠ[•a‚É‚¨‚¯‚鑊úŒŸ¸Ef’fEŽ¡—ÂÌd—v«@`ƒtƒ@ƒuƒŠ[•a‘Îô‚Ìd“_ƒ|ƒCƒ“ƒg`
  18. ƒˆê”ÊŒû‰‰6 ‹•ŒŒ«Ž¾Š³1„

  19. ‹yì‘ì–çAâ“c‘וFAŽR“à‹BA’ÒŒOØŽqA¬–죄¶AŠ}Œ´M‘¾˜YA”’ŒË’A‚‹´A‹{“c•qA‰ºìG–¾FƒXƒ^ƒ`ƒ“‚ª‹•ŒŒ«S•s‘SгŽÒ‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢@-CHART-2 Œ¤‹†‚É‚¨‚¯‚é–òÜ‹­“x•ʂ̌Ÿ“¢-
  20. ƒˆê”ÊŒû‰‰11 ‰æ‘œf’f„

  21. ŽR–{¹DA—é–ØG–¾A™‘ºGˆê˜YAŒš•”r‰îA–ؗ³’jAŽO‰Y³’¨A–î”ö”ÂM—TA‚˜QŒ’‘¾˜YA‚£Œ\A‰ºìG–¾FFabry•aгŽÒ‚É‚¨‚¯‚éS‹ØMIBGƒVƒ“ƒ`ƒOƒ‰ƒtƒB[‚Ì—L—p«
  22. ƒˆê”ÊŒû‰‰12 ƒoƒCƒIƒ}[ƒJ[3„

  23. ‘å’Î’mLA²“¡Œö—YA‘呺~ˆêA‹e’nM—TA²“¡‘åŽ÷A»‘ºTˆê˜YA™‘ºGˆê˜YAŒš•”r‰îA‹{“c•qA‰ºìG–¾FŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éS•s‘SгŽÒ‚Ì’·Šú—\Œã—\‘ª
  24. ƒˆê”ÊŒû‰‰13 •Ù–ŒÇ1„

  25. ’|“à‰ëŽjA¼–{‘׎¡Aì–{r•ãAŒF’J‹Iˆê˜YAŽO‰Y³’¨A™‘ºGˆê˜YA‚‹´A֖؉ÀŽA㌎³”ŽA‰ºìG–¾FSƒŠƒn‚͑哮–¬•Ù‹·óǂɑ΂·‚é‘Sg–ƒŒ‰ºTAVIŒã‚ɒቺ‚·‚ég‘Ì‹@”\‚ð‰ü‘P‚·‚éFƒtƒŒƒCƒ‹•]‰¿‚Ìd—v
  26. ƒˆê”ÊŒû‰‰26 CRT„

  27. ç—t‹M•FA•Ÿ“c_“ñA’†–ì½A’·’J•”—Y”òA•½–쓹ŠîA–Ø‘º‹`—²A[àV‹±”V˜NAŽO–ØŒi‘¾A”‘ò‘EA‰ºìG–¾F–{–M‚É‚¨‚¯‚éCRTƒy[ƒVƒ“ƒO•”ˆÊ‚É‚æ‚é—Õ°Œø‰Ê‚ÉŠÖ‚·‚錟“¢
  28. ƒƒ|ƒXƒ^[6 S‹Ø‰Ši1j-Ç—á•ñ„

  29. ®–ì—ºA–ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA_’ÃŽ–çAHŽR³”NA֖؉ÀŽA‰ºìG–¾FƒƒLƒVƒŒƒ`ƒ“‚É‚æ‚é–òÜ«‰ß•qÇÇŒóŒQiDIHSj‚ÉŒ€ÇŒ^S‹Ø‰Š‚𕹔­‚µ‚½ˆê—á
  30. ƒE ƒ|ƒXƒ^[9 Šî‘bŒ¤‹†4„

  31. »‘ºTˆê˜YA²“¡Œö—YA—é–ØN‘¾A’r“c®•½A‘呺~ˆêA‹e’n‡—TA²“¡‘åŽ÷A–ì–Ø³“¹A´…‹œA‰ºìG–¾Fƒ}ƒEƒX‚̈³•‰‰×S•s‘Sƒ‚ƒfƒ‹‚É‚¨‚¯‚éROCK1‚É‚æ‚éS‹@”\ˆÛŽ‹@\
  32. ƒE ƒ|ƒXƒ^[13 International3„

  33. Š}Œ´M‘¾˜YAâ“c‘וFAŽR“à‹BA¬–죄¶A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çA”’ŒË’A‹{“c•qA‰ºìG–¾FHFpEF‚ÆHFrEF‚É‚¨‚¯‚éBNP‚Ì“¯“™‚È—\Œã—\‘ªŒø‰Ê -CHART-2Œ¤‹†‚©‚ç‚Ì•ñ-
‘æ1‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïi2016”N10ŒŽ1`2“úA“Œ‹žj

    ƒYIA ƒZƒbƒVƒ‡ƒ“„

  1. ‘呺 ~ˆêA²“¡ Œö—YA‹e’n ‡—TA²“¡ ‘åŽ÷A•àV —ºAÂ–Ø —³’jAŒš•” r‰îA™‘º Gˆê˜YA¯ì NA‰ª“c Ž“TA‰ºì G–¾FAMPK ‚Ì”x‚ŒŒˆ³Ç”­Ç‚ɑ΂·‚é—}§‹@\‚̉ð–¾i—DGÜŽóÜj
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€3 ‹­”çǂɂæ‚é”x‚ŒŒˆ³Ç‚Ì–â‘è“_if’fAŽ¡—ÃA“W–]j„

  3. é“c —SŽqAÎˆä —IãÄA¯ —z‰îA“¡“c —mŽqA”’ˆä „ŽuA“¡ˆä ”ŽŽiA™‘º Gˆê˜YA‰ºì G–¾AÎˆä ’q“¿A’£‘Ö G˜YF‹­”çǂƃVƒF[ƒOƒŒƒ“ÇŒóŒQ‡•¹”x“®–¬«”x‚ŒŒˆ³Ç‚ÌŽ¡—Ã
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€6 PH ‚ɑ΂·‚éÅVŠî‘bŒ¤‹†‚̬‰Ê„

  5. ²“¡ Œö—YA‹e’n ‡—TA‘呺 ~ˆêA²“¡ ‘åŽ÷A•àV —ºAŒš•” r‰îA™‘º Gˆê˜YA¯ì NA‰ª“c Ž“TA‰ºì G–¾F”x“®–¬«”x‚ŒŒˆ³Ç‚ÌV‹K•aˆö’`”’”­Œ©‚ÆV‹KŽ¡—Öò’Tõ
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€7 ”x“®–¬Œ`¬‚Ì‚·‚ׂĄ

  7. ™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽR–{ ¹DA–î”ö” M—TA—é–Ø G–¾A_’Ã Ž–çA²“¡ —yA²“¡ Œö—YA‰ºì G–¾FOCT guided BPA
  8. ƒˆê”ʉ‰‘è2 Ç—á•ñ1„

  9. ‹e’n —ƒAŽR–{ ¹DA™‘º Gˆê˜YAÈÀ ‚肱A‘å–{ ‰pŽŸ˜YA“n•” Œ«A‚‹´ Ž–¾A¼ˆä в”VAŒã“¡ •q˜aA‰ºì G–¾F––½ŒŒŠ²×–EˆÚA‚É‚æ‚è”x‚ŒŒˆ³‚ª‰ü‘P‚µ‚½POEMS ÇŒóŒQ‚Ì‚P—á
  10. ƒˆê”ʉ‰‘è3 —Õ°Œ¤‹†1„

  11. Â–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŽR–{ ¹DA–î”ö” M—TA_’Ã Ž–çA²“¡ Œö—YAHŽR ³”NAì–{ r•ãAâV–Ø ‰ÀŽA‰ºì G–¾FA‚¦ž‚ÝŒ^•â•lHS‘Ÿ‘•’…гŽÒ‚É‚¨‚¯‚é”x‚ŒŒˆ³Ç‚ÉŠÖ‚·‚錟“¢
  12. ƒˆê”ʉ‰‘è5 ”x‚ŒŒˆ³E”xzŠÂ‚ÌŠî‘b„

  13. •àV —ºA²“¡ Œö—YA‹e’n ‡—TA‘呺 ~ˆêA²“¡ ‘åŽ÷AMohammad Abdul Hai SiddiqueA Md. Elias Al-MamunAŒš•” r‰îAÂ–Ø —³’jA™‘º Gˆê˜YA‰ºì G–¾F‰»‡•¨ƒXƒNƒŠ[ƒjƒ“ƒO‚É‚æ‚éV‹K”x‚ŒŒˆ³ÇŽ¡—Öò‚ÌŠJ”­
  14. ‹e’n ‡—TA²“¡ Œö—YA‘呺 ~ˆêA²“¡ ‘åŽ÷A•àV —ºA–ì–Ø ³“¹AŒš•” r‰îAÂ–Ø —³’jA™‘º Gˆê˜YA‰ºì G–¾FV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“P ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\
  15. ²“¡ ‘åŽ÷A²“¡ Œö—YA–î”ö” M—TA‹e’n ‡—TA‘呺 ~ˆêA•àV —ºAMd. Elias Al-MamunA Mohammad Abdul Hai SiddiqueA™‘º Gˆê˜YA‰ºì G–¾FV‹K•aˆö’`”’TAFI ‚É‚æ‚é–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì”­Ç‹@\
  16. ƒˆê”ʉ‰‘è6 ŠO‰ÈŽ¡—ÃiPEAA”xˆÚAjE‚»‚Ì‘¼„

  17. HŒŽ ŽO“ÞA™‘º Gˆê˜YAÂ–Ø —³’jAŠ`‰Ô —²ºAˆÉ“¡ CA㌎ ³”ŽA‰ºì G–¾FCTEPH ‚ɑ΂·‚éŒÄ‹CƒKƒX•ªÍ‚ð—p‚¢‚½”ñNP“I‚ÈdÇ“x•]‰¿–@
  18. —é–Ø G–¾A™‘º Gˆê˜YAŒš•” r‰îAÂ–Ø —³’jA‰ºì G–¾F–«ŒŒðÇð«”x‚ŒŒˆ³ÇiCTEPHj‚Æ“‡Ž¸’²Ç‚ÌŠÖ˜A
  19. ƒˆê”ʉ‰‘è9 ”x‚ŒŒˆ³Ç‚Æ–òÜ„

  20. ®–ì —ºAÂ–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŽR–{ ¹DA–î”ö” M—TA²“¡ —yA_’Ã Ž–çA²“¡ Œö—YA‰ºì G–¾F“–‰@‚É‚¨‚¯‚éƒgƒŒƒvƒƒXƒeƒBƒjƒ‹‚ÌŽg—pŒoŒ±
  21. ƒˆê”ʉ‰‘è10 Ç—á•ñ2„

  22. –î”ö” M—TA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’¨AŒš•” r‰îAŽR–{ ¹DA²“¡ Œö—YA‰ºì G–¾F‘O–Ñ׌ŒŠÇ«”x‚ŒŒˆ³Ç‚©‚çŒã–Ñ׌ŒŠÇ«”x‚ŒŒˆ³Ç‚ƂȂÁ‚½‚P—á
  23. ƒˆê”ʉ‰‘è11 –«”xŒŒðÇðÇ ”x‚ŒŒˆ³Ç„

  24. _’Ã Ž–çA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’¨AŽR–{ ¹DA–î”ö” M—TA—é–Ø G–¾A‹{“c •qA‰ºì G–¾FCTEPH ‚̃oƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ă̌ŒŸ÷Cyclophilin A ”Z“x‚Ì—L—p«
  25. Â–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŒã‰ª L‘¾˜NAŽR–{ ¹DA–î”ö” M—TA²“¡ —yA_’Ã Ž–çA²“¡ Œö—YA‰ºì G–¾F”ñŽèp“K‰ž‚ÌCTEPH Ç—á‚ɑ΂·‚éBPA ‚Ì’·Šú—\Œã‚ÆŽüpŠú‡•¹Ç
‘æ64‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2016”N9ŒŽ23`25“úA“Œ‹žj

    ƒ“Á•ÊŠé‰æ1 Žc‘¶ƒŠƒXƒNŒ¸­‚Ì‚½‚ß‚ÌV‚½‚ȃoƒCƒIƒ}[ƒJ[’T‚µ„

  1. ²“¡Œö—YFLDL-C‚Ɉˑ¶‚µ‚È‚¢‘S‚­V‚µ‚¢V‹K•aˆö’`”’‚ƃoƒCƒIƒ}[ƒJ[‚Ì—Õ°‰ž—p
  2. ƒ“Á•ÊŠé‰æ5 S‘Ÿ•a—Õ°Œ¤‹†‚ÌV‚µ‚¢•ûŒü«‚ðl‚¦‚é„

  3. â“cN•FF‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^iCHART-2jŒ¤‹†‚ÌŒ»ó‚Æ“W–]
  4. ƒ“Á•ÊŠé‰æ9 kЂÆSŒŒŠÇ޾гF‚»‚Ì‘Îô‚ÆŽÀ‘H„

  5. Â–Ø —³’jF“Œ“ú–{‘åkЂ©‚çŠw‚ñ‚¾‚±‚Æ
  6. ƒ“Á•ÊŠé‰æ10 “ú–{‚ÌACS“o˜^Œ¤‹†‚ÌŒ»ó‚©‚玟‚ÌŽž‘ã‚Ö„

  7. ‚‹´ A‰H”ö ´‹MA›Á Œ³‹gAˆÉ“¡ Œ’‘¾Aâ“c ‘וFA‰ºì G–¾ F ‹}«S‹Ø[Ç”­Ç—¦‹y‚щ@“àŽ€–S—¦‚̋ߔN‚É‚¨‚¯‚éŒo”N•ω»\Miyagi AMI Registry Studyi1985-2014j‚©‚ç‚Ì•ñ\
  8. ƒ“Á•ÊŠé‰æ14 ICT‚ðŠˆ—p‚µ‚½ƒrƒbƒOƒf[ƒ^‚©‚ç‚Ì’mޝ‚̶¬F‰ä‘‚ÌŒ»ó‚Ɖۑè„

  9. ’†ŽR ‰ë°A‰ºìG–¾Ff—Ãî•ñƒXƒgƒŒ[ƒW•W€‹K–ñSS-MIX2‚ð—p‚¢‚½ƒrƒbƒOƒf[ƒ^ŽûW‚É‚¨‚¯‚éŒ»ó‚Æ–â‘è“_
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€3 S–[ד®ƒAƒuƒŒ[ƒVƒ‡ƒ“‚̃Xƒgƒ‰ƒeƒW[‚Æ’·Šú—\Œã„

  11. [àV ‹±”V˜NA•Ÿ“c _“ñA’†–ì ½A‹ß“¡ ³‹PA£ì «lAç—t ‹M•FAŽO–Ø Œi‘¾A‰ºì G–¾ FS–[ד®ƒAƒuƒŒ[ƒVƒ‡ƒ“Œã‚Ì“´’²—¥ˆÛŽ‚ª‰^“®‘Ï—p”\‚É—^‚¦‚é—L—p«
  12. ƒƒVƒ“ƒ|ƒWƒEƒ€8 S‹Ø‹•ŒŒ‚ð‚Ç‚¤•]‰¿‚µAŽ¡—Âɔ½‰f‚³‚¹‚é‚©„

  13. ¬‘é —I“ñA‚‹´ Aš¢’J —²Ž¡A ‰H”ö ´‹MA¼‹{ Œ’‰îA{“c •jA¬¼ ^‹±A¼–{ ‘׎¡A ˆÉ“¡ Œ’‘¾A‰ºì G–¾FŠ¥”÷¬ŒŒŠÇáŠQ‚ÆŒŒŸ÷ƒZƒƒgƒjƒ“”Z“x
  14. ƒƒVƒ“ƒ|ƒWƒEƒ€13 “ñŽŸ«S‹ØÇ‚Ìf’f‚Ìi•à`ƒCƒ[ƒWƒ“ƒO‚ƃoƒCƒIƒ}[ƒJ[`„

  15. ŽR–{ ¹DA™‘º Gˆê˜YA—é–Ø G–¾AÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’¨A–î”ö” M—TA²“¡ —yA_’Ã Ž–çA²“¡ Œö—YA‚˜Q Œ’‘¾˜YA‰ºì G–¾FFabry•aгŽÒ‚É‚¨‚¯‚鉿‘œf’f‚ƃoƒCƒIƒ}[ƒJ[
  16. ƒƒVƒ“ƒ|ƒWƒEƒ€15 “ú–{‚©‚ç”­M‚·‚é”x‚ŒŒˆ³f—Ä

  17. ²“¡ Œö—YA™‘º Gˆê˜YAŒš•” r‰îAÂ–Ø —³’jA–î”ö” M—TA‘呺 ~ˆêA‹e’n ‡—TA²“¡ ‘åŽ÷A•àV —ºA–ì–Ø ³“¹A»‘º Tˆê˜YA_’Ã Ž–çA‰ºì G–¾F”x‚ŒŒˆ³Ç‚Ì‘S‚­V‚µ‚¢•aˆö’`”’‚É’…–Ú‚µ‚½‘Šúf’f‚ÆŽ¡—ÖòŠJ”­‚̉”\«
  18. ƒŽRŒû“O‚ÆŠw‚ÔzŠÂŠí•a‚Ìŋ߂̎¡—ÃPart III ”x‚ŒŒˆ³„

  19. ²“¡ Œö—YA–î”ö” M—TA‘呺 ~ˆêA‹e’n ‡—TA²“¡ ‘åŽ÷A•àV —ºAŽR–{ ¹DAÂ–Ø —³’jAŒš•” r‰îA™‘º Gˆê˜YA‰ºì G–¾F”x‚ŒŒˆ³Ç‚ÌÅV‚Ì–ò•¨Ž¡—ÂơŒã‚ÌŽ¡—ÖòŠJ”­
  20. ƒJCC-ACCƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€ Current and Future in TAVI and BRS in US and Japan„

  21. ‚‹´ FAn Excellent Experience of the ACC Leadership Training Program yReport-ACC Leadership training programz
  22. ƒ“ú–{S‘Ÿ•aŠw‰ïE“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€ S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ŃtƒŒƒCƒ‹‚ðŽ•ž‚µ‚悤„

  23. ’|“à ‰ëŽjA¼–{ ‘׎¡AX M–FA‚‹´ A™‘º Gˆê˜YAŽO‰Y ³’¨Aì–{ r•ãAŒF’J ‹Iˆê˜YA㌎ ³”ŽAâV–Ø ‰ÀŽA‰ºì G–¾FŒoƒJƒe[ƒeƒ‹‘å“®–¬•Ù—¯’up‚É‚¨‚¯‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“\—Šw—Ö@Žm‚Ì—§ê‚©‚çuƒtƒŒƒCƒ‹v‚ð”Fޝ‚µ‘Ήž‚·‚éd—v«\
  24. ƒƒtƒ@ƒCƒA[ƒTƒCƒhƒVƒ“ƒ|ƒWƒEƒ€6 Š¥¹k‚ÌÅV’mŒ©„

  25. ‘åŽR @”nFŠ¥“®–¬‰ßŽûk”½‰ž‚É‚¨‚¯‚銥“®–¬ŽüˆÍމ–b‘gD‚Ì–ðŠ„\Š¥“®–¬ŠO–Œ‘¤‚É’–Ú‚µ‚Ä\
  26. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘S@”ñ–ò•¨“I—Ö@A•a‘Ô„

  27. ”öŒ` „AˆÉ“¡ Œ’‘¾Ai“¡ ’q•FA”©’† ˜a–¾A]Œû ‹v”üŽqA‘ë G•¶A‹àˆä _A‰ºì G–¾F’áo—̓pƒ‹ƒX”g‚ð—p‚¢‚½’´‰¹”gŒŒŠÇV¶—Ö@‚ÍAˆ³•‰‰×S•s‘Sƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¢‚ÄAS‹@”\’ቺ‚ð—}§‚·‚é
  28. ƒˆê”ʉ‰‘è@Œû‰‰ •Ù–ŒÇ2„

  29. ‚–Ø —S‰îA™ ³•¶AH“¡ rA”· Œ’ˆê˜YA“ñ•r ‘¾˜YA£ì «lA‘ŠàV Œ’‘¾˜YAŽR–{ ‹`lA‰ºì G–¾FdǑ哮–¬•Ù‹·óǂɑ΂·‚éƒoƒ‹[ƒ“Šg’£p‚Ì—Õ°¬Ñ
  30. ƒˆê”ʉ‰‘è@Œû‰‰ ‹~‹}E“Ë‘RŽ€EŽ©—¥_ŒoEƒXƒgƒŒƒXESg„

  31. ¬–ì£ „¶Aâ“c ‘וFAŽR“à ‹BA’Ò ŒOØŽqA‹yì ‘ì–çAŠ}Œ´ M‘¾˜YA‚‹´ A‹{“c •qA‰ºì G–¾FSŒŒŠÇ޾ггŽÒ‚É‚¨‚¯‚铌“ú–{‘åkÐŒã‚ÌS“IŠOŒãƒXƒgƒŒƒXáŠQ‚ÌŒoŽž•ω»‚Æ—\Œã‚É‹y‚Ú‚·‰e‹¿\CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  32. ƒˆê”ʉ‰‘è@Œû‰‰ ’·Šú—\Œã—\‘ªˆöŽq„

  33. ‘å’Î ’mLA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’¨AŽR–{ ¹DA–î”ö” M—TA—é–Ø G–¾A²“¡ —yA_’Ã Ž–çA“ñ•r ‘¾˜YA‚‹´ A‹{“c •qA‰ºì G–¾FŒŒŸ÷’†Cyclophilin A‚É‚æ‚銥“®–¬Ž¾Š³‚Ì’·Šú—\Œã—\‘ª
  34. ƒˆê”ʉ‰‘è@Œû‰‰ ’·Šú—\Œã—\‘ªˆöŽq„

  35. ‘å’Î ’mLA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’¨AŽR–{ ¹DA–î”ö” M—TA—é–Ø G–¾A²“¡ —yA_’Ã Ž–çA“ñ•r ‘¾˜YA‚‹´ A‹{“c •qA‰ºì G–¾FŒŒŸ÷’†Adipsin”Z“x‚É‚æ‚銥“®–¬Ž¾Š³‚Ì’·Šú—\Œã—\‘ª
  36. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘SE‚»‚Ì‘¼„

  37. Š}Œ´ M‘¾˜YAâ“c ‘וFAŽR“à ‹BA¬–ì£ „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çA²“¡ ‰ë”VA‚‹´ A‹{“c •qA‰ºì G–¾FHFpEFгŽÒ‚É‚¨‚¯‚éBNP’l‚Æ—\Œã‚Ƃ̊֘A‚ÍHFrEFгŽÒ‚Æ“¯“™‚Å‚ ‚é
  38. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘SE‚»‚Ì‘¼„

  39. ¬–ì£ „¶Aâ“c ‘וFAŽR“à ‹BA’Ò ŒOØŽqA‹yì ‘ì–çAŠ}Œ´ M‘¾˜YA‚‹´ A‹{“c •qA ‰ºì G–¾FS•s‘SгŽÒ‚É‚¨‚¯‚铌“ú–{‘åkÐŒã‚ÌS“IŠOŒãƒXƒgƒŒƒXáŠQ‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿\CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  40. ƒˆê”ʉ‰‘è@Œû‰‰ S•s‘SE‚»‚Ì‘¼„

  41. ŽR“à ‹BAâ“c ‘וFA‚“c „A‹{“c •qAŽO‰Y ³’¨A’A–Ø šáˆê˜YA¬–ì£ „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çAŠ}Œ´ M‘¾˜YAŒã‰ª L‘¾˜YA ‚‹´ A‰ºì G–¾F–«S•s‘SгŽÒ‚Ì—\Œã‚É‚¨‚¯‚é¶Žº‹ìo—¦‚Æ•nŒŒ‚̘AŠÖ‚̉e‹¿‚ÌŒŸ“¢\CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  42. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S‚Ì—\Œã—\‘ª„

  43. Š}Œ´ M‘¾˜YAâ“c ‘וFA’A–Ø šáˆê˜YAŽR“à ‹BA¬–ì£ „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çA‚‹´ A‹{“c •qA‰ºì G–¾F–«S•s‘SгŽÒ‚É‚¨‚¯‚éV‚µ‚¢—\Œã—\‘ªƒŠƒXƒNƒXƒRƒA
  44. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S‚Ì—\Œã—\‘ª„

  45. ŽR“à ‹BAâ“c ‘וFA”’ŒË ’A¬–ì£ „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žA‹yì ‘ì–çAŠ}Œ´ M‘¾˜YA²“¡ ‰ë”VAŒã‰ª L‘¾˜YA‚‹´ A‹{“c •qA‰ºì G–¾FS•s‘SƒnƒCƒŠƒXƒNÇ—á‚É‚¨‚¯‚éS–[ד®‚Ì—\Œã‚ւ̉e‹¿‚Æ”­Ç—\‘ªƒŠƒXƒNƒXƒRƒA‚ÌŒŸ“¢\CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  46. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S‚Ì—\Œã—\‘ª„

  47. ‹yì ‘ì–çAâ“c ‘וFAŽO‰Y ³’¨A’A–Ø šáˆê˜YAŽR“à ‹BA¬–ì£ „¶A’Ò ŒOØŽqAŠ}Œ´ M‘¾˜YA‚‹´ A‹{“c •qA‰ºì G–¾FƒXƒ^ƒ`ƒ“‚Ì–òÜ‹­“x‚ªS‹Ø[ÇŠ³ŽÒ‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢ \ CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  48. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ Ç—á•ñ@S“à–Œ‰Š„

  49. –î”ö” M—TA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’¨AŽR–{ ¹DA—é–Ø G–¾A²“¡ Œö—YA ‰ºì G–¾FBartonella quintanaŠ´õ‚É”º‚¤Š´õ«S“à–Œ‰Š‚̈ê—á
  50. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ Ç—á•ñ@S“à–Œ‰Š„

  51. –î”ö” M—TA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’¨AŽR–{ ¹DA—é–Ø G–¾A²“¡ Œö—YA‰ºì G–¾FBartonella quintanaŠ´õ‚É”º‚¤Š´õ«S“à–Œ‰Š‚̈ê—á
  52. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ •s®–¬Eƒy[ƒXƒ[ƒJ[‚ÆSƒGƒR[„

  53. ŽO–Ø Œi‘¾A•Ÿ“c _“ñA’†–ì ½A‹ß“¡ ³‹PA£ì «lA•½–ì “¹ŠîA[àV ‹±”V˜NA”‘ò ‘EA‰ºì G–¾FS–[ד®Š³ŽÒ‚É‚¨‚¯‚é¶SލŒŒ—¬‘¬“x’ቺ‚ÌŠñ—^ˆöŽq‚ÌŒŸ“¢
  54. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ S•s‘S@—\‘ªˆöŽq2„

  55. ç—t ‹M•FA’†–ì ½A‹ß“¡ ³‹PA£ì «lA•½–ì “¹ŠîA[àV ‹±”V˜NAŽO–Ø Œi‘¾A”‘ò ‘EA•Ÿ“c _“ñA‰ºì G–¾FS‘ŸÄ“¯Šú—Ö@iCRTj‚Ì¶Žº4‹ÉƒŠ[ƒh‚É‚¨‚¯‚é—LŒø«‚¨‚æ‚ÑSŒŒŠÇƒCƒxƒ“ƒg‚ÉŠÖ‚·‚錟“¢
  56. ƒˆê”ʉ‰‘è@ƒ|ƒXƒ^[ CTPEHE”xŒŒð„

  57. Œš•” r‰îA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’¨AŽR–{ ¹DA–î”ö” M—TA—é–Ø G–¾A²“¡ —yA_’Ã Ž–çA²“¡ Œö—YA‰ºì G–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éƒoƒ‹[ƒ“”x“®–¬Œ`¬p‚Ì’·Šú—\Œã‰ü‘PŒø‰Ê
‘æ22‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2016”N7ŒŽ16“ú`17“úA“Œ‹žj

    ƒƒVƒ“ƒ|ƒWƒEƒ€9FŠî‘bŒ¤‹†‚ð—\–hS‘Ÿ•aŠw‚Ì–¢—ˆ‚ÉŠˆ‚©‚·„

  1. ¼–{‘׎¡A‹ààV³”ÍA‰F’Ë—T‹IA‰ºìG–¾FS‹Ø[ÇŒã‚Ìœ‚̕ω»‚Ɖ^“®—Ö@‚É‚æ‚é‰î“üŒø‰ÊF“®•¨ƒ‚ƒfƒ‹‚ð—p‚¢‚½SEœŠÖ˜Ai‘æ13‰ñ–Ø‘º“oÜiŠw‰ïÜjŽóÜj
  2. ƒYIAƒZƒbƒVƒ‡ƒ“„

  3. ’|“à‰ëŽjA¼–{‘׎¡Aì–{r•ãAXM–FAŒF’J‹Iˆê˜YAˆÉ“¡Œ’‘¾Aâ“c‘וFA㌎³”ŽAâV–؉ÀŽA‰ºìG–¾F‘å“®–¬áŽE‰ð—£‚ɑ΂·‚ép‘O‚©‚ç‚̌ċzƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚ÍŽüpŠúŒÄ‹zŠí‡•¹Ç‚ðŒ¸­‚·‚éiÅ—DGÜŽóÜj
  4. ’A–Øšáˆê˜YAâ“c‘וFA•Ÿ–{‹`OA–î–ì‰ë•¶A–å•¶r–¾A‘ã“c_”VAˆÀ“c‘A‰ºìG–¾FS•s‘SгŽÒ‚¨‚æ‚уnƒCƒŠƒXƒNŒQ‚É‚¨‚¯‚é‰^“®‘jŠQˆöŽq‚ÌŒŸ“¢|‘S‘‘½Ž{Ý‹¤“¯ƒRƒz[ƒgŒ¤‹†‚æ‚èi—DGÜŽóÜj
  5. ƒƒVƒ“ƒ|ƒWƒEƒ€4F”x‚ŒŒˆ³Ç‚ɑ΂·‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“„

  6. HŒŽŽO“ÞA™‘ºGˆê˜YA–ؗ³’jAŠ`‰Ô—²ºAXM–FAˆÉ“¡CA‰ºìG–¾A㌎³”ŽF–«ŒŒðÇð«”x‚ŒŒˆ³‚ɑ΂·‚éŒÄ‹CƒKƒX•ªÍ‚ð—p‚¢‚½”ñNP“I‚ÈdÇ“x•]‰¿–@
‘æ162‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2016”N6ŒŽ4“úA·‰ªj

    ƒYIAÇ—á”­•\•”–å„

  1. ŽO–ØŒi‘¾A•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA£ì«lA•½–쓹ŠîAç—t‹M•FA[àV‹±”V˜NA”‘ò@‘EA‰ºìG–¾F•s®–¬Œ´«‰EŽºS‹ØÇ‚Ì—Õ°‘œ‚ɓޗ‚µ‚½SƒTƒ‹ƒRƒCƒh[ ƒVƒX‚Ì‚P—á
  2. ƒYIAŒ¤‹†”­•\•”–å„i–Å—DGÜŽóÜj

  3. ¬‘é—I“ñA‚‹´@Aš¢’J—²Ž¡A‰H”ö´‹MA¼‹{Œ’‰îA{“c@•jA¬¼^‹±A¼–{‘׎¡A ˆÉ“¡Œ’‘¾A‰ºìG–¾FŒŒŸ÷ƒZƒƒgƒjƒ“”Z“x‚ÍŠ¥”÷¬ŒŒŠÇáŠQ‚𔽉f‚·‚é
  4. ƒˆê”ʉ‰‘è„

  5. ‚Œ´^ŒáA‰Í’Ã@‘AHŽR³”NAì–{r•ãAâV–؉ÀŽA–ؗ³’jA™‘ºGˆê˜YA‰ºìG–¾FR‘ÌŠÖ˜AŒ^‹‘┽‰žiAMRj‚ð‡•¹‚µ‚½S‘ŸˆÚA‚̈ê—á
  6. {“c@•jA¼‹{Œ’‰îAš¢’J—²Ž¡A‰H”ö´‹MA¼–{‘׎¡A‚‹´@AˆÉ“¡Œ’‘¾A‰ºìG–¾A²“¡‰pºAXìF‘¥AŠC–ì—Ï–¾FHybridŽèpŽº‚É‚¨‚¢‚ÄW–ñ“I‰Á—Âð—v‚µ‚½u‚½‚±‚‚ڌ^S‹ØÇv‚̈ê—á
  7. ›Á@Œ³‹gA‰H”ö´‹MA¼‹{Œ’‰îAš¢’J—²Ž¡A¼–{‘׎¡A‚‹´@AˆÉ“¡Œ’‘¾A‰ºìG–¾FSƒTƒ‹ƒRƒCƒh[ƒVƒX‚ÉŠ¥¹k«‹·SÇ‚ð‡•¹‚µ‚½2Ç—á
  8. Š}Œ´M‘¾˜YAâ“c‘וFA’A–Ø‘sˆê˜YAŽR“à@‹BA¬–죄¶A’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çA‚‹´@A‰ºìG–¾A‹{“c@•qF–«S•s‘SгŽÒ‚̊ȕւȗ\Œã—\‘ªƒŠƒXƒNƒX ƒRƒA‚ÌŠJ”­
  9. ˆ¢•”—Ú—žAâ“c‘וFAŽO‰Y³’¨AŽR“à@‹BA¬–죄¶A’ÒŒOØŽqA ‹yì‘ì–çAŠ}Œ´M‘¾˜YAŒã‰ªL‘¾˜YA‚‹´@A‰ºìG–¾A‹{“c@•qF“ú–{‚Ì–«S•s‘SгŽÒ‚É‚¨‚¯‚éݑNŠÇ—‚Æ—\Œã‚ÉŠÖ‚·‚錤‹†|CHART-2Œ¤‹†‚©‚ç‚Ì•ñ|
  10. ’ÒŒOØŽqAâ“c‘וFAŽO‰Y³’¨AŒã‰ªL‘¾˜YA ’A–Ø‘sˆê˜YAŽR“à@‹BA¬–죄¶Aˆ¢•”—Ú—žA‹yì‘ì–çAŠ}Œ´M‘¾˜YA‚‹´@A‰ºìG–¾A‹{“c@•qF¶Žº‹ìo—¦‚ª’ቺ‚µ‚½S•s‘S‚Æ¶Žº‹ìo—¦‚ª•Û‚½‚ꂽS•s‘S‚Ì—Õ°Šw“I“Á’¥‚É‚¨‚¯‚é·|CHART-2Œ¤‹†‚Ì’mŒ©|
  11. ’†–ì@½A•Ÿ“c_“ñA’·’J•”—Y”òA–Ø‘º‹`—²A•½–쓹ŠîA[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘¾A”‘ò@‘EA‰ºìG–¾Fƒtƒ@ƒ[Žl’¥ÇpŒã‚ÌPVC‚ɑ΂µA‘å“®–¬Š¥ë‚©‚ç‚Ì’Ê“d‚ª—LŒø‚Å‚ ‚Á‚½ˆê—á
  12. [àV‹±”V˜NA’†–ì@½A‹ß“¡³‹PA£ì«lAç—t‹M•FAŽO–ØŒi‘¾A•Ÿ“c_“ñA‰ºìG–¾FJ wave‚ÌŠÖ˜A‚ªŽ¦´‚³‚ê‚éSŽº×“®”­ì‚ð‹N‚±‚µ‚½Žá”NBrugadaÇŒóŒQ‚̈ê—á
  13. ’†–ì@½A•Ÿ“c_“ñA’·’J•”—Y”òA–Ø‘º‹`—²A•½–쓹ŠîA[àV‹±”V˜NAç—t‹M•FAŽO–ØŒi‘¾A”‘ò@‘EA‰ºìG–¾Fì“®Šm”FƒeƒXƒg‚É‚æ‚è“K³‚ÈICDݒ肪‰Â”\‚Å‚ ‚Á‚½•ÂÇ«”ì‘åŒ^S‹ØÇ‚Ì1—á
  14. ç—t‹M•FA•Ÿ“c_“ñA’†–ì@½A’·’J•”—Y”òA•½–쓹ŠîA[àV‹±”V˜NA–Ø‘º‹`—²AŽO–ØŒi‘¾A”‘ò@‘EA‰ºìG–¾FŠ¥¹k«‹·Sǂ̊֗^‚ª‹^‚í‚ê‚éSŽº×“®‚ɑ΂µ‚ÄS-ICDAž‚Ý‚ðŽ{s‚µ‚½1—á
  15. ™àV@AŒš•”r‰îA™‘ºGˆê˜YA–ؗ³’jAŽO‰Y³’¨AŽR–{¹DA–î”ö”ÂM—TA—é–ØG–¾A²“¡@—yA_’ÃŽ–çA²“¡Œö—YA‰ºìG–¾F”½•œ‚·‚é”sŒŒÇ«”xÇð‚ÅŽèpŽ¡—ÂƂȂÁ‚½VSD‡•¹Š´õ«S“à–Œ‰Š‚Ì1—á
  16. Œš•”r‰îA™‘ºGˆê˜YA–ؗ³’jAŽO‰Y³’¨AŽR–{¹DA–î”ö”ÂM—TA—é–ØG–¾A²“¡@—yA_’ÃŽ–çA²“¡Œö—YA‰ºìG–¾A¬ŽRk‘¾˜YA’†¼é•¶AXè—TŽqA‰ª“cŽ“WAˆÀ’B@—AâV–؉ÀŽFBMPR2ˆâ“`Žq•ψقªf’f‚³‚ꂽASD‡•¹”x“®–¬«‚ŒŒˆ³Ç‚Ì1—á
  17. –î”ö”ÂM—TA™‘ºGˆê˜YAŒš•”r‰îA–ؗ³’jAŽO‰Y³’¨AŽR–{¹DA—é–ØG–¾A²“¡Œö—YA‰ºìG–¾F‹}‘¬‚Éis‚µ‚½‹­”çǂɔº‚¤”x‚ŒŒˆ³Ç‚Ì1—á
  18. –ؗ³’jA™‘ºGˆê˜YA—é–ØG–¾AŽO‰Y³’¨AŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡@—yA_’ÃŽ–çA²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Æ“‡Ž¸’²Ç‚ɂ‚¢‚Ă̌Ÿ“¢
  19. ‚‹´A‰ºìG–¾F‰ä‚ª‘‚Ì–x«S•s‘SгŽÒ‚É‚¨‚¢‚ÄS–[ד®‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿| CHART-2Œ¤‹†‚©‚ç‚Ì•ñˆê
  20. ¬–죄¶Aâ“c‘וFAŒã‰ªL‘¾˜YAŽO‰Y³’¨A’A–Ø‘sˆê˜YAŽR“à‹BA’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}Œ´M‘¾˜YA‹{“c@•qA‚‹´A‰ºìG–¾FSŒŒŠÇ޾ггŽÒ‚É‚¨‚¯‚铌“ú–{‘åkÐŒã‚ÌS“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ì’nˆæ•ʂɂ¨‚¯‚éŒoŽž•ω»‚ÌŒŸ“¢
  21. _’ÃŽ–çA–ؗ³’jA™‘ºGˆê˜YAŽO‰Y³’¨AŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA—é–ØG–¾A²“¡—yA²“¡Œö—YA‰ºìG–¾F––½Œ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•a•ÏŒ`‘Ô[OFDI‚É‚æ‚錟“¢[
‘æ2‰ñ“ú–{S‹ØÇŒ¤‹†‰ïi2016”N5ŒŽ14“úA¼–{Žsj

    ƒƒVƒ“ƒ|ƒWƒEƒ€FS‹ØÇ‚̉摜f’f„

  1. £ì«lA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA•½–쓹ŠîAç—t‹M•FA[àV‹±”V˜NAŽO–ØŒi‘¾A”‘ò@‘EA‰ºìG–¾FRecent progress in the management of cardiac sarcoidosis.
  2. ƒˆê”ÊŒû‰‰„

  3. ¼“‡«ŽmAŒ¦ì^‘¾˜YA–k•—­ŽjA•Ÿ“cŒbˆêA’|΋±’mA‰ºìG–¾AÖ“¡”\•FA“›ˆä—T”VF‚킪‘‚ÌŠg’£‘Š”ì‘åŒ^S‹ØÇ‚ð‘ÎÛ‚Æ‚µ‚½‘½Ž{Ý“o˜^ŠÏŽ@Œ¤‹†.
  4. ƒƒ|ƒXƒ^[”­•\„

  5. ™àV@A‰H”ö´‹MA¼‹{Œ’‰îAŽR–{¹DAš¢’J—²Ž¡A¼–{‘׎¡A™‘ºGˆê˜YA‚‹´@AˆÉ“¡Œ’‘¾A‰ºìG–¾FFabry•a‚ÉŠ¥¹k«‚ð‡•¹‚µ‚½ˆê—á.
  6. ŽO–ØŒ[‘¾A•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA£ì«lA•½–쓹ŠîAç—t‚•FA[àV‹±”V˜NA‰ºìG–¾F•s®–¬Œ´«‰EŽºS‹ØÇ‚Ƃ̊ӕʂɋꗶ‚µ‚½SƒTƒ‹ƒRƒCƒh[ƒVƒX‚̈ê—á.
  7. _’ÃŽ–çA—é–ØG–¾A¼ŽRC•½A²“¡@ê¡A–î”ö”ÂM—TAŽR–{¹DA‰H”ö´‹MAŽO‰Y³’¨A–ؗ³’jA¼–{‘׎¡A™‘ºGˆê˜YA–سŽuA‰ºìG–¾F‘½”­«d‰»Ç‚Ì”]в•a•ςɂæ‚邽‚±‚‚ÚS‹ØÇ‚̈ê—á.
  8. ¼‹{Œ’‰îA¼–{‘׎¡A‰H”ö´‹MAš¢’J—²Ž¡A‚‹´@AˆÉ“¡Œ’‘¾A“nç²—´HA¯ì@NA‰ª“cŽ“TA‰ºìG–¾F•ÂÇ«”ì‘åŒ^S‹ØÇ‚É‚½‚±‚‚ÚS‹ØÇ‚𕹔­‚µ‚½”xˆÚAÇ—á.
“Œ–k‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È•‘®‘n¶‰ž—pˆãŠwŒ¤‹†ƒZƒ“ƒ^[ 2016ƒVƒ“ƒ|ƒWƒEƒ€i2016”N3ŒŽ22“úAå‘äŽsj
  1. ‰ºìG–¾Fƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`•”–åЉî.
  2. ‰ºìG–¾Fæiˆã—ÊJ”­ƒRƒAƒZƒ“ƒ^[.
‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2016”N3ŒŽ18“ú`20“úAå‘äj

    ƒCongress Chairperson's Lecture„

  1. Shimokawa H. The Past, Present and Future of Cardiovascular Medicine in Japan\Lessons from the Great East Japan Earthquake\Circ J. 2016, 80(Suppl. I):I-3
  2. ƒPlenary Session„

  3. (PL01:Creating New Trends for Diagnosis and Treatment of Heart Failure\Integration of Basic Science, Clinical Research and Medical Practice\) Suzuki H, Matsumoto Y, Sumiyoshi A, Kaneta T, Ota H, Yoshikawa T, Sugimura K, Aoki T, Tatebe S, Miura M, Takahashi J, Satoh K, Miyata S, Ito K, Furukawa K, Fukumoto Y, Arai H, Yanai K, Kawashima R, Taki Y, Shimokawa H. Emerging Role of the Heart-Brain Axis via the Hippocampus in the Pathogenesis of Heart Failure. Circ J. 2016, 80(Suppl. I):I-29
  4. (PL03:The Great East Japan Earthquake: What We Learned in the past 5 Years and Future Perspectives) Aoki T, Sugimura K, Nakano M, Hao K, Onose T, Takahashi J, Fukuda K, Sakata Y, Shimokawa H. Lessons from the Great East Japan Earthquake Disaster. Circ J. 2016, 80(Suppl. I):I-40
  5. Yasuda S, Tahara Y, Miyamoto Y, Nishimura K , Takegami M, Ogawa H, Hirata K, Morino Y, Nakamura M, Takeishi Y, Shimokawa H, Naito H. Survey of Emergencies Adapting Business Continuity Plan for (non) Disaster-Base Hospitals; Report from Ministry of Health, Labour and Welfare Grant-in-Aid Investigators. Circ J. 2016, 80(Suppl. I):I-45
  6. (PL05:Treatment Paradigm of Coronary Artery Disease: 20 Years From Now!!) Hao K, Takahashi J, Sai G, Miyata S, Nishimiya K, Tsuburaya R, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Temporal Trends in the Incidence and Mortality of AMI for 30 Years \A Report from the Miyagi AMI Registry Study\ Circ J. 2016, 80(Suppl. I):I-53
  7. (PL07:Let's Discuss the Near Future of Cardiovascular Medicine)Ito K, Shindo T, Hatanaka K, Ogata T, Kurosawa R, Eguchi K, Kagaya Y, Nishimiya K, Tsuburaya R, Hao K, Taki H, Matsumoto Y, Takahashi J, Kanai H, Shimokawa H. Non-invasive Angiogenic Therapies with Acoustic Waves for Cardiovascular Diseases \Promising Approaches for the Future\ Circ J. 2016, 80(Suppl. I):I-68
  8. (PL08:Progress and Future in Pulmonary Hypertension Clinic) Satoh K, Sato T, Kikuchi N, Omura J, Kurosawa R, Suzuki K, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Miura M, Yaoita N, Fukumoto Y, Miyata S, Nakamura K, Ito H, Kadomatsu K, Shimokawa H. Cyclophilin A and Its Receptor Basigin Promote Vascular Smooth Muscle Proliferation and Pulmonary Hypertension \Possible Novel Therapeutic Target Pathway\ Circ J. 2016, 80(Suppl. I):I-76
  9. (PL09:Gender-Specific Medicine in Cardiovascular Disease\Up to Date\)Tsuji K, Sakata Y, Miura M, Miyata S, Nochioka K, Tadaki S, Ushigome R, Yamauchi T, Sato K, Onose T, Abe R, Oikawa T, Kasahara S, Takahashi J, Shimokawa H. Sex Differences in the Clinical Characteristics and Prognosis of Heart Failure with Preserved Ejection Fraction \Insights from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-85
  10. ƒSymposium„

  11. (SY02:Diagnosis and Treatment Using Recently Developed and Emerging Devices) Chiba T, Nakano M, Fukuda K, Kondoh M, Segawa M, Hirano M, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Impacts of Quadripolar Left Ventricular Lead and Left Ventricular Reverse Remodeling in Patients with Cardiac Resynchronization Therapy. Circ J. 2016, 80(Suppl. I):I-110
  12. (SY05:Frontline of CTEPH Practice in Japan in 2016) Yaoita N, Satoh K, Sato T, Kikuchi N, Omura J, Kurosawa R, Nogi M, Otsuki T, Kouzu K, Numano K, Suzuki K, Sunamura S, Tatebe S, Aoki T, Sugimura K, Horiuchi H, Shimokawa H. Crucial Role of Thrombin-Activated Fibrinolysis Inhibitor in the Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-131
  13. (SY07:Unsolved Issues in Heart Failure with Preserved Ejection Fraction (HFpEF) Based on Cohort Studies and Clinical Trials) Miura M, Sakata Y, Ushigome R, Tsuji K, Sato K, Tadaki S, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Perspectives of Medical Therapies for Heart Failure with Preserved Ejection Fraction \Lessons from the CHART Studies and the SUPPORT Trial\ Circ J. 2016, 80(Suppl. I):I-145
  14. (SY10:New Strategy for the Secondary Prevention after Acute Coronary Syndrome Based on Cohort Studies) Oikawa T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Prognostic Impacts of Statins after Myocardial Infarction in the CHART-2 Study\A Validation Analysis of the gFire and Forgeth Theory\ Circ J. 2016, 80(Suppl. I):I-165
  15. (SY15:Bioresorbable Scaffolds (BRS) in Current and Future) Nishimiya K, Matsumoto Y, Uzuka H, Amamizu H, Oyama K, Hirano M, Shindo T, Tsuburaya R, Takahashi J, Ito K, Shimokawa H. Beneficial Effects of Novel Bioresorbable Polymer Coating on Enhanced Coronary Vasoconstricting Responses after Drug-Eluting Stent Implantation in Pigs in Vivo. Circ J. 2016, 80(Suppl. I):I-195
  16. (SY19:How Do We Establish Usefulness of Left Ventricular Assist Device in Japan?) Akiyam Ma, Fujiwara H, Katahira S, Kumagai K, Aoki T, Sugimura K, Fukuda K, Takahashi J, Kawamoto S, Shimokawa H, Saiki Y. Patient Selection for Mechanical Circulatory Support: A Single Center Review of 39 Patients. Circ J. 2016, 80(Suppl. I):I-224
  17. (SY20:Functional Impairment of Coronary Arteries; Clinical Implications and Further Evaluation)Tsuburaya R, Takahashi J, Nakamura A, Nozaki E, Sugi M, Yamamoto Y, Hiramoto T, Horiguchi S, Inoue K, Gotoh T, Katoh A, Shinozaki T, Miyata S, Yasuda S, Shimokawa H. Beneficial Effects of Long-acting Nifedipine on Coronary Vasomotion Abnormalities after Drug-Eluting Stent Implantation \The NOVEL Study\ Circ J. 2016, 80(Suppl. I):I-230
  18. (SY22:The Role of Heart Team Approach for Patients with CVD; Prevention to Rehabilitation)Kajikawa A, Miura M, Tanaka H, Saito Y, Suzuki H, Kakihana T, Takeuchi M, Syojima K, Myochin C, Kondoh M, Hao K, Sugimura K, Shimokawa H. Importance of Evidence-Based Approach for Heart Team in Heart Failure Practice. Circ J. 2016, 80(Suppl. I):I-244
  19. (SY24:How Should We Design and Conduct Sensible Clinical Research in Japan?) Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. The CHART-2 (Chronic Heart Failure Analysis and Registry in the Tohoku District-2) Study \Working Model of Observational Study in Japan\ Circ J. 2016, 80(Suppl. I):I-256
  20. (SY27:Mechanisms of Atherosclerosis in Metabolic Syndrome: From Bench to Bedside) Noda K, Fukumoto Y, Saito H, Godo S, Tsutsui M, Shimokawa H. Crucial Role of Rho-kinase in the Pathogenesis of Metabolic Syndrome \Suppression of Endothelial Nitric Oxide Synthase and AMP-activated Protein Kinase. Circ J. 2016, 80(Suppl. I):I-277
  21. ƒSpecial Session„

  22. (SS01:Let's Learn Medical Statistics in 3 Days! ‡@) Miyata S. Let's Learn Medical Statistics in 3 Days! ‡@ Circ J. 2016, 80(Suppl. I):I-288
  23. (SS04:Editors-in-Chief of the Top Medical Journals) Shimokawa H. Circulation Journal. Circ J. 2016, 80(Suppl. I):I-301
  24. (SS05:Let's Learn Medical Statistics in 3 Days! ‡A) Miyata S. Let's Learn Medical Statistics in 3 Days! ‡A Circ J. 2016, 80(Suppl. I):I-308
  25. (SS06:Novel Therapeutic Targets in Cardiovascular Disease)Satoh K, Suzuki K, Sunamura S , Otsuki T, Shimizu T, Ikeda I, Aoki T, Tatebe S, Sugimura K, Shimokawa H. Crucial Roles of Rho-kinase, Cyclophilin A and Its Receptor, Basigin, for Cardiac Hypertrophy, Fibrosis and Failure\Novel Therapeutic Targets of Heart Failure\ Circ J. 2016, 80(Suppl. I):I-310
  26. (SS07:Heart Failure Pandemic: An Emerging Agenda in the Super-aged Society) Miura M, Sakata Y, Miyata S, Ushigome R, Sato K, Tadaki S, Yamauchi T, Tsuji K, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Shimokawa H. Current Status and Future Perspectives of Chronic Heart Failure in Japan \Lessons from the CHART Studies\ Circ J. 2016, 80(Suppl. I):I-318
  27. (SS08:30th Anniversary of NO Research: What Have We Learned and Where to Go) Tsutsui M, Shimokawa H, Yanagihara N, Mukae H, Otsuji Y. Circ J. Diverse Roles of NO Synthases \ Lessons from Genetically Modified Mice \ Circ J. 2016, 80(Suppl. I):I-324
  28. (SS09:Development of Non-invasive Therapy for Cardiovascular Diseases)Matsubara T, Ito K, Shimokawa H. Cardiac Shock Wave Therapy. Circ J. 2016, 80(Suppl. I):I-329
  29. Ito K, Shindo T, Kanai H, Shimokawa H. A New Angiogenic Therapy Using Low-intensity Pulsed Ultrasound for Angina Pectoris. Circ J. 2016, 80(Suppl. I):I-330
  30. (SS14:Let's Learn Medical Statistics in 3 Days! ‡B)Miyata S. Let's Learn Medical Statistics in 3 Days! ‡B Circ J. 2016, 80(Suppl. I):I-354
  31. (SS15:Large-scale Disasters and Cardiovascular Disease)Aoki T, Sugimura K, Nakano M, Hao K, Nihei T, Onose T, Takahashi J, Fukuda K, Sakata Y, Shimokawa H . Cardiovascular Diseases after the Great East Japan Earthquake Disaster \ Risk Factor for Cardiovascular Diseases. Circ J. 2016, 80(Suppl. I):I-357
  32. (SS17:Information and Communication Technology Will Launch a New Era in Cardiovascular Medicine)Ito K, Takahashi J, Hao K, Inoue K, Hiramoto T, Shimokawa H. A Prehospital 12-lead Electrocardiogram Transmission System in Emergency Cardiovascular Care in Miyagi. Circ J. 2016, 80(Suppl. I):I-371
  33. (SS18:Importance of Cardio-Oncology)Sugimura K, Yaoita N, Shimokawa H. Pulmonary Vascular Diseases in Patients with Malignancy. Circ J. 2016, 80(Suppl. I):I-377
  34. ƒESC-JCS Joint Symposium„

  35. (ESC-JCS JS:Coronary Microvascular Dysfunction Revisited)Takahashi J, Odaka Y, Shimokawa H. Plasma Serotonin Level is a Novel Biomarker for Presence of Coronary Microvascular Dysfunction in Patients with Unobstructive Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-384
  36. ƒRound Table Discussion„

  37. (RT04:Management of Heart Failure Patients in the Highly Aged Society in Japan) Sakata Y, Miura M, Sato K, Tadaki S, Ushigome R, Yamauchi T, Miyata S, Takahashi J, Shimokawa H. Clinical Characteristics Treatments and Prognosis of Elderly Patients with Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-424
  38. (RT08:The Present Situation of Sudden Cardiac Death and the Role of ICDs in Japan)Fukuda K. Satake H, Sakata Y, Miyata S, Nakano M, Kondo M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Current Status of Sudden Cardiac Death with Implantable Cardioverter-Defibrillator in Patients with Chronic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-444
  39. ƒTopic„

  40. (TP02:Clinical Practice of Right Heart Failure)Tatebe S, Sugimura K, Aoki T, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Satoh K, Shimokawa H. Pathophysiology and Treatment of Right Heart Failure in Patients with Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-479
  41. (TP07:The Vascular Adventitia: An Active Participant in Vessel Pathogenesis from the gOutside inh)Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Wang H, Tsuburaya R, Hao K, Ohyama K, Odaka Y, Miyata S, Ito K, Shimokawa H. Enhanced Adventitial Vasa Vasorum Formation in Patients with Vasospastic Angina \Assessment with Optical Frequency Domain Imaging\ Circ J. 2016, 80(Suppl. I):I-516
  42. (TP08:Implication of Frailty and Sarcopenia in Cardiology Practice)Matsumoto Y, Takeuchi M, Mori N , Takahashi J, Sugimura K, Miura M, Kumagai K, Kawamoto S, Furukawa K, Arai H, Saiki Y, Kohzuki M, Shimokawa H. Important Roles of Frailty Assessment and Rehabilitation for the Elderly Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. Circ J. 2016, 80(Suppl. I):I-521
  43. ƒMeet the Expert„

  44. (ME01:Therapeutic Strategy for Brugada Syndrome)Nakano M, Fukuda K, Kondo M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Overview of Brugada Syndrome \Epidemiology and Diagnosis\ Circ J. 2016, 80(Suppl. I):I-542
  45. Matsumoto Y, Takeuchi M, Mori N, Takahashi J, Sugimura K, Miura M, Kumagai K, Kawamoto S, Furukawa K, Arai H, Saiki Y, Kohzuki M, Shimokawa H. Roles of Transcatheter Aortic Valve Replacement and Cardiac Rehabilitation for the Elderly Patients with Aortic Stenosis. Circ J. 2016, 80(Suppl. I):I-550
  46. (ME04:Balloon Pulmonary Angioplasty: Recent Advances of Management for Patients with Chronic Thromboembolic Pulmonary Hypertension)Sugimura K, Aoki T, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kozu K, Satoh K, Shimokawa H . Efficacy and Safety of Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-559
  47. (ME05:Use of Bio-makers in the Cardiovascular Medicine)Satoh K, Otsuki T, Shimokawa H. Cyclophilin A: A Novel Biomarker for Patients with Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-562
  48. (ME10:Diagnosis of Vasospastic Angina)Tsuburaya R, Takahashi J, Nishimiya K, Hao K, Matsumoto Y, Shimokawa H. Coronary Hyperconstricting Response Induced by a Drug-eluting Stent as a Remaining Important Issue Even in the Second Generation Era \ Beneficial Effects of Long-acting Nifedipine. Circ J. 2016, 80(Suppl. I):I-593
  49. ƒMorning Lecture„

  50. (ML22:Management of Chronic Tromboembolic Pulmonary Hypertension)Sugimura K, Shimokawa H. Management of Chronic Tromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-618
  51. ƒLate Breaking Clinical Trials/Cohort Studies„

  52. (LBCT/LBCS I:Coronary Artery Disease)Oikawa T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Prognostic Impact of Statin Intensity in Patients with Ischemic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-627
  53. (LBCT/LBCS II:Arrhythmia, Hypertension)Ikeda T, Ogawa H, Atarashi H, Inoue H, Uchiyama S, Kitazono T, Yamashita T, Shimizu W, Kaikita K, Kamouchi M, Fukuda K, Matsui K, Shimokawa H. Effectiveness and Safety of Rivaroxaban in Patients with Non-Valvular Atrial Fibrillation \The Second Report from the EXPAND Study\ 11 Circ J. 2016, 80(Suppl. I):I-632
  54. (LBCT/LBCS III:Intervention)Tsuburaya R, Takahashi J, Nakamura A, Nozaki E, Sugi M, Yamamoto Y, Hiramoto T, Horiguchi S, Inoue K, Gotoh T, Katoh A, Shinozaki T, Miyata S, Yasuda S, Shimokawa H. Beneficial Effects of Long-acting Nifedipine on Coronary Vasomotion Abnormalities after Drug-Eluting Stent Implantation \The NOVEL Study\ Circ J. 2016, 80(Suppl. I):I-639
  55. (LBCT/LBCS IV:Heart Failure)Miura M, Sakata Y, Miyata S, Tadaki S, Ushigome R, Sato K, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Shimokawa H. Beneficial Effect of Additive Use of Olmesartan to Beta-Blockers in Hypertensive Patients with Heart Failure with Preserved Ejection Fraction. Circ J. 2016, 80(Suppl. I):I-643
  56. Sugimura K, Miura M, Aoki T, Tatebe S, Yamamoto S, Suzuki H, Yaoita N, Kouzu K, Miyata S, Sakata Y, Shimokawa H. Prognostic Impact of Furosemide in Chronic Heart Failure\A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-645
  57. Kotooka N, Sato Y, Mizuno A, Eguchi K, Inomata T, Yamamoto K, Tsutsui H, Masuyama T, Kitakaze M, Inoue T, Shimokawa H, Shin-Ichi Momomura, Yoshihiko Seino, Koichi Node. Home Telemonitoring Study for Japanese Patients with Heart Failure (HOMES-HF). Circ J. 2016, 80(Suppl. I):I-647
  58. ƒFeatured Research Session„

  59. (FRS05:Heart Failure, Treatment)Suda A, Takahashi J, Hao K, Sakata Y, Miyata S, Miura M, Shimokawa H. Prognostic Impacts of Revascularization Strategy and Residual Coronary Stenosis in Patients with Ischemic Heart Failure. Circ J. 2016, 80(Suppl. I):I-688
  60. (FRS06:Heart Failure, Basic and Cardiac Function)Suzuki K, Satoh K, Ikeda S, Sunamura S, Otsuki T, Sato T, Kikuchi N, Omura J, Kurosawa R, Nogi M, Numano K, Sugimura K, Aoki T, Tatebe S, Miyata S, Mukherjee R, Francis G Spinale, Kadomatsu K, Shimokawa H. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure-Overload in Mice. Circ J. 2016, 80(Suppl. I):I-695
  61. (FRS13:Coronary Artery Disease, Treatment)Uzuka H, Matsumoto Y, Nishimiya K, Amamizu H, Ohyama K, Hirano M, Hao K, Tsuburaya R, Ito K, Takahashi J, Shimokawa H. Catheter-based Renal Denervation Suppresses Coronary Hyperconstricting Responses after Drug-eluting Stent Implantation in Pigs in Vivo. Circ J. 2016, 80(Suppl. I):I-733
  62. Hatanaka K, Ito K, Shindo T, Ogata T, Kurosawa R, Kagaya Y, Eguchi K, Shimokawa H. Molecular Mechanisms of Angiogenic Effects of Low-energy Shock Wave Therapy: Potential Involvement of Mechanotransduction Pathways. Circ J. 2016, 80(Suppl. I):I-734
  63. (FRS14:Cardiovascular Disease, Preventive Medicine)Kasahara S, Sakata Y, Miura M, Ushigome R, Sato K, Tadaki S, Onose T, Tsuji K, Yamauchi T, Abe R, Oikawa T, Takahashi J, Miyata S, Shimokawa H. The Risk Score to Predict Long-term Prognosis of Patients with Chronic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-739
  64. Yamauchi T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Clinical Backgrounds and Prognostic Impacts of New Onset Atrial Fibrillation \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-742
  65. (FRS19:Heart Failure, Pulmonary Hypertension)Kikuchi N, Satoh K, Omura J, Sato T, Kurosawa R, Nogi M, Otsuki T, Numano K, Kouzu K, Suzuki K, Sunamura S, Tatebe S, Aoki T, Sugimura K, Shimokawa H. Selenoprotein P Promotes Vascular Smooth Muscle Cell Proliferation and Pulmonary Hypertension \A Possible Novel Therapeutic Target\ Circ J. 2016, 80(Suppl. I):I-769
  66. Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Sunamura S, Nogi M, Suzuki K, Shimokawa H. nvolvement of Thrombin Activatable Fibrinolysis Inhibitor in the Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-771
  67. Tsutsui M, Ishida M, Noguchi K, Shimokawa H. Protective Role of Myelocytic Nitric Oxide Synthases in Hypoxic Pulmonary Hypertension in Mice. Circ J. 2016, 80(Suppl. I):I-773
  68. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  69. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Miyata S, Furukawa K, Arai H, Fukumoto Y, Taki Y, Shimokawa H. Hippocampus Abnormalities are Associated with Depressive Symptoms and Cognitive Impairment in Patients with Chronic Heart Failure. Circ J. 2016, 80(Suppl. I):I-841
  70. Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Wang H, Tsuburaya R, Hao K, Ohyama K, Odaka Y, Miyata S, Ito K, Shimokawa H. Enhanced Adventitial Vasa Vasorum Formation in Patients with Vasospastic Angina \Assessment with Optical Frequency Domain Imaging\ Circ J. 2016, 80(Suppl. I):I-844
  71. ƒYoung Investigator's Award Finalists Lectures (Basic Research) )„

  72. Godo S, Sawada A, Saito H, Ikeda S, Enkhjargal B, Suzuki K, Tanaka S, Shimokawa H. Disruption of Physiological Balance between Nitric Oxide and Endothelium-dependent Hyperpolarization Impairs Cardiovascular Homeostasis in Mice. Circ J. 2016, 80(Suppl. I):I-846
  73. ƒOral Presentation (English)„

  74. (OE07:ACS/AMI, Basic)Shindo T, Ito K, Ogata T, Hatanaka K, Kurosawa R, Eguchi K, Kagaya Y, Hanawa K, Aizawa K, Shirato T, Miyata S, Taki H, Hasegawa H, Kanai H, Shimokawa H. Low-intensity Pulsed Ultrasound Enhances Angiogenesis and Ameliorates Left Ventricular Dysfunction in a Mouse Model of Acute Myocardial Infarction. Circ J. 2016, 80(Suppl. I):I-894
  75. (OE12:ACS/AMI, Clinical/Pathophysiology 1)Nihei T, Yamamoto Y, Kudo S, Hanawa K, Hasebe Y, Takagi Y, Minatoya Y, Sugi M, Shimokawa H. Impact of the Fukushima Daiichi Nuclear Power Plant Disaster on Acute Myocardial Infarction in Iwaki City. Circ J. 2016, 80(Suppl. I):I-923
  76. (OE17:Heart Failure, Basic 1)Mukaiyama Y, Matsuhashi T, Kikuchi K, Shima H, Takeuchi Y, Mishima E, Akiyama Y, Suzuki C, Suzuki T, Aoki T, Ito S, Nakada K, Hayashi K, Osaka H, Abe T. Mitochonic Acid MA-5 Binds to Mitochondria and Ameliorates Mitochondrial Disease Cardiac Myocyte Damage. Circ J. 2016, 80(Suppl. I):I-950
  77. (OE32:Atherosclerosis, Clinical 1) Otsuki T, Satoh K, Sugimura K Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kouzu K, Nihei T, Takahashi J, Miyata S, Shimokawa H. Prognostic Impacts of Plasma Levels of Cyclophilin A in Patients with Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-1043
  78. (OE38:Preventive Medicine/Epidemiology/Education 2)Onose T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Abe R, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Temporal Changes in Post-Traumatic Stress Disorder after the Great East Japan Earthquake \A Report from the CHART-2 Study\Circ J. 2016, 80(Suppl. I):I-1076
  79. (OE39:Ventricular Arrhythmia 4)Nakano M, Fukuda K, Kondoh M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S , Shimokawa H. Effectiveness of Radiofrequency Catheter Ablation on Premature Ventricular Contraction-Triggered Ventricular Fibrillation in Patients with Idiopathic Ventricular Fibrillation. Circ J. 2016, 80(Suppl. I):I-1082
  80. (OE44:Heart Failure, Basic 2) Sunamura S, Satoh K, Suzuki K, Ikeda S, Omura J, Kikuchi N, Sato Th, Kurosawa R, Nogi M, Numano K, Shimizu T, Shimokawa H . Crucial Role of ROCK1 to Maintain Contractile Function in Response to Pressure-Overload in Mice. Circ J. 2016, 80(Suppl. I):I-1114
  81. (OE48:Atherosclerosis, Clinical 2) Otsuki T, Satoh K, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kouzu K, Nihei T, Takahashi J, Miyata S, Shimokawa H . Prognostic Impacts of Plasma Levels of Adipsin in Patients with Coronary Artery Disease. Circ J. 2016, 80(Suppl. I):I-1139
  82. (OE59:CTEPH BPA)Kozu K, Satoh K, Sugimura K, Aoki T, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Otsuki T, Sato H, Miyata S, Shimokawa H. Plasma Cyclophilin A as a Useful Biomarker for the Effects of Percutaneous Transluminal Pulmonary Angioplasty in Patients with CTEPH. Circ J. 2016, 80(Suppl. I):I-1202
  83. Aoki T, Sugimura K, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Sato H, Kouzu K, Satoh K, Shimokawa H. Effects of Percutaneous Transluminal Pulmonary Angioplasty on Oxygenation Capacity in Patients with Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-1203
  84. ƒOral Presentation (Japanese) „

  85. (OJ01:ACS/AMI, Clinical/Treatment)Kagaya Y, Ito K, Takahashi J, Matsumoto Y, Tsuburaya R, Hao K, Nishimiya K, Shindo T, Ogata T, Kurosawa R, Eguchi K, Hatanaka K, Miyata S, Shimokawa H. Low-energy Cardiac Shock Wave Therapy Ameliorates Left Ventricular Remodeling in Patients with Acute Myocardial Infarction. Circ J. 2016, 80(Suppl. I):I-1225
  86. (OJ04:Ventricular Arrhythmia, Conduction Block)Segawa M, Fukuda K, Nakano M, Kondoh M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Prognostic Impacts of Corticosteroid Therapy in Cardiac Sarcoidosis Patients with Advanced Heart Block. Circ J. 2016, 80(Suppl. I):I-1243
  87. (OJ07:Preventive Medicine/Epidemiology/Education)Oikawa T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Abe R, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. LDL-independent Beneficial Prognostic Impacts of Statins in Patients with Old Myocardial Infarction \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-1256
  88. (OJ12:Pulmonary Circulation)Omura J, Satoh K, Kikuchi N, Sato T, Kurosawa R, Nogi M, Otsuki T, Kouzu K, Suzuki K, Sunamura S, Tatebe S, Aoki T, Sugimura K, Shimokawa H . Disruption of Endothelial AMP-activated Protein Kinase Worsens Hypoxia-induced Pulmonary Hypertension in Mice. Circ J. 2016, 80(Suppl. I):I-1291
  89. (OJ18:Intravascular Imaging)Ohyama K, Matsumoto Y, Amamizu H, Uzuka H, Nishimiya K, Hao K, Tsuburaya R, Takahashi J, Shimokawa H . Increased Coronary Perivascular Adipose Tissue Volume in Patients with Vasospastic Angina\Correlations with Adventitial Vasa Vasorum Formation and Rho-kinase Activity\ Circ J. 2016, 80(Suppl. I):I-1326
  90. (OJ30:Coronary Artery Disease, Clinical)Nishimiya K, Wang H, Matsumoto Y, Takahashi J, Uzuka H, Hao K, Tsuburaya R, Amamizu H, Ohyama K, Masayasu Komatsu, Odaka Y, Ito K, Shimokawa H. Association of Enhanced Adventitial Vasa Vasorum Formation with Atherosclerotic Changes Adjacent to Myocardial Bridge \An Optical Frequency Domain Imaging Study\ Circ J. 2016, 80(Suppl. I):I-1395
  91. Yada T, Shimokawa H, Gotoh M, Ogasawara Y, Kajiya F. Important Role of Endogenous H2O2 during Reactive Hyperemia in Dogs in Vivo \An Infrared Fluorescence Microscope Study\ Circ J. 2016, 80(Suppl. I):I-1397
  92. (OJ40:Cost-health Care System) Nakayama M, Takehana K, Kohro T, Shimokawa H, IHE-J Cardiology Technical Committee. Japanese Circulation Society Releases the Standard Export Data Format for Standardized Structured Medical Information Exchange Extended Storage. Circ J. 2016, 80(Suppl. I):I-1457
  93. (OJ43:Heart Failure, Treatment 3)Miura M, Sakata Y, Miyata S, Sato K, Ushigome R, Tadaki S, Yamauchi T, Tsuji K, Onose T, Oikawa T, Kasahara S, Abe R, Nochioka K, Takahashi J, Shimokawa H. Prognostic Impacts of Supplemental Use of Angiotensin Receptor Blocker Olmesartan with a Special Reference to Left Ventricular Ejection Fraction. Circ J. 2016, 80(Suppl. I):I-1473
  94. ƒPoster Session (English)„

  95. (PE043:Metabolic Disorder 1)Tadaki S, Sakata Y, Miura Y, Fukumoto Y, Miura T, Yano M, Kadokami T, Daida H, Kitakaze M, Shimokawa H. Prognostic Impacts of Metabolic Syndrome in Patients with Chronic Heart Failure\A Report from the Multicenter Prospective Cohort Study\ Circ J. 2016, 80(Suppl. I):I-1759
  96. (PE044:Stroke)Tsutsui M, Kubota H, Noguchi K, Ishida M, Shimokawa H, Ohya Y. Complete Disruption of All Nitric Oxide Synthases Markedly Reduces Cerebral Infarct Size after Middle Cerebral Artery Occlusion in Mice. Circ J. 2016, 80(Suppl. I):I-1767
  97. (PE085:Preventive Medicine/Epidemiology/Education 1)Abe R, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Yamauchi T, Tsuji K, Onose T, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Assessment of Self-care Behavior in Patients with Chronic Heart Failure \A Report from the CHART Study\ Circ J. 2016, 80(Suppl. I):I-2039
  98. (PE089:Atrial/Supraventricular Arrhythmia, Clinical/Treatment 10)Fukasawa K, Fukuda K, Nakano M, Kondoh M, Segawa M, Hirano M, Chiba T, Miki K, Morosawa S, Shimokawa H. Impact of Sinus Rhythm Maintenance with Atrial Fibrillation Ablation on Exercise Tolerance. Circ J. 2016, 80(Suppl. I):I-2063
  99. (PE098:Cardiomyopathy 2)Segawa M, Fukuda K, Nakano M, Kondoh M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H . Improved Long-term Prognosis of Patients with Cardiac Sarcoidosis in the Present Era. Circ J. 2016, 80(Suppl. I):I-2115
  100. (PE099:Heart Failure, Prognosis)Kasahara S, Sakata Y, Miura M, Ushigome R, Sato K, Tadaki S, Onose T, Tsuji K, Yamauchi T, Abe R, Oikawa T, Takahashi J, Miyata S, Shimokawa H. B-Type Natriuretic Peptide Predicts Long-term Prognosis of Patients with Chronic Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2122
  101. (PE107:Preventive Medicine/Epidemiology/Education 2)Tadaki S, Sakata Y, Miura Y, Fukumoto Y, Yano M, Kadokami T, Yasuda S, Daida H, Shimokawa H. Prognostic Impacts of Factors Interfering Daily Exercise in Patients with Chronic Heart Failure \A Multicenter Prospective Cohort Study\ Circ J. 2016, 80(Suppl. I):I-2180
  102. (PE117:Pulmonary Circulation 1)Hidenobu Takagi, Ota H, Sugimura K, Shimokawa H, Takase K. Clinical Severity of Chronic Thromboembolic Pulmonary Hypertension: Assessment on Lung Perfused Blood Volume Images Acquired by Dual-energy CT. Circ J. 2016, 80(Suppl. I):I-2241
  103. ƒPoster Session (Japanese)„

  104. (PJ019:Arrhythmia, Clinical/Diagnosis/Treatment 3)Hasebe Y, Kudo S, Nihei T, Hanawa K, Takagi Y, Minatoya Y, Yamamoto Y, Sugi M, Shimokawa H. Current Status of Triplet Therapy in Patients with Atrial Fibrillation Undergoing Coronary Angioplasty with Drug-eluting Stent in the NOAC Era. Circ J. 2016, 80(Suppl. I):I-2425
  105. (PJ029:Heart Failure, Prognosis)Tsuji K, Sakata Y, Miura M, Miyata S, Nochioka K, Tadaki S, Ushigome R, Sato K, Yamauchi T, Onose T, Abe R, Kasahara S, Takahashi J, Shimokawa H. Different Clinical Characteristics between HFpEF and HFrEF \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2492
  106. (PJ042:CTEPH BPA)Yaoita N, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Miura M, Satoh K, Shimokawa H. Influence of Discontinuation of Medications after Successful Percutaneous Transluminal Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-2574
  107. Sato H, Ota H, Sugimura K, Aoki T, Miura M, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Kouzu K, Satoh K, Takase K, Shimokawa H. Percutaneous Transluminal Pulmonary Angioplasty Improves Biventricular Functions and Pulmonary Flow in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016, 80(Suppl. I):I-2576
  108. (PJ044:Heart Failure, Treatment 1)Sugimura K, Miura M, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Suzuki H, Sato H, Miyata S, Sakata Y, Shimokawa H. Prognostic Effect of Diuretics for Japanese Patients with Chronic Heart Failure\A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2588
  109. (PJ066:Heart Failure, Pathophysiology)Sato K, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Clinical Characteristics and Prognostic Factors of Elderly Patients with Heart Failure \A Report from the CHART-2 Study\ Circ J. 2016, 80(Suppl. I):I-2729
  110. (PJ070:Arrhythmia, Clinical/Diagnosis/Treatment 8)Hirano M, Yamamoto H, Hasebe Y, Fukuda K, Amamizu H, Morosawa S, Oyama K, Uzuka H, Takayama K, Shimokawa H. Development of a Novel Shock Wave Catheter Ablation System \A Preclinical Validation Study\ Circ J. 2016, 80(Suppl. I):I-2762
  111. (PJ079:Vascular Biology 1)Saito H, Sato S, Itoh A, Ikumi Y, Tanaka S, Godo S, Ida T, Fujii S, Akaike T, Shimokawa H. Important Roles of Endothelial Caveolin-1 in Maintaining Microvascular Homeostasis \Possible Protective System against Nitrative Stress\ Circ J. 2016, 80(Suppl. I):I-2820
  112. (PJ094:Thromboembolism/Antithrombotic Therapy/Thrombolysis 4)Miki K, Fukuda K, Nakano M, Kondo M, Segawa M, Hirano M, Chiba T, Morosawa S, Fukasawa K, Shimokawa H. Effectiveness and Safety of NOACs in Atrial Fibrillation Patients Undergoing Ablation Therapy with a Special Reference to Left Atrial Function. Circ J. 2016, 80(Suppl. I):I-2920
  113. (PJ107:Preventive Medicine/Epidemiology/Education 3)Ushigome R, Sakata Y, Miyata S, Miura M, Sato K, Tadaki S, Yamauchi T, Tsuji K, Onose T, Oikawa T, Abe R, Nochioka K, Shimokawa H. Temporal Changes in Sex Differences in Clinical Profiles of Patients with Symptomatic Heart Failure \A Report from the CHART Studies\ Circ J. 2016, 80(Suppl. I):I-3005
  114. (PJ108:Congenital Heart Disease/Kawasaki's Disease)Kondo M, Fukuda K, Nakano M, Segawa M, Hirano M, Chiba T, Fukasawa K, Miki K, Morosawa S, Shimokawa H. Impact of Prolonged QRS Duration for Tachyarrhythmic Events in Adult Patients with Postoperative Tetralogy of Fallot. Circ J. 2016, 80(Suppl. I):I-3011
‘æ207‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2016”N2ŒŽ29“úAå‘äŽsj
  1. ™àVA¼‹{Œ’‰îA‰H”ö´‹MAš¢’J—²Ž¡A¼–{‘׎¡A‚‹´@AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾F‹}«S‹Ø[ÇŽ¡—ÃŒã‚ɃwƒpƒŠƒ“‹Nˆö«ŒŒ¬”ÂŒ¸­ÇiHITj‚É‚æ‚鈟‹}«ƒXƒeƒ“ƒgŒŒðÇiSATj‚ðŒJ‚è•Ô‚µ‚½1—á.
‘æ39‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ïi2016”N2ŒŽ13“úAå‘äŽsj
  1. ™àVA¼‹{Œ’‰îA‰H”ö´‹MAš¢’J—²Ž¡A¼–{‘׎¡A‚‹´@AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾F‹}«S‹Ø[ÇŽ¡—ÃŒã‚ɃwƒpƒŠƒ“‹Nˆö«ŒŒ¬”ÂŒ¸­ÇiHITj‚É‚æ‚鈟‹}«ƒXƒeƒ“ƒgŒŒðÇiSATj‚ðŒJ‚è•Ô‚µ‚½1—á.
  2. {“c•jA‚‹´@A_ŒË–ΗYA‹{ì”T—ŽqA¼‹{Œ’‰îA‰H”ö´‹MAš¢’J—²Ž¡A¼–{‘׎¡A‹vŽu–{–ÎŽ÷A‰ºìG–¾FŠO«‚­‚à–Œ‰ºoŒŒ‚Æ‹}«S‹Ø[Ç‚ð‡•¹‚µ‚½ˆê—á.
‘æ45‰ñ“ú–{S–¬ŠÇì“®•¨Ž¿Šw‰ïŠwpW‰ïi2016”N2ŒŽ5`6“úA“¿“‡Žsj
  1. ‘呺~ˆêA²“¡Œö—YA‹e’n‡—TA²“¡‘åŽ÷A•àV@—ºA_’ÃŽ–çA–ؗ³’jAŒš•”r‰îA™‘ºGˆê˜YA‰ºìG–¾F”x“®–¬ŒŒŠÇ“à”çAMPK‚Í”x‚ŒŒˆ³Ç‚Ìis‚ð—}§‚·‚é.
  2. ‘å’Î’mGA²“¡Œö—YA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îA“ñ•r‘¾˜YA‚‹´@A‹{“c@•qA‰ºìG–¾FƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚銥“®–¬Ž¾Š³‚Ì’·Šú—\Œã—\‘ª.
‘æ9‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2016”N1ŒŽ30“ú`31“úAŽD–yŽsj

    ƒÅ—DG‰‰‘èÜ„

  1. ’Ò@ŒOØŽqAâ“c‘וFAŽO‰Y³’¨A’A–Ø‘sˆê˜YAŽR“à@‹BA¬–죄¶Aˆ¢•”—Ú—žAŒã‰ªL‘¾˜YA‚‹´@A‹{“c@•qA‰ºìG–¾F‚킪‘‚É‚¨‚¯‚é¶Žº‹ìo—¦‚ª•Û‚½‚ꂽS•s‘SгŽÒ‚Ì—Õ°“I“Á’¥‚É‚¨‚¯‚é«·@\CHART-2Œ¤‹†‚©‚ç‚Ì’mŒ©\
  2. ƒÅ—DG‰‰‘èÜ„

  3. ›Á@Œ³‹gA‰H”ö´‹MA‚‹´@AˆÉ“¡Œ’‘¾A‹{“c@•qA¼‹{Œ’‰îAš¢’J—²Ž¡A¼–{‘׎¡Aâ“c‘וFA‰ºìG–¾F‹}«S‹Ø[Ç”­Ç—¦‹y‚щ@“àŽ€–S—¦‚ÌŒo”N•ω»‚Ì«·‚ÉŠÖ‚·‚錟“¢@\Miyagi AMI Registry‚©‚ç‚Ì•ñ\
  4. ƒˆê”ʉ‰‘è„

  5. ŽR–{¹DA™‘ºGˆê˜YAŒš•”r‰îA–ؗ³’jAŽO‰Y³’¨A—é–ØG–¾A‰ºìG–¾Fƒtƒ@ƒuƒŠ[•a‚É‚¨‚¯‚éƒwƒeƒÚ‡‘Ì—«Š³ŽÒ‚̃XƒNƒŠ[ƒjƒ“ƒO.
  6. ç—t‹M•FA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA£ì«lA•½–쓹ŠîA[àV‹±Žj˜NAŽO–ØŒi‘¾A”‘ò@‘EA‰ºìG–¾F—¼SŽº‚Ø[ƒVƒ“ƒO‚É‚æ‚é¶Žºk¬Œø‰Ê‚ÆSŒŒŠÇƒCƒxƒ“ƒg‚ÌŠÖ˜A‚É‚¨‚¯‚é«·‚ÌŒŸ“¢.
  7. ŽO–ØŒi‘¾A•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA£ì«lA•½–쓹ŠîAç—t‹M•FA[àV‹±Žj˜NA”‘ò@‘EA‰ºìG–¾FS–[ד®‚Ì”xÖ¬Šu—£p‘ÎÛŠ³ŽÒ‚É‚¨‚¯‚é¶–[‚Ì\‘¢“I‚¨‚æ‚Ñ‹@”\“I•ω»‚Ì«·.
  8. ¬–죄¶Aâ“c‘וFA‹{“c@•qAŽO‰Y³’¨A’A–Ø‘sˆê˜YAŽR“à@‹BA’Ò@ŒOØŽqAˆ¢•”—Ú—žAŒã‰ªL‘¾˜YA‚‹´@A‰ºìG–¾FSŒŒŠÇ޾ггŽÒ‚É‚¨‚¯‚铌“ú–{‘åkÐŒã‚ÌS“IŠOŒãƒXƒgƒŒƒXáŠQ‚ÌŒo”N•ω»‚Æ«·@\CHART-2Œ¤‹†‚©‚ç\
  9. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OA–î–ì‰ë•¶A–åãr–¾A‘ã“c_”VAˆÀ“c@‘A‰ºìG–¾F–«S•s‘SгŽÒ‚¨‚æ‚Ñ‚»‚̃nƒCƒŠƒXƒNŒQ‚É‚¨‚¯‚é‰^“®‘jŠQˆöŽq‚Ì«·‚ÌŒŸ“¢@\‘S‘‘½Ž{Ý‹¤“¯ƒRƒz[ƒgŒ¤‹†‚æ‚è\
  10. Œš•”r‰îA™‘ºGˆê˜YA–ؗ³’jAŽO‰Y³’¨AŽR–{¹DA–î”ö”ÂM—TA—é–ØG–¾A²“¡@ê¡A_’ÃŽ–çA²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³ÇгŽÒ‚Ì«·‚É‚æ‚é—\Œã‚ÌŒŸ“¢.

Œ¤‹†‹ÆÑˆê——‚Ö@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2015”N
‘æ161‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2015”N12ŒŽ5“úAå‘äj

    ƒYIAŒ¤‹†”­•\•”–å„i–—DGÜŽóÜj

  1. _’ÃŽ–çA—é–ØG–¾A²“¡—yA–î”ö”ÂM—TAŽR–{¹DA‰H”ö´‹MAŽO‰Y³’¨AŒš•”r‰îA–ؗ³’jA¼–{‘׎¡A™‘ºGˆê˜YA‰ºìG–¾F‘½”­«d‰»Ç‚Ì”]в•a•ςɂæ‚邽‚±‚‚ÚS‹ØÇ‚̈ê—á
  2. ƒYIAÇ—á”­•\•”–å„i–—DGÜŽóÜj

  3. £ì«lA•Ÿ“c_“ñA’†–ì½A‹ß“¡³‹PA•½–쓹•æAç—t‹M•FA[’˱”V˜NAŽO–ØŒi‘¾A”‘ò‘EA‰ºìG–¾FS‘ŸƒTƒ‹ƒRƒCƒh[ƒVƒX‚É‚¨‚¯‚éƒXƒeƒƒCƒhŽ¡—ÊJŽnŒã‚ÌSŽº«•s®–¬‚ÌŒoŽž“I“Á’¥‚Ɖe‹¿ˆöŽq‚ÉŠÖ‚·‚錟“¢
  4. ƒˆê”ʉ‰‘è„

  5. ŽR–{¹DA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽO‰Y³’¨A—é–ØG–¾A–î”ö”ÂM—TA²“¡—yA²“¡Œö—YA‰ºìG–¾F“–‰È‚É‚¨‚¯‚éFabry•a‚Ìf—Âɂ‚¢‚Ä
  6. ’†–ì½A•Ÿ“c_“ñA‹ß“¡³‹PA£ì«lA•½–쓹•æAç—t‹M•FA[•Y‹±”V˜NAŽO–ØŒi‘¾A”‘ò‘EA‰ºìG–¾Fƒsƒ‹ƒWƒJƒCƒjƒh“Š—^‚ÅoŒ»‚µ‚½’x‰„“dˆÊ‚Ö‚ÌRFCA‚ª—LŒø‚Å‚ ‚Á‚½‚Æl‚¦‚ç‚ê‚éBrugadaÇŒóŒQÇ—á
  7. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì½A£ì«lA•½–쓹ŠîAç—t‹M•FA[’˱”V˜NAŽO–ØŒi‘¾A”‘ò‘EA‰ºìG–¾F¶”xÖ¬‹¤’ÊŠ²‚ð—L‚µCryoballoonablationŽ{sŒã‚ÉÄ”­‚ð”F‚ß‚½”­ì«S–[ד®‚̈ê—á
  8. ‹yì‘ì–çAâ“c‘וFA’A–Ø‘sˆê˜YA‹ž—ºˆêA²“¡Œª“ñ˜YAŽR“à‹BA’ÒŒOØŽqA¬–죄¶Aˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YAŒã‰ªL‘¾˜YA‚‹´AŽO‰Y³’¨A‹{“c•qA‰ºìG–¾F6ƒXƒ^ƒ`ƒ“‹­“x‚ªS‹Ø[ÇŠ³ŽÒ‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢| CHART-2Œ¤‹†‚æ‚è[
  9. {“c•jA_ŒË–ΗYA‚‹´A¼‹{Œ’‰îA‰H”ö´‹MAš¢’J—²Ž¡A¼–{‘׎¡A‰ºìG–¾FŠO«‚­‚à–Œ‰ºoŒŒ‚Æ‹}«S‹Ø[Ç‚ð‡•¹‚µ‚½ˆê—á
  10. ‰Á‰ê’J—T‘¾AˆÉ“¡Œ’‘¾A‚‹´A¼–{‘׎¡A‰€’J—²Ž¡A‰H”ö´‹MA¼‹{Œ’‰îAi“¡’q•FA”öŒ`„A•àV—ºA]Œû‹v”üŽqA”©’†˜a–¾A‹{“c•qA‰ºìG–¾F‹}«S‹Ø[ÇŒã‚Ì¶ŽºƒŠƒ‚ƒfƒŠƒ“ƒO‚ɑ΂·‚é’áo—͑̊OÕŒ‚”gŽ¡—Â̌ø‰Ê
  11. ‰H”ö´‹MA¼‹{Œ’‰îAŽR–{¹DA‰€’J—²Ž¡A¼–{‘׎¡A™‘ºGˆê˜YA‚‹´AˆÉ“¡Œ’‘¾A‰ºìG–¾FFabry•a‚ÉŠ¥Šlk«‹·SÇ‚ð‡•¹‚µ‚½ˆê—á
  12. [àV‹±”V˜NAŒ—’J—²Ž¡A‚‹´A{“c•jA¼‹{Œ’‰îA‰H”ö´‹MA¼–{‘׎¡AˆÉ“¡Œ’‘¾A‰ºìG–¾F”ñS‘ŸŽèp’†‚É”­Ç‚µ‚½–òÜ—noƒXƒeƒ“ƒg—¯’uŒãˆŸ‹}«ƒXƒeƒ“ƒgŒŒðǂ̈ê—á
  13. “n•”Œ«A‹e’n—ƒAŽuŠ™@‘ñA‘哹ޛ”ò—Y”nA‰Á“¡d•FA‚‹´Ž–¾A‹Ê“c–F–¾A•Ÿˆäº’jA–îì@—F•ÛA¼ˆäв”VAŒã“¡•q˜aAŽR–{¹DA™‘ºGˆê˜YA‰ºìG–¾F‰Â‹t«‚Ì¶ŽºáŠQ‚ð‚«‚½‚µ”x‚ŒŒˆ³‚ð‡•¹‚µ‚½POEMSÇŒóŒQ‚Ì1—á
  14. ‘å]’@–ؗ³’jA_’ÃŽ–çA—é–ØG–¾AŽR–{¹DAŽO‰Y³’¨AŒš•”r‰îA™‘ºGˆê˜YA‰ºìG–¾FŠO‰È“IŒŒð“Eœp‚Å—ÇD‚ÈŒo‰ß‚ª“¾‚ç‚ꂽ”xÇðǂ̈ê—á
  15. —é–ØG–¾A™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽO‰Y³’¨AŽR–{¹DA–î”ö”ÂM—TA‰ºìG–¾F“‡Ž¸’²Ç‚ð”wŒi‚ÉRƒŠƒ“Ž‰Ž¿R‘ÌÇŒóŒQ‚Å”­Ç‚µ‚½”xÇðǂ̈ê—á
  16. ŽR“à‹BAâ“c‘וFA’A–Ø‘sˆê˜YA‹ž—ºˆêA²“¡Œª“ñ˜YA¬–죄¶A’ÒŒOØŽqAˆ¢•”—Ú—žAŠ}Œ´M‘¾˜YA‹yì‘ì–çAŒã‰ªL‘¾˜YA‹{“c•qAŽO‰Y³’¨A‚‹´A‰ºìG–¾F‰ä‚ª‘‚Ì–x«S•s‘SгŽÒ‚É‚¨‚¢‚ÄS–[ד®‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿| CHART-2Œ¤‹†‚©‚ç‚Ì•ñˆê
  17. ¬–죄¶Aâ“c‘וFAŒã‰ªL‘¾˜YAŽO‰Y³’¨@’A–Ø‘sˆê˜YAŽR“à‹BA’ÒŒOØŽqAˆ¢•”—Ú—žA‹yì‘ì–çAŠ}Œ´M‘¾˜YA‹{“c@•qA‚‹´A‰ºìG–¾FSŒŒŠÇ޾ггŽÒ‚É‚¨‚¯‚铌“ú–{‘åkÐŒã‚ÌS“IŠOŒãƒXƒgƒŒƒXáŠQ‚Ì’nˆæ•ʂɂ¨‚¯‚éŒoŽž•ω»‚ÌŒŸ“¢
  18. _’ÃŽ–çA–ؗ³’jA™‘ºGˆê˜YAŽO‰Y³’¨AŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA—é–ØG–¾A²“¡—yA²“¡Œö—YA‰ºìG–¾F––½Œ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•a•ÏŒ`‘Ô[OFDI‚É‚æ‚錟“¢[
‘æ56‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2015”N10ŒŽ29“ú`31“úA“Œ‹žj
  1. ¬‘é—I“ñA‚‹´@A{“c@•jA¬¼^‹±A¼‹{Œ’‰îA‰H”ö´‹MA‰~’J—²Ž¡A¼–{‘׎¡AˆÉ“¡Œ’‘¾A‰ºìG–¾FŠ¥”÷¬zŠÂáŠQ‚ÆŒŒ’†ƒZƒƒgƒjƒ“‚ÌŠÖ˜A‚ÌŒŸ“¢.
  2. _’ÃŽ–çA–ؗ³’jA™‘ºGˆê˜YAŽO‰Y³’¨AŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA—é–ØG–¾A²“¡@ê¡A²“¡Œö—YA‰ºìG–¾F––½Œ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•a‘ÔŒ`¬@\OFDI‚É‚æ‚錟“¢\
  3. –ؗ³’jA™‘ºGˆê˜YAŽO‰Y³’¨AŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA—é–ØG–¾A²“¡@ê¡A²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚éŒo”ç“I”x“®–¬Šg’£p‚ÌŽ_‘f‰»”\‚Ö‚ÌŒø‰Ê.
‘æ19‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2015”N10ŒŽ22`24“úA‘åãj

    ƒYIAR¸u‰‰FŠî‘bŒn„iYIAŽóÜj

  1. Suzuki K, Satoh K, Omura J, Sato T, Kudo S, Otsuki T, Shimokawa H. Basigin promotes cardiac fibrosis and failure in response to chronic pressure-overload in mice
  2. ƒYIAR¸u‰‰F—Õ°Œn„iFinalistj

  3. Otsuki T, Satoh K, Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Miyata S, Shimokawa H. Prognostic impacts of plasma levels of cyclophilin A in patients with heart failure
  4. ƒ“Á•ÊŠé‰æ3F“ú–{E‰¢BE•Ä‘S•s‘SŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€„

  5. Sakata Y, Shimokawa H. Temporal trends in clinical profiles of symptomatic heart failure in Japan@- A report from the CHART Studies -
  6. ƒ“Á•ÊŠé‰æ4F“ú–{EŠØ‘S•s‘SŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€„

  7. Sakata Y, Shimokawa H. Differences in clinical characteristics and prognosis between HFpEF and HFrEF@-A report from the CHART-2 Study-
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€4FS•s‘S‚É‚¨‚¯‚é‹@”\•]‰¿|Žûk‹@”\EŠg’£‹@”\E‰ES‹@”\|„

  9. ²“¡@—yA™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽO‰Y³’¨AŽR–{¹DA–î”ö”ÂM—TA²“¡Œö—YA‘å“c‰p‹PA‰ºìG–¾FS‘ŸMRI‚ð—p‚¢‚½–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚ÌŒø‰ÊŒŸ“¢
  10. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“4FƒTƒ‹ƒRƒCƒh[ƒVƒXS‹ØÇ‚É”º‚¤––ŠúS•s‘S‚ɑ΂·‚鎡—Ä

  11. £ì«lA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA•½–쓹ŠîAç—t‹M•FAŽO–ØŒi‘¾A”‘ò@‘EA[àV‹±”V˜NA‰ºìG–¾ASƒTƒ‹ƒRƒCƒh[ƒVƒX––ŠúS•s‘S‚É‚¨‚¯‚題ã‚̉ۑè
  12. ƒƒ[ƒNƒVƒ‡ƒbƒv1FHFpEF‚Ìf’f‚ÆŽ¡—Ä

  13. ’ÒŒOØŽqAâ“c‘וFAŽO‰Y³’¨AŒã‰ªL‘¾˜YA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹´@A‹{“c@•qA‰ºìG–¾F‰ä‚ª‘‚É‚¨‚¯‚é¶Žº‹ìo—¦‚ª•Û‚½‚ꂽS•s‘SгŽÒ‚Ì—\Œã‚ÆŽ¡—à -CAHRT-2Œ¤‹†‚©‚ç‚Ì•ñ-
  14. ƒƒ[ƒNƒVƒ‡ƒbƒv6FS•s‘SŠî‘bŒ¤‹†‚ÌÅ‘Oü„

  15. Sato K, Suzuki K, Sunamura S, Otsuki T, Shimizu T,Ikeda S, Aoki T, Tatebe S, Sugimura K, Shimokawa H. Crucial roles of Rho-kinase, cyclophilin A and its receptor, basigin, for cardiac hypertrophy, fibrosis and failure -novel therapeutic targets-
  16. ƒƒ[ƒNƒVƒ‡ƒbƒv7F¬læ“V«S޾г––ŠúгŽÒ‚ÌŠÇ—„

  17. Tatebe S, Sugimura K, Aoki T, Miura M, Yamamoto S, Yaoita N, Suzuki H, Sato H, Sato K, Shimokawa H. Current status of the management for adult congenital heart disease associated with end-stage pulmonary arterial hypertension
  18. ƒƒ[ƒNƒVƒ‡ƒbƒv9F‘å‹K–ÍŒ¤‹†@|ƒŒƒWƒXƒgƒŠŒ¤‹†‚Æ‘OŒü‚«Š„‚è•t‚¯ŽŽŒ±|„

  19. Miura M, Sakata Y, Miyata S, Tadaki S, Ushigome R, Yamauchi T, Sato K, Nochioka K, Takahashi J, Shimokawa H. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartaniSUPPORTjtrial
  20. Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Onose T, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H. The chronic heart failure analysis and registry in the Tohoku District-2iCHART-2jStudy as a model of Japanese observational study
  21. ƒƒn[ƒgƒ`[ƒ€ƒVƒ“ƒ|ƒWƒEƒ€2FS•s‘S•a‘ÔƒXƒe[ƒW•ʂ̉h—{ŠÇ—„

  22. “c’†—T”üAŽO‰Y³’¨Aâ“c‘וFA™‘ºGˆê˜YA‹ß“¡³‹PA‰H”ö´‹MA¯“‡˜a¢A—é–ØŽõŽ÷AŠ`‰Ô—²ºA‰ºìG–¾FS•s‘SгŽÒ‚É‚¨‚¯‚éCONUTƒXƒRƒA‚É‚æ‚é‰h—{•]‰¿‚Ì—L—p«
  23. ƒƒn[ƒgƒ`[ƒ€ƒVƒ“ƒ|ƒWƒEƒ€3FS•s‘SƒPƒA‚É‚¨‚¯‚é—‘z“I‚Ȉã—Ãê–åEƒ`[ƒ€iIPWj‚ð\’z‚·‚é‚É‚ÍH„

  24. ŠìƒAƒ†ƒ~AŽO‰Y³’¨A™‘ºGˆê˜YA‹ß“¡³‹PA‰H”ö´‹MA¯“‡˜a¢A—é–ØŽõŽ÷AŠ`‰Ô—²ºA“c’†—T”üA‰ºìG–¾F“–‰@‚É‚¨‚¯‚éƒn[ƒgƒ`[ƒ€‚Ì—§‚¿ã‚°‚ÌŒ»ó‚Ɖۑè
  25. ƒƒn[ƒgƒ`[ƒ€ƒVƒ“ƒ|ƒWƒEƒ€6F‚—îŽÒS•s‘SгŽÒ‚ɑ΂·‚éƒAƒvƒ[ƒ`@|ƒtƒŒƒCƒ‹A”F’mÇA‘ŸŠíáŠQ|„

  26. ²“¡Œª“ñ˜YAâ“c‘וFA‹{“c@•qAŽO‰Y³’¨A‹ž—ºˆêA’A–Ø‘sˆê˜YA¬–죄¶A’Ò@ŒOØŽqAŽR“à@‹BA‰ºìG–¾F ‚—îŽÒS•s‘SгŽÒ‚É‚¨‚¯‚é‰îŒì•K—v“x‚¨‚æ‚щh—{ó‘Ô‚Ì•]‰¿‚Æ‘Îô‚Ìd—v«: CHART-2Œ¤‹†‚©‚ç‚Ì•ñ
  27. ƒˆê”ÊŒû‰‰2F“ñŽŸ«S‹ØÇi1j`SƒTƒ‹ƒRƒCƒh[ƒVƒX`„

  28. Segawa M, Fukuda K, Nakano M, Kondo M, Hirano M, Chiba T, Miki K, Morosawa S, Fukazawa K, Shimokawa H. The significance of advanced heart block in patients with cardiac sarcoidosis
  29. ƒˆê”ÊŒû‰‰10F‚½‚±‚‚ÚS‹ØÇ„

  30. Suzuki H, Matsumoto Y, Sugimura K, Takahashi J, Fukumoto Y, Shimokawa H. Evidence for brain activation in patients with Takotsubo cardiomyopathy -A new finding of cardio-cerebral connection-
  31. Kochi R, Aoki T, Sugimura K, Tatebe S, Miura M, Yaoita N, Takahashi J, Matsumoto Y, Satou K, Shimokawa H. Takotsubo cardiomyopathy in a case of recurrent pheochromocytoma
  32. ƒˆê”ÊŒû‰‰15F–«S•s‘Si‚Pj„

  33. Yamauchi T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Miyata S, Shimokawa H. Prognostic impact of de-novo atrial fibrillation in patients with chronic heart failure - A report from the CHART-2 Study-
  34. ƒˆê”ÊŒû‰‰18FS•s‘SES”ì‘å‚Ì•ªŽq‹@\i‚Pj„

  35. Sunamura S, Satoh K, Suzuki K, Omura J, Kikuchi N, Satoh T, Kurosawa R, Kudo S, Ikeda S, Shimokawa H. ROCK1 plays a crucial role to maintain cardiac function in response to pressure-overload in mice
  36. ƒˆê”ÊŒû‰‰35F“ñŽŸ«S‹ØÇi3j`”ì‘åŒ^`„

  37. Nakano M, Fukuda K, Kondo M, Segawa M, Hirano M, Chiba T, Fukazawa K, Miki K, Morosawa S, Shimokawa H. Implantable cardioverter defibrillator for primary prevention properly perminated ventricular tachycardia in patient with cardiac fabry disease
  38. ƒˆê”ÊŒû‰‰37F–«S•s‘Si3j„

  39. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Sato K, Yamauchi T, Onose T, Shimokawa H. Temporal trends in drug therapies and clinical outcomes in patients with symptomatic heart failure: Lessons from the CHART Studies
  40. ƒƒ|ƒXƒ^[6F‰æ‘œf’f„

  41. Obe H, Suzuki H, Ota H, Aoki T, Sugimura K, Matsumoto Y, Kushimoto S, Shimokawa H. Cardiac magnetic resonance as an alternative diagnostic method for Takotsubo cardiomyopathy in a patient with allergy to iodine contrast media
  42. ƒƒ|ƒXƒ^[9F—˜”AÜŽ¡—Ä

  43. Sugimura K, Miura M, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Satoh K, Miyata S, Sakata Y, Shimokawa H. Prognostic impacts of diuretics in Japanese patients with chronic heart failure
‘æ4‰ñ “ú–{”xzŠÂŠw‰ïE‘æ3‰ñ“ú–{”x‚ŒŒˆ³Šw‰ïŠwpW‰ïi10ŒŽ3“ú`4“úA2015”NA“Œ‹žj

    ƒYIAƒZƒbƒVƒ‡ƒ“„

  1. ²“¡@‘åŽ÷A²“¡@Œö—YA–î”ö”Â@M—TA‹e’n@‡—TA‘呺@~ˆêA•àV@—ºA™‘º@Gˆê˜YA’†‘º@ˆê•¶AˆÉ“¡@_A‰ºì@G–¾FTEPH ‚É‚¨‚¯‚éV‹K•aˆö’`”’ TAFI ‚ÌŠî‘b“I E —Õ°“I‹@”\‰ðÍ.
  2. “nç³@—´HA¯ì@NAˆÀ’B@—AVˆäì@O“¹A¼“c@ˆÀŽjA–ì“c@‰ëŽjAŒš•”@r‰îA™‘º@Gˆê˜YA‰ºì@G–¾AÄ–Ø@‰ÀŽA‰ª“c@Ž“TF“V«S޾г‚ÉŠÖ˜A‚µ‚½”x‚ŒŒˆ³Ç‚ɑ΂·‚é”xˆÚA.
  3. ƒƒVƒ“ƒ|ƒWƒEƒ€2F‰ES•s‘S‚̃Cƒ[ƒWƒ“ƒO„

  4. Œš•”@r‰îA™‘º@Gˆê˜YA–Ø@—³’jAŽO‰Y@³’¨AŽR–{@¹DA–î”ö”Â@M—TA —é–Ø@G–¾A²“¡@—yA_’Ã@Ž–çA²“¡@Œö—YA‰ºìG–¾FOCT‚É‚æ‚éPH‚Ìf’f.
  5. ƒƒVƒ“ƒ|ƒWƒEƒ€6FTEPH ––½Œ^‚ɑ΂·‚éƒoƒ‹[ƒ“Šg’£p‚̬тƖâ‘è“_ /CTEPH ‚ɑ΂·‚é PEA‚¨‚æ‚Ñ EPA ‚Ì’†ŠúE‰“Šu¬Ñ„

  6. ™‘º@Gˆê˜YA–Ø@—³’jAŽO‰Y@³’¨AŒš•”@r‰îAŽR–{@¹DA–î”ö”Â@M—TA —é–Ø@G–¾A²“¡@—yA²“¡@Œö—YA‰ºì@G–¾F“–‰@‚É‚¨‚¯‚é PTPA ‚̬тƖâ‘è
  7. ƒƒVƒ“ƒ|ƒWƒEƒ€8F”x‚ŒŒˆ³Ž¡—Öò‚Ì”xŒŒŠÇˆÈŠO‚Ö‚Ìì—p‚ð‰î‚µ‚½”x‚ŒŒˆ³•a‘Ô‰ü‘P‚̉”\«„

  8. ²“¡@Œö—YA‰ºì@G–¾FƒTƒCƒNƒƒtƒBƒŠƒ“ A ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\‚Æ‚»‚Ì—Õ°‰ž—p.
  9. ƒˆê”ʉ‰‘è„

  10. ‘呺@~ˆêA²“¡@Œö—YA‹e’n@‡—TA²“¡@‘åŽ÷A•àV@—ºA_’Ã@Ž–çAÀ–ì@˜a•FA–Ø@—³’jAŒš•”@r‰îA™‘º@Gˆê˜YA‰ºì@G–¾F”x“®–¬ŒŒŠÇ“à”ç AMPK ‚Í”x‚ŒŒˆ³Ç‚Ìis‚ð—}§‚·‚é.
  11. À–ì@˜a•FA²“¡@Œö—YA‘å’Î@’mLA‹e’n@‡—TA‘呺@~ˆêA²“¡@‘åŽ÷A•àV@—ºA–Ø@—³’jAŒš•”@r‰îA™‘º@Gˆê˜YA‰ºì@G–¾FPH гŽÒ‚ÌŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“ A ‚ƉŠÇ«ƒTƒCƒgƒJƒCƒ“‚Ì‘ŠŠÖ.
  12. •àV@—ºA²“¡@Œö—YA‹e’n@‡—TA‘呺@~ˆêA²“¡@‘åŽ÷A–ì–Ø@³“¹AÀ–ì@˜a•FAMohammad SiddiqueAElias Al-MamunA™‘º@Gˆê˜YA‰ºì@G–¾F‰»‡•¨ƒXƒNƒŠ[ƒjƒ“ƒO‚É‚æ‚éV‹K”x‚ŒŒˆ³ÇŽ¡—Öò‚ÌŠJ”­.
  13. Œš•”@r‰îA™‘º@Gˆê˜YA–Ø@—³’jAŽO‰Y@³’¨AŽR–{@¹DA–î”ö”Â@M—TA—é–Ø@G–¾A²“¡@—yA²“¡@Œö—YA‰ºì@G–¾FDiastolic pulmonary gradient ‚É‚æ‚é Group2 PH гŽÒ‚Ì—\Œã—\‘ª.
  14. ‹e’n@‡—TA²“¡@Œö—YA‘呺@~ˆêA²“¡@‘åŽ÷A•àV@—ºA–ì–Ø@³“¹A‘å’Î@’mLAŒš•”@r‰îA–Ø@—³’jA™‘º@Gˆê˜YA‰ºì@G–¾FV‹K•aˆö’`”’ƒZƒŒƒmƒvƒƒeƒCƒ“ P ‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\
  15. –Ø@—³’jA™‘º@Gˆê˜YAŽO‰Y@³’¨AŒš•”@r‰îA–î”ö”Â@M—TA—é–Ø@G–¾A²“¡@—yA_’Ã@Ž–çA²“¡@Œö—YA‰ºì@G–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚¨‚¯‚é OFDI ‚ð—p‚¢‚½•a•ÏŒ`‘Ô‚ÌŠÏŽ@.
  16. –î”ö”Â@M—TA²“¡@Œö—YA²“¡@‘åŽ÷A™‘º@Gˆê˜YA–Ø@—³’jAŽO‰Y@³’¨AŒš•”@r‰îA•Ÿ–{@‹`OA‰ºì@G–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•aˆö‚É‚¨‚¯‚é TAFI ‚ÌŠÖ—^.
  17. –Ø@—³’jA™‘º@Gˆê˜YAŽO‰Y@³’¨AŒš•”@r‰îAŽR–{@¹DA–î”ö”Â@M—TA—é–Ø@G–¾A²“¡@—yA²“¡@Œö—YA‰ºì@G–¾FCTEPH‚É‚¨‚¯‚éŒo”ç“I”x“®–¬Šg’£p‚̌ċz‹@”\‚Ö‚ÌŒø‰Ê.
  18. ²“¡@Œö—YA™‘º@Gˆê˜YA–Ø@—³’jAŒš•”@r‰îAŽO‰Y@³’¨A–î”ö”Â@M—TA—é–Ø@G–¾AŽR–{@¹DA_’Ã@Ž–çA‘å’Î@’mLA‰ºì@G–¾FŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“ A ‚Í PTPA Ž¡—Â̗LŒø«‚𔽉f‚·‚é.
  19. ²“¡@—yA‘å“c@‰pŠöA™‘º@Gˆê˜YA–Ø@—³’jAŒš•”@r‰îAŽO‰Y@³’¨AŽR–{@¹DA–î”ö”Â@M—TA—é–Ø@G–¾A²“¡@Œö—YA‰ºì@G–¾FS‘Ÿ MRI ‚ð—p‚¢‚½Œo”ç“I”x“®–¬Œ`¬p‚ÌŒø‰ÊŒŸ“¢.
  20. ŽO‰Y@³’¨A™‘º@Gˆê˜YA–Ø@—³’jAŒš•”@r‰îAŽR–{@¹DA–î”ö”Â@M—TA
  21. —é–Ø@G–¾A²“¡@—yA²“¡@Œö—YA‰ºì@G–¾FƒCƒ}ƒ`ƒjƒu“Š—^‚É‚æ‚è’·Šú¶‘¶‚ª“¾‚ç‚ꂽ”xÖ¬•ÂÇ«Ž¾Š³‚̈ê—á.
  22. —é–Ø@G–¾A™‘º@Gˆê˜YA–Ø@—³’jAŒš•”@r‰îAŽO‰Y@³’¨AŽR–{@¹DA–î”ö”Â@M—TA²“¡@Œö—YA‹vŽu–{@¬Ž÷A‰ºì@G–¾F“‡Ž¸’²Ç‚É”º‚¤RƒŠƒ“Ž‰Ž¿R‘ÌÇŒóŒQ‚Å”­Ç‚µ‚½”xÇðǂ̈ê—á.
  23. ¯Žq@Œ\A™‘º@Gˆê˜YAŽO‰Y@³’¨A‹g“c@KŽ}AŽ›¼@Œb”üA¯“‡@˜a¢A–¾’¿@çŒbA—é–Ø@ŽõŽ÷AŠ`‰Ô@—²ºA‰ºì@G–¾F”x“®–¬«”x‚ŒŒˆ³ÇгŽÒ‚ɑ΂·‚éƒ`[ƒ€ˆã—Ã.
‘æ63‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2015”N9ŒŽ18`20“úA‰¡•lj

    ƒƒVƒ“ƒ|ƒWƒEƒ€1FŒŒŠÇ‹@”\•]‰¿‚ÌŒ»ó‚Ɖۑè„

  1. ¼‹{ Œ’‰îA¼–{ ‘׎¡A‰F’Ë —T‹IA‘åŽR @”nAi“¡ ’q•FA•½–ì “¹ŠîA¬‘é —I“ñA‰H”ö ´‹MAš¢’J —²Ž¡A‚‹´ AˆÉ“¡ Œ’‘¾A‰ºì G–¾FŠ¥“®–¬¹k‚É‚¨‚¯‚銥“®–¬ƒCƒ[ƒWƒ“ƒO‚Ìd—v«
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€2F‹}«Š¥ÇŒóŒQ‚Ìf—ÂÌi•à|‚³‚ç‚È‚é—\Œã‚̉ü‘P‚ÉŒü‚¯‚Ä|„

  3. ‰H”ö ´‹MA‚‹´ AˆÉ“¡ Œ’‘¾A‹{“c •qA›Á Œ³‹gA¼‹{ Œ’‰îAš¢’J —²Ž¡A¼–{ ‘׎¡Aâ“c ‘וFA‰ºì G–¾F‹}«S‹Ø[ǂ̔­Ç—¦‚Ɖ@“àŽ€–S—¦‚̋ߔN‚É‚¨‚¯‚éŒo”N•ω»\MIYAGI-AMI Registry Study‚©‚ç‚Ì•ñ\
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€3FS‘Ÿ“Ë‘RŽ€‚Ì—\’m‚Æ—\–h‚ÌÅ‘Oü„

  5. ²’| —m”VA•Ÿ“c _“ñAâ“c ‘וFA‹{“c •qA’†–ì ½A‹ß“¡ ³‹PA•½–ì “¹ŠîA£ì «lA‰ºì G–¾F–{–M–«S•s‘SгŽÒ‚ÌS‘Ÿ“Ë‘RŽ€‚ɑ΂·‚éˆêŽŸ—\–h–Ú“I‚ÌA‚¦ž‚ÝŒ^œ×“®Ší‚ÌŒ»ó\CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€4FŠó­SŒŒŠÇ޾г‚ðŒ©’¼‚·„

  7. ™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’¨A–î”ö” M—TA²“¡ —yA²“¡ Œö—YA‰ºì G–¾F“–‰@‚É‚¨‚¯‚éFabry•af—Â̌»ó
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€5FV‚½‚ȃGƒrƒfƒ“ƒX‚ÉŠî‚­kÐŽžzŠÂŠí޾г‚Ì—\–h‚ÆŠÇ—F‹}«Šú‚©‚ç–«Šú‚Ö„

  9. ‚‹´ A‰ºì G–¾F‘åkЂÆS•s‘S ¬–ì£ „¶Aâ“c ‘וFAŒã‰ª L‘¾˜YA‹{“c •qAŽO‰Y ³’¨A’A–Ø šáˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA’Ò ŒOØŽqAˆ¢•” —Ú—žA‚‹´ A‰ºì G–¾FSŒŒŠÇ޾ггŽÒ‚É‚¨‚¯‚铌“ú–{‘åkÐŒã‚ÌS“IŠOŒãƒXƒgƒŒƒXáŠQ‚Æ‚»‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿\CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€8FS•s‘S‘ˆ«‚ð‚à‚½‚ç‚·”ñS‘ŸˆöŽqi”]A”xj„

  11. ŽR“à ‹BAâ“c ‘וFA‚“c „A‹{“c •qAŽO‰Y ³’¨A’A–Ø ‘sˆê˜YA‹ž —ºˆêA²“¡ Œª“ñ˜YA¬–ì£ „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žAŒã‰ª L‘¾˜YA‚‹´ A‰ºì G–¾F–«S•s‘SгŽÒ‚Ì—\Œã‚ɑ΂·‚é•nŒŒ‚̉e‹¿‚ÌŒŸ“¢\CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  12. ƒƒVƒ“ƒ|ƒWƒEƒ€9F‰uŠwŒ¤‹†‚ðzŠÂŠí޾г—\–h‚ÉŠˆ‚©‚·„

  13. â“c ‘וFAŽO‰Y ³’¨A’A–Ø ‘sˆê˜YA‹ž —ºˆêA²“¡ Œª“ñ˜YAŽR“à ‹BA¬–ì£ „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žAŒã‰ª L‘¾˜YA‚‹´ A‹{“c •qA‰ºì G–¾F‰ä‚ª‘‚É‚¨‚¯‚é–«S•s‘S‘å‹K–ÍŠÏŽ@Œ¤‹†FCHART-2Œ¤‹†
  14. ƒƒVƒ“ƒ|ƒWƒEƒ€14FS޾ггŽÒ‚É‚¨‚¯‚铜”A•a‚ÌŠÇ—„

  15. ŽO‰Y ³’¨Aâ“c ‘וFA‹{“c •qA’A–Ø ‘sˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA¬–ì£ „¶A’Ò ŒOØŽqAˆ¢•” —Ú—žAŒã‰ª L‘¾˜YA‚‹´ A‰ºì G–¾F‹•ŒŒ«/”ñ‹•ŒŒ«S•s‘S‚É‚¨‚¯‚铜”A•a‚Ì—\Œã‚ւ̉e‹¿\tǂ̊ϓ_‚©‚ç‚ÌlŽ@\
  16. ƒ“ú–{S‘Ÿ•aŠw‰ïE“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€FS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚©‚çƒtƒŒƒCƒ‹‚ðl‚¦‚é„

  17. ¼–{ ‘׎¡A’|“à ‰ëŽjA‚‹´ A™‘º Gˆê˜YAŽO‰Y ³’¨A㌎ ³”ŽA‰ºì G–¾FŒoƒJƒe[ƒeƒ‹‘å“®–¬•Ù—¯’up‚É‚¨‚¯‚éS‘ŸƒŠƒnƒrƒŠ‚Ì–ðŠ„`ƒtƒŒƒCƒ‹iFrailtyj‚Ì”Fޝ‚ƌċzE‰^“®‹@”\ŠÇ—‚Ìd—v«`
  18. ƒ—DG‰‰‘èƒZƒbƒVƒ‡ƒ“iˆãŽtj„

  19. š¢’J —²Ž¡A‚‹´ A’†‘º –¾_A–ìè ‰p“ñA™ ³•¶AŽR–{ ‹`lA•½–{ “N–çA–xŒû ‘Aˆäã Š°ˆêAŒã“¡ •q˜aA‰Á“¡ “ÖAŽÂè ‹BA‰ºì G–¾F’·ŽžŠÔì—pŒ^ƒjƒtƒFƒWƒsƒ“‚É‚æ‚é–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ÌŒŒŠÇ•ÛŒìŒø‰ÊFNOVELŽŽŒ±
  20. ƒŽáŽèÇ—áPresenterÜF”ñNP“I‰æ‘œf’f„

  21. ‘åç³ Š°KA—é–Ø G–¾A‘å“c ‰pŠöAÂ–Ø —³’jA™‘º Gˆê˜YA¼–{ ‘׎¡A‹vŽu–{ ¬Ž÷A‰ºì G–¾F“®–¬ƒKƒX”]Çðǂɇ•¹‚µ‚½‚½‚±‚‚ÚS‹ØÇ‚Ì1—áFƒˆ[ƒh‘¢‰e܃AƒŒƒ‹ƒM[Ç—á‚É‚¨‚¯‚éS‘ŸMRI‚Ì—L—p«
  22. ƒƒ‚[ƒjƒ“ƒOƒŒƒNƒ`ƒƒ[3F–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ÌŠ¥¹k‚ÆŒŒŠÇ‹@”\•ÛŒìí—ª„

  23. ‚‹´ F–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ÌŠ¥¹k‚ÆŒŒŠÇ‹@”\•ÛŒìí—ª
  24. ƒƒtƒ@ƒCƒA[ƒTƒCƒhƒVƒ“ƒ|ƒWƒEƒ€6FŠ¥¹k‚ÌÅV’mŒ©„

  25. ¼‹{ Œ’‰îFŠ¥¹k«‹·Sǂɂ¨‚¯‚éŠO–ŒVasa vasorum‚ÌŠÖ—^`Optical frequency domain imagingiOFDIj‚ð—p‚¢‚½ŒŸ“¢`
  26. ƒˆê”ʉ‰‘èFŒû‰‰„

  27. –î”ö” M—TA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’¨AŒš•” r‰îA‰ºì G–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì•aˆö‚É‚¨‚¯‚éTAFI‚Ì–ðŠ„‚Æ‚»‚Ì‹@”\“IˆÓ‹`
  28. ‘å’Î ’mLA²“¡ Œö—YA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’¨AŽR–{ ¹DA–î”ö” M—TA—é–Ø G–¾A²“¡ —yA_’Ã Ž–çA“ñ•r ‘¾˜YA‚‹´ A‹{“c •qA‰ºì G–¾FŒŒŸ÷’†ƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚銥“®–¬Ž¾Š³‚Ì’·Šú—\Œã—\‘ª
  29. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  30. ²“¡ Œª“ñ˜YAâ“c ‘וFA‹{“c •qAŽO‰Y ³’¨A‹ž —ºˆêA’A–Ø šáˆê˜YA¬–ì£ „¶A’Ò ŒOØŽqAŽR“à ‹BAˆ¢•” —Ú—žAŒã‰ª L‘¾˜YA‚‹´ A‰ºì G–¾F‰ä‚ª‘‚É‚¨‚¯‚é‚—îŽÒS•s‘S‚Ì—Õ°“I“Á’¥‚Æ—\Œã‹K’èˆöŽq: ‘æ“ñŽŸ“Œ–k–«S•s‘S“o˜^(CHART-2)Œ¤‹†‚©‚ç‚Ì•ñ
  31. ‹ž —ºˆêAâ“c ‘וFA‹{“c •qAŽO‰Y ³’¨A’A–Ø šáˆê˜YA²“¡ Œª“ñ˜YAŽR“à ‹BA¬–ì£ „¶A’Ò ŒOØŽqA‹yì ‘ì–çAŠ}Œ´ M‘¾˜YAŒã‰ª L‘¾˜YA‚‹´ A‰ºì G–¾F‰ä‚ª‘‚Ìnj󫖫S•s‘Sf—Â̕ϑJ‚Æ«·FCHARTŒ¤‹†‚©‚ç‚Ì•ñ
  32. ›Á Œ³‹gA‰H”ö ´‹MA‚‹´ AˆÉ“¡ Œ’‘¾A‹{“c •qA¼‹{ Œ’‰îAš¢’J —²Ž¡A¼–{ ‘׎¡Aâ“c ‘וFA‰ºì G–¾F‹}«S‹Ø[Ç”­Ç—¦‹y‚щ@“àŽ€–S—¦‚Ì”N‘ã•ÊŒo”N•ω»‚ÌŒŸ“¢\Miyagi AMI Registry Study‚©‚ç‚Ì•ñ
  33. Â–Ø —³’jA™‘º Gˆê˜YAŽO‰Y ³’¨AŒš•” r‰îA–î”ö” M—TA²“¡ —yA²“¡ Œö—YA‰ºì G–¾FŒo”ç“I”x“®–¬Šg’£p‚Í–«ŒŒðÇð«”x‚ŒŒˆ³Š³ŽÒ‚É‚¨‚¢‚ÄŒŒs“®‘ԂɉÁ‚¦‚ÄŽ_‘f‰»‚à‰ü‘P‚·‚é
  34. ²“¡ —yA‘å“c ‰pŠöA™‘º Gˆê˜YAÂ–Ø —³’jAŒš•” r‰îAŽO‰Y ³’¨AŽR–{ ¹DA–î”ö” M—TA²“¡ Œö—YA‰ºì G–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚ÌŒø‰ÊŒŸ“¢
  35. ’†–ì ½A•Ÿ“c _“ñA‹ß“¡ ³‹PA£ì «lA•½–ì “¹ŠîAç—t ‹M•FA‰ºì G–¾FICDƒŠ[ƒh‚Ì•ÏX‚ª—LŒø‚Å‚ ‚Á‚½‚œ×“®è‡’l‚ð’æ‚µ‚½BrugadaÇŒóŒQ‚̈ê—á
  36. “c’† îc˜NAÂ–Ø —³’jA™‘º Gˆê˜YAŒš•” r‰îAŽO‰Y ³’¨A–î”ö” M—TA²“¡ —yA‰ºì G–¾F‘½Šj‹×–E‚ð”F‚ß‚½Œ€ÇŒ^S‹Ø‰Š‚̈ê—á
  37. £ì «lA•Ÿ“c _“ñAÂ–Ø —³’jA’†–ì ½A‹ß“¡ ³‹PA•½–ì “¹ŠîA™‘º Gˆê˜YA‰ºì G–¾FPETAMRIŽž‘ã‚É‚¨‚¢‚ăKƒŠƒEƒ€ƒVƒ“ƒ`‚ªSƒTƒ‹ƒRƒCƒh[ƒVƒXf—Âɉʂ½‚·–ðŠ„
  38. Œš•” r‰îA™‘º Gˆê˜YAÂ–Ø —³’jAŽO‰Y ³’¨A–î”ö” M—TA—é–Ø G–¾A²“¡ —yA²“¡ Œö—YA‰ºì G–¾FDiastolic pulmonary gradient‚ð—p‚¢‚½post-capillary PHгŽÒ‚Ì—\Œã—\‘ª
‘æ21‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2015”N7ŒŽ18`19“úA•Ÿ‰ªŽsj

    ƒYIA session„

  1. ‹ààV³”ÍA¼–{‘׎¡AŠÝ–{ŒõŽiAAxel LinkeA‰ºìG–¾FƒgƒŒƒbƒhƒ~ƒ‹‰^“®—Ö@‚ÍS‹Ø[ÇŒã‚Ìœ–§“x’ቺ‚ð—\–h‚·‚é@\S‹Ø[ǃ}ƒEƒXƒ‚ƒfƒ‹‚ł̌Ÿ“¢\iÅ—DGÜŽóÜj
  2. ƒˆê”ʉ‰‘èFŒû‰‰„

  3. ‰H”ö´‹MA¼–{‘׎¡AX@M–FA¼‹{Œ’‰îA‰~’J—²Ž¡A‚‹´@AˆÉ“¡Œ’‘¾Aâ“c‘וFA㌎³”ŽA‰ºìG–¾FŠ¥¹k«‹·SÇŠ³ŽÒ‚ɑ΂·‚éƒJƒ‹ƒVƒEƒ€hR–ò‚̉^“®‘Ï—e”\‰ü‘PŒø‰Ê‚ɂ‚¢‚Ă̌Ÿ“¢
  4. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OA–î–ì‰ë•¶A–åãr–¾A‘ã“c_”VAˆÀ“c@‘A‰ºìG–¾F–«S•s‘SгŽÒ‚¨‚æ‚уnƒCƒŠƒXƒNŒQ‚É‚¨‚¯‚ég‘ÌŠˆ“®‚Ɖ^“®‘jŠQˆöŽq‚ÌŒŸ“¢@\‘S‘‘½Ž{Ý‹¤“¯ƒRƒz[ƒgŒ¤‹†‚æ‚è[
  5. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  6. ŽO‰Y³’¨A™‘ºGˆê˜YAŒš•”r‰îA–ؗ³’jA–î”ö”ÂM—TA²“¡@ê¡A“c’†—T”üAŠìƒAƒ†ƒ~A²X–Ø•S‡‰ÔAŠ`‰Ô—²ºA—é–ØŽõŽ÷A²“¡Œö—YA‰ºìG–¾FS•s‘SŽè’ ‚ðŽg—p‚µŠO—ˆ‚ÅŒo‰ßŠÏŽ@‚µ‚½Šg’£Œ^S‹ØÇ‚É‚æ‚édÇS•s‘S‚̈ê—á.
‘æ15‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2015”N6ŒŽ26`27“úA–L’†Žsj

    ƒYIA session„

  1. Ö“¡‘åŽ÷A²“¡¹—¢A“c’†C•½A_ŒË–ΗYA‰ºìG–¾FŒŒŠÇ“à”ç‚É‚¨‚¯‚éCaveolin-1/“à”çŒ^ˆêŽ_‰»’‚‘f‡¬y‘f•¡‡‘̂̌`¬‚ªEDH‚ð‰î‚µ‚½”÷¬zŠÂ‚ÌPí«‚ÌˆÛŽ‚Éd—v‚Å‚ ‚é.i—DGÜŽóÜj
  2. ƒˆê”ʉ‰‘èFŒû‰‰„

  3. “›ˆä³lA“à“c‘¾˜YA’J–{º‰pA‰ºìG–¾A–öŒ´‰„ÍA”ö’Ò@–LA“c‘º‰ëmFƒCƒ‹ƒxƒTƒ‹ƒ^ƒ“‚ƃAƒ€ƒƒWƒsƒ“‚Ì•¹—p“Š—^‚Í2/3t“ENOSsŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚¨‚¯‚é‹}«S‹Ø[ǂ̔­Ç‚ð’˜–¾‚É—}§‚·‚é.
  4. ¶‰z‹M–¾AéŒË‹MŽuA“›ˆä³lA–˜a”ŽAΖ{—TŽmAŽR“c‘‘—ºA–L•½—R”üŽqA‰ºìG–¾A–öŒ´‰„ÍAŒ}@аFNO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚¨‚¯‚é’áŽ_‘f«”x‚ŒŒˆ³Ç.
  5. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  6. _ŒË–ΗYAÖ“¡‘åŽ÷A“c’†C•½A²“¡¹—¢A‰ºìG–¾F“à”çˆË‘¶«’oŠÉ”½‰ž‚É‚¨‚¯‚éNO‚ÆEDHF‚̶—“Iƒoƒ‰ƒ“ƒX‚Ìd—v«.
  7. ²’|—m•½A²“¡Œö—YAŠC–@N—TArˆä—zˆêA‰ºìG–¾FäNã÷Žûk’oŠÉ‹@\‚É‚¨‚¯‚éŠeŽíNOŽY¶‡¬y‘f‚Ì‹@”\“I–ðŠ„•ª’S.
  8. –î“c–L—²A‰ºìG–¾A—§‰Ô”Ž”VA¬Š}Œ´N•vFƒCƒk¶‘Ì“à“œ”A•a«Š¥”÷¬‘¤•›ŒŒŠÇ‚É‚¨‚¢‚ĉߎ_‰»…‘f‚É‚æ‚銥”÷¬‘¤•›ŒŒŠÇŠg’£‚ÍAŠ¥“®–¬•ÂÇŽž‚ÌNO‚É‚æ‚錌ŠÇ“à”çáŠQ‚ð‘ãž‚·‚é.
  9. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[„

  10. ‰ºìG–¾Fd—v«‚ð‘‚·S•s‘S‚Ìf—Ã.
‘æ205‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2015”N6ŒŽ20“úAå‘äŽsj
  1. ŽR–{—´ˆêA‹vŽu–{¬Ž÷A—é–ØG–¾A‰ºìG–¾FSepsis-induced encephalopathy‚É‚æ‚é‘J‰„«ˆÓޝáŠQ‚ð’æ‚µ‚½Š´õ«S“à–Œ‰Š‚Ì1—á.
  2. “c’†Œ’ŽqAóÀŒhˆê˜YA‹vŽu–{¬Ž÷A—é–ØG–¾A’†–ì@½A™‘ºGˆê˜YAâ“c‘וFA‰ºìG–¾F“ª•”ŠO‚É‚æ‚éR‹ÃŒÅ—Ö@’†’fŒã‚É”­Ç‚µ‚½‘½”­ÇðÇ‚Ì1—á.
  3. ˆÉ“¡‚ä‚«‚ÌA‘å粊°KA‹vŽu–{¬Ž÷A—é–ØG–¾AŒš•”r‰îA–ؗ³’jA™‘ºGˆê˜YA‰ºìG–¾F‘–Œ‰Š‚ɂ͔­Ç‚µ‚½”x‰Š‹…‹Û‚É‚æ‚銴õ«S“à–Œ‰Š‚Ì1—á.
‘æ160‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2015”N6ŒŽ6“úA·‰ªŽsj

    ƒYIAÇ—á”­•\•”–å„

  1. ²“¡@—yAŽO‰Y³’¨A™‘ºGˆê˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡Œö—YA‰ºìG–¾FƒCƒ}ƒ`ƒjƒu“Š—^‚É‚æ‚è’·Šú¶‘¶‚ª“¾‚ç‚ꂽ”xÖ¬•ÂÇ«Ž¾Š³‚̈ê—á.
  2. ƒYIAÇ—á”­•\•”–å„i–Å—DGÜŽóÜj

  3. ¬–죄¶Aâ“c‘וFAŒã‰ªL‘¾˜YAŽO‰Y³’¨A’A–Ø‘sˆê˜YA‹ž@—ºˆêAŽR“à@‹BA²“¡Œª“ñ˜YA’Ò@ŒOØŽqAˆ¢•”—Ú—žA‚‹´@A‹{“c@•qA‰ºìG–¾FS‘Ÿ•aгŽÒ‚É‚¨‚¯‚铌“ú–{‘åkÐŒã‚ÌS“IŠOŒãƒXƒgƒŒƒXáŠQ‚ÌŒoŽž•ω»‚Æ—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÌŒŸ“¢.
  4. ƒˆê”ʉ‰‘è„

  5. –ؗ³’jA™‘ºGˆê˜YAŽO‰Y³’¨AŒš•”r‰îA–î”ö”ÂM—TA²“¡@—yA²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Š³ŽÒ‚É‚¨‚¢‚ÄŒo”ç“I”x“®–¬Šg’£p‚ÍŒŒs“®‘ԂɉÁ‚¦‚ÄŽ_‘f‰»‚à‰ü‘P‚³‚¹‚é.
  6. ŒÃ’m—´ŽO˜YA–ؗ³’jA™‘ºGˆê˜YAŒš•”r‰îAŽO‰Y³’¨A–î”ö”ÂM—TA²“¡@—yA‚‹´@A¼–{‘׎¡A‰H”ö´‹MA²“¡Œö—YA‰ºìG–¾: ‚½‚±‚‚ڌ^S‹ØÇ—l‚ÌŽûkáŠQ‚𗈂½‚µ‚½ŠŒF×–EŽî‚̈ê
  7. ¼‹{Œ’‰îA‰H”ö´‹MAš¢’J—²Ž¡A¼–{‘׎¡A‚‹´@AˆÉ“¡Œ’‘¾A‰ºìG–¾A“nç²—´HA¯ì@NA‰ª“c@Ž“TF•ÂÇ«”ì‘åŒ^S‚É‚½‚±‚‚ڌ^S‹ØÇ‚𕹔­‚µ‚½”xˆÚAÇ—á.
  8. š¢’J@—²Ž¡A‚‹´@A¼‹{Œ’‰îA‰H”ö´‹MA¼–{‘׎¡AˆÉ“¡Œ’‘¾A‰ºìG–¾:“ûŽ_ƒAƒVƒh[ƒVƒX‚ð‡•¹‚µ‚½”ñST 㸌^S‹Ø[ǂ̈ê—á.
  9. “c’†Œ’ŽqAóÀŒhˆê˜YA‹vŽu–{¬Ž÷A—é–ØG–¾A’†–ì@½A™‘ºGˆê˜YAâ“c‘וFA‰ºìG–¾: “ª•”ŠOŒã‚ÌR‹ÃŒÅ—Ö@’†’f‚É‚æ‚è‘Sg«ÇðÇ‚ð”­Ç‚µ‚½S–[ד®‚̈ê—á.
  10. ŽRè—´ˆêA‹vŽu–{¬Ž÷A—é–ØG–¾A‰ºìG–¾FSepsis-induced encepharopathy ‚É‚æ‚è‘J‰„«ˆÓޝáŠQ‚ð’æ‚µ‚½Š´õ«S“à–Œ‰Š‚̈ê—á.
  11. ˆÉ“¡‚ä‚«‚ÌA‘å糊°KA‹vŽu–{¬Ž÷A—é–ØG–¾AŒš•”r‰îA–ؗ³’jA™‘ºGˆê˜YA‰ºìG–¾: ׋۫‘–Œ‰Š‚ɂĔ­Ç‚µ‚½”x‰Š‹…‹Û‚É‚æ‚銴õ«S“à–Œ‰Š‚Ì1—á.
  12. ’A–Øšáˆê˜YAâ“c‘וFAŽO‰Y³’¨A‹ž—ºˆêA²“¡Œª“ñ˜YA¬–죄¶AŽR“à@‹BA’Ò@ŒOØŽqAˆ¢•”@—Ú—žA‹{“c@•qA‰ºìG–¾F–«S•s‘S‚É‚¨‚¯‚郃^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚ÌŒŸ“¢\CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  13. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@½A£ì«lA•½–쓹ŠîAç—t‹M•FA‰ºìG–¾F‰“Šuƒ‚ƒjƒ^ƒŠƒ“ƒOƒVƒXƒeƒ€‚É‚æ‚èICDƒVƒ‡ƒbƒNì“®•s‘S‚ð‘Šú‚Éf’f‚Å‚«‚½Šg’£Œ^S‹ØÇ‚̈ê—á.
  14. ’†–ì@½A•Ÿ“c_“ñA‹ß“¡³‹PA£ì«lA•½–쓹ŠîAç—t‹M•FA‰ºìG–¾: High DFT‚ð’æ‚µAICDƒŠ[ƒh‚Ì•ÏX‚ª—LŒø‚Å‚ ‚Á‚½Brugada ÇŒóŒQ‚̈ê—á.
  15. ç—t‹M•FA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA£ì«lA•½–쓹ŠîA‰ºìG–¾F‘å“®–¬‰EŠ¥ë‚©‚ç‚Ì’Ê“d‚ª—LŒø‚Å‚ ‚Á‚½‰EŽº—¬o˜H‚ÌExit ‚ð‚à‚—¬o˜H‹NŒ¹PVC ‚̈ê—á.
  16. •Е½W‘¾˜YAHŽR³”NA‰Í’Ã@‘A‚Œ´^ŒáA“nç²W—CA“¡Œ´‰p‹LAˆÀ’B@—AŒF’J‹Iˆê˜YAì–{r•ãAâV–؉ÀŽA™‘ºGˆê˜YA‰ºìG–¾F‘ÌŠOŽ®VAD ‚©‚çAžŒ^VAD ‚Öconversion ‚µ‚½Ç—á‚ÌŒŸ“¢.
  17. HŽR³”NA•Е½W‘¾˜YA‰Í’Ã@‘A“nç²W—CA‚Œ´^ŒáA“¡Œ´‰p‹LAˆÀ’B@—AŒF’J‹Iˆê˜YAì–{r•ãAâV–؉ÀŽA–ؗ³’jA•Ÿ“c_“ñA‚‹´@A™‘ºGˆê˜YA‰ºìG–¾FŠg’£‘Š”ì‘åŒ^S‹ØÇ‚ɑ΂·‚é‹@ŠB“I•â•zŠÂŽ¡—Â̎¡—Ãí—ª‚ÌŒŸ“¢.
‘æ79‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2015”N4ŒŽ24“ú`26“úA‘åãj

    ƒSpecial Session„

  1. (SS05:The Prediction for the Future in the Large-scale Registry of Cardiovascular Disease) Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Abe R, Nochioka K, Miyata S, Takahashi J, Shimokawa H. Perspectives from the chronic heart failure analysis and registry in the Tohoku District 2 (CHART-2) Study. Circ J 79(Suppl. I):I-47,2015.
  2. (SS09:Rapid Development of Antithrombotic Therapy: Current Status and Future Directions) Fukuda K , Ogawa H, Hirotsug A, Inoue H, Uchiyama S, Kitazono T, Ikeda T, Kaikita K, Kamouchi M, Matsui K, Shimokawa H. Effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation@\First report from the EXPAND study\ Circ J79(Suppl. I):I-74,2015.
  3. (SS10:Therapeutic Strategies of Coronary Artery Disease from the Point of View of Vasomotion and Microvascular Function) Kensuke Nishimiya1 ,Yasuharu Matsumoto1 , Uzuka H1 , Oyama K1 , Tomohiko Shindo1 , Ryuji Tsuburaya1 , Takashi Shiroto1 , Takahashi J , Kenta Ito1 , Hatsue Ishibashi-Ueda2 , Satoshi Yasuda3 , Hiroaki Shimokawa. Involvement of Rho-Kinase pathway in the pathogenesis of coronary hyperconstricting responses after drug-eluting stents implantation. Circ J 79(Suppl. I):I-78,2015.
  4. ƒPlenary Session„

  5. (PL01: New Multi-Modality Cardiovascular Imaging and the Dedicated Management of Diseases) Ota H, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Miura M, Satoh K, Shimokawa H. 4D flow MRI for pulmonary hypertension: an imaging tool to monitor mean pulmonary arterial pressure. Circ J 79(Suppl. I):I-99,2015.
  6. (PL02:Explore the Japanese Style Clinical Investigation beyond the Global Trends) Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Onose T, Tsuji K, Abe R, Miyata S, Takahashi J, Shimokawa H. The chronic heart failure analysis and registry in the Tohoku District-2 (CHART-2) Study: A model case of Japanese observational study. Circ J 79(Suppl. I):I-101,2015.
  7. ƒSymposium„

  8. (SY03:Novel and Advanced Therapy against Acute Coronary Syndrome\From Bench to Bedside\) Ito K, Takahashi J, Matsumoto Y, Tsuburaya R, Hao K, Nishimiya K, Kagaya Y, Shindo T, Ogata T, Kurosawa R, Shimokawa H. Low-energy cardiac shock wave therapy suppresses left ventricular remodeling after acute myocardial infarction\From bench to bedside\ Circ J 79(Suppl. I):I-176,2015.
  9. (SY10:The Importance of the Right Ventricle in Adult Congenital Heart Disease\Physiological Properties, Diagnosis, and Management of Right Heart Failure in ACHD\) Fujiwara J, Onuma H, Funamizu Y, Tatebe S, Sugimura K, Sakata Y, Saijoh Y, Shimokawa H. Echocardiographic evaluation of right ventricular dysfunction in adult patients with Tetralogy of Fallot. Circ J 79(Suppl. I):I-218,2015.
  10. (SY13:Recent Progress in Pulmonary Hypertension) Aoki T, Tatebe S, Sugimura K, Nochioka K, Miura M, Yamamoto S, Yaoita N, Sato H, Satoh K, Shimokawa H. Importance of acute hemodynamic responses to inhaled nitric oxide in patients with pulmonary hypertension due to left heart disease. Circ J 79(Suppl. I):I-243,2015.
  11. (SY15:Prevention and Control of Cardiovascular Disease: the WHO Global Strategy) Tadaki S, Sakata Y, Miura M, Miura Y, Fukumoto Y, Miura T, Kadokami T, Daida H, Kitakaze M, Shimokawa H. Prognostic impacts of physical activity in patients with chronic heart failure. A multicenter prospective cohort study. Circ J 79(Suppl. I):I-255,2015.
  12. (SY20:Diagnosis and Treatment of Functional Angina Pectoris\Insight into Vasospasm and Microvascular Disease) Takahashi J, Nihei T, Odaka Y, Tsuburaya R, Hao K, Nishimiya K, Matsumoto Y, Ito K, Shimokawa H. Prognostic impact of Rho-kinase activity in circulating leukocytes of patients with vasospastic angina. Circ J 79(Suppl. I):I-288,2015.
  13. ƒESC-JCS Joint Symposium„

  14. (ESC:Coronary Vasomotion Abnormalities) Takahashi J, Tsuburaya R, Nishimiya K, Matsumoto Y, Shimokawa H. Coronary vasomotion abnormalities induced by drug-eluting stents. Circ J 79(Suppl. I):I-327,2015.
  15. ƒRound Table Discussion„

  16. (RT05:The Current Status and Future Perspective of Acute Cardiovascular Care: the Evolving Real World Evidence from Nation-wide Registry Studies) Takahashi J, Hao K, Ito K, Sakata Y, Shimokawa H. Trends in the emergency care of AMI in Japan\A report from the Miyagi AMI registry study\Circ J 79(Suppl. I):I-381,2015.
  17. ƒTopic„

  18. (TP05:Diagnosis and Treatment of Chronic Thromboembolic Pulmonary Hypertension after an Advent and Development of Balloon Pulmonary Angioplasty) Sugimura K, Aoki T, Tatebe S, Miura M, Yaoita N, Sato H, Kato T, Satoh K, Shimokawa H. Usefulness of optical coherence tomography imaging in management of chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-431,2015.
  19. ƒLate Breaking Clinical Trials„

  20. (LBCT4) Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, Takada T, Shimokawa H. Impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: A report from the SUPPORT Trial. Circ J 79(Suppl. I):I-592,2015.
  21. ƒLate Breaking Cohort Studies„

  22. (LBCS1) Onose T, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Tsuji K, Abe R, Nochioka K, Takahashi J, Miyata S, Shimokawa H. Adverse prognostic impacts of post-traumatic stress disorder in patients with cardiovascular disease after the Great East Japan Earthquake. Circ J 79(Suppl. I):I-597,2015.
  23. ƒYoung Investigator's Award Finalists Lectures (Clinical Research)„

  24. (YIA-C-3) Satake H, Fukuda K, Sakata Y, Miyata S, Nakano M, Kondo M, Hasebe Y, Segawa M, Shimokawa H. Current status of primary prevention of sudden cardiac death with implantable cardioverter-defibrillator in patients with chronic heart failure\A report from the CHART-2 Study\ Circ J 79(Suppl. I):I-625,2015.
  25. ƒYoung Investigator's Award for International Students Finalists Lectures„

  26. (I-YIA-2) Elias-Al-Mamun M, Satoh K, Tanaka S, Shimizu T, Nergui S, Miyata S, Fukumoto Y, Shimokawa H. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension through synergistic inhibition of Rho-kinase. Circ J 79(Suppl. I):I-632,2015.
  27. ƒFeatured Research Session„

  28. (FRS-009) Satoh K , Sugimura K , Aoki T, Nochioka K, Tatebe S, Yamamoto S, Miura M, Shimizu T, Ikeda S, Yaoita N, Kudo S, Suzuki K, Omura J, Kikuchi N, Satoh T, Kurosawa R, Sunamura S, Nogi M, Shimokawa H. Plasma Cyclophilin A as a useful biomarker for effective percutaneous transluminal pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-650,2015.
  29. (FRS-126) Nihei T, Takahashi J, Miyata S, Odaka Y, Nishimiya K, Hao K, Tsuburaya R, Matsumoto Y, Ito K, Sakata Y, Shimokawa H. Combined Japanese Coronary Spasm Association risk score and Rho-kinase activity provide useful risk stratification in patients with vasospastic angina. Circ J 79(Suppl. I):I-791,2015.
  30. ƒOral Presentation (English)„

  31. (OE-033:Heart Failure (Basic) and Translational Science) Suzuki K, Satoh K, Sunamura S, Omura J, Kikuchi N, Satoh T, Kurosawa R, Kudo S, Ikeda S, Shimokawa H. Basigin promotes cardiac fibrosis and failure in response to chronic pressure-overload in mice. Circ J 79(Suppl. I):I-824,2015.
  32. (OE-254:Intravascular Imagings OCT/OFDI) Nishimiya K, Matsumoto Y, Takahashi J, Kato T, Oyama K, Uzuka H, Odaka Y, Nihei T, Hao K, Tsuburaya R, Ito K, Shimokawa H. Enhanced adventitial vasa vasorum formation in patients with vasospastic angina\Assessment with optical frequency domain imaging\Circ J 79(Suppl. I):I-1044,2015.
  33. (OE-307: Cardiomyopathy/Hypertrophy (Basic)) Kudo S, Satoh K, Suzuki K, Sunamura S, Nogi M, Kikuchi N, Ohmura J, Ikeda S, Shimokawa H. Crucial role of SmgGDS in the inhibitory effects of statins on cardiac hypertrophy and fibrosis in mice. Circ J 79(Suppl. I):I-1097,2015.
  34. (OE-347:Pulmonary Circulation) Omura J, Satoh K, Kikuchi N, Satoh T, Kurosawa R, Suzuki K, Shimokawa H. Endothelial cell-specific AMPK deletion accelerates hypoxia-induced pulmonary hypertension in mice in vivo. Circ J 79(Suppl. I):I-1137,2015.
  35. (OE-350:Pulmonary Circulation) Satoh K, Suzuki K, Omura J, Kikuchi N, Satoh T, Sunamura S, Kurosawa R, Nogi M, Shimizu T, Ikeda S, Yaoita N, Kudo S, Aoki T, Sugimura K, Shimokawa H. Plasma levels of Cyclophilin A correlate with circulating inflammatory cytokines in patients with pulmonary hypertension. Circ J 79(Suppl. I):I-1140,2015.
  36. (OE-352:Pulmonary Circulation) Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Sunamura S, Suzuki K, Kudo S, Shimokawa H. Thrombin activatable fibrinolysis inhibitor plays a crucial role in the pathogenesis of chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-1142,2015.
  37. (OE-358:Prevention/Epidemiology) Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Sato K, Yamauchi T, Onose T, Tsuji K, Takahashi J, Shimokawa H. Recent trends in clinical characteristics, management and prognosis in patients with symptomatic heart failure\The CHART Studies\ Circ J 79(Suppl. I):I-1148,2015.
  38. ƒOral Presentation (Japanese) „

  39. (OJ-009:Heart Failure (Diagnosis)) Miura M, Sakata Y, Miyata S, Nochioka K, Ushigome R, Tadaki S, Yamauchi T , Sato K, Onose T, Tsuji K, Abe R, Takahashi J, Shimokawa H. Prognostic impact of diabetes mellitus in patients with chronic heart failure\With special references to ischemic heart disease and nephropathy\Circ J 79(Suppl. I):I-1210,2015.
  40. (OJ-012:Heart Failure (Diagnosis)) Yamauchi T, Sakata Y, Miyata S, Nochioka K, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Takahashi J, Shimokawa H. Prognostic impacts of anemia in patients with CHF with a special reference to background\A report from the CHART-2 Study\ Circ J 79(Suppl. I):I-1213,2015.
  41. (OJ-137: Heart Failure (Basic) and Translational Science) Kanazawa M, Matsumoto Y, Takahshi K, Suzuki H, Nishimiya K, Shimokawa H. Post-infarction heart failure reduces bone mineral density and strength in apolipoprotein E-deficient mice. Circ J 79(Suppl. I):I-1336,2015.
  42. (OJ-158:Coronary Circulation/Chronic Coronary Disease (Basic/Clinical)) Odaka Y, Takahashi J, Tsuburaya R, Nihei T, Nishimiya K, Hao K, Matsumoto Y, Ito K, Hirowatari Y, Shimokawa H. Plasma level of serotonin is a novel biomarker for coronary microvascular dysfunction in patient with vasospastic angina. Circ J 79(Suppl. I):I-1357,2015.
  43. (OJ-180: Vascular Disease (Therapy)) Shindo T, Ito K, Ogata T, Hatanaka K, Kurosawa R, Kagaya Y, Hanawa K, Aizawa K, Hasegawa H, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound improves left ventricular dysfunction in a porcine model of chronic myocardial ischemia\Potential involvement of mechanotransduction\Circ J 79(Suppl. I):I-1379,2015.
  44. (OJ-254: Pulmonary Circulation) Yaoita N, Taiju Sato , Satoh K, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Horiuchi H, Fukumoto Y, Shimokawa H. Involvement of thrombin-activated fibrinolysis inhibitor in chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-1453,2015.
  45. (OJ-269:Prevention/Epidemiology) Sato K, Sakata Y, Miura M, Tadaki S, Ushigome R, Yamauchi T, Onose T, Tsuji K, Abe R, Nochioka K, Miyata S, Shimokawa H. The risk score for the three-year mortality in Japanese patients with aortic stenosis@\A report from the CHART-2 Study\ Circ J 79(Suppl. I):I-1468,2015.
  46. ƒPoster Session (English)„

  47. (PE-212:Coronary Circulation/Chronic Coronary Disease (Basic/Clinical)) Uzuka H, Matsumoto Y, Nishimiya K, Oyama K, Hirano M, Ogata T, Shindo T, Hanawa K, Hasebe Y , Hao K, Tsuburaya R, Ito K, Takahashi J, Shimokawa H. Possible involvement of adventitial vasavasorum and sympathetic nerves in coronary hyperconstricting responses after drug-eluting stent implantation in pigs in vivo. Circ J 79(Suppl. I):I-1704,2015.
  48. (PE-226:Cardiomyopathy/Hypertrophy (Clinical)) Segawa M, Fukuda K, Nakano M, Kondo M, Satake H, Hirano M, Shimokawa H. Time-course and influencing factors of ventricular tachy-arrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ J 79(Suppl. I):I-1718,2015.
  49. (PE-522:Vascular Biology) Godo S, Ikeda S, Saito H, Suzuki K, Tanaka S, Ito A, Shimokawa H. Disruption of physiological balance between nitric oxide and endothelium-derived hyperpolarizing factor causes impairment of cardiovascular homeostasis in mice in vivo. Circ J 79(Suppl. I):I-2014,2015.
  50. (PE-695:Prevention/Epidemiology) Hao K, Takahashi J, Ito K, Sai G, Miyata S, Nishimiya K, Tsuburaya R, Matsumoto Y, Sakata Y, Shimokawa H. Recent trends in the incidence and mortality of acute myocardial infarction\ A report from the MIYAGI-AMI Registry Study\Circ J 79(Suppl. I):I-2187,2015.
  51. (PE-711:Pulmonary Circulation) Aoki T, Sugimura K, Nochioka K, Tatebe S, Miura M, Yamamoto S, Yaoita N, Sato H, Satoh K, Shimokawa H. Effects of PTPA on respiratory functions in patients with chronic thromboembolic pulmonary hypertension\Possible importance of intra-pulmonary shunt\Circ J 79(Suppl. I):I-2203,2015.
  52. (PE-713:Pulmonary Circulation) Sato H1, Miura M, Sugimura K, Aoki T, Tatebe S, Yamamoto S, Yaoita N, Ota H, Satoh K, Shimokawa H. Usefulness of cardiac MRI for evaluating the effectiveness of percutaneous transluminal pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Circ J 79(Suppl. I):I-2205,2015.
  53. ƒPoster Session (Japanese)„

  54. (PJ-103:Autonomic Nervous System and Stress-Psychosomatic Medicine) Suzuki H, Satoh K, Tatebe S, Matsumoto Y, Kondo M, Nakano M, Fukuda K, Watanuki S, Hiraoka K, Tashiro M, Shimokawa H. Evidence for activation of cerebral autonomic center in response to cardiac electrical stimulation in humans\New finding of cardio-cerebral connection\Circ J 79(Suppl. I):I-2326,2015.
  55. (PJ-103: Cardiac Arrest/Resuscitation/Cardiopulmonary/Critical Care/ACLS) Komatsu M, Takahashi J, Nakano M, Kondo M, Tsuburaya R, Hao K, Nishimiya K, Nihei T, Matsumoto Y, Ito K, Fukuda K, Shimokawa H. Usefulness of dual-induction tests for coronary artery spasm and lethal ventricular arrhythmias in patients surviving out-of-hospital cardiac arrest. Circ J 79(Suppl. I):I-2410,2015.
  56. (PJ-508:Pulmonary Circulation) Sugimura K, Aoki T, Tatebe S, Miura M, Yamamoto S, Yaoita N, Sato H, Satoh K, Shimokawa H. Effectiveness of vasodilator therapy for patients with inoperable chronic thromboembolic pulmonary hypertension in prior to percutaneous transluminal pulmonary angioplasty. Circ J 79(Suppl. I):I-2731,2015.
  57. (PJ-525:Arrhythmia, Others (Clinical/Diagnosis/Treatment)) Nakano M, Fukuda K, Kondo M, Satake H, Segawa M, Hirano M, Chiba T, Shimokawa H. Usefulness of late potentials for risk stratification in patients with type 2 brugada electrocardiogram. Circ J 79(Suppl. I):I-2748,2015.
  58. (PJ-655:Pulmonary Circulation) Sato H, Tatebe S, Sugimura K, Aoki T, Miura M, Yaoita N, Nochioka K , Yamamoto S, Satoh K, Shimokawa H. Current status of the treatment for adult congenital heart disease associated with pulmonary arterial hypertension. Circ J, 79(Suppl. I):I-2878,2015.
  59. (PJ-734: Cost-health Care System/DPC/Laws) Nakayama M, Takehana K, Takeda K, Kohro T, Shimokawa H. Report data format of medical examination in cardiology should be standardized for standardized structured medical information exchange extended storage. Circ J 79(Suppl. I):I-2957,2015.
“ú–{“à‰ÈŠw‰ï–k—¤Žx•”‘æ64‰ñ¶ŠU‹³ˆçu‰‰‰ïi2015”N3ŒŽ8“úA‹à‘òŽsj
  1. ‰ºìG–¾FŠ¥¹k«‹·SÇ‚Ìŋ߂̒mŒ©.
‘æ204‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2015”N2ŒŽ21“úAå‘äŽsj
  1. Š™“c—TŠîA—é–ØG–¾A‰ºìG–¾A–쑺—º‰îA“ü–ìŽ÷”üA‹vŽu–{–ÎŽ÷F‹}«–ò•¨’†“łɂæ‚é––½_ŒoáŠQ‚©‚ç’·Šú“I‚ÈlHŒÄ‹zŠíˆË‘¶‚ɊׂÁ‚½‚P—á.
  2. ²“¡@ê¡A–ؗ³’jA–î”ö”ÂM—TAŽR–{¹DAŒš•”r‰îAŽO‰Y³’¨A²“¡Œö—YA™‘ºGˆê˜YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç—á‚ÉŒo”ç“I”x“®–¬Šg’£p‚ðŽ{s‚µ”x“®–¬úE‚𗈂µ‚½2 Ç—á.
  3. “c’†Ë˜NA¼‹{Œ’‰îA¬¼^‹±A‚‹´@Aš¢’J—²Ž¡A‰H”ö´‹MA¼–{‘׎¡AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾FƒXƒeƒƒCƒh•â[ŠJŽnŒã‚ÉŠ¥¹k«‹·SÇ”­ì‚ð”F‚ß‚½ACTH’P“ÆŒ‡‘¹Ç‚Ì1—á.
‘æ44‰ñ“ú–{S–¬ŠÇì“®•¨Ž¿Šw‰ïŠwpW‰ïi2015”N2ŒŽ6`7“úA‚¼j

    ƒŠî’²u‰‰„

  1. ‰ºìG–¾FzŠÂŠí•a‚̃gƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`.
  2. ƒYIA„

  3. –î”ö”ÂM—TA²“¡‘åŽ÷A²“¡Œö—YA™‘ºGˆê˜YA‘呺~ˆêA•Ÿ–{‹`OA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ÌV‹K•aˆö’`”’TAFI‚Ì”­Œ©‚Æ‚»‚Ì‹@”\“IˆÓ‹`.
  4. ƒYIAÅIŒó•â„

  5. H“¡@rA²“¡Œö—YA—é–ØN‘¾A»‘ºTˆê˜YA–ì–Ø³“¹A“c’†^ˆêA“ì@’B˜YA‹e’n‡—TA‘呺~ˆêA’r“c®•½A‰ºìG–¾FƒXƒ^ƒ`ƒ“‚É‚æ‚鑽–Ê“IŒø‰Ê‚ÌŒ´ˆö’`”’SmgGDS‚Ì“¯’è‚Æ‚»‚ÌS”ì‘åEüˆÛ‰»‚Ì—}§‹@\.
  6. ƒˆê”ʉ‰‘èiƒ|ƒXƒ^[j„

  7. ²“¡Œö—YA—é–ØN‘¾A‘呺~ˆêA‹e’nM—TA²“¡‘åŽ÷A•àV@—ºA–î”ö”ÂM—TA™‘ºGˆê˜YA•Ÿ–{‹`OA’†‘ºˆê•¶AˆÉ“¡@_A‰ºìG–¾FƒTƒCƒNƒƒtƒBƒŠƒ“AŽó—e‘ÌBasigin‚É‚æ‚é”x‚ŒŒˆ³Ç‘£i‹@\.
‘æ8‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2015”N1ŒŽ31“ú`2ŒŽ1“úA“¿“‡j

    ƒƒVƒ“ƒ|ƒWƒEƒ€1FŠef—ÉȂɂ¨‚¯‚é«·ˆãŠw‚Ìi•à„

  1. ‰ºì G–¾FzŠÂŠí“à‰È—̈æ‚É‚¨‚¯‚é«·ˆãŠw‚Ìi•à
  2. ƒÅ—DG‰‰‘è„

  3. ‰H”ö ´‹MA‚‹´ AˆÉ“¡ Œ’‘¾A›Á Œ³‹gA‹{“c •qA¼‹{ Œ’‰îAš¢’J —²Ž¡A¼–{ ‘׎¡Aâ“c ‘וFA‰ºì G–¾F‹}«S‹Ø[Ç”­Ç—¦‚Ɖ@“àŽ€–S—¦‚ÌŒo”N•ω»‚É‚¨‚¯‚é«·‚ÌŒŸ“¢ -MIYAGI-AMI Registry Study‚©‚ç‚Ì•ñ-
  4. ƒ—DG‰‰‘èŒó•â„

  5. ’Ò ŒOØŽqAâ“c ‘וFAŽO‰Y ³’¨A’A–Ø ‘sˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA¬–ì£ „¶Aˆ¢•” —Ú—žAŒã‰ª L‘¾˜YA‚‹´ A‹{“c •qA‰ºì G–¾F¶ŽºŽûk”\‚ª•Û‚½‚ꂽS•s‘SгŽÒ‚É‚¨‚¯‚é«·|CHART-2Œ¤‹†‚É‚¨‚¯‚é’mŒ©|
  6. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  7. Â–Ø —³’jA–ؗ³’jA™‘ºGˆê˜YA£ì«lA–î”ö”ÂM—TAŒš•”r‰îAŽO‰Y³’¨A²“¡@—yA²“¡Œö—YA•Ÿ“c_“ñA‰ºìG–¾FSƒTƒ‹ƒRƒCƒh[ƒVƒX‚Ì—Õ°“I“Á’¥‚Ì«·‚ÉŠÖ‚·‚錟“¢
  8. ’A–Ø šáˆê˜YAâ“c ‘וFA•Ÿ–{ ‹`OAŽO‰Y r˜YA–åã r–¾A‘ã“c _”VA–k•— ­ŽjA‰ºì G–¾F–«S•s‘SгŽÒ‚É‚¨‚¢‚ăƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚ª—\Œã‚É‹y‚Ú‚·‰e‹¿‚Æ«·
  9. ¬–ì£ „¶Aâ“c ‘וFA‹{“c •qAŽO‰Y ³’¨A’A–Ø ‘sˆê˜YA‹ž —ºˆêAŽR“à ‹BA²“¡ Œª“ñ˜YA‚‹´ AŒã‰ª L‘¾˜YA‰ºì G–¾FSŒŒŠÇ•aгŽÒ‚É‚¨‚¯‚铌“ú–{‘åkÐŒã‚ÌS“IŠOŒãƒXƒgƒŒƒXáŠQ‚Æ«·|CHART-2Œ¤‹†‚©‚ç‚Ì•ñ|

Œ¤‹†‹ÆÑˆê——‚Ö@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2014”N
‘æ55‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2014”N10ŒŽ30“ú`11ŒŽ1“úA‘q•~j
  1. ˆÉ“¡Œ’‘¾A‚‹´@A¼–{‘׎¡A‰~’J—²Ž¡A‰H”ö´‹MA¼‹{Œ’‰îA“ñ•r‘¾˜YA‰ºìG–¾F’áo—͑̊OÕŒ‚”gŽ¡—ÃFSŒŒŠÇ޾г‚ɑ΂·‚éV‚µ‚¢”ñNP«ŒŒŠÇV¶—Ö@.
  2. »‘ºTˆê˜YAŽO‰Y³’¨A™‘ºGˆê˜YAŒã‰ªL‘¾˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡@ê¡A²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚ƉEŽº‹@”\‚ÉŠÖ‚·‚錟“¢.
‘æ18‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2014”N10ŒŽ10`12“úA‘åãj

    ƒƒVƒ“ƒ|ƒWƒEƒ€6FS•s‘S‚É‚¨‚¯‚éŠÏŽ@Œ¤‹†„

  1. Sakata Y, Nochioka K, Miura M, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Miyata S, Shimokawa H. The Chronic Heart Failure Analysis and Registry in the Tohoku District) Study.
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€22FzŠÂŠí—̈æ‚É‚¨‚¯‚éƒrƒbƒOƒf[ƒ^‚Ìì‚è•û„

  3. Shimokawa H. Large-scale registry study with chronic heart failure -Lessons from the CHART-2 Study-
  4. ƒYIAR¸u‰‰FŠî‘bŒnF—DGÜŽóÜ„

  5. Ikeda S, Satoh K, Kikuchi N, Miyata S, Suzuki K, Omura J, Shimizu T, Fukumoto Y, Sakata Y, Shimokawa H. Crucial role of Rho-kinase in pressure overload-induced right ventricular hypertrophy and dusfunction in mice.
  6. ƒYIAR¸u‰‰F—Õ°ŒnF—DGÜŽóÜ„

  7. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Sato K, Yamauchi T, Tsuji K, Shimokawa H. Recent trends in clinical outcomes and prognostic factors in patients with dilated cardiomyopathy -The CHART Studies-
  8. ƒˆê”ʉ‰‘è„

  9. “¡Œ´~ŽqA‘åÀG˜aA‘D…N—zAˆÉ“¡‹I•FAŽO–Ø@rAŒš•”r‰îA™‘ºGˆê˜YAâ“c‘וFA¼žŠ–F•¶A‰ºìG–¾FSƒGƒR[‚ð—p‚¢‚½ƒtƒ@ƒ[Žl’¥Ç‚¨‚æ‚Ñ”x‚ŒŒˆ³Ç—á‚É‚¨‚¯‚é‰EŽº‹@”\’ቺ‹@˜‚Ì”äŠr.
  10. Yamauchi T, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Shimokawa H. Differences in clinical characteristics of anemic patients with chronic heart failure between ischemic and dilated cardiomyopathy -The CHART-2 Study-
  11. Sato K, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. Three-year mortality and prognostic predictors in patients with aortic stenosis -A report from the CHART-2 Study-
  12. Onose T, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, Ushigome R, Yamauchi T, Sato K, Shimokawa H. Post-traumatic stress disorder after the Great East Japan Earthquake in patients with heart failure -A report from the CHART-2 Study-
  13. Aoki T, Sugimura K, Yaoita N, Yamamoto S, Tatebe S, Miura M, Nochioka K, Sato H, Satoh K, Shimokawa H. Effects of conventional medical therapy prior to percutaneous transluminal pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension.
  14. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H. Prognostic impacts of aldosterone antagonists in patients with heart failure with preserved ejection fraction -A report from the CHART-2 Study-
  15. Tadaki S, Sakata Y, Fukumoto Y, Miura T, Kadokami T, Daida H, Kitakaze M, Shimokawa H. Prognostic impact of physical activity level in patients with chronic heart failure -A multicenter prospective cohort study-
  16. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[”­•\„

  17. Sato H, Aoki T, Miura M, Yaoita N, Yamamoto S, Tatebe S, Nochioka K, Satoh K, Sugimura K, Shimokawa H. Two cases of pulmonary hypertension associated with portosystemic shunt.
  18. Aoki T, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Miura M, Satoh K, Akiyama M, Saiki Y, Shimokawa H. Impact of implantable ventricular assist devices on long-term prognosis of patients with advanced heart failure.
  19. Sato H, Aoki T, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Miura M, Yaoita N, Satoh K, Shimokawa H. A case of successful immunosuppressive therapy for chronic myocarditis.
‘æ2‰ñ“ú–{”x‚ŒŒˆ³Šw‰ïE‘æ3‰ñ“ú–{”xzŠÂŠw‰ïŠwpW‰ïi2014”N10ŒŽ3`4“úA“Œ‹žj

    ƒƒVƒ“ƒ|ƒWƒEƒ€1F“ú–{‚©‚碊E‚ÉŒü‚¯‚Ä”x‚ŒŒˆ³Ç‚ÌŠî‘bŒ¤‹†‚ð‚Ç‚¤”­M‚µ‚Ä‚¢‚­‚©H„

  1. •Ÿ–{‹`OA‰ºìG–¾F”x‚ŒŒˆ³Ž¡—Âɂ¨‚¯‚éRhoƒLƒi[ƒ[‘jŠQ–ò‚Ö‚ÌŠú‘ÒFŠî‘b`—Õ°.
  2. ƒƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€1FCTEPH„

  3. ŽO‰Y³’¨A™‘ºGˆê˜YAŒã‰ªL‘¾˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡@ê¡A²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éPTPA‚̉EŽº‹@”\‚ÉŠÖ‚·‚錟“¢.
  4. Œš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘¾˜YA–ؗ³’jAŽO‰Y³’¨AŽR–{¹DA–î”ö”ÂM—TA²“¡@ê¡A²“¡Œö—YA‰ºìG–¾F”x“®–¬ƒoƒ‹[ƒ“Œ`¬p‚ªCTEPHгŽÒ‚Ì‘ãŽÓEt‹@”\‚Ö‹y‚Ú‚·‰e‹¿.
  5. ƒƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€3FŠî‘b„

  6. ²“¡Œö—YA—é–ØN‘¾A‘呺~ˆêA‹e’n‡—SA–î”ö”ÂM—TA™‘ºGˆê˜YA•Ÿ–{‹`OA’†‘ºˆê•¶AˆÉ“¡@_A‰ºìG–¾FBasigin‚ÍŒŒŠÇ•½ŠŠ‹Ø×–E‘B‚ð‘£i‚µ”x‚ŒŒˆ³Ç‚ðˆ«‰»‚³‚¹‚é.
  7. ƒˆê”ʉ‰‘è„

  8. ™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘¾˜YA–ؗ³’jAŽR–{¹DAŽO‰Y³’¨A–î”ö”ÂM—TA²“¡@ê¡A²“¡Œö—YA‰ºìG–¾FŒã–Ñ׊ǫ”x‚ŒŒˆ³Ç‚ɑ΂·‚éˆêŽ_‰»’‚‘f”xŒŒŠÇ”½‰žŽŽŒ±‚̈Ӌ`.
  9. –î”ö”ÂM—TA™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŽO‰Y³’¨A–ؗ³’jAŒš•”r‰îAŽR–{¹DA²“¡@ê¡A²“¡Œö—YA‰ºìG–¾FŒ´”­«’_`«ŠÌd•ς̶‘̊̈ÚAŒã‚É”­Ç‚µ‚½”x‚ŒŒˆ³Ç‚̈ê—á.
  10. ‘Õ@“Ná©A™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘¾˜YA–ؗ³’jAŽR–{¹DAŽO‰Y³’¨A–î”ö”ÂM—TA²“¡Œö—YA‰ºìG–¾FOCT‚ÅƒŠƒo[ƒXƒŠƒ‚ƒfƒŠƒ“ƒO‚ð”F‚ß‚½”x“®–¬«”x‚ŒŒˆ³Ç‚̈ê—á.
  11. ŽO•r@‘zAé“c—SŽqA“n•”@—´AŠ›ì—R‹NŽqA“¡“c—mŽqA“¡ˆä”ŽŽiAÖ“¡^ˆê˜YAΈä’q“¿A‰ºìG–¾A’£‘ÖG˜YF–Ɖu—}§—Ö@‚ª‘tŒ÷‚µ‚½‹­”çÇE‹«ŠEŒ^”x“®–¬«”x‚ŒŒˆ³Ç‚Ì1—á.
  12. ²“¡@ê¡AŽO‰Y³’¨A–î”ö”ÂM—TAŽR–{¹DAŒš•”r‰îA–ؗ³’jAŒã‰ªL‘¾˜YA²“¡Œö—YA™‘ºGˆê˜YA‰ºìG–¾F–å–¬\‘åzŠÂƒVƒƒƒ“ƒg‚É”º‚¤”x‚ŒŒˆ³Ç‚Ì2Ç—á.
‘æ62‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2014”N9ŒŽ26`28“úAå‘äjiŽåÃj

    ƒ‰ï’·u‰‰„

  1. ‰ºìG–¾F–Ú‚ÉŒ©‚¦‚È‚¢‚à‚Ì‚Ì‘åØ‚³
  2. ƒA Year in Cardiology --The EHJ Perspective/The 62nd Annual Japanese College Scientific Session of Cardiology„

  3. Shimokawa H : Conclusion.
  4. ƒ“Á•ÊŠé‰æ6F”x‚ŒŒˆ³f—ÂÌi•à„

  5. •Ÿ–{‹`OA‰ºìG–¾F”x‚ŒŒˆ³Ç‚ÌV–ò‚Ö‚ÌŠú‘Ò.
  6. ƒ“Á•ÊŠé‰æ8F“ú–{‚Ì—Õ°Œ¤‹†‚ÌŒ»ó‚Æ“W–]„

  7. â“c‘וFA‹{“c@•qAŒã‰ªL‘¾˜YAŽO‰Y³’¨A’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹´@A‰ºìG–¾F“Œ–k–«S•s‘S“o˜^iCHART-2jŒ¤‹†‚ÌŒ»ó‚Æ“W–].
  8. ƒ“Á•ÊŠé‰æ9FInternational Symposium on Coronary Vasomotion Abnormalities„

  9. Shimokawa H. Importance of coronary vasomotion abnormalities.
  10. ƒ“Á•ÊŠé‰æ10FzŠÂŠí—̈æ‚É‚¨‚¯‚é”ñi’ájNP«Ž¡—ÂÌi•à„

  11. ˆÉ“¡Œ’‘¾A‰ºìG–¾FdÇ‹·Sǂɑ΂·‚é’áo—͑̊OÕŒ‚”gŽ¡—Â̊J”­.
  12. ¼Œ´—²•vA‹à’J–@”EA‰ºìG–¾AˆÉ“¡Œ’‘¾F’áo—͑̊OÕŒ‚”gŽ¡—Ã@-Î쌧—§’†‰›•a‰@‚É‚¨‚¯‚鎡—ÃŒoŒ±-
  13. ƒƒVƒ“ƒ|ƒWƒEƒ€10FdÇS•s‘S‚ÌŽ¡—ÂÌi•à„

  14. HŽR³”NAHê”ü‹IA‰Í’Ã@‘Aì–{r•ãAŒã‰ªL‘¾˜YA™‘ºGˆê˜YA•Ÿ“c_“ñA֖؉ÀŽA‰ºìG–¾FAž‚ÝŒ^•â•lHS‘ŸŽ¡—Â̌»‹µFAž‚ÝŒãÄ“ü‰@‚ð—v‚·‚鎡—Â̌»ó‚Æ‘Îô.
  15. ƒƒVƒ“ƒ|ƒWƒEƒ€11FAdult Congenital Heart Disease (ACHD)‚Ìf—ÂÌi•à„

  16. Œš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŽO‰Y³’¨AŽR–{¹DA²“¡Œö—YAˆÀ’B@—A‰ª“cŽ“TA–Ø‘º³lAHê”ü‹IA֖؉ÀŽA‹ß“¡@‹uA‰ºìG–¾F”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚½ACHDf—Â̎¡—Ãí—ª.
  17. ƒƒVƒ“ƒ|ƒWƒEƒ€12FS•s‘SгŽÒ‚ɑ΂·‚鑽–Ê“IƒAƒvƒ[ƒ`„

  18. â“c‘וFA‹{“c@•qAŒã‰ªL‘¾˜YAŽO‰Y³’¨A‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹´@A‰ºìG–¾FÇ—á”wŒi‚ðl—¶‚µ‚½S•s‘S‚ւ̃Aƒvƒ[ƒ`FCHART-2Œ¤‹†‚Ì’mŒ©‚©‚ç.
  19. ƒƒVƒ“ƒ|ƒWƒEƒ€13FV‹KŒoŒûR‹ÃŒÅ–ò(NOAC)‚ð‚Ç‚¤Žg‚¢‚±‚È‚·‚©„

  20. •Ÿ“c_“ñA¬ì‹v—YAV@”ŽŽŸAˆäã@”ŽA“àŽR^ˆê˜YA–k‰€F¬A’r“cF“¿AŠC–kKˆêAŠ›‘ų_A¼ˆä–M•FA‰ºìG–¾F”ñ•Ù–ŒÇ«S–[ד®Š³ŽÒ‚ɑ΂·‚郊ƒo[ƒƒLƒTƒoƒ““o˜^ŠÏŽ@Œ¤‹†EXPAND Study“o˜^Ç—á‚Ì”wŒiˆöŽq.
  21. ƒƒVƒ“ƒ|ƒWƒEƒ€17F–«Ž¾Š³E¶ŠˆKе•a‚ð‡•¹‚µ‚½S޾ггŽÒ‚ÌŠÇ—„

  22. ŽO‰Y³’¨Aâ“c‘וFA‹{“c@•qAŒã‰ªL‘¾˜YA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹´@A‰ºìG–¾F‹•ŒŒ«/”ñ‹•ŒŒ«S•s‘S‚É‚¨‚¯‚铜”A•a‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚ÉŠÖ‚·‚錟“¢.
  23. ƒƒrƒWƒ…ƒAƒ‹ƒ[ƒNƒVƒ‡ƒbƒv4F”x‚ŒŒˆ³‚ðf‚é„

  24. ‘¾“cGŠöA™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’¨A‰ºìG–¾F4D flow MRI (3D phase contrast MRI)‚É‚¨‚¯‚é”x“®–¬“àvortex flow‚Æ”x‚ŒŒˆ³Ç‚Ƃ̊֘A.
  25. ™‘ºGˆê˜YAŒã‰ªL‘¾˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DAŽO‰Y³’¨A–î”ö”ÂM—TA²“¡@—yA²“¡Œö—YA‰ºìG–¾F”x‚ŒŒˆ³Ç‚Ìf’f‚ÆŽ¡—Âɂ¨‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
  26. ƒƒƒfƒBƒJƒ‹ƒXƒ^ƒbƒtƒZƒbƒVƒ‡ƒ“1F“dŽqƒJƒ‹ƒeŽž‘ã‚̃NƒŠƒjƒJƒ‹ƒpƒX„

  27. ‰~’J—²Ž¡A’†ŽR‰ë°A‘¾“c—L‰ÀAŒã‰ªL‘¾˜YA’†–ì@½A™‘ºGˆê˜YA‚‹´@A•Ÿ“c_“ñA‰ºìG–¾F“dŽqƒJƒ‹ƒeŽž‘ã‚̃NƒŠƒjƒJƒ‹ƒpƒX`“dŽqƒJƒ‹ƒe“±“üˆÚsŠú‚É‚¨‚¯‚é–â‘è“_.
  28. ƒ“ú–{S‘Ÿ•aŠw‰ïE“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïƒWƒ‡ƒCƒ“ƒgƒVƒ“ƒ|ƒWƒEƒ€„

  29. ¼–{‘׎¡A‹ààV³”ÍA’|“à‰ëŽjA‰H”ö´‹MA‰ºìG–¾F‘å“®–¬•Ùd‰»ÇE‹·óǂɑ΂·‚é‰^“®—Ö@‚Í—LŒø‚©‹ÖŠõ‚©H
  30. ƒ—DG‰‰‘èƒZƒbƒVƒ‡ƒ“EŒû‰‰„

  31. ãâ—T[A¼Œ´—²•vA‘å–쑌bA•ГcŒ\ˆêA‹à’J–@”EAˆÉ“¡Œ’‘¾A‰ºìG–¾FdÇ‹•ŒŒ«S޾ггŽÒ‚̉^“®‘Ï—e”\‚ɑ΂·‚é’áo—ÍÕŒ‚”gŽ¡—Â̌ø‰Ê.
  32. ƒƒ‚[ƒjƒ“ƒOƒŒƒNƒ`ƒƒ[11„

  33. •Ÿ“c_“ñA‰ºìG–¾F¬nŠú‚ðŒ}‚¦‚½S–[ד®ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Ã.
  34. ƒˆê”ʉ‰‘èEŒû‰‰„

  35. “ñ•r‘¾˜YA‚‹´@A¬‘é—I“ñA¼‹{Œ’‰îA‰H”ö´‹MA‰~’J—²Ž¡A¼–{‘׎¡AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾F–òÜ—no«ƒXƒeƒ“ƒg—¯’uŒã‚ɃXƒeƒ“ƒg—£’f‚ð‚«‚½‚µŠ¥“®–¬áŽ‚ðŒ`¬‚µ‚½Žá”Nìè•aŒãˆâǂ̈ê—á.
  36. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OAŽO‰Yr˜YA–åãr–¾A‘ã“c_”VA–k•—­ŽjA‰ºìG–¾F–«S•s‘S‚¨‚æ‚Ñ‚»‚̃nƒCƒŠƒXƒNÇ—á‚É‚¨‚¯‚ég‘ÌŠˆ“®‚Ɖ^“®‘jŠQˆöŽq‚ÌŒŸ“¢@-‘S‘‘½Ž{Ý‹¤“¯ƒRƒz[ƒgŒ¤‹†-
  37. ŽR“à@‹BAâ“c‘וFA‹{“c@•qAŒã‰ªL‘¾˜YAŽO‰Y³’¨A‚“c@„A’A–Ø‘sˆê˜YA‹ž—ºˆêA‰ºìG–¾F–«S•s‘SгŽÒ‚Ì—\Œã‚ɑ΂·‚é•nŒŒ‚̉e‹¿‚ÌŒŸ“¢ -CHART-2Œ¤‹†‚©‚ç‚Ì•ñ-
  38. ™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘¾˜YAŽR–{¹DAŽO‰Y³’¨A–ؗ³’jA–î”ö”ÂM—TA²“¡@ê¡A²“¡Œö—YA‰ºìG–¾FŒã–Ñ׊ǫ”x‚ŒŒˆ³Ç‚É‚¨‚¯‚éˆêŽ_‰»’‚‘f‹z“ü”xŒŒŠÇ”½‰žŽŽŒ±‚É‚æ‚錟“¢.
  39. ¼‹{Œ’‰îA¼–{‘׎¡A‰F’Ë—T‹IAi“¡’q•FA’·’J•”—Y”òA“ñ•r‘¾˜YA‰H”ö´‹MA‰~’J—²Ž¡A‚‹´@AˆÉ“¡Œ’‘¾A‰ºìG–¾FOptical Frequency Domain Imaging (OFDI)‚É‚æ‚銥“®–¬ŠO–ŒVasa Vasorum‚̶‘Ì“à‰æ‘œ•]‰¿.
  40. ¼‹{Œ’‰îA¼–{‘׎¡A‚‹´@A‰F’Ë—T‹IA¬‘é—I“ñA“ñ•r‘¾˜YA‰H”ö´‹MA‰~’J—²Ž¡AˆÉ“¡Œ’‘¾A‰ºìG–¾FŠ¥¹k«‹·Sǂ̕a‘Ô‚É‚¨‚¯‚銥“®–¬ŠO–ŒVasa Vasorum‚ÌŠÖ—^-ŒõŠ±Â’f‘w‰æ‘œ(OFDI)‚ð—p‚¢‚½—Õ°“IŒŸ“¢-
  41. ‰H”ö´‹MA‚‹´@A–ؗ³’jA‹{“c@•qA“ñ•r‘¾˜YA¼‹{Œ’‰îA‰~’J—²Ž¡A¼–{‘׎¡AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾F“Œ“ú–{‘åkÐŒã‚É”F‚ß‚ç‚ꂽS”x’âŽ~Ç—á‚Ì‘‰Á‚ÉŠÖŒW‚·‚éˆöŽq‚ÌŒŸ“¢.
  42. ‰~’J—²Ž¡A‚‹´@A“ñ•r‘¾˜YA¼‹{Œ’‰îA‰H”ö´‹MA”’ŒË@’A¼–{‘׎¡AˆÉ“¡Œ’‘¾A‰ºìG–¾Fd“xt‹@”\áŠQ—á‚É‚¨‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Œã‚Ìt‹@”\ˆ«‰»‚ɑ΂·‚é—\–h“IŒŒ‰t“§Í‚ÌŒø‰Ê‚ÉŠÖ‚·‚錟“¢.
  43. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@½A’·’J•”—Y”òA²’|—m”VA£ì«lA•½–쓹ŠîA‰ºìG–¾F‹·‚¢QRS•‚ð’æ‚µ‚Ä‚¢‚½‚ªCRT‚ª’˜Œø‚µSˆÚA‚ð‰ñ”ð‚Å‚«‚½‰Æ‘°«Šg’£Œ^S‹ØÇ‚̈ê—á.
  44. “ñ•r‘¾˜YA‚‹´@A¬‘é—I“ñA¼‹{Œ’‰îA‰H”ö´‹MA‰~’J—²Ž¡A¼–{‘׎¡AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾FŠ¥¹k«‹·Sǂ̒·Šú—\Œã—\‘ª‚É‚¨‚¯‚éRhoƒLƒi[ƒ[Šˆ«‚Ì—L—p«.
  45. ¬‘é—I“ñA‰~’J—²Ž¡A‚‹´@A“ñ•r‘¾˜YA¼‹{Œ’‰îA‰H”ö´‹MA¼–{‘׎¡AˆÉ“¡Œ’‘¾AœA“n—SŽjA‰ºìG–¾FŠ¥”÷¬ŒŒŠÇ¹k‚ÆŒŒ’†ƒZƒƒgƒjƒ“‚ÌŠÖ˜A‚ÌŒŸ“¢.
  46. ŽO‰Y³’¨A™‘ºGˆê˜YAŒã‰ªL‘¾˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA–î”ö”ÂM—TA²“¡@ê¡A²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚̉EŽº‹@”\‚É‹y‚Ú‚·Œø‰Ê‚ÉŠÖ‚·‚錟“¢.
  47. ‹ž—ºˆêAâ“c‘וFAŒã‰ªL‘¾˜YA‹{“c@•qAŽO‰Y³’¨A‚“c„ŽjA’A–Ø‘sˆê˜YAŽR“à@‹BA‰ºìG–¾F–{–M‚É‚¨‚¯‚édÇS•s‘S‚Ì—Õ°”wŒi‚Æ—\Œã‚ÌŽž‘ã“I•Ï‘JFCHARTŒ¤‹†‚©‚ç‚Ì’mŒ©.
  48. ‚ŒK—uŽqAŽMˆä³‹`AŒ³ŽR’åŽqA’Ŗ쌛“ñA‰Í‡GŽ÷AˆÉ“¡@‘nA‰iŒ´NbA‚“c‰À‘ãŽqA‹{é‰èˆßŽqA¬£Š°”VA‰œ‘º‰ë“¿A‘º¼@’AˆÉ“¡Œ’‘¾A‰ºìG–¾A”öès—YFdÇS‹Ø‹•ŒŒ‚ɑ΂·‚é’áo—͑̊OÕŒ‚”gŽ¡—ÂÌCT perfusion‚É‚æ‚錟“¢.
  49. ‰H”ö´‹MA‚‹´@AˆÉ“¡Œ’‘¾A‹{“c@•qAâ“c‘וFA“ñ•r‘¾˜YA¼‹{Œ’‰îA‰~’J—²Ž¡A¼–{‘׎¡AˆÀ“c@‘A‰ºìG–¾F‹}«S‹Ø[ÇŠ³ŽÒ‚É‚¨‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“–¢Ž{s—á‚Ì“Á’¥@\‹{錧S‹Ø[Ç‘Îô‹¦‹c‰ï‚©‚ç‚Ì•ñ\
  50. ‚–Ø—S‰îA™@³•¶A–ì–Ø³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA–©’J@–LAŒË“c@’¼AŽR–{‹`lA‰ºìG–¾FˆÙŽí‚Ì–òÜ—no«ƒXƒeƒ“ƒg‚ð‘g‚݇‚킹‚½Š¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚Ì—Õ°¬Ñ‚ÌŒŸ“¢.
  51. ¼Œ´—²•vAˆÀ“c•q•FAŽO—ÖŒ’“ñAˆäã@ŸA–ð“c—m•½A–û”ö@‹œA¼ˆä’¶A“Œ@Œc”V‰îA‹à’J–@”EAˆÉ“¡Œ’‘¾A‰ºìG–¾FdÇ‹•ŒŒ«S޾г‚ɑ΂·‚é’áo—͑̊OÕŒ‚”gŽ¡—Â̗հŒø‰Ê‚Æ“à”ç×–E‹@”\‚ւ̉e‹¿.
  52. ‰®•~@“µA¼Œ´—²•vA‹à’J–@”EAˆÉ“¡Œ’‘¾A‰ºìG–¾AŽÄ“c—R”üŽqFdÇ‹•ŒŒ«S޾г‚ɑ΂·‚é’áo—ÍÕŒ‚”gŽ¡—ÑOŒã‚É‚¨‚¯‚邤‚Âó‘Ԃ̕ω»‚ɂ‚¢‚Ä.
  53. ƒƒ|ƒXƒ^[”­•\„

  54. –î“c–L—²A‰ºìG–¾AŒã“¡^ŒÈAŠ’J•¶•FF¶‘Ì“àƒCƒk‹}«Š¥“®–¬•ÂÇŽžA‘¤•›ŒŒs˜H‚Ì“à”ç—R—ˆ‰ß•ª‹ÉˆöŽqA‰ßŽ_‰»…‘f‚É‚æ‚錌ŠÇŠg’£‚ÍA“œ”A•a«Š¥”÷¬ŒŒŠÇ“à”çáŠQ‚ð‘ãž‚·‚é.
  55. –©’J@–LA–ì–Ø³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îAŒË“c@’¼AŽR–{‹`lA™@³•¶A‰ºìG–¾FDrug Eluting Balloon Šg’£’¼Œã‚Ì‹»–¡[‚¢OFDI‰æ‘œ.
  56. ]Œû‹v”üŽqAŽR–{‹`lA–ì–Ø³“¹A›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îA–©’J@–LAŒË“c@’¼A™@³•¶A‰ºìG–¾F‰EŠ¥“®–¬CTO•a•ςɑ΂µ‚ÄCART–@‚É‚æ‚é‹Uo‚ւ̃Xƒeƒ“ƒg—¯’uŒãA–«Šú‚ɃXƒeƒ“ƒgŠO^oÄŠJ’Ê‚ð”F‚ß‚½‚Æl‚¦‚ç‚ê‚é1—á.
  57. ’†–ì@½A•Ÿ“c_“ñA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA£ì«lA•½–쓹ŠîA‰ºìG–¾FType 2 BrugadaS“d}гŽÒ‚ÌƒŠƒXƒN‘w•ʉ»‚É‚¨‚¯‚éLate potentials‚Ì—L—p«.
  58. Œš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘¾˜YA–ؗ³’jAŽO‰Y³’¨AŽR–{¹DA–î”ö”ÂM—TA²“¡@ê¡A‰ºìG–¾FS‘ŸˆÚA“o˜^\¿“K‰žŠO‚Æ”»’f‚µ‚½•s‰Â‹t“IŠÌüˆÛÇ‚ð‡•¹‚µ‚½ƒtƒ@ƒ[Žl’¥ÇS“àC•œpŒã‚Ì1—á.
  59. ŽO‰Y—²‰îA—é–ØG–¾A¼–{‘׎¡A”öè@‘×A‰H”ö´‹MA‰~’J—²Ž¡A‚‹´@AˆÉ“¡Œ’‘¾AˆÉ“¡’å‰ÃA‰Á‰ê’J@–LA‹vŽu–{¬Ž÷A‰ºìG–¾Fƒvƒ‰ƒ“ƒ}[•a‚ɇ•¹‚µ‚½‚½‚±‚‚ڌ^S‹ØÇ‚Ì1—á.
  60. ŽR–{‹`lA–ì–Ø³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îA–©’J@–LAŒË“c@’¼A™@³•¶A‰ºìG–¾FCoronary CTO•a•Ï‚ÌPCI‚É‚¨‚¯‚éRendez-vous–@‚ÌlŽ@
  61. –©’J@–LA–ì–Ø³“¹A]Œû‹v”üŽqA›Á@Œ³‹gA”·@Œ’ˆê˜YA‚–Ø—S‰îAŒË“c@’¼A™@³•¶A‰ºìG–¾FCART–@‚É‚ÄRCA-CTO‚ÌPCI‚ðs‚¢Septal Rupture‚𗈂µ‚½1—á‚Æ‚»‚Ì’·ŠúŒo‰ß.
  62. £ì«lA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•½–쓹ŠîA‰ºìG–¾FdÇS•s‘S‚ð’æ‚µ‚½•p”—U”­«S‹ØÇ‚Ì2—á.
  63. –ؗ³’jA™‘ºGˆê˜YA–î”ö”ÂM—TAŽR–{¹DAŒš•”r‰îAŽO‰Y³’¨AŒã‰ªL‘¾˜YA²“¡@ê¡A²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚é–ò•¨—Ö@‚ÌŒø‰Ê.
  64. •½–쓹ŠîA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA£ì«lA‰ºìG–¾FS–[‘eד®‚Ö‚Ì–[ŽºŒ‹ßECTIƒAƒuƒŒ[ƒVƒ‡ƒ“‚ªS•s‘SƒRƒ“ƒgƒ[ƒ‹‚É‘tŒ÷‚µ‚½CRT-DA‚¦ž‚ÝŒã‚ÌŠg’£Œ^S‹ØÇ‚̈ê—á.
  65. •Ÿˆä—æ–µA—é–ØG–¾A‹{ì”T—ŽqA‰““¡’q”VA‹à“c•ü—mA™‘ºGˆê˜YA¼–{‘׎¡A‰Á‰ê’J@–LA‹vŽu–{¬Ž÷A‰ºìG–¾FL”͈͔MгŽÒ‚É”­Ç‚µ‚½Šg’£Œ^S‹ØÇ‚̈ê—á.
  66. ŽO‰Y’¼WA—é–ØG–¾A‘OàVãÄ‘¾A¬扑’m–¾A•Ÿ“c_“ñA‰Á‰ê’J@–LA‹vŽu–{¬Ž÷A‰ºìG–¾F‰ESŒnS“à–Œ‰Š‚ð‡•¹‚µAƒy[ƒXƒ[ƒJ[—¯’u‚ðs‚í‚È‚©‚Á‚½èò‘¹‚É‚æ‚éS’âŽ~‚̈ê—á.
  67. ²“¡@ê¡A–ؗ³’jA™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’¨A–î”ö”ÂM—TA²“¡Œö—YA‰ºìG–¾F–«S‹Ø‰Š‚ɖƉu—}§—Ö@‚ª’˜Œø‚µ‚½ˆê—á.
‘æ203‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2014”N9ŒŽ6“úAH“cj
  1. ’†‘º‹M•jCŒš•”r‰îC™‘ºGˆê˜YCŒã‰ªL‘¾˜YCŽO‰Y³’¨CŽR–{¹DC–î”ö”ÂM—TC²“¡@—yC²“¡Œö—YC‰ºìG–¾FOFDI (ŒõŽü”g”—Ìˆæ‰æ‘œ) ‚É‚æ‚èŠÏŽ@‚µ‚¦‚½ŒŒŠÇ‰Š‚É”º‚¤”x“®–¬‹·ó‚Ì1—á
‘æ29‰ñ“ú–{•s®–¬Šw‰ïE‘æ31‰ñ“ú–{S“dŠw‰ï‡“¯Šwp‘å‰ïi2014”N7ŒŽ22“ú`25“úA“Œ‹žj

    ƒSpecial symposium: Digital recording of ECG data„

  1. Nakayama M, Shimokawa H. Practical issues in the development of cardiovascular disease databases for cardiovascular disease.
  2. ƒRegular papers„

  3. Kondo M, Fukuda K, Nakano M, Hasebe Y, Satake H, Hirano M, Shimokawa H. The significance of the QRS duration for arrhythmic events in postoperative Tetralogy of Fallot.
  4. Nakano M, Fukuda K, Kondo M, Hasebe, Y, Satake H, Hirano M, Shimokawa H. Late potentials could be markers for high-risk patients with type 2 Brugada electrocardiogram.
‘æ20‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2014”N7ŒŽ19“ú`20“úA‹ž“sj

    ƒƒVƒ“ƒ|ƒWƒEƒ€7FƒnƒCƒuƒŠƒbƒhS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“FƒfƒoƒCƒX‘S·Žž‘ã‚ł̂ ‚è•û„

  1. ˆÉ“¡Œ’‘¾A¼–{‘׎¡A‚‹´@A‰ºìG–¾F’áo—͑̊OÕŒ‚”gŽ¡—ÂÆS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“.
  2. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“2FV‚½‚ȗ̈æ‚Ö‚ÌS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“FÌ‚Ì펯‚Í¡‚Ì”ñ펯„

  3. ¼–{‘׎¡AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾F‘å“®–¬•Ùd‰»ÇE‹·óǂɑ΂·‚é‰^“®—Ö@‚ÌŒø‰Ê‚Ƌ֊õ.
  4. ƒˆê”ʉ‰‘èFŒû‰‰„

  5. ŽO‰Y³’¨Aâ“c‘וFA‹{“c@•qAŒã‰ªL‘¾˜YA‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‚‹´@A‰ºìG–¾FSŒŒŠÇ•aгŽÒ‚É‚¨‚¯‚é‰îŒì—\–h•K—vó‘Ô‚Í—\Œã•s—ǂƊ֘A‚·‚é@--CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  6. ’A–Ø‘sˆê˜YAâ“c‘וFA•Ÿ–{‹`OAŽO‰Yr˜YA–åãr–¾A‘ã“c_”VA–k•—­ŽjA‰ºìG–¾F–«S•s‘SгŽÒ‚É‚¨‚¯‚ég‘ÌŠˆ“®—ʂ̈Ӌ`‚ÌŒŸ“¢.
  7. ’|“à‰ëŽjA¼–{‘׎¡A’‡•y‚¿‚ÃA²“¡–[˜YAX@M–FAˆä“c‰ëËA¼”ö—@ŽuAˆÉ“¡Z‹PA‘’ÃKOA‰Í’Ã@‘AÖ“¡•ŽuAˆÀ’B@—AHŽR³”NAŒF’J‹Iˆê˜YA–{‹g’¼FAì–{r•ãAˆÉ“¡@CA㌎³”ŽA֖؉ÀŽA‰ºìG–¾F‘å“®–¬áŽ‚ð’†S‚Æ‚µ‚½‘匌ŠÇ޾г‚Ìp‘OŒÄ‹zƒŠƒn‚͈À‘S‚ÉŽÀŽ{‰Â”\‚Å‚ ‚èICUÝŽºEpŒã݉@“ú”‚ð’Zk‚·‚é.
  8. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  9. ’|“à‰ëŽjA¼–{‘׎¡A–x“cˆêŽ÷AŠ`‰Ô—²ºA–îŒût…AX@M–FAˆä“c‰ëËAˆÉ“¡Z‹PA‰Í’Ã@‘AHŽR³”NAŒF’J‹Iˆê˜YAˆÉ“¡Œ’‘¾Aì–{r•ãAˆÉ“¡@CA㌎³”ŽA֖؉ÀŽA‰ºìG–¾F“ñŠú“I‘匌ŠÇ’uŠ·pŒã‚Ì‘Þk‚ÉŽŠ‚Á‚½Ç—á@\p‘OŒã‚̌ċzƒŠƒn‚ð’†S‚Æ‚µ‚½—Šw—Ö@‰î“ü\
‘æ202‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2014”N6ŒŽ21“úAå‘äj
  1. ŽO‰Y—²‰îA—é–ØG–¾A¼–{‘׎¡A”öè@‘×A‰H”ö´‹MA‚‹´@AˆÉ“¡’å‰ÃA‰Á‰ê’J@–LA‹vŽu–{–ÎŽ÷A‰ºìG–¾Fƒvƒ‰ƒ“ƒ}[•a‚ɇ•¹‚µ‚½‚½‚±‚‚ڌ^S‹ØÇ‚Ì1—á.
  2. ŽO‰Y’¼WA—é–ØG–¾A‘OàVãÄ‘¾A¬‰º’m–¾A•Ÿ“c_“ñA‰Á‰ê’J@–LA‹vŽu–{–ÎŽ÷A‰ºìG–¾FS’âŽ~E‰ESŒnS“à–Œ‰Š‚ð‡•¹‚µ‚½èò‘¹‚Ì1—á.
  3. ŽO‰Y³’¨A™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŒš•”r‰îAŽR–{¹DA‰Á“¡@‹A²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éOCT‚ð—p‚¢‚½Œo”ç“I”x“®–¬Œ`¬p‚Ì—L—p«.
‘æ158‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2014”N6ŒŽ7“úA·‰ªj

    ƒÇ—á”­•\•”–åYIAF—DGÜŽóÜ„

  1. ’·’J•”—Y”òA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA²’|—m”VA•½–쓹ŠîA‰ºìG–¾FSŽº’†Šu‹NŒ¹SŽº•p”‚ÌŽ¡—Âɓïa‚µ‚½ƒ‰ƒ~ƒ“A/C ˆâ“`ŽqŠÖ˜A‰Æ‘°«Šg’£Œ^S‹ØÇ‚̈ê–UŒŸ—á.
  2. ƒŒ¤‹†”­•\•”–åYIAF—DGÜŽóÜ„

  3. ŽR“à@‹BAâ“c‘וFAŒã‰ªL‘¾˜YAŽO‰Y³’¨A‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêA‚‹´@A‰ºìG–¾A‹{“c@•qF–«S•s‘SгŽÒ‚Ì—\Œã‚É‹y‚Ú‚·•nŒŒ‚̉e‹¿‚Æ¶Žº‹ìo—¦‚ÌŠÖ˜A\CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  4. ƒˆê”ʉ‰‘è„

  5. HŽR³”NA‰Í’Ã@‘A‘’ÃKOAì–{r•ãAâV–؉ÀŽAŒã‰ªL‘¾˜YA™‘ºGˆê˜YA•Ÿ“c_“ñA‰ºìG–¾F“–‰@‚É‚¨‚¯‚éAž‚ÝŒ^•â•lHS‘ŸŽ¡—Â̬Ñ.
  6. •Е½W‘¾˜YAHŽR³”NA‰Í’Ã@‘AŒF’J‹Iˆê˜YAì–{r•ãA֖؉ÀŽA™‘ºGˆê˜YA‰ºìG–¾F‹}‘¬‚ÈLVAD ‘•’…‚Å‹~–½‚µ‚½S‹ØÇ‹}«‘ˆ«‚Ì1—á
  7. “ñ•r‘¾˜YA‚‹´@Aš¢’J—²Ž¡A‰H”ö´‹MA¼‹{Œ’‰îA¬‘é—I“ñA¼–{‘׎¡AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾FŠ¥“®–¬ƒXƒeƒ“ƒg”j‘¹‚ªŠ¥“®–¬áŽŒ`¬‚ÉŠÖ—^‚µ‚½Žá”Nìè•aŒãˆâǂ̈ê—á.
  8. ‰H”ö´‹MA‚‹´@A“ñ•r‘¾˜YA¼‹{Œ’‰îAš¢’J—²Ž¡A¼–{‘׎¡AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾FŠ¥¹k«‹·Sǂ̊ӕʂª—L—p‚Å‚ ‚Á‚½Š¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“‚É‚æ‚銮‘SŒŒsÄŒšŒã‚Ì1—á.
  9. ŽR“à—I•½Aš¢’J—²Ž¡A“ñ•r‘¾˜YA¼‹{Œ’‰îA‰H”ö´‹MA¼–{‘׎¡A‚‹´@AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾F–òÜ•‰‰×S‹ØŒŒ—¬ƒVƒ“ƒ`‚ɂėz«ŠŒ©‚ð’æ‚µ‚½Š¥¹k«‹·Sǂ̈ê—á.
  10. •½–쓹ŠîA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA‰ºìG–¾FS–[‘eד®‚ɑ΂·‚éCTIƒuƒƒbƒNƒ‰ƒCƒ“쬂¨‚æ‚Ñ–[ŽºŒ‹ßƒAƒuƒŒ[ƒVƒ‡ƒ“‚ª‘tŒ÷‚µ‚½CRT-DˆÚAŒã‚ÌDCM‚̈ê—á.
  11. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@½A’·’J•”—Y”òA²’|—m”VA•½–쓹ŠîA‰ºìG–¾F“àèòÖ¬ƒAƒvƒ[ƒ`‚ª—LŒø‚Å‚ ‚Á‚½ŽOë•Ù—Ö‹NŒ¹SŽº«ŠúŠOŽûk‚̈ê—á.
  12. ’†–ì@½A•Ÿ“c_“ñA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•½–쓹ŠîA‰ºìG–¾FLate potential‚Ítype2ƒuƒ‹ƒKƒ_S“d}гŽÒ‚ÌƒŠƒXƒN‘w•ʉ»‚É—L—p‚ȉ”\«‚ª‚ ‚é.
  13. –î”ö”ÂM—TAŽO‰Y³’¨A™‘ºGˆê˜YAŒã‰ªL‘¾˜YA–ؗ³’jAŒš•”@r‰îAŽR–{¹DA‰ºìG–¾A“¡ˆä”ŽŽiAΈä’q“¿F¬‡«Œ‹‡‘gD•a‚É”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚½ˆê—á.
  14. –ؗ³’jA™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŽO‰Y³’¨AŒš•”r‰îAŽR–{¹DA²“¡Œö—YA‰ºìG–¾:––½Œ^–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éŒo”ç“I”x“®–¬Œ`¬p‚Ì—L—p«.
‘æ14‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2014”N5ŒŽ16`17“úA²‰êj

    ƒƒVƒ“ƒ|ƒWƒEƒ€1FNOƒVƒOƒiƒŠƒ“ƒO‚ÌŽž‹óŠÔÝŒv‚É‚æ‚éSzŠÂƒ_ƒCƒiƒ~ƒYƒ€‚Ì“‡“I—‰ð„

  1. “›ˆä³lA‰ºìG–¾A–öŒ´‰„ÍA”ö’Ò@–LFzŠÂŠíE‘ãŽÓ«Ž¾Š³‚É‚¨‚¯‚é“àˆö«‚¨‚æ‚ÑŠOˆö«NOŽY¶Œn‚Ì–ðŠ„.
  2. ƒYIAƒZƒbƒVƒ‡ƒ“FÅ—DGÜŽóÜ„

  3. _ŒË–ΗYAÖ“¡‘åŽ÷A’r“c®•½AàV“cˆ¼ŽqABudbazar EnkhjargalA‰ºìG–¾F“à”çˆË‘¶«’oŠÉ”½‰ž‚É‚¨‚¯‚éNO‚ÆEDHF‚̃oƒ‰ƒ“ƒX‚ÍSŒŒŠÇŒn‚ÌPí«ˆÛŽ‚Éd—v‚Å‚ ‚é.
  4. ƒˆê”ʉ‰‘èFŒû‰‰„

  5. ²“¡Œö—YA—é–ØN‘¾A‘呺~ˆêA‹e’n‡—TA™‘ºGˆê˜YA’†‘ºˆê•¶AˆÉ“¡@_A–弌’Ž¡A‰ºìG–¾FBasigin promotes vascular smooth muscle proliferation and pulmonary hypertension.
  6. “à“c‘¾˜YAŒÃ–ì—R”üA’J–{º‰pA‰ºìG–¾A‘剮—S•ãA–öŒ´‰„ÍA”ö’Ò@–LF‘n–ò‚ÉŽ‘‚·‚鎩‘R”­Ç‹}«S‹Ø[ǃ‚ƒfƒ‹‚ÌŠJ”­F2/3t“Etriple NOSs-/-ƒ}ƒEƒX.
  7. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[„

  8. –î“c–L—²A‰ºìG–¾A•½¼@CAŒã“¡^ŒÈA¬Š}Œ´N•vAŠ’J•¶•FFƒCƒk¶‘Ì“à‹}«Š¥“®–¬•ÂÇŽžA‰ßŽ_‰»…‘f‚É‚æ‚銥”÷¬‘¤•›ŒŒs˜HŠg’£‚ÍA“œ”A•a«Š¥”÷¬ŒŒŠÇ“à”çáŠQ‚ð‘ãž‚·‚é.
  9. Ö“¡‘åŽ÷A_ŒË–ΗYAàV“cˆ¼ŽqABudbazar EnkhjargalA‰ºìG–¾F”÷¬ŒŒŠÇ‚É‚¨‚¢‚Ä“à”çˆË‘¶«‰ß•ª‹ÉiEDHj”½‰ž‚ª˜´i‚µ‚Ä‚¢‚镪Žq‹@˜‚ÌŒŸ“¢.
‘æ51‰ñ“ú–{—Õ°•ªŽqˆãŠw‰ïŠwpW‰ïi2014”N4ŒŽ11“úA“Œ‹žj

    ƒƒVƒ“ƒ|ƒWƒEƒ€2F‰ä‚ª‘‚É‚¨‚¯‚éƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`‚ÌŒ»ó‚Æ‚±‚ê‚©‚ç‚̉ۑè„

  1. ‰ºìG–¾F“Œ–k‘åŠw‚É‚¨‚¯‚éƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`.
‘æ78‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2014”N3ŒŽ21“ú`23“úA“Œ‹žj

    ƒPlenary Session„

  1. (PL01:Coronary Revascularization Based on Evidence Based Medicine-ComparingPCI and CABG-Reality and Ideal) Takahashi J, Sakata Y, Miyata S, Nochioka K, Miura M, Takada T, Shimokawa H. Prognostic impacts of revascularization strategy and residual coronary stenosis in patients with ischemic heart failure. Circ J. 78(Suppl. I):I-56,2014.
  2. (PL05:Current Status and Management of Cardiac Failure, Arrhythmias, Pulmonary Hypertension and Sudden Death in Adults with Congenital Heart Disease) Tatebe S, Fukumoto Y, Sugimura K, Nochioka K, Miura M, Yamamoto S, Shimokawa H. Adult patients with congenital heart disease as an emerging population in cardiovascular medicine. Circ J. 78(Suppl. I):I-75,2014.
  3. ƒSymposium„

  4. (SY01:Coronary Circulation Revisited: Pathogenesis of Myocardial Ischemia and Its Evaluation) Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Shindo T, Hanawa K, Hasebe Y, Nihei T, Hao K, Tsuburaya R, Shiroto T, Ito K, Ishibashi-ueda H, Yasuda S, Shimokawa H. Important role of the adventitia in the pathogenesis of coronary hyperconstricting responses after drug-eluting stent implantation in pigs in vivo. Circ J. 78(Suppl. I):I-100,2014.
  5. (SY07:EBM in Hypertension) Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. Clinical significance of low diastolic blood pressure in development of de-novo heart failure \A report from the CHART-2 Study\ Circ J. 78(Suppl. I):I-137,2014.
  6. (SY09:Frontiers of Coronary Imaging Modalities) Matsumoto Y, Nishimiya K, Tanaka A, Taruya A, Takahashi J, Shindo T, Hanawa K, Hasebe Y, Tsuburaya R, Shirato T, Ito K, Yasuda S, Shimokawa H. Usefulness of micro-CT and optical coherence tomography for vasa vasorum imaging in porcine coronary arteries with stent implantation. Circ J. 78(Suppl. I):I-148,2014.
  7. (SY11:Clinical Network and Disease Registry for Cardiovascular Disease) Sakata Y, Nochioka K, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Miyata S, Shimokawa H. Experience and perspectives from the chronic heart failure analysis and registry in the Tohoku District 2 (CHART-2) Study. Circ J. 78(Suppl. I):I-161,2014.
  8. (SY15:Treatment Strategy of CKD: Collaboration by Cardiologists and Nephrologists) Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H. Prognostic impact of subclinical albuminuria in chronic heart failure \A report from the CHART-2 Study\ Circ J. 78(Suppl. I):I-184,2014.
  9. (SY17:New Treatment Methods Expected for Pulmonary Hypertension) Sugimura K, Tatebe S, Fukumoto Y, Nochioka K, Yamamoto S, Miura M, Kimio Satoh, Shimokawa H. Reactive post-capillary pulmonary hypertension as a new therapeutic target for left heart disease. Circ J. 78(Suppl. I):I-193,2014.
  10. ƒYoung Investigator's Award for International Students Finalists Lectures„

  11. Nergui S, Fukumoto Y, Do.e Z, Nakajima S, Shimizu T, Ikeda S, Elias-Al-Mamun M, Shimokawa H. Molecular and cellular mechanisms of right ventricular remodeling in pulmonary hypertension. Circ J. 78(Suppl. I):I-516,2014.
  12. ƒFeatured Research Session„

  13. Nihei T, Takahashi J, Kikuchi Y, Hao K, Takagi Y, Tsuburaya R, Shirato T, Yoshitaka Itoh, Matsumoto Y, Nakayama M, Ito K, Shimokawa H. Circadian variation of Rho-kinase activity in circulating leukocytes in patients with vasospastic angina. Circ J. 78(Suppl. I):I-597,2014.
  14. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Takada T, Tadaki S, Yamauchi T, Shimokawa H. Improved long-term prognosis of patients with dilated cardiomyopathy\A report from the CHART Studies\ Circ J. 78(Suppl. I): I-549,2014.
  15. ƒOral Presentation (English)„

  16. Nakayama M, Takehana K, Shimokawa H. Data transition platforms in hospital information system should be established to construct database with information communication technology. Circ J. 78(Suppl. I):I-856,2014.
  17. Satoh K, Fukumoto Y, Sugimura K, Aoki T, Nochioka K, Tatebe S, Yamamoto S, Miura M, Shimizu T, Ikeda S, Yaoita N, Minami T, Miyata S, Suzuki K, Omura J, Kikuchi N, Nakamura K, Ito H, Kadomatsu K, Shimokawa H. Basigin promotes inflammation and pulmonary hypertension through synergistic cooperation with extracellular Cyclophilin A. Circ J. 78(Suppl. I):I-1066,2014.
  18. Suzuki K, Satoh K, Ikeda S, Kadomatsu K, Shimokawa H. Basigin promotes cardiac fibrosis and failure in pressure-overload-induced cardiac hypertrophy in mice. Circ J. 78(Suppl. I):I-1020,2014.
  19. ƒOral Presentation (Japanese)„

  20. Godo S, Saito H, Ikeda S, Sawada A, Shiroto T, Enkhjargal B, Shimokawa H. Importance of the physiological balance between nitric oxide and endotheliumderived hyperpolarizing factor in vascular homeostasis in mice. Circ J. 78(Suppl. I):I-1149,2014.
  21. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. U-Shaped relationship between left atrial diameter and prognosis of patients with heart failure with preserved ejection fraction \The CHART-2 Study\ Circ J. 78(Suppl. I):I-1266,2014.
  22. ƒPoster Session (English)„

  23. Al-mamun E, Satoh K, Tanaka S, Shimizu T, Nergui S, Miyata S, Fukumoto Y, Shimokawa H. Combination therapy with fasudil and sildenafil exerts synergistic effects through inhibition of Rho-kinase in pulmonary hypertension. Circ J. 78(Suppl. I):I-1831,2014.
  24. Hao K, Takahashi J, Ito K, Miyata S, Sakata Y, Nihei T, Tsuburaya R, Shirato T, Matsumoto Y, Nakayama M, Yasuda S, Shimokawa H. Characteristics of patients with acute myocardial infarction who did not undergo primary percutaneous coronary intervention \A Report from MIYAGI-AMI Registry\ Circ J. 78(Suppl. I):I-2038,2014.
  25. Nakano M, Fukuda K. Wakayama Y, Kondoh M, Hasebe Y, Satake H, Shimokawa H. Clinical characteristics of J wave in patients with Brugada syndrome. Circ J. 78(Suppl. I):I-1413,2014.
  26. Tsuburaya R, Takahashi J, Hao K, Shirato T, Matsumoto Y, Ito K, Nakayama M, Shimokawa H. Beneficial effects of a single prophylactic hemodialysis on renal function worsening after percutaneous coronary intervention in patients with severe CKD. Circ J. 78(Suppl. I):I-1796,2014.
  27. ƒPoster Session (Japanese)„

  28. Abe Y, Ito K, Hao K, Hanawa K, Shindo T, Nishimiya K, Hasebe Y, Yamamoto H, Satoh K, Kawakami K, Shimokawa H. Extracorporeal low-energy shock wave therapy improves left ventricular remodeling and reduces inflammatory responses after acute myocardial infarction in rats. Circ J. 78(Suppl. I):I-2399,2014.
  29. Hanawa K, Ito K, Aizawa K, Shindo T, Nishimiya K, Hasebe Y, Tsuburaya R, Hasegawa H, Yasuda S, Kanai H, Shimokawa H. Low-intensity pulsed ultrasound induces angiogenesis and ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia. Circ J. 78(Suppl. I):I-2578,2014.
  30. Hasebe Y, Yamamoto H, Fukuda K, Nishimiya K, Hanawa K, Shindo T, Hirano M, Kondoh M, Nakano M, Wakayama Y, Shimokawa H. Development of a novel shock wave catheter ablation system \A feasiblity study in pigs in vivo\ Circ J. 78(Suppl. I):I-2718,2014.
  31. Ikeda S, Satoh K, Fukumoto Y, Suzuki K, Shimizu T, Shimokawa H. Crucial role of Rho-kinase in pressure-overload myocardial hypertrophy in mice \Comparison between the left and right ventricles\ Circ J. 78(Suppl. I):I-2612,2014.
  32. Kondo M, Fukuda K, Wakayama Y, Nakano M, Hasebe Y, Satake H, Shimokawa H. Different characteristics of postoperative atrial tachyarrhythmias between congenital and non-congenital heart disease. Circ J. 78(Suppl. I):I-2871,2014.
  33. Miura M, Sugimura K, Nochioka K, Tatebe S, Yamamoto S, Hiramoto T, Inoue K, Tamaki K, Shimokawa H. Prognostic impact of acid-base balance on admission in acute heart failure syndrome\A report from the Tohoku Acute Failure Registry\ Circ J. 78(Suppl. I):I-2463,2014.
  34. Satake H, Fukuda K, Wakayama Y, Nakano M, Kondoh M, Hasebe Y, Hirano M, Shimokawa H. Papillary muscles as an important site of origin of lethal ventricular tachyarrhythmias \Usefulness of the new intra-cardiac echo system\ Circ J. 78(Suppl. I):I-2744,2014.
  35. Shiroto T, Takahashi J, Takagi Y, Tsuburaya R, Matsumoto Y, Nakayama M, Ito K, Kondoh M, Nakano M, Wakayama Y, Fukuda K, Yasuda S, Shimokawa H. Prognostic importance of dual-induction tests for coronary artery spasm and ventricular arrhythmias in patients surviving out-of-hospital cardiac arrest. Circ J. 78(Suppl. Ij :I-2284,2014.
  36. Suzuki H, Matsumoto Y, Ota H, Sugimura K, Takahashi J, Ito K, Furukawa K, Fukumoto Y, Arai H, Takahashi S, Taki Y, Shimokawa H. Decreased activity of the hippocampus is associated with depression in heart failure patients \Brain Investigation in Heart Failure Trial (B-HeFT)\ Circ J. 7(8 Suppl. I):I-2867,2014.
  37. Tadaki S, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Takada T, Ushigome R, Yamauchi T, Shimokawa H. Accumulation of metabolic disorders is a cardiovascular risk in patients with central obesity \The CHART-2 Study\ Circ J. 78(Suppl. I):I-2346,2014.
  38. Tatebe S, Fukumoto Y, Sugimura K, Nochioka K, Miura M, Yamamoto S, Satoh K, Shimokawa H. Percutaneous transluminal pulmonary angioplasty ameliorates metabolic and renal dysfunctions associated with hemodynamic improvement in patients with chronic thromboembolic pulmonary hypertension. Circ J. 78(Suppl. I):I-2825,2014.
  39. Yaoita N, Fukumoto Y, Horiuchi H, Shimokawa H. Involvement of thrombinactivated fibrinolysis inhibitor in chronic thromboembolic pulmonary hypertension. Circ J. 78(Suppl. I):I-2478,2014.
•½¬25”N“x•¶•”‰ÈŠwÈ‹´“n‚µŒ¤‹†‰Á‘¬ƒlƒbƒgƒ[ƒNƒvƒƒOƒ‰ƒ€i2014”N2ŒŽ28“úA“Œ‹žj
  1. ‰ºìG–¾FˆãH˜AŒg‚ðŠî”Õ‚Æ‚µ‚½ƒgƒ‰ƒ“ƒXƒŒ[ƒVƒ‡ƒiƒ‹ƒŠƒT[ƒ`‹’“_Œ`¬
‘æ4‰ñ‹´“n‚µŒ¤‹†‰Á‘¬ƒlƒbƒgƒ[ƒNƒvƒƒOƒ‰ƒ€‰^‰cˆÏˆõ‰ïi2014”N2ŒŽ27“úA“Œ‹žj
  1. ‰ºìG–¾F“Œ–k”­‚̈ã—Ë@ŠíŠJ”­‹’“_
‘æ201‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2014”N2ŒŽ15“úAå‘äj
  1. —L’|G”üC‰Á‰ê’J–LC—é–ØG–¾, ‰~’J—²Ž¡, ¼–{‘׎¡, ‚‹´@, ˆÉ“¡Œ’‘¾, ‰ºìG–¾, H“¡‘å‰î, ‹vŽu–{¬Ž÷FlHS”xŠÇ—‚ð—v‚µ‚½’á‘̉·—Ö@‚É‚æ‚éS‹@”\’ቺ‚Ì1—á
  2. ŽO‰Y’¼W,ŽO‰Y³’¨, ™‘ºGˆê˜Y, Œã‰ªL‘¾˜Y, Œš•”r‰î, ŽR–{¹D, ‰ºìG–¾F•â•zŠÂ‚ð—v‚µ‚½dÇS•s‘S‚ɃwƒpƒŠƒ“—U”­«ŒŒ¬”ÂŒ¸­Ç‚ð‡•¹‚µ‚½2Ç—á‚ÌŒŸ“¢
  3. •Ÿˆä—æ–µC‰Á‰ê’J–LC—é–ØG–¾, ™‘ºGˆê˜Y, ‰ºìG–¾, ‹{ì”T—Žq, ‹vŽu–{¬Ž÷FL”͈͔MгŽÒ‚É”­Ç‚µ‚½Šg’£Œ^S‹ØÇ‚Ì1—á
‘æ35‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ïi2014”N2ŒŽ15“úAŒSŽRj
  1. ‚‹´@C‰H”ö´‹MCˆÉ“¡Œ’‘¾C‹{“c@•qCâ“c‘וFC“ñ•r‘¾˜YC‰~’J—²Ž¡C¼–{‘׎¡CˆÀ“c@‘C‰ºìG–¾F“Œ“ú–{‘åkÐŒã‚ɉü‘P‚ð”F‚ß‚½‹}«S‹Ø[ÇŠ³ŽÒ‚ɑ΂·‚é‹~‹}ˆã—Ņ̃‚ɂ‚¢‚Ă̌Ÿ“¢@\‹{錧S‹Ø[Ç‘Îô‹¦‹c‰ï‚©‚ç‚ÌŒŸ“¢\
‘æ43‰ñ“ú–{S–¬ŠÇì“®•¨Ž¿Šw‰ïi2014”N2ŒŽ15`16“úA_ŒËj

    ƒƒVƒ“ƒ|ƒWƒEƒ€F“®–¬d‰»‚ÌÅV’mŒ©„

  1. ²“¡Œö—YC‰ºìG–¾FƒTƒCƒNƒƒtƒBƒŠƒ“A ‚É‚æ‚é“®–¬d‰»‚Ì”­Ç‹@\‚ÆV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ẳ”\«
  2. ƒˆê”ʉ‰‘è„

  3. ’r“c®•½C²“¡Œö—YC•Ÿ–{‹`OC´…@‹œC‹{“c@•qC—é–ØN‘¾C‹e’n‡—TC‘呺~ˆêC‰ºìG–¾F¶Žº‚ƉEŽº‚̈³•‰‰×‚ɑ΂·‚é—U“±ˆâ“`Žq‚ÌŽž‹óŠÔ“I·ˆÙ‚ÆS”ì‘åES•s‘S‚Ì”­Ç‹@\
  4. —é–ØN‘¾C²“¡Œö—YC’r“c®•½C–弌’Ž¡C‰ºìG–¾Fƒ}ƒEƒXˆ³•‰‰×ƒ‚ƒfƒ‹‚É‚¨‚¢‚ÄBasigin‚ÍS‘Ÿ‚ÌüˆÛ‰»CS•s‘S‚Ì‘ˆ«‚ÉŠñ—^‚·‚é
‘æ14‰ñ“®–¬d‰»‹³ˆçƒtƒH[ƒ‰ƒ€ in Sendaii2014”N2ŒŽ2“úAå‘äj
  1. ‰ºìG–¾F“Œ“ú–{‘åkЂÆSŒŒŠÇƒCƒxƒ“ƒg
‘æ7‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2014”N1ŒŽ31“ú`2ŒŽ1“úA“Œ‹žj

    ƒ‹³ˆçu‰‰„

  1. ‰ºìG–¾FzŠÂŠí޾г‚Æ«·
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€„

  3. ŽR“à@‹BAâ“c‘וFA‹{“c@•qAŒã‰ªL‘¾˜YAŽO‰Y³’¨A‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêA‚‹´@A‰ºìG–¾F–{–M‚ÌStage C/DS•s‘S‚Ì”wŒiAŽ¡—ÃA’·Šú—\Œã‚É‚¨‚¯‚é«·.
  4. ƒˆê”ʉ‰‘è/ƒ|ƒXƒ^[”­•\„

  5. ’A–Ø‘sˆê˜YAâ“c‘וFAŒã‰ªL‘¾˜YAŽO‰Y³’¨A‚“c„ŽjA‹{“c@•qA‰ºìG–¾FS•s‘SгŽÒ‚É‚¨‚¯‚郃^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚Æ«·‚ÌŒŸ“¢.
  6. ’·’J•”—Y”òA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA²’|—m”VA•½–쓹ŠîA‰ºìG–¾F’ÊíŒ^S–[‘e“®‚Ì—Õ°“I“Á’¥‚É‚¨‚¯‚é«·‚ÉŠÖ‚·‚錟“¢.
  7. ‰H”ö´‹MA‚‹´@A–ؗ³’jA‹{“c@•qA‰~’J—²Ž¡A”’ŒË@’A¼–{‘׎¡AˆÉ“¡Œ’‘¾Aâ“c‘וFA‰ºìG–¾F“Œ“ú–{‘åkÐŒã‚É”F‚ß‚ç‚ꂽS”x’âŽ~Ç—á‚Ì‘‰Á‚ÉŠÖ‚·‚é«·‚ÌŒŸ“¢.
  8. ŽR–{¹DA™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘¾˜YAŽO‰Y³’¨A²“¡Œö—YA‰ºìG–¾F¶S޾г‚É”º‚¤Œã–Ñ׊ǫ”x‚ŒŒˆ³Ç‚É‚¨‚¯‚錌s“®‘Ô“I’j—·‚ÌŒŸ“¢.
‘æ24‰ñ“ú–{‰uŠw‰ïŠwpW‰ïi2014”N1ŒŽ23`25“úAå‘äj
  1. ‹ž—ºˆêCâ“c‘וFCŒã‰ªL‘¾˜YC‹{“c@•qCŽO‰Y³’¨C‚“c„ŽjC’A–Ø‘sˆê˜YCŽR“à@‹BC‰ºìG–¾FŠg’£Œ^S‹ØÇ‚Ì“Á’¥‚Æ‚»‚Ì—\Œã‚ÌŽž‘ã“I•Ï‘JFCHART-1Œ¤‹†‚ÆCHART-2Œ¤‹†‚Ì”äŠr
  2. ‚“c„ŽjCâ“c‘וFC‹{“c@•qC‚‹´@CŒã‰ªL‘¾˜YCŽO‰Y³’¨C’A–Ø‘sˆê˜YC‹ž—ºˆêCŽR“à@‹BC‰ºìG–¾FS•s‘S”­ÇƒnƒCƒŠƒXƒNгŽÒ‚É‚¨‚¯‚éV‹KS•s‘S”­Ç‹K’èˆöŽq@\CHART-2Œ¤‹†\

Œ¤‹†‹ÆÑˆê——‚Ö@b‚±‚̃y[ƒW‚ÌTOP‚Ö

2013”N
‘æ157‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2013”N12ŒŽ7“úAå‘äj

ƒYIAÇ—á”­•\•”–å„

  1. ‘呺~ˆêA™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŒš•”r‰îAŽO‰Y³’¨AŽR–{¹DA²“¡Œö—YA‰ºìG–¾F–«Šˆ“®«Epstein-BarrƒEƒCƒ‹ƒXŠ´õǂɇ•¹‚µ‚½”x‚ŒŒˆ³Ç‚Éä`‘ÑŒŒŠ²×–EˆÚA‚ª’˜Œø‚µ‚½ˆê—á.iÅ—DGÜŽóÜj
  2. ƒYIAŒ¤‹†”­•\•”–å„

  3. Œã‰ªL‘¾˜YAâ“c‘וFAŽO‰Y³’¨A‚“c„ŽjA’A–Ø‘sˆê˜YA‹ž—ºˆêAŽR“à@‹BA‹{“c@•qA‰ºìG–¾FŠg’£Œ^S‹ØÇŽ¡—ìт̎ž‘ã“I•Ï‘J‚ÌŒŸ“¢FCHARTŒ¤‹†‚Ì’mŒ©‚æ‚è.iÅ—DGÜŽóÜj
  4. ƒˆê”ʉ‰‘è„

  5. —L’|G”üA‰Á‰ê’J@–LA—é–ØG–¾Aš¢’J—²Ž¡A”’ŒË@’A¼–{‘׎¡A‚‹´@AˆÉ“¡Œ’‘¾A‰ºìG–¾A‘呺@‘ñAH“¡‘å‰îA“ü–ì“c@’A‹vŽu–{¬Ž÷F’á‘̉·—Ö@’†‚ÉS‹@”\’ቺ‚ð‚«‚½‚µAŒo”ç“IlHS”x‚É‚æ‚éŠÇ—‚ð—v‚µ‚½ˆê—á.
  6. ”öŒ`@„A”’ŒË@’Aš¢’J—²Ž¡A¼–{‘׎¡Aâ“c‘וFAˆÉ“¡Œ’‘¾A¬‘é@—I“ñA‚‹´@A‰ºìG–¾F”­Ç‹}«Šú‚É‘½Ž}Š¥“®–¬¹k‚ª—U”­‚³‚ꂽ‚½‚±‚‚ڌ^S‹ØÇ‚̈ê—á.
  7. •Е½W‘¾˜YAHŽR³”NA׎RŸŠ°A‰Í’Ã@‘AŒF’J‹Iˆê˜YA–{‹g’¼FAì–{r•ãAâV–؉ÀŽAŽO‰Y³’¨AŒã‰ªL‘¾˜YA™‘ºGˆê˜YA‚‹´@A•Ÿ“c_“ñA‰ºìG–¾F’°ŠÇ‹•ŒŒ‚𕹔­‚µ‚½Œ€ÇŒ^S‹Ø‰Š2Ç—á.
  8. ¬‘é—I“ñA‚‹´@AˆÉ“¡Œ’‘¾A¼–{‘׎¡A”’ŒË@’Aš¢’J—²Ž¡A‰H”ö´‹MA‰ºìG–¾FŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“’†‚ɶ‚¶‚½Slow flow‚ÉRhoƒLƒi[ƒ[‘jŠQ–ò‰–Ž_ƒtƒ@ƒXƒWƒ‹Š¥’‚ª—LŒø‚Å‚ ‚Á‚½ˆê—á.
  9. ‹ß“¡³‹PA•Ÿ“c_“ñA’†–ì@½A’·’J•”—Y”òA²’|—m”VA•½–쓹ŠîA‰ºìG–¾FS–[•p”‚ð‡•¹‚µ‚“x–[ŽºƒuƒƒbƒN‚ð‚«‚½‚µ‚½ƒtƒ@ƒ[Žl’¥ÇpŒã‚̈ê—á.
  10. âV“¡ˆ»ŽqAš¢’J—²Ž¡A‚‹´@AˆÉ“¡ˆ¤„A‰H”ö´‹MA”’ŒË@’A¼–{‘׎¡AˆÉ“¡Œ’‘¾A‰ºìG–¾F‘å“®–¬‰ŠÇŒóŒQ‚ð”wŒi‚Æ‚µ‚½¶Š¥“®–¬Žåв•”‚Ì‹·ó•a•ςɂæ‚è‹}«S‹Ø[Ç‚ð”­Ç‚µ‚½Žá”N—«‚Ì1—á.
  11. ²’|—m”VA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA’·’J•”—Y”òA•½–쓹ŠîA‰ºìG–¾F‘å“®–¬–³Š¥ë‚©‚çKent ‘©‚Ì—£’f‚ɬŒ÷‚µ‚½–[Žº‰ñ‹A«•p”‚̈ê—á.
  12. ²“¡‘åŽ÷C“¡“c@‰›CŽRŒû“WаC”öã‹IŽqCÎ’Ë@‹CŽÂè@‹BF–«S•s‘SгŽÒ‚̶ŠUÄ“ü‰@‰ðÍ.
  13. ’|“à@’qA•Ÿ“c_“ñA’†–ì@½A‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•½–쓹ŠîA‰ºìG–¾FSŽº•p”‚ðŒ_‹@‚Éf’f‚ÖŽŠ‚Á‚½Sƒtƒ@ƒuƒŠ[•a‚̈ê—á.
  14. ’†–ì@½A•Ÿ“c_“ñA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VA•½–쓹A‰ºìG–¾F‰EŽº—¬o˜HS“à–Œ‘¤‚̈Ùí’x‰„“dˆÊ‚ɑ΂·‚éRFCA‚ªVF”­ì—}§‚É—LŒø‚Å‚ ‚Á‚½BrugadaÇŒóŒQ‚̈ê—á.
  15. ’·’J•”—Y”òA•½–쓹ŠîA²’|—m”VA‹ß“¡³‹PA’†–ì@½A•Ÿ“c_“ñA‰ºìG–¾FŒã’†ŠuKent‘©‚ɑ΂µ‚ÄŠ¥óÖ¬“´“à‚ł̒ʓd‚É‚æ‚莡—ÂɬŒ÷‚µ‚½ƒnƒCƒŠƒXƒN‹U«SŽº•p”‚Ì2—á.
  16. –x“cˆêŽ÷A’|“à‰ëŽjAˆÉ“¡‘å—ºAŠ`‰Ô—²ºA²“¡–[˜YA‚‹´ŽìAX@M–FAˆÉ“¡@CA㌎³”ŽA™‘ºGˆê˜YA‰ºìG–¾FŠÔŸ[“IƒgƒŒ[ƒjƒ“ƒO‚É‚æ‚è‰^“®‘Ï—e”\‚̉ü‘P‚ª“¾‚ç‚ꂽ–«S•s‘Sˆê—á.
  17. ŽO‰Y’¼WAŽO‰Y³’¨A™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŒš•”r‰îAŽR–{¹DA‰ºìG–¾AHŽR³”NAâV–؉ÀŽF–„‚ßž‚ÝŒ^•â•lHS‘Ÿ‚ɂċ~–½‚µ‚¦‚½‘ŸŠí•s‘S‚𗈂µ‚½dÇS•s‘S‚̈ê—á.
  18. ŽR“à@‹BAš¢’J—²Ž¡A‚‹´@A‰H”ö´‹MA”’ŒË@’A¼–{‘׎¡AˆÉ“¡Œ’‘¾A‰ºìG–¾Fìè•aŒãˆâǂɂæ‚銥“®–¬‹·ó‚ɑ΂µŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—ÂðŽ{s‚µ‚½Žá”NŽÒ‚Ì2—á.
  19. ŽR“à—I•½A‰Á‰ê’J@–LA—é–ØG–¾A™‘ºGˆê˜YA‰ºìG–¾A‘OàVãÄ‘¾A‹{ì”T—ŽqAŒÃì@@A²“¡•—gA‹vŽu–{¬Ž÷A²’|—¥ŽqA‘Šêß–çF‘½Œ`Ÿøo«g”Á‚ð‡•¹‚µ‚½S‹Ø‰Š‚̈ê—á.
  20. ŽR–{¹DA™‘ºGˆê˜YAŒš•”r‰îAŒã‰ªL‘¾˜YAŽO‰Y³’¨A‰ºìG–¾F¬l‚Ì––½«”x“®–¬‹·óÇ‚Ì1—á.
‘æ36‰ñ“ú–{•ªŽq¶•¨Šw‰ïi2013”N12ŒŽ3`6“úA_ŒËj

ƒƒ[ƒNƒVƒ‡ƒbƒv„

  1. ’†ŽR‰ë°C‹{“c •qC‰ºìG–¾F—Õ°ˆã‚ɂƂÁ‚Ä•K—v‚ȃoƒCƒIƒCƒ“ƒtƒHƒ}ƒeƒBƒVƒƒƒ“E“Œvê–副
“ú–{“à‰ÈŠw‰ïŠwpW‰ï‘æ41‰ñ“à‰ÈŠw‚Ì“W–]i2013”N12ŒŽ1“úAå‘äj

ƒ“Œ“ú–{‘åkЂ©‚çŠw‚Ô“à‰È޾г@`“Á’¥A‘ΉžA—\–h`„

  1. ‰ºìG–¾FzŠÂŠí޾г.
‘æ17‰ñ“ú–{S•s‘SŠw‰ïŠwpW‰ïi2013”N11ŒŽ28“ú`30“úA‘å‹{j

ƒESC-HFA/JHFSƒWƒ‡ƒCƒ“ƒgƒZƒbƒVƒ‡ƒ“„

  1. Shimokawa H. Changing heart failure management in Japan --Report from CHART Studies-
  2. ƒ“Á•ÊŠé‰æFЊQ‚ÆS•s‘S„

  3. Nochioka K, Sakata Y, Miyata S, Takahashi J, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Shimokawa H. Longitudinal study of post-traumatic stress disorder after the Great East Japan Earthquake Disaster in cardiovascular disease patients -The CHART Study-
  4. ƒYIAF—Õ°Œ¤‹†•”–å„

  5. Nochioka K, Sakata Y, Miyata S, Takahashi J, Miura M, Takada T, Tadaki S, Ushigome R, Shimokawa H. Prognsotic impact of statin in Japanese patients with heart failure with preserved ejection frcation --A report from the CHART-2 Study-i—DGÜŽóÜj
  6. Suzuki H, Matsumoto Y, Takahashi J, Tsuburaya R, Sugimura K, Ito K, Fukumoto Y, Shimokawa H. Interactions between the heart and the brain in heart failure patients assessed by MRI -Interim results from the B-HeFT Study-iÅ—DGÜŽóÜj
  7. ƒŒû‰‰”­•\„

  8. Hao K, Takahashi J, Miyata S, Sakata Y, Tsuburaya R, Shiroto T, Matsumoto Y, Ito K, Yasuda S, Shimokawa H. Emergency care of acute myocardial infarction during the Great East Japan Earthquake Disaster -Report from the Miyagi AMI Registry Study-
  9. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, Takahashi J, Shimokawa H. Prognostic impact of urine protein in diabetic patients with ischemic heart failure -A report from the CHART-2 Study-
  10. Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Shimokawa H. Different impact of anemia in chronic heart failure with preserved vs. reduced ejection fraction --A report from the CHART-2 Study-
  11. Tatebe S, Fukumoto Y, Sugimura K, Nochioka K, Miura M, Yamamoto S, Shimokawa H. Percutaneous transluminal balloon angioplasty improves metabolic and renal dysfunctions associated with hemodynamic improvement in patients with chronic thromboembolic pulmonary hypertension.
  12. ƒƒ|ƒXƒ^[”­•\„

  13. Nakano M, Fukuda K, Wakayama Y, Kondo M, Hasebe Y, Satake H, Shimokawa H. MIBI scintigraphy could be useful to identify heart failure patients with narrow QRS who respond to cardiac resynchronization therapy.
  14. Satoh T, Fujita H, Yamaguchi N, Onoue N, Ishizuka T, Shinozaki T. When rehospitalization due to chronic heart failure occurs during life time?
  15. Takada N, Sugimura K, Fukumoto Y, Nochioka K, Tatebe S, Yamamoto S, Miura M, Satoh K, Shimokawa H. Triglyceride deposit cardiomyovasculopathy with severe heart failure.
  16. Yamamoto S, Matsumoto Y, Fukumoto Y, Nochioka K, Miura M, tatebe S, Sugimura K, Suzuki T, Shimokawa H. Potential involvement of functional tricuspid regurgitation in the diagnostic errot to assess pulmonary arterial pressure by Doppler echocardiography.
‘æ33‰ñˆã—Ãî•ñŠw˜A‡‘å‰ïE‘æ14‰ñ“ú–{ˆã—Ãî•ñŠw‰ïŠwp‘å‰ïi2013”N11ŒŽ21`23“úA_ŒËj

ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“„

  1. ’†ŽR‰ë°FƒAƒŒƒ‹ƒM[î•ñ‚Ì•W€‰»‚ð‚ß‚´‚µ‚Ä@\ƒAƒŒƒ‹ƒM[î•ñ‚Ì‹¤—L‚ɂ͉½‚ª•K—v‚©\‘S‘ƒAƒ“ƒP[ƒg’²¸‚æ‚è.
‘æ28‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠî‘bŠwpW‰ïi2013”N10ŒŽ17`18“úA–‹’£j
  1. ŠÚ“c@‘C›–ì°•vC¬àV_ŽiC”ª”¦Œ’ˆê˜YCŽR‰®½ŽiCˆÉ“¡Œ’‘¾C‰ºìG–¾Cˆä”ó‰h“ñFÒ‘‘¹‚ɑ΂·‚é’áo—͑̊OÕŒ‚”gŽ¡—Ã@\ƒAƒƒfƒBƒjƒA‚Ö‚ÌŒø‰Ê‚ÌŒŸ“¢\.
  2. ”ª”¦Œ’ˆê˜YC›–ì°•vC¬àV_ŽiCŠÚ“c‘CŽR‰®½ŽiCˆÉ“¡Œ’‘¾C‰ºìG–¾Cˆä”ó‰h“ñF‹}«ŠúÒ‘‘¹‚É‚¨‚¯‚é’áo—͑̊OÕŒ‚”gŽ¡—ÂÌVEGF ”­Œ»‘£iE‰^“®‹@”\‰ü‘PŒø‰Ê.
‘æ54‰ñ“ú–{–¬ŠÇŠw‰ï‘‰ïi2013”N10ŒŽ10“ú`12“úA“Œ‹žj

ƒ–¬ŠÇê–åˆã‹³ˆçƒZƒbƒVƒ‡ƒ“„

  1. ‰ºìG–¾F–¬ŠÇf—Â̓W–].
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€2F”x‚ŒŒˆ³‚ÌŽ¡—ÂÌÅ‘Oü@–ò•¨Ž¡—ÂÆNPŽ¡—Ä

  3. Œã‰ªL‘¾˜YA™‘ºGˆê˜YA•Ÿ–{‹`OAŒš•”r‰îAŽR–{¹DAŽO‰Y³’¨A²“¡Œö—YA‰ºìG–¾FdÇ–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚鎡—Ãí—ª.
  4. ƒƒ|ƒXƒ^[”­•\„

  5. –î”ö”ÂM—TA‘Õ@“NA•Ÿ–{‹`OAŒš•”r‰îA™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŽR–{¹DAŽO‰Y³’¨A²“¡Œö—YA‰ºìG–¾F”x“®–¬ƒŠƒ‚ƒfƒŠƒ“ƒO‚Í”x‚ŒŒˆ³”­Ç‘O‚©‚çoŒ»‚·‚éFŒõŠ±Â’f‘w–@‚ð—p‚¢‚½ŒŸ“¢.
‘æ21‰ñ“ú–{ŒŒŠÇ¶•¨ˆãŠw‰ïŠwpW‰ïi2013”N9ŒŽ26`28“úA–L’†j

ƒ‰ï’·µ‘Òu‰‰„

  1. ‰ºìG–¾FŒŒŠÇ•a‚̬ˆö‚É‚¨‚¯‚éRho-kinase‚̈Ӌ`@-Š¥¹kƒ‚ƒfƒ‹‚©‚ç—Õ°‰ž—p‚Ü‚Å-
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€F‘å“®–¬Ž¾Š³‚É‚¨‚¯‚édanger signal‚ƉŠÇ„

  3. ²“¡Œö—YA‰ºìG–¾F‘å“®–¬Ž¾Š³‚É‚¨‚¯‚édanger signal.
‘æ61‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ïi2013”N9ŒŽ20`22“úAŒF–{j

ƒzŠÂŠíƒ^ƒCƒ€ƒgƒ‰ƒxƒ‹ƒtƒH[ƒ‰ƒ€„

  1. ‰ºìG–¾FŠ¥“®–¬¹k\“®•¨ƒ‚ƒfƒ‹‚ÌŠJ”­‚©‚番Žq‹@\‚̉𖾂܂Å\
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€1FˆÀ’芥“®–¬Ž¾Š³‚ɑ΂·‚鎡—Ãí—ª„

  3. ‚‹´@Aâ“c‘וFA‹{“c@•qAŒã‰ªL‘¾˜YAŽO‰Y³’¨A‚“c„ŽjAŽÄ@MsA‰ºìG–¾F‹•ŒŒ«–«S•s‘S‚É‚¨‚¯‚銥“®–¬ŒŒsÄŒšp‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿.
  4. ƒƒVƒ“ƒ|ƒWƒEƒ€2F“œ”A•aгŽÒ‚ÌS޾гޡ—ÂÌevidence„

  5. ŽO‰Y³’¨Aâ“c‘וFAŒã‰ªL‘¾˜YA‚“c„ŽjA’A–Ø‘sˆê˜YA‹{“c@•qA‚‹´@A‰ºìG–¾F“œ‘ãŽÓˆÙí‚ð—L‚·‚é‹•ŒŒ«S•s‘SÇ—á‚Ì—\Œã—\‘ª‚É‚¨‚¯‚é”A’`”’•]‰¿‚̈Ӌ`.
  6. ƒƒVƒ“ƒ|ƒWƒEƒ€5F‚—îŽÒS•s‘SŽ¡—Â̌»ó‚Æ“W–]„

  7. â“c‘וFAŒã‰ªL‘¾˜YAŽO‰Y³’¨A‚“c„ŽjA‚‹´@A‰ºìG–¾F–{–M‚É‚¨‚¯‚é‚—îŽÒS•s‘SÇ—á‚Ì—Õ°“I“Á’¥.
  8. ƒƒVƒ“ƒ|ƒWƒEƒ€12FS•s‘S‚É‚¨‚¯‚éŽûk•s‘S‚ÆŠg’£•s‘S‚̃gƒsƒbƒNƒX„

  9. ‚“c„ŽjAâ“c‘וFA‹{“c@•qA‚‹´@AŒã‰ªL‘¾˜YAŽO‰Y³’¨A’A–Ø‘sˆê˜YA‰ºìG–¾FŽûk”\‚̒ቺ‚µ‚½S•s‘S‚ÆŽûk”\‚̕ێ‚³‚ꂽS•s‘SгŽÒ‚É‚¨‚¯‚éS””‚Ì—\Œã‚É‹y‚Ú‚·‰e‹¿‚Ì”äŠr.
  10. ƒƒVƒ“ƒ|ƒWƒEƒ€13F––½ŒŒŠÇ޾гޡ—ÂÌÅ‘Oü„

  11. ˆÉ“¡Œ’‘¾A‹Ú‘ò@ŒºA‰Í‘ºŒ\ˆê˜YA²“¡@¬A‰ºìG–¾F‰ºŽˆ––½“®–¬Ž¾Š³‚ɑ΂·‚é’áo—͑̊OÕŒ‚”gŽ¡—Ã.
  12. ƒƒrƒWƒ…ƒAƒ‹ƒ[ƒNƒVƒ‡ƒbƒv3„

  13. ‘Õ@“NA•Ÿ–{‹`OAŒš•”r‰îA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘¾˜YA–ؗ³’jAŽR–{¹DA–î”ö”ÂM—TA‰ºìG–¾F”x“®–¬ƒŠƒ‚ƒfƒŠƒ“ƒO‚Í”x‚ŒŒˆ³”­Ç‘O‚©‚çoŒ»‚·‚éFOCT‚ð—p‚¢‚½ŒŸ“¢.
  14. ƒƒƒfƒBƒJƒ‹ƒXƒ^ƒbƒtƒZƒbƒVƒ‡ƒ“4FƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—Âɂ¨‚¯‚郃fƒBƒJƒ‹ƒXƒ^ƒbƒt‚̘AŒg„

  15. ¯@^—R”üA•Ÿ“c_“ñA‰ºìG–¾A‘å—¢‚é‚èFƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ÂÉÛ‚µ•K—v‚Æ‚³‚ê‚éŠÅŒìŽÀ‘H‚Ì—v‘f.
  16. ƒYIAƒZƒbƒVƒ‡ƒ“„

  17. ‰H”ö´‹MA‚‹´@AˆÉ“¡Œ’‘¾A‹{“c@•qAâ“c‘וFA“ñ•r‘¾˜YAš¢’J—²Ž¡A”’ŒË@’AˆÉ“¡ˆ¤„A¼–{‘׎¡A’†ŽR‰ë°AˆÀ“c@‘A‰ºìG–¾FEmergency care of acute myocardial infarction and the Great East Japan Earthquake Disaster.
  18. ƒˆê”ÊŒû‰‰‰‰‘è„

  19. ²’|—m”VA•Ÿ“c_“ñA‹ß“¡³‹PA’†–ì@½A’·’J•”—Y”òAŽáŽR—TŽiA™‘ºGˆê˜YAŽÂè@‹BA‰ºìG–¾F–«S•s‘SгŽÒ‚É‚¨‚¯‚釖°ŒÄ‹záŠQ‚Æ’vŽ€“I•s®–¬ƒCƒxƒ“ƒg‚Ì”­¶‚ÌŒŸ“¢.
  20. ’A–Ø‘sˆê˜YAâ“c‘וFAŒã‰ªL‘¾˜YAŽO‰Y³’¨A‚“c„ŽjA‹{“c@•qA‰ºìG–¾FS•s‘SгŽÒ‚É‚¨‚¯‚郃^ƒ{ƒŠƒbƒNÇŒóŒQ‚̈Ӌ`‚ÌŒŸ“¢.
  21. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŽáŽR”ü“ÞŽqAŒã‰ªL‘¾˜YAŽO‰Y³’¨AŽR–{¹DA‰Á‰ê’J@–LA‰ºìG–¾F‰EŽºFDGŽæž‚ݘ´i‚Í”x‚ŒŒˆ³Š³ŽÒ‚Ì’·Šú—\Œã‚ð—\‘ª‚·‚é.
  22. “ñ•r‘¾˜YA‚‹´@A‹e’r@—ƒA‰H”ö´‹MA¼–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘¾A‰ºìG–¾FŠ¥¹k«‹·SÇŠ³ŽÒ‚É‚¨‚¯‚éRhoƒLƒi[ƒ[Šˆ«‚Ì“ú“à•Ï“®F––½ŒŒ”’ŒŒ‹…RhoƒL ƒi[ƒ[Šˆ«‚ÉŠî‚­ŒŸ“¢.
  23. ƒÇ—áŒû‰‰”­•\„

  24. ™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’¨A²“¡Œö—YA‰ºìG–¾F–«Šˆ“®«Epstein-BarŠ´õǂɇ•¹‚µ‚½”x‚ŒŒˆ³Ç‚̈ê—á.
  25. ™‘ºGˆê˜YA•Ÿ–{‹`OAŒã‰ªL‘¾˜YAŒš•”r‰îAŽR–{¹DAŽO‰Y³’¨A‰ºìG–¾FŒõŠ±Â’f‘w–@ŽOŽŸŒ³\’z‘œ‚É‚æ‚è”x“®–¬•a•Ï‚ð•]‰¿‚µ“¾‚½–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚̈ê—á.
  26. ƒÇ—áƒ|ƒXƒ^[”­•\„

  27. ¼–{‘׎¡AâV“¡ˆ»ŽqAˆÉ“¡ˆ¤„A‰~’J—²Ž¡AˆÉ“¡Œ’‘¾A™‘ºGˆê˜YA‚‹´@A‰ºìG–¾FIgGŠÖ˜A޾г‚ɇ•¹‚µ‚½Š¥¹k«‹·SÇ‚Ì1—á.
  28. ƒ‰ŠúŒ¤Cˆã§—ãÜ@ƒ|ƒXƒ^[„

  29. ‘å’Î’mGAŒš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŒã‰ªL‘¾˜YAŽO‰Y³’¨AŽR–{¹DA‰ºìG–¾Fƒ_ƒTƒ`ƒjƒuŽ¡—Ã’†‚É”x“®–¬«”x‚ŒŒˆ³Ç‚ð‡•¹‚µ‚½‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚Ì1—á.
‘æ5‰ñ“Œ–k—Õ°•s®–¬Œ¤‹†‰ïŠwpW‰ïi2013”N9ŒŽ14“úAŽRŒ`j
  1. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@½C’·’J•”—Y”òC²’|—m”VC‰ºìG–¾FŽOë•Ù—ÖˆâŽc‚Ɖº‘åÖ¬ŠÔ‚Ì‹¬•”‚ª‰ñ˜H‚̈ꕔ‚ÉŠÖ—^‚µ‚½FontanpŒãS–[•p”‚̈ê—á.
‘æ200‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2013”N8ŒŽ31“úAÂXj
  1. —L’|G”üCš¢’J—²Ž¡CŽR“à@‹BC‰H”ö´‹MC”’ŒË@’C¼–{‘׎¡C‚‹´@C’†ŽR‰ë°CˆÉ“¡Œ’‘¾C‰ºìG–¾Fìè•aŒãˆâǂɂæ‚銥“®–¬‹·ó‚ɑ΂µŠ¥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—ÂðŽ{s‚µ‚½2—á.
  2. ›Œ´ÍlC™‘ºGˆê˜YC‹e’n‡—TC•Ÿ–{‹`OCŒã‰ªL‘¾˜YCŒš•”r‰îCŽO‰Y³’¨CŽR–{¹DC–î”ö”ÂM—TC‰ºìG–¾Ff’f‚܂łɎžŠÔ‚ð—v‚µ‚½Žá”N”­Ç“Á”­«”x“®–¬«”x‚ŒŒˆ³Ç‚Ì1—á.
‘æ19‰ñ“ú–{S‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“Šw‰ïŠwpW‰ïi2013”N7ŒŽ13“ú`14“úAå‘äj

ƒƒVƒ“ƒ|ƒWƒEƒ€4FdÇS•s‘S‚ɑ΂·‚é•“IƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚Ìi•à„

  1. ˆÉ“¡Œ’‘¾A‰ºìG–¾F’áo—͑̊OÕŒ‚”gŽ¡—Ã.
  2. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“3F‘å‹K–ÍЊQ‚©‚ç‚Ì‹³ŒP‚Ɖۑè„

  3. •Ÿ–{‹`OA–ؗ³’jA‰ºìG–¾F‘åkЂɂ¨‚¯‚éS•s‘S‚Ì‘‰Á‚Æ‚»‚Ì‘Îô.
  4. ƒƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“4FS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‚̈ã—ÃE‘²‘OE‘²Œã‹³ˆç‚ÌŒ»ó‚Ɖۑè„

  5. ˆÉ“¡@CA•Ÿ–{‹`OA‰ºìG–¾A㌎³”ŽFS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‘²‘OE‘²Œã‹³ˆç‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²¸Œ‹‰Ê‚Æ“Œ–k‘åŠw‚ÌŒ»ó.
  6. ƒ‹³ˆçƒZƒbƒVƒ‡ƒ“6„

  7. ˆÉ“¡Œ’‘¾FPCI‚Ìi•à
  8. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸ¸m1„

  9. ’†–ì@½A•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òA²’|—m”VAƒ‚ƒnƒƒhƒAƒuƒfƒ‹ƒVƒƒƒtƒB[A‰ºìG–¾FS•s‘Sf’fEŽ¡—Âɂ¨‚¯‚éBNP‚Ì–ðŠ„.
  10. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸ¸m3„

  11. •Ÿ“c_“ñFQRS”gŒ`‚Ì–¡•û
  12. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸ¸m4„

  13. ™‘ºGˆê˜YA•Ÿ–{‹`OA‰ºìG–¾FzŠÂŠíf—Âɂ¨‚¯‚鋹•”ƒŒƒ“ƒgƒQƒ“ŽÊ^‚̓ǂݕû.
  14. ƒ‚æ‚­‚í‚©‚ézŠÂŠíŒŸ¸m6„

  15. ¼–{‘׎¡FS‘ŸƒJƒe[ƒeƒ‹ŒŸ¸
  16. ƒYIAƒZƒbƒVƒ‡ƒ“„

  17. ‚“c„ŽjAâ“c‘וFA‹{“c@•qA‚‹´@AŒã‰ªL‘¾˜YAŽO‰Y³’¨A’A–Ø‘sˆê˜YA‰ºìG–¾FSŒŒŠÇ•aгŽÒ‚É‚¨‚¢‚ĉîŒì‚ª•K—v‚ƂȂé—vˆö‚ɂ‚¢‚Ă̌Ÿ“¢@|CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
  18. ƒˆê”ʉ‰‘èFŒû‰‰”­•\„

  19. ‚‹´@“wA‘å–î“à@–LA–k‘ºKŽqA”‘qŽu•ÛA¯Žq‹v”üŽqA‹g“c˜aŽqA•Ÿ–{‹`OA¼–{‘׎¡A㌎³”ŽA‰ºìG–¾F‹}«S•s‘S‚É‚¨‚¯‚éS‘ŸƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“ƒvƒƒOƒ‰ƒ€“±“ü‘OŒã‚Ì”äŠrŒŸ“¢.
  20. ’|“à‰ëŽjA¼–{‘׎¡A’‡•yçA“쓇‘å•ãAV‘‰xOA’Ø“c@‹BA˜a’n‘וFA–”铎qA‚‹´•‘ŽqA²“¡–[˜YAX@M–FAŽRŒû‘fŽjAŽRçŒõOAˆä“c‰ëËA•Ÿ–{‹`OAŒF’J‹Iˆê˜YAì–{r•ãA㌎³”ŽAâV–؉ÀŽA‰ºìG–¾F‘å“®–¬áŽ‚ð’†S‚Æ‚µ‚½‘匌ŠÇ޾г‚Ìp‘OŒÄ‹zƒŠƒn‚͈À‘S‚ÉŽÀŽ{‰Â”\‚Å‚ ‚é@|ŒŒˆ³‘ª’艺‚Ì‹C“¹ƒNƒŠƒAƒ‰ƒ“ƒX—ûK\
  21. ’A–Ø‘sˆê˜YAâ“c‘וFAŒã‰ªL‘¾˜YA‚‹´@AŽO‰Y³’¨A‚“c„ŽjA‹{“c@•qA‰ºìG–¾F‚—îS•s‘SгŽÒ‚É‚¨‚¯‚é”]‘²’†Šù‰‚Ì—\Œã‚ւ̉e‹¿‚ÉŠÖ‚·‚錟“¢@|CHART-2‚©‚ç‚Ì•ñ\
  22. ŽO‰Y³’¨Aâ“c‘וFA‹{“c@•qA‚‹´@AŒã‰ªL‘¾˜YA‚“c„ŽjA’A–Ø‘sˆê˜YAŽÄ@MsA‰ºìG–¾FSŒŒŠÇ•a‚Ì—\Œã‚É‚¨‚¯‚é‰îŒì—\–h‚Ìd—v«@|CHART-2Œ¤‹†‚©‚ç‚Ì•ñ\
‘æ22‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ïŠwpW‰ïi2013”N7ŒŽ11-13“úA_ŒËj

ƒƒVƒ“ƒ|ƒWƒEƒ€4FDES —¯’uŒãƒXƒpƒXƒ€FŒ»ó‚Æ‘Îô„

  1. Nishimiya K, Matsumoto Y, Takahashi J, Tsuburaya R, Ito Y, Shiroto T, Ito K, Yasuda S, Shimokawa H. New generation biolimus A9-eluting stents suppress coronary hyperconstricting responses after stent implantations through Rho-kinase pathway inhibition in pigs in vivo.
  2. Yasuda S, Aizawa K, Takahashi J, Shimokawa H. Rho-kinase involvement in the pathogenesis of coronary hyperconstricting responses induced by drug-eluting stents in patients with coronary artery disease.
‘æ28‰ñ“ú–{•s®–¬Šw‰ïŠwpW‰ïi2013”N7ŒŽ4-6“úA“Œ‹žj
  1. Kondo M, Fukuda K, Wakayama Y, Nakano M, Hasebe Y, Kanawa A, Satake H, Shimokawa H. The importance of low voltage area in right atrium as the mechanisms of atrial tachycardia in postoperative Tetralogy of Fallot.
  2. Nakano M, Fukuda K, Wakayama Y, Kondo M, Hasebe Y, Kanawa A, Satake H, Shafee MB, Shimokawa H. Catheter ablation to premature ventricular contraction originated from tricuspid valvular annulus suppresses ventricular fibrillation in Brugada syndrome.
‘æ13‰ñ“ú–{NOŠw‰ïŠwpW‰ïi2013”N6ŒŽ28“ú`29“úA“ß”ej

ƒƒVƒ“ƒ|ƒWƒEƒ€2F“à”ç‹@”\Œ¤‹†‚Ìŋ߂Ìi•à„

  1. ²“¡Œö—YA•Ÿ–{‹`OA™‘ºGˆê˜YAŒã‰ªL‘¾˜YA–ؗ³’jAŒš•”r‰îAŽR–{¹DA‚–Ø—S‰îA‰~’J—²Ž¡AˆÉ“¡ˆ¤„A’†ŽR‰ë°A•“cŽç•FA‚‹´@AˆÉ“¡Œ’‘¾AˆÀ“c@‘A‰ºìG–¾FƒTƒCƒNƒƒtƒBƒŠƒ“A‚É‚æ‚éSŒŒŠÇ•a‘£i‹@\‚ƃoƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ẳ”\«.
  2. ƒƒVƒ“ƒ|ƒWƒEƒ€4FNO“™‚̃Cƒ[ƒWƒ“ƒO„

  3. “›ˆä³lA‰ºìG–¾A–öŒ´‰„ÍA”ö’Ò@–LFzŠÂŠíEt‘Ÿ•a‚É‚¨‚¯‚éNOSsŒn‚Ì•aˆö“I–ðŠ„.
  4. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[1„

  5. ‰ºìG–¾FŒŒŠÇ“à”ç‹@”\‚ÌŒ¤‹†Fŋ߂̒mŒ©.
  6. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[3„

  7. ˆÉ“¡Œ’‘¾F’áo—͑̊OÕŒ‚”g‚ð—p‚¢‚½V‚µ‚¢ŒŒŠÇV¶—Ö@.
  8. ƒƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[4„

  9. ‰ºìG–¾FŽ‰Ž¿ˆÙíǂɊւ·‚éŋ߂̒mŒ©.
  10. ƒYIAƒZƒbƒVƒ‡ƒ“„

  11. –ì“cˆêŽ÷A•Ÿ–{‹`OAâV“¡‘åŽ÷A_ŒË–ΗYAƒuƒhƒoƒUƒ‹@ƒGƒ“ƒwƒWƒƒƒ‰ƒJƒ‹A“›ˆä³lA‰ºìG–¾FŽ‰Ž¿‘ãŽÓ‚É‚¨‚¯‚éˆêŽ_‰»’‚‘f‚ÆRho-kinase‚Ì–ðŠ„@\NO‡¬y‘fŒ‡‘¹ƒ}ƒEƒX‚É‚¨‚¯‚錟“¢\
  12. ŒÃ–ì—R”üA“à“c‘¾˜YA‰ºìG–¾A‘剮—S•ãA–öŒ´‰„ÍA”ö’Ò@–LA“c‘º‰ëmA“›ˆä³lF‘n–ò‚É—L—p‚ÈŽ©‘R”­Ç‹}«S‹Ø[ǃ‚ƒfƒ‹‚ÌŠJ”­.
  13. ƒŒû‰‰”­•\„

  14. ŒŽ”ŽŽuA¬‘܉Á“ÞŠGA‰„‰iŠóAX‰ªOŽuA‹vPº“NA‰ºìG–¾A“›ˆä³lFNOˆË‘¶“I‚È_Œoƒyƒvƒ`ƒh܂肽‚½‚Ý•s‘S˜´i‚É‚æ‚鎋°‰º•”ƒIƒŒƒLƒVƒ“ƒjƒ…[ƒƒ“‚Ì‘I‘ð“I•Ï«.
  15. ƒƒ|ƒXƒ^[”­•\„

  16. ã–ì@WA“›ˆä³lA–L•½—R”üŽqA“瓇r—²A‰ºìG–¾A–öŒ´‰„ÍFNOSŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚¨‚¯‚é_Œos“®‚ɂ‚¢‚Ă̌Ÿ“¢i1jF•sˆÀŠÖ˜As“®‚Ì”­Œ»‚ÆNOSŒn‚Ƃ̊֘A«‚ɂ‚¢‚Ä.
  17. ã–ì@WA“›ˆä³lA–L•½—R”üŽqA“瓇r—²A‰ºìG–¾A–öŒ´‰„ÍFNOSŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚É‚¨‚¯‚é_Œos“®‚ɂ‚¢‚Ă̌Ÿ“¢i2jFR‚¤‚–ò‚ɑ΂·‚锽‰ž«‚©‚猟“¢‚µ‚½NOSŒn‚Ì–ðŠ„‚É‚Â‚¢‚Ä.
  18. _ŒË–ΗYAƒuƒhƒoƒUƒ‹@ƒGƒ“ƒwƒWƒƒƒ‰ƒJƒ‹AâV“¡‘åŽ÷AàV“cˆ¼ŽqA–ì“cˆêŽ÷A‰ºìG–¾F“à”çˆË‘¶«’oŠÉ”½‰ž‚É‚¨‚¯‚éNO/EDHF‚̃oƒ‰ƒ“ƒX‚Ìd—v«.
  19. ŒÃ–ì—R”üA–L•½—R”üŽqAã–ì@WAâ—œ‚Ü‚äŽqA¼èr”ŽA–ìŒûŽ•FA–öŒ´‰„ÍA‰ºìG–¾A”ö’Ò@–LA“c‘º‰ëmA“›ˆä³lFœ‘—R—ˆŒŒŠÇ‘O‹ì×–E‚É”­Œ»‚·‚éNO‡¬y‘fŒn‚̃}ƒEƒXŒŒŠÇ•a•ÏŒ`¬‚ɑ΂·‚é—}§ì—p.
  20. Ô“cŒ›‘¾˜NA–˜a”ŽA‰¤@Ž—bA–ìŒû^ŒáAì”g•q‘¥AΖ{—TŽmA–L•½—R”üŽqA‰ºìG–¾A–öŒ´‰„ÍA“›ˆä³lAŒ}@аF‹CŠÇŽxšb‘§‚É‚¨‚¯‚éNO‚¨‚æ‚ÑŠeNOSƒAƒCƒ\ƒtƒH[ƒ€‚Ì–ðŠ„.
  21. –ìŒû^ŒáA–˜a”ŽA‰¤@Ž—bAÔ쌛‘¾˜NAŽRè@Œ[Aì”g•q‘¥AΖ{—TŽmA–L•½—R”üŽqA‰ºìG–¾A–öŒ´LÍA“›ˆä³lAŒ}@аFNO‡¬y‘fŠ®‘SŒ‡‘¹ƒ}ƒEƒX‚ð—p‚¢‚½ƒuƒŒƒIƒ}ƒCƒVƒ“”xüˆÛ‰»ƒ‚ƒfƒ‹‚É‚¨‚¯‚éNO‚Ì–ðŠ„‚ÌŒŸ“¢.
  22. ƒuƒhƒoƒUƒ‹@ƒGƒ“ƒwƒWƒƒƒ‰ƒJƒ‹A_ŒË–ΗYAâV“¡‘åŽ÷Aà_“cˆ¼ŽqA–ì“cˆêŽ÷A‰ºìG–¾FImportant role of endothelial AMPK in endothelium-derived hyperpolarizing factor-mediated relaxations in mouse coronary artery.
  23. X’å’¼ÆA”Ñ“‡ˆê½A‰ºìG–¾A“›ˆä³lFˆê‘¤”AŠÇŒ‹ãFŒã‚Ìt•a•ÏŒ`¬‚É‚¨‚¯‚éNO‡¬y‘fƒVƒXƒeƒ€‚Ìt•ÛŒìì—p.
  24. –î“c–L—²A‰ºìG–¾A•½¼@CAŒã“¡^ŒÈA¬Š}Œ´N•vAŠ’J•¶•FF“œ”A•a«‹}«S‹Ø[ÇŽžŠ¥”÷¬‘¤•›ŒŒŠÇ‚É‚¨‚¯‚é“à”ç—R—ˆ‰ß•ª‹ÉˆöŽq‚Æ‚µ‚Ẳߎ_‰»…‘f‚ƃAƒ“ƒWƒIƒeƒ“ƒVƒ“ƒ^ƒCƒvIŽó—e‘ÌhR–ò‚ÌŒŒŠÇŠg’£Œø‰Ê‚ɂ‚¢‚Ä.
‘æ2‰ñ“ú–{”xzŠÂŠw‰ïŠwpW‰ïi2013”N6ŒŽ22“ú`23“úA“Œ‹žj

ƒƒVƒ“ƒ|ƒWƒEƒ€2@–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚錌ŠÇ“àŽ¡—Â̌»ó‚Æ“W–]„

  1. ™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘¾˜YCŒš•”r‰îCŽR–{¹DCŽO‰Y³’¨C²“¡Œö—YC‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ìf’f‚ÆŽ¡—Âɂ¨‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
  2. ƒƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€2@”x‚ŒŒˆ³”­Ç‚Ì•ªŽq¶•¨Šw“IƒAƒvƒ[ƒ`„

  3. ´… ‹œC•Ÿ–{‹`OC“c’†áÁˆêC²“¡Œö—YC’r“c®•½C‰ºìG–¾Fƒ}ƒEƒX”x‚ŒŒˆ³Çƒ‚ƒfƒ‹‚ð—p‚¢‚½ŒŒŠÇ•½ŠŠ‹Ø‚É‚¨‚¯‚éROCK2‚Ì–ðŠ„‚Ì‰ð–¾.
  4. ƒƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€3@¶S޾г‚ÉŠÖ˜A‚µ‚½”x‚ŒŒˆ³Ç„

  5. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YCŒã‰ªL‘¾˜YCŽO‰Y³’¨CŽR–{¹DC‰ºìG–¾F¶SŒnS޾г‚É”º‚¤”x‚ŒŒˆ³Ç‚ª—\Œã‚É—^‚¦‚é‰e‹¿.
  6. ƒƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€4@”x“®–¬«”x‚ŒŒˆ³ÇŽ¡—ÂÌÅ‘Oü„

  7. •Ÿ–{‹`OF”x“®–¬«”x‚ŒŒˆ³Ç‚Ì•a‘Ô‚É‚¨‚¯‚éRhoƒLƒi[ƒ[Œo˜H‚ÉŠÖ‚·‚éÅV‚Ì’mŒ©.
  8. ƒÇ—á“O’ê“¢˜_„

  9. ™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘¾˜YCŒš•”r‰îCŽO‰Y³’¨C²“¡Œö—YC‰ºìG–¾F’·ŠúƒGƒ|ƒvƒƒXƒeƒm[ƒ‹Ž¡—ÃŒã‚É–å–¬ˆ³˜´iÇ‚ð’æ‚µ‚½“«”x‚ŒŒˆ³Ç‚Ì1—á.
  10. ƒˆê”ʉ‰‘èFŒû‰‰”­•\„

  11. –ؗ³’jC™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘¾˜YCŒš•”r‰îCŽO‰Y³’¨C²“¡Œö—YC‰ºìG–¾F”xŒŒðÇðǂ̔­Ç‚É‚¨‚¯‚铌“ú–{‘åkЂ̉e‹¿.
  12. ’r“c®•½C•Ÿ–{‹`OC´… ‹œC‰ºìG–¾Fˆ³•‰‰×‚É‚æ‚éS•s‘S‚Ì•a‘Ô‚É‚¨‚¯‚éRho-kinase‚Ì–ðŠ„.
  13. ‘å’Î’mLCŒš•”r‰îC•Ÿ–{‹`OC™‘º Gˆê˜YCŽO‰Y—TCŒã‰ªL‘¾˜YCŽO‰Y³’¨C‰ºìG–¾F‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚ɑ΂·‚éƒ_ƒTƒ`ƒjƒuŽ¡—Ã’†‚ɇ•¹‚µ‚½”x“®–¬«”x‚ŒŒˆ³Ç‚Ì1—á.
  14. ²“¡Œö—YC•Ÿ–{‹`OC™‘ºGˆê˜YCŒã‰ªL‘¾˜YCŒš•”r‰îC´… ‹œC–î”ö”ÂM—TC’†‘ºˆê•¶CˆÉ“¡ _C‰ºìG–¾F”x‚ŒŒˆ³‚ÌdÇ“x‚Æ—\Œã—\‘ª‚Ì‚½‚ß‚ÌV‹KƒoƒCƒIƒ}[ƒJ[¥ƒTƒCƒNƒƒtƒBƒŠƒ“A.
  15. ™‘ºGˆê˜YC•Ÿ–{‹`OCŽO‰Y —TCŒã‰ªL‘¾˜YCŒš•”r‰îCŽO‰Y³’¨C²“¡Œö—YC‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éf’f‚ÆŽ¡—Âɂ¨‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
  16. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y —TCŒã‰ªL‘¾˜YCŽO‰Y³’¨CŽáŽR”ü“ÞŽqC‰Á‰ê’J –LC‰ºìG–¾F”x‚ŒŒˆ³Š³ŽÒ‚Ì—\Œã—\‘ª‚ɑ΂·‚éFDG-PET‚Ì—L—p«.
  17. ‘O“c ŒbC”ªŠªd—YCˆÀ“¡‘¾ŽOC•Ÿ–{‹`OC”óŒû‹`˜YC‹àŽq Š®C‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì”x¶ŒŸf’f53—Ⴄ‚¿Ž€–S3Ç—á‚Ì•a—‘gDŠw“IŒŸ“¢.
  18. –î”ö”ÂM—TC•Ÿ–{‹`OC–x“à‹v“¿C‰ºìG–¾F”x‚ŒŒˆ³Ç‚É‚¨‚¯‚錌¬”“àSmall GTPase‚Ì•]‰¿.
  19. –î”ö”ÂM—TC•Ÿ–{‹`OC–x“à‹v“¿C‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚É‚¨‚¯‚錌ðü—n’ïR«|Thrombin activated fibrinolysis inhibitor|‚ÌŠÖ—^.
  20. Md. Elias Al-MamunC²“¡Œö—YC“c’†áÁˆêC´… ‹œCSuvd NerguiC•Ÿ–{‹`OC‰ºì –¾FCombination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension in rats.
  21. Suvd NerguiC•Ÿ–{‹`OCŽì—–‘´‘´ŠiCMd. Elias Al-MamunC‰ºìG–¾FImpact of endothelial nitric oxide synthase on the development of right ventricular dysfunction caused by pulmonary hypertension.
  22. ƒˆê”ʉ‰‘èFƒ|ƒXƒ^[”­•\„

  23. Œš•”r‰îC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y —TCŒã‰ªL‘¾˜YCŽO‰Y³’¨C‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚é”x“®–¬ƒoƒ‹[ƒ“Œ`¬pŽž‚ÌOCT‚Ì—L—p«|IVUS‚Ƃ̔äŠr|
  24. ƒƒRƒƒfƒBƒJƒ‹ƒZƒbƒVƒ‡ƒ“„

  25. Œ´‹|ŠGC“¡“ˆŒbŽqC‰ºìG–¾FŽ‘±Ã’—Ö@‚ÌŽ©ŒÈŠÇ—Žw“±’†‚ÌŠ³ŽÒ‚ªŽw“±‚ð’†’f‚µÄŠJ‚ÉŽŠ‚Á‚½—vˆö
‘æ199‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2013”N6ŒŽ15“úAå‘äj
  1. âV“¡ˆ»ŽqA‚‹´@AˆÉ“¡ˆ¤„A‰~’J—²Ž¡A”’ŒË@’A¼–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘¾A‰ºìG–¾AÄ“¡^ˆê˜YF‘å“®–¬‰ŠÇŒóŒQ‚ð”wŒi‚Æ‚µ‚½¶Š¥“®–¬Žåв•”‚Ì‹·ó•a•ςɂæ‚è‹}«S‹Ø[Ç‚ð”­Ç‚µ‚½1—á.
  2. £ì«lAŒË“c@’¼A›Á@Œ³‹gA‚–Ø—S‰îA–©’J@–LAŽR–{‹`lA™@³•¶A‰ºìG–¾FIsoproterenol“Š—^‚ªelectrical storm‚̃Rƒ“ƒgƒ[ƒ‹‚É—LŒø‚Å‚ ‚Á‚½J wave syndrome‚Ì1—á.
  3. Œš•”r‰îA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAŒã‰ªL‘¾˜YAŽO‰Y³’¨A‰ºìG–¾F‰@ŠOS’âŽ~‚©‚ç‘h¶‚³‚ê‚½Š®‘S–[ŽºƒuƒƒbƒN‡•¹–¢C•œ‹@”\“I’PSŽºiDORVj‚Ì1—á.
  4. ™‘ºGˆê˜YA•Ÿ–{‹`OAŽO‰Y@—TAŒã‰ªL‘¾˜YAŒš•”r‰îAŽO‰Y³’¨A²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚ɑ΂·‚éf’f‚ÆŽ¡—Âɂ¨‚¯‚éŒõŠ±Â’f‘w–@‚Ì—L—p«.
‘æ66‰ñ“ú–{Ž_‰»ƒXƒgƒŒƒXŠw‰ïŠwpW‰ïi2013”N6ŒŽ13`14“úA–¼ŒÃ‰®j
  1. ²“¡Œö—YC•Ÿ–{‹`OC™‘ºGˆê˜YCŽO‰Y@—TCŒã‰ªL‘¾˜YC–ؗ³’jCŒš•”r‰îCŽR–{¹DC´…@‹œC–î”ö”ÂM—TC’†‘ºˆê•¶CˆÉ“¡@_C‰ºìG–¾FŽ_‰»ƒXƒgƒŒƒX•ª”å’`”’FƒTƒCƒNƒƒtƒBƒŠƒ“A ‚É‚æ‚é”x‚ŒŒˆ³‚Ì—\Œã—\‘ª.
‘æ156‰ñ“ú–{zŠÂŠíŠw‰ï“Œ–k’n•û‰ïi2013”N6ŒŽ1“úA·‰ªj
  1. HŽR³”NAì–{r•ãA֖؉ÀŽA•Ÿ“c_“ñA•Ÿ–{‹`OA‰ºìG–¾FdÇS•s‘S‚ɑ΂·‚é•â•lHS‘ŸAS‘ŸˆÚAŽ¡—Ã.
  2. •Е½W‘¾˜YAHŽR³”NA–{‹g’¼FAì–{r•ãA֖؉ÀŽAŽO‰Y³’¨AŒã‰ªL‘¾˜YAŽO‰Y@—TA™‘ºGˆê˜YA•Ÿ–{‹`OA‚‹´@A•Ÿ“c_“ñA‰ºìG–¾FŠg’£Œ^S‹ØÇ‹}«‘ˆ«‚ɑ΂µBridge to decision‚ðs‚Á‚½2Ç—á‚ÌŒoŒ±.
  3. _“cŒj•ãA–{‹g’¼FAì–{r•ãA֖؉ÀŽA•Ÿ–{‹`OA‰ºìG–¾FŽ©ŒÈ•Ù‰·‘¶Šî•”’uŠ·p‚ÌŽ¡—ìÑ.
  4. ‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@½Aì–¼‹ÅŽqA’·’J•”—Y”òA²’|—m”VAAbdel-Schafee MohamedA‰ºìG–¾FCARTO SOUND‚ª—L—p‚Å‚ ‚Á‚½—¼‘匌ŠÇ‰EŽº‹NŽnÇªŽ¡pŒãSŽº•p”‚̈ê—á.
  5. Ö“¡ˆ»ŽqA¼–{‘׎¡AˆÉ“¡ˆ¤„Aš¢’J—²Ž¡A”’ŒË@’A‰H”ö´‹MA’†ŽR‰ë°AˆÉ“¡Œ’‘¾A™‘ºGˆê˜YA‚‹´@A‰ºìG–¾A’†àV‚¿‚ЂëAΈä’q“¿A_“cŒj•ãAì–{r•ãA‘å“c‰pŠöA‚£@Œ\FIgG4ŠÖ˜A޾г‚ɇ•¹‚µ‚½Š¥¹k«‹·SÇ‚Ì1—á.
  6. ²’|—m”VA•Ÿ“c_“ñA‹ß“¡³‹PA’†–ì@½A’·’J•”—Y”òAAbdel-Schafee MohamedAŽáŽR—TŽiA™‘ºGˆê˜YA‰ºìG–¾AŽÂè@‹BF–«S•s‘SгŽÒ‚É‚¨‚¯‚釖°ŽžŒÄ‹záŠQ‚Æ’vŽ€«•s®–¬ƒCƒxƒ“ƒg‚ÌŒŸ“¢.
  7. ”’ŒË@’A‚‹´@A¼–{‘׎¡AˆÉ“¡ˆ¤„Aš¢’J—²Ž¡A“ñ•r‘¾˜YA’†ŽR‰ë°AˆÉ“¡Œ’‘¾A‰ºìG–¾F•ÂÇ•”‚©‚番Šò‚·‚é‘ΊpŽ}‚ÆŒŒŠÇ“à’´‰¹”gŽg—p‚ªƒƒCƒ„[’ʉ߂ɗLŒø‚Å‚ ‚Á‚½–«Š®‘S•ÂÇ‚Ì1—á.
  8. ™‘ºGˆê˜YA•Ÿ–{‹`OAŽO‰Y@—TAŒã‰ªL‘¾˜YAŒš•”r‰îAŽO‰Y³MA²“¡Œö—YA‰ºìG–¾F–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì––½”x“®–¬‚É‚¨‚¯‚éŒõŠ±Â’f‘w–@‚ð—p‚¢‚½•]‰¿.
  9. ’†–ì@½A•Ÿ“c_“ñAŽáŽR—TŽiA‹ß“¡³‹PA’·’J•”—Y”òAì–¼‹ÅŽqA²’|—m”VAAbdel-Schafee MohamedA‰ºìG–¾F”­ìŽž‚ÉJ wave‚ð”F‚ß‚½Žá”N«SŽº×“®‚̈ê—á.
  10. Œã‰ªL‘¾˜YA•Ÿ–{‹`OA™‘ºL‘¾˜YAŽO‰Y@—TAŒš•”r‰îAŽO‰Y³’¨AŽR–{¹DA²“¡Œö—YA‰ºìG–¾AHŽR³”NAì–{r•ãA֖؉ÀŽAHê”ü‹IF—¼S•â•lHS‘Ÿ‚𓱓ü‚µ‚½‚ª‹~–½•s‰Â”\‚Å‚ ‚Á‚½Œ€ÇŒ^S‹Ø‰Š‚Ì1—á.
  11. ’·’J•”—Y”òA’†–ì@½AŽáŽR—TŽiA‹ß“¡³‹PA²’|—m”VAAbdel-Schafee MohamedA•Ÿ“c_“ñA‰ºìG–¾Fޏ_‚ÌŒ´ˆö‚ƂȂÁ‚½SŽº«ŠúŠOŽûk‹Nˆö«ˆê‰ß«SŽº×“®‚ɑ΂µ‚ăAƒuƒŒ[ƒVƒ‡ƒ“Ž¡—ª—LŒø‚Å‚ ‚Á‚½ˆê—á.
  12. ŽO‰Y³’¨Aâ“c‘וFAŒã‰ªL‘¾˜YA‚“c„ŽjA‹{“c@•qA‚‹´@A‰ºìG–¾FS•s‘SгŽÒ‚É‚¨‚¯‚é‰îŒì—\–h•K—v“x‚Æ—\‘ªˆöŽq‚ÌŒŸ“¢@CHART-2‚©‚ç‚Ì•ñ.
  13. ‰¡ì—T‘åAì–{r•ãAHŽR³”NA‰Í’Ã@‘A–{‹g’¼FA֖؉ÀŽA•Ÿ–{‹`OA‰ºìG–¾FŽûk«S–Œ‰Š‚ÌŠO‰ÈŽ¡—ìт̌ŸØ.
‘æ35‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ïi2013”N5ŒŽ30“úAŽRŒ`j
  1. * ‰ºìG–¾F“Œ“ú–{‘åkЂÆzŠÂŠí޾г.
‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ïi2013”N3ŒŽ15`17“úA‰¡•lj

ƒPlenary Sessions„

  1. (PL03: To Improve Outcomes of Acute Heart Failure Patients: Lessons from Asian and Western Registries) Miura M, Sakata Y, Takada T, Nochioka K, Miyata S, Takahashi J, Hiramoto T, Inoue K, Tamaki K, Shiba N, Shimokawa H. Prognostic impact of blood urea nitrogen increase during hospitalization in patients with acute decompensated heart failure. Circ J. 77(Suppl. I):I-63,2013.
  2. ƒSymposiums„

  3. (SY01: Progress in Coronary Revascularization: CABG and PCI for Severe Coronary Artery Disease) Takahashi J, Sakata Y, Nochioka K, Miura M, Takada T, Miyata S, Shimokawa H. Prognostic impact of coronary revascularization therapy in patients with ischemic heart failure. Circ J. 77(Suppl. I):I-90,2013.
  4. (SY07: Advances in the Cardiovascular Regenerative Medicine -Lesson from the Clinical Studies-) Ito K, Fukumoto Y, Takahashi J, Hanawa K, Shindo T, Serizawa F, Sato A, Shimokawa H. Development of non-invasive regenerative therapies for cardiovascular disorders -Low-energy shock wave therapy and low-intensity pulsed ultrasound therapy- Circ J. 77(Suppl. I):I-120,2013.
  5. (SY10: New Biomarkers for Cardiovascular Disease Prevention) Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimizu T, Takagi Y, Tsuburaya R, Itoh Y, Matsumoto Y, Nakayama M, Takeda M, Takahashi J, Ito K, Yasuda S, Shimokawa H. Plasma cyclophilin A is a novel biomarker for oxidative stress and coronary artery disease. Circ J. 77(Suppl. I):I-139,2013.
  6. (SY14: Establishment of Caring Facilities in Adults with Congenital Heart Disease) Tatebe S, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamaoto S, Satoh K, Shimokawa H. Current status of chronic heart failure with adult congenital heart disease in Japan. Circ J. 77(Suppl. I):I-162,2013.
  7. (SY17: Recent Progress in Pulmonary Hypertension) Fukumoto Y, Sugimura K, Shimizu T, Qiqige Z, Yamamoto S, Tatebe S, Aoki T, Nochioka K, Miura Y, Satoh K, Shimokawa H. Recent research progress on the role of Rho-kinase pathway in the pathogenesis of pulmonary arterial hypertension -From Bench to Bedside- Circ J. 77(Suppl. I):I-180,2013.
  8. (SY23: Disasters and Cardiovascular Diseases) Aoki T, Fukumoto Y, Yasuda S, Ito K, Takahashi J, Miyata S, Shinozaki T, Inoue K, Yagi T, Komaru T, Katahira Y, Shimokawa H. Impact of the Great East Japan Earthquake Disaster on cardiovascular diseases. Circ J. 77(Suppl. I):I-215,2013.
  9. ƒLate Breaking Cohort Studies„

  10. (LBCS2-4) Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Tadaki S, Shimokawa H. Different impact of elevated baseline heart rate on outcomes in patients with HFrEF vs. HFpEF: The CHART-2 Study. Circ J. 77(Suppl. I):I-552,2013.
  11. ƒYoung Investigatorfs Award for International Students„

  12. Ellawindy A, Satoh K, Tanaka S, Ikeda S, Shimizu T, Noda K, Fukumoto Y, Kobayashi K, Nakayama K, Shimokawa H. Spontaneous development of arrhythmogenic right ventricular cardiomyopathy in mice overexpressing dominant-negative Rho-kinase in cardiovascular system. Circ J. 77(Suppl. I): I-568,2013.
  13. ƒESC-JCS Joint Symposium„

  14. (Recent Progress in the Understanding, Management and Prevention of Sudden Cardiac Death) Yasuda S, Ogawa H, Shimokawa H. Coronary artery spasm and out-of- hospital cardiac arrest. Circ J. 77(Suppl. I):I-230,2013.
  15. ƒRound Table Discussion„

  16. (RT12: How to Manage Intractable Coronary Artery Spasm) Takagi Y, Takahashi J, Yasuda S, Ogata Y, Sumiyoshi T, Goto T, Ogawa H, Shimokawa H. Nitrates as a concomitant therapy in patients with vasospastic angina -A report from the Japanese Coronary Spasm Association- Circ J. 77(Suppl. I):I-303,2013.
  17. ƒMorning Lecture„

  18. Sugimura K, Fukumoto Y, Shimokawa H. Management of chronic thromboembolic pulmonary hypertension. Circ J. 77(Suppl. I):I-525,2013.
  19. ƒFeatured Research Sessions„

  20. (FRS10: Angina pectoris) Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Takagi Y, Tsuburaya R, Itoh Y, Matsumoto Y, Nakayama M, Takeda M, Takahashi J, Ito K, Yasuda S, Shimokawa H. Plasma cyclophilin A level is a novel biomarker of vasospastic angina. Circ J. 77(Suppl. I):I-636,2013.
  21. Nihei T, Jun Takahashi J, Kikuchi Y, Hao K, Takagi Y, Tsuburaya R, Shirato T, Itoh Y, Matsumoto Y, Nakayama M, Ito K, Shimokawa H. Circadian variation of Rho-kinase activity in patients with vasospastic angina. Circ J. 77(Suppl. I):I-637,2013.
  22. (FRS17: Vascular Diseaese) Takagi Y, Takahashi J, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Ogawa H, Shimokawa H. Chronic nitrate therapy in patients with vasospastic angina -Multicenter registry study of the Japanese Coronary Spasm Association- Circ J. 2013;77(Suppl. I):I-679,2013.
  23. (FRS18: Pulmonary Circulation) Satoh K, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimizu T, Nakamura K, Ito H, Shimokawa H. Plasma cyclophilin A as a novel biomarker for pulmonary hypertension in humans. Circ J. 77(Suppl. I):I-686,2013.
  24. (FRS20: Heart Failure) Takada T, Sakata Y, Miyata S, Takahashi J, Nochioka K, Miura M, Shimokawa H. Factors influencing development of de novo heart failure from Stage-B asymptomatic status -A report from the CHART-2 Study- Circ J. 77(Suppl. I):I-698,2013.
  25. ƒOral presentations„

  26. Abdel-Shafee M, Fukuda K, Wakayama Y, Nakayama M, Nakano M, Kondoh M, Hasebe Y, Kawana A, Shimokawa H. Improved long-term prognosis of patients with cardiac sarcoidosis in the modern era. Circ J. 77(Suppl. I):I-873,2013.
  27. Hao K, Takahashi J, Nihei T, Tsuburaya R, Shirato T, Itoh Y, Matsumoto Y, Nakayama M, Kenta Ito, Yasuda S, Shimokawa H.@Improved emergency care of acute myocardial infarction during the Great East Japan Earthquake Disaster -The Miyagi AMI Registry Study-@Circ J. 77(Suppl. I):I-835,2013.
  28. Miura M, Sakata Y, Nochioka K, Takada T, Miyata S, Takahashi J, Shiba N, Shimokawa H. Stratification of mortality risk according to heart rate and systolic blood pressure in heart failure patients. Circ J. 77(Suppl. I):I-1086,2013.
  29. Nochioka K, Sakata Y, Takahashi J, Miyata S, Miura M, Takada T, Fukumoto Y, Shimokawa H. Psychological impact of the Fukushima Daiichi Nuclear Accident in patients with cardiovascular diseases -An interim analysis from the CHART-2 Study- Circ J. 277(Suppl. I):I-1054,2013.
  30. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Takahashi J, Fukumoto Y, Shimokawa H. Psychological impact of the Great East Japan Earthquake Disaster in patients with cardiovascular diseases; A report from the CHART-2 Study. Circ J. 77(Suppl. I):I-1055,2013.
  31. Shiroto T, Romero N, Sugiyama T, Sartoretto JL, Kalwa H, Yan Z, Shimokawa H, Michel T, Caveolin-1 plays a key role in the regulation of vascular oxidative stress. Circ J. 77(Suppl. I):I-1024,2013.
  32. Tatebe S, Fukumoto Y, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Wakayama M, Kagaya Y, Shimokawa H. Prognostic impact of enhanced [18F]fluorodeoxyglucose accumulation in the right ventricle in patients with pulmonary hypertension. Circ J. 77(Suppl. I):I-1079,2013.
  33. Uchida T, Furuno Y, Tanimoto A, Toyohira Y, Sakanashi M, Matsuzaki T, Noguchi K, Nakasone J, Ohya Y, Yanagihara N, Shimokawa H, Tamura M, Otsuji Y, Tsutsui M. Development of an experimentally useful model of spontaneous myocardial infarction. Circ J. 77(Suppl. I):I-810,2013.
  34. Yada T, Shimokawa H, Hiramatsu O, Goto M, Ogasawara Y, Kajiya F. Beneficial effects of angiotensin type 1 receptor blocker on H2O2-induced vasodilatation of native coronary collateral microvessels in dogs in vivo. Circ J. 77(Suppl. I):I-883,2013.
  35. ƒPoster presentations„

  36. Abe Y, Ito K, Hao K, Shimokawa H. Beneficial effects of low-energy shock wave therapy on inflammatory responses after acute myocardial infarction in rats. Circ J. 77(Suppl. I):I-2013,2013.
  37. Al-Mamun E, Satoh K, Tanaka S, Shimizu T, Nergui S, Fukumoto Y, Shimokawa H. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension in rats. Circ J. 77(Suppl. I):I-1766,2013.
  38. Dai Z, Fukumoto Y, Tatebe S, Sugimura K, Miura Y, Nochioka K, Aoki T, Yamamoto S, Shimokawa H. Pulmonary arterial remodeling occurs in the very early stage of pulmonary hypertension -An optical coherence tomography study- Circ J. 77(Suppl. I):I-1762,2013.
  39. Enkhjargal B, Saito H, Godo S, Sawada A, Noda K, Shimokawa H. Important role of endothelial AMPK in endothelium-derived hyperpolarizing factor-mediated relaxations in mice. Circ J. 77(Suppl. I):I-1640,2013.
  40. Hanawa K, Ito K, Kentaro Aizawa K, Tomohiko Shindo1, Kensuke Nishimiya1, Yuhi Hasebe1, Junyi Gao1, Hideyuki Hasegawa2, Satoshi Yasuda3, Hiroshi Kanai2, Hiroaki Shimokawa1 Low-Intensity Pulsed Ultrasound Induces Angiogenesis and Ameliorates Left Ventricular Dysfunction in a Porcine Model of Chronic Myocardial IschemiaCirculation Journal 2013, 77(Suppl. I):I-2524,2013.
  41. Hao K, Takahashi J, Nihei T, Tsuburaya R, Shirato T, Itoh Y, Matsumoto Y, Nakayama M, Ito K, Yasuda S, Shimokawa H. Characteristics of patients with acute myocardial infarction who did not receive primary PCI -A report from the Miyagi AMI Study- Circ J. 77(Suppl. I):I-2827,2013.
  42. Hasebe Y, Fukuda K, Yamamoto H, Nishimiya K, Hanawa K, Kondoh M, Nakano M, Wakayama Y, Shimokawa H. Development of a novel shock wave catheter ablation system -A feasiblity study for atrioventricular node ablation in pigs in vivo- Circ J. 77(Suppl. I):I-1354,2013.
  43. Ikeda S, Fukumoto Y, Shimizu T, Shimokawa H. Cardiac-specific overexpression of dominant-negative Rho-kinase suppresses pressure overload-induced right and left heart failure in mice. Circ J. 77(Suppl. I) : I-2905 ,2013.
  44. Kawana A, Takahashi J, Takagi Y, Yasuda S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Gotoh T, Tanabe Y, Sueda S, Kubo N, Momomura S, Ogawa H, Shimokawa H. Age-dependent differences in clinical characteristics and outcomes of female patients with vasospastic angina. Circ J. 77(Suppl. I):I-2370,2013.
  45. Kondoh M, Fukuda K, Wakayama Y, Nakano M, Kawana A, Hasebe Y, Abdel-Shafee M, Satake H, Shimokawa H. New Occurrence of ventricular arrhythmias after cardiac resynchronization therapy in patients with severe heart failure. Circ J. 77(Suppl. I):I-2346,2013.
  46. Miura M, Sakata Y, Nochioka K, Takada T, Miyata S, Takahashi J, Shiba N, Shimokawa H. Emerging healthcare issues in the management of chronic heart failure in Japan -An interim analysis of the CHART-2 Study- Circ J. 77(Suppl. I):I-2981,2013.
  47. Miura Y, Fukumoto Y, Sugimura K, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Satoh K, Shimokawa H. Impact of positive myocardial biopsy on ventricular function and prognosis in patients with cardiac sarcoidosis. Circ J. 77(Suppl. I):I-2547,2013.
  48. Nergui S, Fukumoto Y, Qiqige Z, Al Mamun E, Shimokawa H. Impact of endothelial nitric oxide synthase on the development of right ventricular dysfunction caused by pulmonary hypertension. Circ J. 77(Suppl. I):I-1764,2013.
  49. Nishimiya K, Matsumoto Y, Takahashi J, Shindo T, Hanawa K, Hasebe Y, Tsuburaya R, Shirato T, Ito K, Ishibashi-Ueda H, Yasuda S, Shimokawa H. New generation biolimus A9-eluting stent suppresses coronary hyperconstricting responses after stent implantations through Rho-kinase pathway inhibition in pigs in vivo. Circ J. 77(Suppl. I):I-1851,2013.
  50. Qiqige Z, Fukumoto Y, Sugimura K, Miura Y, Tatebe S, Yamamoto S, Aoki T, Nochioka K, Satoh K, Nergui S, Kondoh M, Nakano M, Wakayama Y, Fukuda K, Nihei T, Takahashi J, Shimokawa H. Enhanced Rho-kinase activity in circulating leukocytes in patients with heart failure. Circ J. 77(Suppl. I) : I-1424 ,2013.
  51. Shimizu T, Fukumoto Y, Tanaka S, Satoh K, Shimokawa H. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Circ J. 77(Suppl. I):I-2276,2013.
  52. Sugimura K, Fukumoto Y, Miura Y, Nochioka K, Aoki T, Tatebe S, Yamamoto S, Shimokawa H. Usefulness of optical coherence tomography for diagnosis and treatment of chronic thromboembolic pulmonary hypertension. Circ J. 77(Suppl. I):I-2575,2013.
  53. Suzuki H, Sumiyoshi A, Taki Y, Matsumoto Y, Fukumoto Y, Kawashima R, Shimokawa H. Usefulness of voxel-based morphometry for in vivo evaluation of hippocampal damage in a rat model of cardiopulmonary resuscitation. Circ J. 77(Suppl. I):I-2073,2013.
  54. Tsuburaya R, Takahashi J, Itoh Y, Shirato T, Yasuharu Matsumoto, Kenta Ito, Masaharu Nakayama, Hiroaki Shimokawa Beneficial Effects of a Single Prophylactic Hemodialysis on Renal Function Worsening after Percutaneous Coronary Intervention in Patients with Severe CKD.Circulation Journal 2013, 77(Suppl. I):I-2395,2013.
  55. Wakayama Y, Fukuda K, Nakano M, Kondoh M, Abdel-Shafee M, Hasebe Y, Kawana A, Satake H, Shimokawa H. Usefulness of quantitative gated SPECT to predict responders of cardiac resynchronization therapy among patients with a relatively narrow QRS. Circ J. 77(Suppl. I):I-1586,2013.
  56. Yaoita N, Fukumoto Y, Horiuchi M, Shimokawa H. Evidence for resistance to fibrinolysis in patients with chronic thromboembolic pulmonary hypertension -Possible involvement of thrombin activated fibrinolysis inhibitor- Circ J. 77(Suppl. I):I-2745,2013.
‘æ15‰ñ“ú–{¬læ“V«S޾гŠw‰ï‘‰ïEŠwpW‰ïi2013”N2ŒŽ19`20“úA“Œ‹žj
  1. ‹ß“¡³‹PC•Ÿ“c_“ñCŽáŽR—TŽiC’†–ì@½Cì–¼‹ÅŽqC’·’J•”—Y”òC²’|—m”VCMohamed A. ShafeeC‰ºìG–¾Fæ“V«S޾гpŒãS–[•p”‚É‚¨‚¯‚é—Õ°“I“Á’¥‚ÌŒŸ“¢.
‘æ198‰ñ“ú–{“à‰ÈŠw‰ï“Œ–k’n•û‰ïi2013”N2ŒŽ16“úAå‘äj

ƒ‰Šú—Õ°Œ¤CˆãƒvƒŒƒiƒŠ[ƒZƒbƒVƒ‡ƒ“E—DGÜŽóÜ„

  1. ‚“cضŽqA™‘ºGˆê˜YA•Ÿ–{‹`OAŽO‰Y@—TAŒã‰ªL‘¾˜YAŽO‰Y³’¨AŒš•”r‰îA‰ºìG–¾A‰Á“¡¹ºF’†«Ž‰–b’~ÏS‹ØŒŒŠÇÇ‚Ì1—á.
  2. ƒˆê”ʉ‰‘è„

  3. ²’|—m”VA‹ß“¡³‹PA•Ÿ“c_“ñAŽáŽR—TŽiA’†–ì@½Aì–¼‹ÅŽqA’·’J•”—Y”òA‰ºìG–¾FŠg‘å”xÖ¬Šu—£pŒã‚ÉŒ°Ý‰»‚µ‚½ŽOë•Ù—Ö‹NŒ¹SŽº«ŠúŠOŽûk‚Ì1—á.
  4. ‚“c“NŽjAŒã‰ªL‘¾˜YA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TAŒš•”r‰îAŽO‰Y³’¨A²“¡Œö—YAΈä’q“¿FCoganÇŒóŒQ‚ɑ哮–¬•½•s‘SÇ‚ð‡•¹‚µS•s‘S‚𗈂µ‚½1—á.
‘æ33‰ñ“ú–{SŒŒŠÇƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“Ž¡—Êw‰ï“Œ–k’n•û‰ïi2013”N2ŒŽ9“úAå‘äj
  1. ‚‹´@C”’ŒË@’C¼–{‘׎¡CˆÉ“¡ˆ¤„C‰~’J—²Ž¡C“ñ•r‘¾˜YC’†ŽR‰ë°CˆÉ“¡Œ’‘¾C‰ºìG–¾F•ÂÇ•”‚©‚番Šò‚·‚é‘ΊpŽ}‚ÆIVUS ‚ð—˜—p‚·‚邱‚ƂőO‰ºsŽ}–{в––½‚ɃƒCƒ„[’ʉ߂ª‰Â”\‚ƂȂÁ‚½1—á.
‘æ42‰ñ“ú–{S–¬ŠÇì“®•¨Ž¿Šw‰ïŠwpW‰ïi2013”N2ŒŽ8“ú`9“úA“Þ—Çj

ƒŽáŽèŒ¤‹†ŽÒÜŽóÜ„

  1. ´…@‹œA•Ÿ–{‹`OA“c’†^ˆêA²“¡Œö—YA‰ºìG–¾F”xŒŒŠÇƒŠƒ‚ƒfƒŠƒ“ƒO‚É‚¨‚¯‚éROCK2‚Ì–ðŠ„@\”x‚ŒŒˆ³ÇƒƒJƒjƒYƒ€‚̉ð–¾\
  2. ƒŽáŽèŒ¤‹†ŽÒÜÅIŒó•â„

  3. –ì“cˆêŽ÷A•Ÿ–{‹`OA’†“ˆ‘s‘¾A‰ºìG–¾Fƒ}ƒEƒX‚É‚¨‚¢‚ÄRho-kinase‚ÍAMPKŒo˜H‚ð—}§‚·‚邱‚Ƃɂæ‚胃^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚ðŽä‚«‹N‚·
  4. ƒˆê”ʉ‰‘è„

  5. ²“¡Œö—YA•Ÿ–{‹`OA™‘ºGˆê˜YAŽO‰Y@—TA–ؗ³’jAŒã‰ªL‘¾˜YAŒš•”r‰îAŽR–{¹DA´…@‹œA–î”ö”ÂM—TA’†‘ºˆê•¶AˆÉ“¡@_A‰ºìG–¾F”x‚ŒŒˆ³‚ÌdÇ“x‚Æ—\Œã—\‘ª‚Ì‚½‚ß‚ÌV‹KƒoƒCƒIƒ}[ƒJ[EƒTƒCƒNƒƒtƒBƒŠƒ“A.
“ú–{“®–¬d‰»Šw‰ï@‘æ13‰ñ“®–¬d‰»‹³ˆçƒtƒH[ƒ‰ƒ€i2013”N2ŒŽ3“úA‹ž“sj
  1. ‰ºìG–¾FŽ‰Ž¿ˆÙíÇf—ÂÌŋ߂Ìi•à.
‘æ6‰ñ“ú–{«·ˆãŠwEˆã—Êw‰ïŠwpW‰ïi2013”N2ŒŽ1`2“úAå‘äj

ƒÅ—DG‰‰‘èÜ„

  1. ŽO‰Y³’¨Aâ“c‘וFAŒã‰ªL‘¾˜YA‚“c„ŽjA‹{“c@•qA‚‹´@AŽÄ@MsA‰ºìG–¾FSŒŒŠÇ•aгŽÒ‚É‚¨‚¯‚é‰îŒì—\–h•K—v“x‚ƉîŒì—\–h‚ª•K—v‚ƂȂé—\‘ªˆöŽq‚ÌŒŸ“¢\CHART-2Œ¤‹†‚É‚¨‚¯‚é’mŒ©\
  2. ƒÅ—DG‰‰‘èŒû‰‰„

  3. ‚“c„ŽjAâ“c‘וFA‹{“c@•qAŽO‰Y³’¨AŒã‰ªL‘¾˜YA‚‹´@A‰ºìG–¾F¶ŽºŽûk”\‚̕ۂ½‚ꂽ–«S•s‘SгŽÒ‚É‚¨‚¯‚éS””‚Ì—\Œã‚É—^‚¦‚é‰e‹¿‚Æ‚»‚ê‚ÉŠÖ˜A‚·‚éˆöŽq‚ÌŒŸ“¢\«·‚ÌŠÏ“_‚àŠÜ‚ß‚Ä[
  4. ‰H”ö´‹MA‚‹´@A“ñ•r‘¾˜YA‰~’J—²Ž¡A”’ŒË@’AˆÉ“¡ˆ¤„A¼–{‘׎¡A’†ŽR‰ë°AˆÉ“¡Œ’‘¾AˆÀ“c@‘A‰ºìG–¾F‹}«S‹Ø[ÇŠ³ŽÒ‚É‚¨‚¯‚銥“®–¬ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“–¢Ž{s—á‚Ì«·‚ÉŠÖ‚·‚錟“¢\‹{錧S‹Ø[Ç‘Îô‹¦‹c‰ï‚©‚ç‚Ì•ñ\
  5. ƒƒ|ƒXƒ^[”­•\„

  6. ˆÉ“¡ˆ¤„A‚‹´@A‰H”ö´‹MA‰~’J—²Ž¡A”’ŒË@’A¼–{‘׎¡A“ñ•r‘¾˜YA’†ŽR‰ë°AˆÉ“¡Œ’‘¾AˆÀ“c@‘A‰ºìG–¾F‹}«S‹Ø[ǂ̉@“àŽ€–S—¦‚Ì«·‚ÉŠÖ‚·‚éˆöŽq‚ÌŒŸ“¢\‹{錧S‹Ø[Ç‘Îô‹¦‹c‰ï‚©‚ç‚Ì•ñ\
  7. ì–¼‹ÅŽqA‚‹´@A‚–Ø—S‰îAˆÀ“c@‘AŠp“c—²•ãA•ûN”ŽAŠÖ